Cancer Reporting in California

California Cancer Reporting System Standards, Volume I: Abstracting and Coding Procedures

Twenty-Third Edition
Version 1.0, September 2023

Prepared By:
California Cancer Registry
Cancer Informatics and IT Systems Unit

Editors:
Mary K. Brant, B.S., CTR
Donna M. Hansen, CTR
Janine Smith, B.S., CTR
Pamela D. Morgan, B.S., MPA, CTR

State of California:
Department of Health Services
Dr. Mark Damesyn, CDRSB, Chief
# Table of Contents

**Cancer Reporting in California** .......................................................... 1  
California Cancer Reporting System Standards, Volume I: Abstracting and Coding Procedure .......................................................... 1

**Preface to the Twenty-Third Edition** .................................................. 12  
**Part I. Introduction** ........................................................................... 13

I.1 Reporting Cancer Statistics .............................................................. 14  
  I.1.1 Role of the Cancer Registry .......................................................... 15  
  I.1.2 The California Cancer Registry ..................................................... 16  
  I.1.3 State Cancer Reporting Requirements ......................................... 17  
  I.1.4 Confidentiality ............................................................................ 18  
  I.1.5 Casefinding ................................................................................ 19  
    I.1.5.1 Casefinding Procedures ......................................................... 20  
    I.1.5.2 Casefinding Sources .............................................................. 21  
      I.1.5.2.1 Casefinding - Laboratory .................................................. 22  
      I.1.5.2.2 Casefinding - Health Information Management (HIM)/ Medical Records .................................................. 23  
      I.1.5.2.3 Casefinding - Other Sources ............................................ 24  
    I.1.5.3 Casefinding - Audits ............................................................... 25  
    I.1.5.4 Casefinding for Follow-Up ...................................................... 26  
  I.1.6 Reporting .................................................................................... 27  
    REQUIRED METHODS OF REPORTING BY CLASS OF CASE ............ 27  
    IS OUTLINED IN THE TABLES BELOW .......................................... 27  
      Analytic Cases.............................................................................. 27  
      Non-Analytic Cases ..................................................................... 28  
      Non-Analytic Cases ..................................................................... 28  
      Non-Analytic Cases ..................................................................... 28  
    I.1.6.1 Definition of Cancer ............................................................... 29  
    I.1.6.2 Abstracting Cancer Data ......................................................... 30  
    I.1.6.3 Entering Dates ...................................................................... 31  
    I.1.6.4 Date Format........................................................................ 33  
  I.1.7 Reporting by Non-Hospital Treatment Centers ............................... 34  
  I.1.8 Cases Diagnosed and Treated Elsewhere ....................................... 35

**Part II. Reportable Neoplasms** ......................................................... 36  
II.1 CCR Reportability Guide - Reportable ............................................ 37
II.1.1 CCR Reportability Guide - Non-Reportable or Historically Reportable ..... 43
II.2 Determining Reportability ................................................................. 45
   II.2.1 Identifying the Primary Neoplasm and Single or Multiple Tumors .... 46
   II.2.2 Ambiguous Diagnostic Reportable Terms .................................... 47
      Ambiguous Terms for Reportability ............................................ 47
   II.2.3 Pathology and Consultation Only Cases ...................................... 50
   II.2.4 Hematopoietic and Lymphoid Neoplasm .................................... 51
      Lymphatic & Hematopoietic Diseases – Subsequent Diagnoses ........ 51
   II.2.5 Benign/Borderline Brain and CNS Tumors .................................. 52
      Cranial Nerve Description ............................................................ 54
      Associated ICD-O-3 Code .............................................................. 54
   II.2.5.1 Date of Diagnosis for Benign/Borderline Brain and CNS Tumors .... 55
   II.2.5.2 Malignant Transformation - Brain and CNS Tumors ................ 56
   II.2.5.3 WHO Grade – Benign/Borderline Brain and CNS Tumors .......... 57
II.3 Abstracting - Accession and Sequence Number .................................. 58
   II.3.1 Year First Seen ........................................................................ 59
   II.3.2 Accession Number ................................................................. 60
   II.3.3 Sequence Number ................................................................... 61
      Code ......................................................................................... 62
      Description ............................................................................... 62
      Code ......................................................................................... 62
      Description ............................................................................... 62
II.3.4 Other Tumors/Primaries ................................................................. 63
Part III. Identification .............................................................................. 64
III.1 Registry Information ................................................................. 65
   III.1.1 Abstractor ............................................................................. 66
   III.1.2 Reporting Facility ................................................................. 67
   III.1.3 CoC Accredited Flag ............................................................. 68
III.2 Patient Information ......................................................................... 69
   III.2.1 Name ................................................................................. 70
      III.2.1.1 Entering Names ........................................................... 71
      III.2.1.2 Religious Names .......................................................... 73
      III.2.1.3 Name Suffix ................................................................. 74
      III.2.1.4 Mother’s First Name ..................................................... 75
   III.2.2 Medical Record Number .......................................................... 76
III.2.3 Social Security Number ................................................................. 77
III.2.4 Medicare Beneficiary Identifier (MBI) ................................................. 79
III.2.5 Phone Number (Patient) ..................................................................... 80
III.2.6 Address at Diagnosis ........................................................................ 81
   III.2.6.1 Number and Street at DX ............................................................. 83
   III.2.6.2 City at DX ................................................................................ 85
   III.2.6.3 State at DX ................................................................................ 86
   III.2.6.4 ZIP at DX ................................................................................ 87
   III.2.6.5 County at DX ............................................................................ 88
   III.2.6.6 Country at DX ........................................................................... 89
III.2.7 Marital Status .................................................................................... 90
III.2.8 Sex .................................................................................................... 91
III.2.9 Religion ........................................................................................... 93
III.2.10 Race and Ethnicity .......................................................................... 94
   III.2.10.1 Codes for Race Data Item ......................................................... 99
   III.2.10.2 Spanish/Hispanic Origin ............................................................ 102
III.2.11 Date of Birth .................................................................................. 104
III.2.12 Age at Diagnosis .......................................................................... 105
III.2.13 Birthplace - Country ..................................................................... 106
   III.2.13.1 Birthplace - State ................................................................... 107
III.2.14 Occupation and Industry .............................................................. 108
   III.2.14.1 Occupation ............................................................................. 109
   III.2.14.2 Industry .................................................................................. 110
   III.2.14.3 Occupation and Industry - Children ....................................... 111
III.2.15 No Patient Contact Flag .................................................................. 112
III.2.16 Height ............................................................................................ 113
   Height Conversion Table ........................................................................ 113
III.2.17 Weight ........................................................................................... 116
   Weight Conversion Table ...................................................................... 116
III.2.18 Tobacco Use .................................................................................. 122
   III.2.18.1 Tobacco Use Smokeless and Tobacco Use, NOS ....................... 123
      Code .................................................................................................... 123
      Description .......................................................................................... 123
   III.2.18.2 Tobacco Use Smoking Status .................................................. 124
      Code .................................................................................................... 124
Description........................................................................................................ 124
III.2.19 Source Comorbidity .............................................................................. 125
III.3 Case Identification .................................................................................... 126
III.3.1 Date of First Contact ............................................................................ 127
III.3.2 Dates of Inpatient Admission and Inpatient Discharge ....................... 128
III.3.3 Date of Diagnosis ................................................................................. 129
  III.3.3.1 Vague Dates .................................................................................... 131
  III.3.3.2 Approximation ............................................................................... 132
  Terms........................................................................................................... 132
  Code To ...................................................................................................... 132
  Terms........................................................................................................... 132
  Code To ...................................................................................................... 132
III.3.4 Place of Diagnosis ............................................................................... 133
III.3.5 Class of Case ........................................................................................ 134
  Analytic Classes of Case ........................................................................... 134
  Non-Analytic Classes of Case .................................................................... 135
III.3.6 Type of Reporting Source .................................................................... 139
III.3.7 Type of Admission ............................................................................... 140
III.3.8 Casefinding Source .............................................................................. 141
III.3.9 Payment Source (Primary and Secondary) and Payment Source Text . 143
  Code........................................................................................................... 143
  Label........................................................................................................... 143
  Definition .................................................................................................... 143
III.3.10 Reporting Facility Referred From ....................................................... 146
III.3.11 Reporting Facility Referred To ............................................................ 147
III.3.12 Physicians............................................................................................ 148
  III.3.12.1 Physician License Numbers ......................................................... 149
  III.3.12.2 Entering Physician NPI Codes .................................................... 150
III.3.13 Secondary Diagnosis 1-10 ................................................................. 151
III.3.14 Comorbidities and Complications ..................................................... 153
III.3.15 ICD Revision - Comorbidities and Complications ......................... 155
III.3.16 Discovered by Screening .................................................................... 156

Part IV. Diagnostic Procedures ......................................................................... 157
IV.1 Text - Diagnostic Procedures Performed .................................................. 158
  IV.1.1 Text - Physical Examination .............................................................. 159
IV.1.2 Text - X-Ray/Scans ................................................................. 160
IV.1.3 Text - Scopes ........................................................................ 161
IV.1.4 Text - Laboratory Tests .......................................................... 162
IV.1.5 Text - Operative Findings ....................................................... 163
IV.1.6 Text - Pathology Findings ....................................................... 164
  IV.1.6.1 Pathology Report Identifier Data Items ............................... 166
IV.1.7 Text - Staging ...................................................................... 168
IV.2 Diagnostic Confirmation ............................................................. 169

**Part V. Tumor Data** ..................................................................... 172
V.1 Primary Site ............................................................................. 173
  Primary Site .................................................................................. 175
  ICD-O-3 Code ................................................................................ 175
  V.1.1 Identification of Separate Sites .............................................. 176
  V.1.2 Indefinite and Metastatic Sites .............................................. 177
  V.1.3 Primary Site - Site-Specific Special Conditions ..................... 178
  V.1.4 Uncertain Primary Site .......................................................... 181
V.2 Laterality .................................................................................. 182
  V.2.1 Laterality - Paired Sites ......................................................... 184
V.3 ICD-O Morphology - Histology and Behavior ............................. 186
  V.3.1 Histologic Type .................................................................... 188
  V.3.2 Unspecified Malignancies ..................................................... 189
  V.3.3 Behavior .............................................................................. 190
    V.3.3.1 In-Situ Coding ................................................................. 192
V.4 Grade and Differentiation ........................................................... 194
  V.4.1 Grade - General Information ............................................... 195
    V.4.1.1 Grade - Clinical ............................................................... 197
    V.4.1.2 Grade - Pathological ....................................................... 198
    V.4.1.3 Grade - Post Therapy Clin (yc) ......................................... 199
    V.4.1.4 Grade - Post Therapy Path (yp) ....................................... 200
V.5 Tumor Size .............................................................................. 201
  V.5.1 Tumor Size Clinical .............................................................. 202
  V.5.2 Tumor Size Pathologic .......................................................... 206
  V.5.3 Tumor Size Summary ............................................................ 211
V.6 Mets at Diagnosis Bone, Brain, Liver, Lung, Distant Lymph Nodes, and Other ... 215
  V.6.1 Mets at Diagnosis - Bone ...................................................... 216
V.6.2 Mets at Diagnosis - Brain ................................................................. 218
V.6.3 Mets at Diagnosis - Liver ............................................................... 220
V.6.4 Mets at Diagnosis - Lung ............................................................... 222
V.6.5 Mets at Diagnosis - Distant Lymph Node(s) .................................... 224
V.6.6 Mets at Diagnosis - Other ............................................................... 226
V.7 Lymphovascular Invasion .................................................................... 228
    Synonyms for Lymphovascular Invasion .............................................. 229
V.8 Terms Indicating In-situ for Staging .......................................................... 231
V.9 Stage at Diagnosis ................................................................................. 233
    V.9.1 Staging Requirements .................................................................. 234
V.10 AJCC TNM Staging .............................................................................. 236
    V.10.1 AJCC TNM Staging General Information .................................... 237
    V.10.2 AJCC TNM Edition Number ......................................................... 239
    V.10.3 AJCC - Ambiguous Terms for Disease Extension ....................... 240
V.11 Extent of Disease (EOD) ..................................................................... 241
    V.11.1 EOD General Information .......................................................... 242
    V.11.1.1 EOD - Primary Tumor ............................................................. 244
    V.11.1.2 EOD - Regional Nodes ........................................................... 247
    V.11.1.3 EOD - Mets ........................................................................... 252
    V.11.2 EOD Prostate Pathological Extension ......................................... 255
    V.11.3 EOD - Ambiguous Terms for Extent of Disease ......................... 257
        Involved ....................................................................................... 258
        Not Involved ............................................................................... 258
V.12 Site-Specific Data Items (SSDIs) ............................................................. 260
    V.12.1 SSDI General Information ......................................................... 261
V.13 SEER Site-Specific Factor 1 ................................................................. 263
    Code .................................................................................................. 264
    Description ....................................................................................... 264
V.14 STandards for Oncology Registry Entry (STORE) .................................. 265
    V.14.1 STORE General Information ..................................................... 266
    V.14.2 STORE - Ambiguous Terms Describing Tumor Spread ............. 267
        Ambiguous Terms Describing Tumor Spread .................................. 267
        Terms that Constitute Tumor Involvement or Extension ................. 267
        Terms that DO NOT Constitute Involvement or Extension ............. 268
V.15 Summary Stage 2018 (SS2018) .............................................................. 269
VI.2.4.2 Surgical Margins of the Primary Site ........................................ 328
VI.2.4.3 Macroscopic Evaluation of the Mesorectum ......................... 330
VI.2.5 Sentinel Lymph Node Biopsy .................................................... 331
  VI.2.5.1 Date of Sentinel Lymph Node Biopsy .............................. 333
  VI.2.5.2 Sentinel Lymph Nodes Positive ..................................... 334
  VI.2.5.3 Sentinel Lymph Nodes Examined .................................... 336
VI.2.6 Scope of Regional Lymph Node Surgery ................................ 337
  Code .......................................................................................... 343
  Label ......................................................................................... 343
  Breast (C50_) .......................................................................... 343
  Code .......................................................................................... 345
  Description ............................................................................. 345
  VI.2.6.1 Date of Regional Lymph Node Dissection ....................... 347
  VI.2.6.2 Regional Lymph Nodes Positive ................................... 348
  VI.2.6.3 Regional Lymph Nodes Examined .................................. 351
VI.2.7 Special Rules for Counting Lymph Nodes .............................. 354
VI.2.8 Surgery of Other Regional Sites, Distant Sites, or Distant Lymph Nodes ........................................................................................................ 355
VI.2.9 Surgery of Synchronous Primaries ....................................... 357
VI.2.10 Systemic Therapy with Surgery Sequence ........................... 358
  Code .......................................................................................... 358
  Description ............................................................................. 358
  VI.2.11 Reason for No Surgery of the Primary Site ....................... 359
VI.3 Radiation Therapy - First Course of Treatment ......................... 361
  VI.3.1 Types of Radiation ......................................................... 363
    VI.3.1.1 External Beam Radiation ......................................... 364
    VI.3.1.2 Radioactive Implants ............................................... 365
  VI.3.2 Date of Radiation Therapy .............................................. 366
  VI.3.3 Radiation Phases I-III General Information ......................... 367
    VI.3.3.1 Radiation Primary Treatment Volume - Phases I-III ....... 368
    VI.3.3.2 Radiation to Draining Lymph Nodes - Phases I-III ........ 379
    VI.3.3.3 Radiation Treatment Modality - Phases I-III ............... 381
    VI.3.3.4 Radiation External Beam Planning Technique - Phases I-III .... 383
    VI.3.3.5 Dose per Fraction - Phases I-III ............................... 386
    VI.3.3.6 Number of Fractions - Phases I-III ............................ 388
Part VIII. Remarks, Final Diagnosis and Extra Reporting Facility Information

Part IX. Transmittal of Case Information and Quality Control

Appendices
Preface to the Twenty-Third Edition


The changes for 2023 include data item name changes, new labels added to race codes 1-5, and multiple retired data items. A major change is the revised surgery codes from a two-digit to a four-character alphanumeric. The Solid Tumor Rules, Other Sites have also undergone a major revision for 2023. Additionally, we will be adopting the implementation of the 2023 revisions to ICD-O-3.2, as well as the 2023 revisions to the Site-Specific Data Items, SEER Summary Stage 2018, SEER EOD 2018, SEER Grade 2018 Manuals, as well as the Commission on Cancer’s STORE Manual. All of the 2023 data changes are requirements from national standard setting agencies and were not initiated by the California Cancer Registry.

Please refer to the document titled “Cancer Reporting in California: Abstracting and Coding Procedures, California Cancer Reporting System Standards, Volume I, Changes and Clarifications –23rd Edition, June 2023”, for page, data item, or formatting updates and revisions. This document will provide a detailed summary of the revision or clarification to Volume I in the 2023 version and is posted to the CCR web site.

I want to acknowledge the Analysts from the Cancer Informatics and IT Systems Unit, California Cancer Reporting and Epidemiologic Surveillance (CalCARES) Program, for this year’s review and revision of Volume I. I would also like to thank the Greater Bay area Cancer Registry, the Cancer Registry of Greater California, and the Los Angeles County Cancer Surveillance Program, for your continued contributions to the success of Volume I.

Reporting facilities in California should direct any corrections, comments, and suggestions regarding this document to their regional registry. The regional registry will send/forward this information to the CCR. If individuals or facilities that are not part of the California reporting system need copies of Volume I, they may download the PDF from the California Cancer Registry website.

Thank you for your continued commitment to ensure that the CCR data is of the highest quality. The data you provide remains the cornerstone of the California Cancer Registry.

Mary Brant, B.S., CTR
Business Analyst Technical Lead
Part I. Introduction

Part I of Volume I introduce the user to the role of the cancer registry, the California Cancer Registry, as well as state cancer reporting requirements. Included in the state requirements: confidentiality, casefinding, reporting by both hospital and non-hospital facilities, and cases diagnosed and treated elsewhere.
I.1 Reporting Cancer Statistics

The systematic gathering of information about the incidence of cancer in designated populations is an indispensable tool in the struggle to contain the disease. With access to reliable statistics on the occurrence of several types of cancer, the people affected, the treatment provided, and other epidemiological factors, researchers and public health officials are better able to identify problems and evaluate remedies. Findings from such studies include possible environmental influences on the development of neoplasms, the susceptibility of certain ethnic and social groups to particular neoplasms, the need for oncology services in various locales, and the appropriateness of diagnostic and therapeutic procedures.
I.1.1 Role of the Cancer Registry

Many California hospitals have had their own cancer registries since the 1950's in accordance with guidelines established by the American College of Surgeons (ACS) and its requirements for accreditation of oncology services. The main purpose of a hospital registry is to provide physicians with the data needed to maintain quality of care through peer review and to compare performance with recognized standards. However, a more comprehensive level of reporting is required by state law and that level is supported by the California Cancer Registry and its statewide database system, Eureka DMS.
I.1.2 The California Cancer Registry

Information from hospital registries and other reporting sources is gathered by the California Cancer Registry (CCR) primarily for use in epidemiological research and for monitoring the occurrence of cancer in the state. A unit in the Chronic Disease Surveillance and Research Branch of the California Department of Public Health, the CCR was established in 1947 as a pilot study to determine the feasibility of basing a central registry on data reported by hospitals. The study was successful, and the registry gradually expanded its coverage from nine hospitals to thirty-six, most of which were in the San Francisco Bay area and Los Angeles County. As a result, valuable statistics were developed about the survival of cancer patients. However, since the data did not apply to a defined segment of the population, it was not possible to calculate the incidence of cancer. A section covering the population of Alameda County was therefore added to the registry in 1960. When the National Cancer Institute (NCI) undertook its Third National Cancer Survey in 1969, the population-based registration was extended to the entire San Francisco-Oakland Standard Metropolitan Statistical Area (SF-O SMSA) consisting of Alameda, Contra Costa, Marin, San Francisco, and San Mateo counties. Support for the SF-O SMSA registration was subsequently provided by the NCI's Surveillance, Epidemiology and End Results (SEER) Program. Established in 1973, SEER is among the largest population-based registries in the Western world, covering approximately 159 million people in twenty-two designated regions of the United States. Twenty of which contribute cases to the current SEER research data.

Expansion of the registration to the SF-O SMSA produced several important benefits. It strengthened the DHS's ability to estimate the incidence of cancer in California, ascertain risk factors in the occurrence of the disease, study variations in risks among different ethnic groups and social classes, identify changes in the incidence of various forms of cancer in subgroups of the population, and study long-term changes in the interrelationship of incidence, early diagnosis, treatment, length of survival, and mortality for a greater understanding of cancer. In addition, it greatly increased the number of cases available to researchers for epidemiological studies of human cancer and its relationship to the environment, genetics, cancer in varied species, and other data items. Because of these benefits, the CCR's coverage was extended to the State's entire population, which now totals over 39 million people.
I.1.3 State Cancer Reporting Requirements
The State of California has specific cancer reporting requirements. An overview of California’s Health and Safety Code and related information is outlined below.

Provisions of the California Health and Safety Code enacted in 1985 (Sections 103875 and 103885) mandate the establishment of a statewide system of cancer reporting. The purpose of the system is to conduct a Program of epidemiological assessments of the incidence of cancer, with a view to identifying cancer hazards to the public health and their remedies. Under the code, any hospital or other health care facility that diagnoses or treats cancer patients within an area designated as a cancer reporting area shall report each case of cancer to the department or the authorized representative of the department.

The Official California Code of Regulations implement the state statutes and have the same force of law as court decisions or legislation, is located on the Reporting Legislation and Legislation page on the California Cancer Registry website.

Guidelines:

- Diagnoses of borderline and benign primary intracranial and central nervous system (CNS) tumors are reportable for cases diagnosed January 1, 2001 and forward. Newly Reportable Hematopoietic Diseases (NRHD), see Hematopoietic and Lymphoid Neoplasm.

- It is the reporting facility’s responsibility to inform patients that their cancer diagnosis has been reported to the California Cancer Registry as required by regulations that govern the cancer reporting law. A Patient Information Sheet has been developed by the California Department of Public Health, which may be used to inform patients. Refer to Appendix F - Patient Information Sheet.

  Note: A reporting facility may modify this information sheet if they so choose.
I.1.4 Confidentiality
The California Health and Safety Code stipulates that the identity of patients whose cases are reported to the CCR must be held in the strictest confidence. Information that could be used to identify a patient may not be released to or discussed with anyone other than authorized personnel at the reporting facility or other reporting sources, unless prior informed consent is received from the patient. Section 100330 of the code states:

All records of interviews, written reports and statements procured by the state Department of Public Health or by any other person, agency or organization acting jointly with the state department, in connection with special morbidity and mortality studies shall be confidential insofar as the identity of the individual patient is concerned and shall be used solely for the purposes of the study. The furnishing of such information to the state or its authorized representative, or to any other cooperating individual, agency or organization in any such special study, shall not subject any person, hospital, sanitarium, rest home, nursing home, or other organization furnishing such information to any action for damages.

Guidelines:

- The CCR also has a policy of maintaining the confidentiality of any information that could be used to identify the caseload of a specific facility or physician.
- Under certain circumstances, confidential information may be released for research purposes without the patient's consent.
  - Legal provisions for these exceptions to the rules of confidentiality are contained in the Information Practices Act, Civil Code 1798.24. Refer to Appendix F for a sample Patient Information Sheet, for use in notifying patients that cancer is reportable.
- For more information regarding the CCR's confidentiality policy, refer to the CCR web site: http://www.ccrcal.org.
I.1.5 Casefinding
Casefinding (case ascertainment): The process of identifying eligible cases through review of sources documents and case listings. Comprehensive casefinding includes investigating all diagnostic and therapeutic services to look for active cancer cases. Casefinding covers a range of cases that need to be accessed to determine whether they are reportable or not.

Although exact procedures might vary from reporting facility to reporting facility, they ordinarily involve careful monitoring of the records kept by the departments that usually provide diagnostic and treatment services to patients with cancer.

Guidelines:
- Refer to Appendix G for the current ICD-10 casefinding lists.
  - Current and previous casefinding lists are also available on the SEER website: http://seer.cancer.gov.
  - Use the casefinding lists to screen prospective reportable cancer cases.
  - A casefinding list is not the same as a reportable list.
  - The casefinding lists are used to identify cases seen at the reporting facility with benign or malignant tumors and/or conditions, which are reportable to the CCR. This aids in the prevention of missed cases.
### I.1.5.1 Casefinding Procedures

Registrars must rely on several sources of documentation to identify all cancer cases diagnosed and/or treated at the facility. More than one type of documentation is generally needed to capture all of the required information for each patient.

**Guidelines:**

- Investigate every department or area where a patient might be seen or treated to identify eligible cases.
  - Sources differ depending on the facility type, services provided, and size.
  - Facility registries should limit the number of casefinding personnel to those who are familiar with the reportable diagnoses. This helps to ensure complete casefinding.

**Note:** Other Standard Setters such as the American College of Surgeons (ACS) and/or the facility’s cancer committee may require registrars to report certain cases in addition to what the CCR requires.

- Effective communication skills are essential in the casefinding process. Registrars will likely interact with other facility staff while looking for and obtaining information on eligible cases.
  - Explain the purpose to departments and requests for information.
  - Describe the nature of cancer case reporting and the function of the state registry. Underscoring:
    - How accurate, timely, and complete data collected at the provider level benefits the public, the facility, and the patient with cancer.
    - How cooperation of ancillary departments involved in cancer care is critical to achieve maximum casefinding results.
  - Open communication extends to the relationships that registrars have among themselves, with fellow members of the cancer committee, and with their regional registry representatives.
    - Regional registry representatives serve as liaisons between the CCR and the reporting facility.
    - Registrars are encouraged to contact their regional registry representative when questions and concerns arise.
I.1.5.2 Casefinding Sources
The hospital and non-hospital departments listed below identify the areas within a facility where eligible cases might be found. Not all facilities contain the departments listed.

Guidelines:
- Include all casefinding sources when searching for reportable cases.
- Each of the following departments are potential sources for finding eligible cancer cases:
  - Laboratory
  - Health Information Management/Medical Records
  - Other departments used in Casefinding:
    - Outpatient, Clinic and Ambulatory Care Services/Surgery
    - Oncology-Related Services
    - Staff Physician’s Offices
    - Long-Term Care Facility/Skilled Nursing Facility
    - Hospice
    - Emergency Department (ED)
I.1.5.2.1 Casefinding - Laboratory

The laboratory department is generally the primary casefinding source for eligible cases to be included in the registry database. Personnel who are knowledgeable in cancer case reporting must review pathology reports, including histology, cytology, hematology, bone marrow, and autopsy findings.

Guidelines:

- Ways to accomplish the review of all laboratory reports:
  - Manually review every report to identify eligible cases.
  - If the pathology reports are computerized, the registrar can request a list.
- Pathology reports, including histology, cytology, hematology, bone marrow, and autopsy findings.
  - Since pathologic studies are made for most patients suspected of having cancer, most reportable cases can be found by reviewing or obtaining copies of reports with positive or indicative diagnoses.
- The pathology department may have distinct divisions with subspecialties such as dermatopathology, eye pathology, oral pathology, GYN pathology and/or pediatric bone marrow pathology.
  - Each division should be reviewed for reportable cases of cancer.
- Experience demonstrates that trained registry personnel perform the most complete and accurate screening of pathology reports.
  - A registrar should audit the findings to ensure casefinding is complete in the event someone outside the registry reviews the pathology reports.
I.1.5.2.2 Casefinding - Health Information Management (HIM)/ Medical Records
The secondary source of cancer casefinding is the HIM/Medical Records Department, especially through the Disease Index. The Disease Index is usually a list run periodically that is either hard copy or in an electronic format. It is typically in medical record or ICD-O code order. The value of the Disease Index cannot be overemphasized.

Guidelines:

- Disease Indexes (See Appendix G - Codes for Casefinding, for applicable ICD-10-CM codes used in health information/medical record departments).
- The index should include the patient name, medical record number, and ICD diagnosis codes.
  - Supplementary information may include admission and/or discharge dates, length of stay, ICD codes for the associated disease and procedures, and the physician’s name and/or license/ID number.
  - When requesting the Disease Index, the cancer registrar should specify the reportable ICD cancer codes to identify pertinent inpatient and outpatient visits.
  - Not every reportable case has a positive histological diagnosis at every facility.
    - Regularly, a case is histologically diagnosed at one hospital or in a physician’s office and the patient is admitted to another facility for treatment.
- Surgery reports.
- Health Information Management/Medical Records Departments can also be a source of information associated with discharges, specifically discharges following a death (death log). Regular review of all hospital deaths reduces the likelihood of Death Certificate Only (DCO) cases in the future.
I.1.5.2.3 Casefinding - Other Sources

Other sources of eligible case ascertainment include inpatient/outpatient departments such as staff physician offices, clinics (ambulatory care/surgery), oncology-related services (diagnostic imaging), emergency departments, long-term care, and hospice facilities. Casefinding procedures should be established for eligible cases.

Guidelines:

- Other facilities and/or departments with potential sources for finding eligible cancer cases:
  - Outpatient, Clinic and Ambulatory Care Services/Surgery
    - Disease Index
    - Daily facility and clinic discharges
    - Surgery and visit logs
    - Billing form copies (contain both diagnosis and ICD codes)
  - Oncology-Related Services
    - Radiation therapy logs
    - Nuclear medicine logs
    - Radiology logs, including logs of scans
    - Radiation and chemotherapy appointment books/logs
  - Staff Physician’s Offices
    - Disease Index
  - Long-Term Care Facility/Skilled Nursing Facility
    - Admissions and discharges
  - Hospice
    - Monitor admissions to facility hospice units for casefinding purposes. Collect eligible cases where:
      - Palliative or comfort care is provided.
      - Active cancer cases whether patients have been diagnosed and/or have received treatment at the facility or not.
  - Emergency Department (ED)
    - ED logs
    - Death Certificates
I.1.5.3 Casefinding - Audits

Periodic casefinding audits are strongly encouraged for every reporting facility to confirm that every eligible case is identified and reported.

Guidelines:

- Develop a system of internal review.
  - Speak with other facility registrars or their field representatives for ideas.
- When significant changes occur in the annual reporting total average, look for changes in services and/or staffing.
- Address fluctuations in reporting totals with regional representatives as soon as they are noted.
I.1.5.4 Casefinding for Follow-Up

To meet the requirements of the State's cancer reporting system, it is necessary to periodically determine the vital status and condition of registered patients. One method of obtaining this information is through the casefinding process.

Guidelines:

- Reporting facilities must have a systematic method of identifying patients who are re-admitted to the facility or who are treated on an outpatient basis, whether for the reported cancer or for another condition.
  - This information can be used to update patient's vital status and condition.
  - Regular review of all hospital deaths reduces the likelihood of Death Certificate Only (DCO) cases in the future.

Refer to Follow-Up Information for additional follow-up information.
I.1.6 Reporting
The reporting facility must report every reportable case first seen as an inpatient or outpatient, either with evidence of cancer or for cancer-directed treatment, on or after the date that mandatory reporting was declared for the region (the region's reference date). Refer to the Regional Registry Reference Date Guide for the specific date when mandatory reporting began in each region.

A Full Abstract is required for any reportable case diagnosed and/or treated at the reporting facility (analytic cases) and for most non-analytic cases. For the list of required data items included in a full abstract, see the California Cancer Reporting Systems Standards, Volume II, and the associated Volume II Appendices. Each regional registry may establish alternative reporting mechanisms for use when an abstract is not prepared.

Cases Not Reportable:
- Hospice Only
- Patients receiving long-term therapy with a history of cancer, but no current evidence of cancer.
- Cancer Conference (Tumor Board) presentation only
- Consult Only and facility is reviewing information only to confirm a diagnosis made elsewhere, rendering a second opinion, or recommending treatment which will be done elsewhere. See Pathology and Consultation Only Cases for more information.
- Catheter placement for cancer therapy only
- Patients receiving transient care
- Outpatient blood draw

REQUIRED METHOD OF REPORTING BY CLASS OF CASE IS OUTLINED IN THE TABLES BELOW

Analytic Cases
Initial Diagnosis at Reporting Facility

<table>
<thead>
<tr>
<th>Class of Case</th>
<th>Required by CCR</th>
<th>Reporting Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>Yes</td>
<td>Abstract</td>
</tr>
<tr>
<td>10</td>
<td>Yes</td>
<td>Abstract</td>
</tr>
<tr>
<td>11</td>
<td>Yes</td>
<td>Abstract</td>
</tr>
<tr>
<td>12</td>
<td>Yes</td>
<td>Abstract</td>
</tr>
<tr>
<td>13</td>
<td>Yes</td>
<td>Abstract</td>
</tr>
<tr>
<td>14</td>
<td>Yes</td>
<td>Abstract</td>
</tr>
</tbody>
</table>
### Non-Analytic Cases

*Patient appears in person at Reporting Facility; Both initial diagnosis and treatment elsewhere.*

<table>
<thead>
<tr>
<th>Class of Case</th>
<th>Required by CCR</th>
<th>Reporting Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>Yes</td>
<td>Abstract</td>
</tr>
<tr>
<td>21</td>
<td>Yes</td>
<td>Abstract</td>
</tr>
<tr>
<td>22</td>
<td>Yes</td>
<td>Abstract</td>
</tr>
</tbody>
</table>

**Non-Analytic Cases**

- **Patient does not appear in person at Reporting Facility**

<table>
<thead>
<tr>
<th>Class of Case</th>
<th>Required by CCR</th>
<th>Reporting Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td>*Yes (see Class of Case for exceptions)</td>
<td>Abstract</td>
</tr>
<tr>
<td>31</td>
<td>No</td>
<td>NR</td>
</tr>
<tr>
<td>32</td>
<td>Yes</td>
<td>Abstract</td>
</tr>
<tr>
<td>33</td>
<td>No</td>
<td>NR</td>
</tr>
<tr>
<td>34</td>
<td>Yes</td>
<td>Abstract</td>
</tr>
<tr>
<td>35</td>
<td>Yes</td>
<td>Abstract</td>
</tr>
<tr>
<td>36</td>
<td>Yes</td>
<td>Abstract</td>
</tr>
<tr>
<td>37</td>
<td>Yes</td>
<td>Abstract</td>
</tr>
<tr>
<td>38</td>
<td>Yes</td>
<td>Abstract</td>
</tr>
</tbody>
</table>

**Non-Analytic Cases**

*Regional Registry Responsibility Only*

<table>
<thead>
<tr>
<th>Class of Case</th>
<th>Required by CCR</th>
<th>Reporting Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>No</td>
<td>NR</td>
</tr>
<tr>
<td>41</td>
<td>No</td>
<td>NR</td>
</tr>
<tr>
<td>42</td>
<td>Yes</td>
<td>Abstract</td>
</tr>
</tbody>
</table>

**Key to Reporting Method:**

- **Abstract** – Full abstract required
- **NR** – Not Reportable
**I.1.6.1 Definition of Cancer**
Cancer is defined by the California Health and Safety Code for registry purposes, as "all malignant neoplasms, regardless of the tissue of origin, including malignant lymphoma, Hodgkin disease, and leukemia, but excluding basal cell and squamous cell carcinoma of the skin."

**Guidelines:**
- Benign and uncertain behavior intracranial and central nervous system (CNS) tumors became reportable along with newly reportable histologies published in ICD-O-3. This applies to cases diagnosed January 1, 2001 and forward.
- The CCR establishes an official list of reportable neoplasms annually.
- A reportable cancer or tumor must be reported to the CCR if it is diagnosed by any physician/health care practitioner, including:
  - Pathologist
  - Radiologist
  - Surgeon
  - Dentist
  - Podiatrist
  - Any other healthcare practitioner diagnosing or providing treatment for cancer patients.

**Examples:** Physician Assistant (PA) and Nurse Practitioner (NP)
- Carcinoma In-situ (including squamous cell and adenocarcinoma) of the cervix and CIN III (cervical intraepithelial neoplasia, grade III) are no longer reportable to the CCR. This applies to cases diagnosed January 1, 1996 and forward.
I.1.6.2 Abstracting Cancer Data

Information about cancer cases is reported to the CCR in the form of abstracts, which summarize pertinent information about individual cases. See the California Cancer Reporting Systems Standards, Volume II, and the associated Volume II Appendices for data item requirements. If in doubt about how certain data items should be completed, the regional registry should be contacted.

Guidelines:

- Whatever reporting software is used, rules for entering data must be followed precisely.
- The text summaries required for the sections on diagnostic procedures and treatment should be as concise as possible.
- Every required data item must be completed, and the entries must be accurate, concise, and clear.
- Coded data items must be supported by text documentation on the abstract.
  - Information which does not require supporting text:
    - Date of Birth (DOB) (unless the patient is 100 years of age or older). Refer to Age at Diagnosis.
    - Social Security Number (SSN)
    - Medical Record Number (MRN)
    - Comorbidities
    - Secondary Diagnosis
I.1.6.3 Entering Dates

Dates transmitted between facility registries and central registries changed to improve the interoperability or communication of cancer registry data with other electronic record systems. Registry software may display dates in the traditional manner or in the interoperable format. Consult your software vendor for specific data entry instructions.

- **Traditional dates** are displayed in MMDDCCYY form, with 99 representing unknown day or month portions, and 99999999 representing a completely unknown date. In traditional form, some dates also permit 88888888 or 00000000 for special meaning.

- **Interoperable dates** are displayed in CCYYMMDD form, with the unknown portions of the date filled with blank spaces. An allowable date must contain the year.

<table>
<thead>
<tr>
<th>Description</th>
<th>Traditional Date</th>
<th>Interoperable Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full date known</td>
<td>MMDDCCYY</td>
<td>CCYYMMDD</td>
</tr>
<tr>
<td>Month and year known</td>
<td>MM99CCYY</td>
<td>CCYYMMbb</td>
</tr>
<tr>
<td>Year only known</td>
<td>9999CCYY</td>
<td>CCYYbbbb</td>
</tr>
<tr>
<td>Unknown date</td>
<td>99999999</td>
<td>bbbbbbb</td>
</tr>
</tbody>
</table>

b = blank

**Coding Instructions:**

- **Vague Dates:** Enter an approximate date when the exact date cannot be determined. At a minimum, a year of diagnosis is required for all analytic cases (Class of Case 00-22). The year of diagnosis must be known or estimated and cannot be blank or unknown. The date of first cancer directed therapy may be used as the date of diagnosis if the therapy was initiated before definitive confirmation of the diagnosis. Documentation must be provided for the basis of the estimated date.

- **Approximate Dates:** At a minimum, a year of diagnosis is required for all analytic cases (Class of Case 00-22). Use the date treatment was started if the patient receives a first course of treatment before a definitive diagnosis. Documentation must be provided for the basis of the estimated date. Use the following coding procedures for estimating dates relating to diagnosis.

- **Estimating Year:** Use whatever information is available to calculate the year. Enter the year of admission when there is no basis for estimation.

<table>
<thead>
<tr>
<th>Terms</th>
<th>Code To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Couple of years ago</td>
<td>Two years ago</td>
</tr>
<tr>
<td>Few years ago</td>
<td>Three years ago</td>
</tr>
</tbody>
</table>
• **Estimating Month:** *Use whatever information is available to calculate the month.* Leave the month blank if there is no basis for approximation.

<table>
<thead>
<tr>
<th>Terms</th>
<th>Code To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recently</td>
<td>Enter the month and year of admission, and unknown (&quot;99&quot; or leave blank depending on your registry software) for the day. If patient was admitted during the first week of a month, enter the previous month</td>
</tr>
<tr>
<td>Several months ago</td>
<td>Assume the case was first diagnosed three months before admission with the day unknown when the patient was not previously treated or if a course of treatment started elsewhere was continued at the reporting facility</td>
</tr>
<tr>
<td>Spring</td>
<td>Enter as April</td>
</tr>
<tr>
<td>Summer</td>
<td>Enter as July</td>
</tr>
<tr>
<td>Fall or Autumn</td>
<td>Enter as October</td>
</tr>
<tr>
<td>Winter</td>
<td>Enter as December or January based on available information i.e. end/beginning of year</td>
</tr>
<tr>
<td>Early in the year</td>
<td>Enter as January</td>
</tr>
<tr>
<td>Middle of the year</td>
<td>Enter as July</td>
</tr>
<tr>
<td>End of the year</td>
<td>Enter as December</td>
</tr>
<tr>
<td>Late in the year</td>
<td>Enter as December</td>
</tr>
</tbody>
</table>
I.1.6.4 Date Format
Dates transmitted between facility registries and central registries changed to improve the interoperability or communication of cancer registry data with other electronic record systems.

Coding Instructions:
- Registry software may display dates in the traditional manner or in the interoperable format. Consult your software vendor for specific data entry instructions.
  - **Traditional dates** are displayed in MMDDCCYY form, with 99 representing unknown day or month portions, and 99999999 representing a completely unknown date. In traditional form, some dates also permit 88888888 or 00000000 for special meaning.
  - **Interoperable dates** are displayed in CCYYMMDD form, with the unknown portions of the date filled with blank spaces. An allowable date must contain the year.

<table>
<thead>
<tr>
<th>Description</th>
<th>Traditional Date</th>
<th>Interoperable Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full date known</td>
<td>MMDDCCYY</td>
<td>CCYYMMDD</td>
</tr>
<tr>
<td>Month and year known</td>
<td>MM99CCYY</td>
<td>CCYYMMbb</td>
</tr>
<tr>
<td>Year only known</td>
<td>9999CCYY</td>
<td>CCYYbbbb</td>
</tr>
<tr>
<td>Unknown date</td>
<td>99999999</td>
<td>bbbbbbbb</td>
</tr>
</tbody>
</table>

b = blank
I.1.7 Reporting by Non-Hospital Treatment Centers

Not all abstracting requirements apply to freestanding radiation therapy centers and other cancer treatment centers that are not part of hospitals and do not have inpatient facilities. Usually, patients seen at these facilities have been hospitalized elsewhere previously, and the treatment center is not the primary source for detailed information about their diagnostic workups. However, case reports from such facilities afford a quality check on the hospitals' reports and, even more important, provide data that complete the information about the patient's first course of treatment. Without these reports, statewide data on patterns of care would not be accurate or clinically useful.

Guidelines:

- When submitting abstracts, treatment centers must provide complete patient identification and treatment information, but they are not required to fill in text data items for diagnostic procedures that were performed elsewhere. See Text – Diagnostic Procedures Performed for additional information.
- Recording stage is also important. When planning treatment, the radiation therapist often performs the most thorough assessment of stage available for the case.
- The treatment center's abstract must be prepared in the same electronic format used by other facilities.

See the California Cancer Reporting Systems Standards, Volume II, and the associated Volume II Appendices for data item requirements.
I.1.8 Cases Diagnosed and Treated Elsewhere
Reporting requirements for cases diagnosed and treated elsewhere are less stringent than those for other cases. The reporting facility's medical record often does not contain the required data, or contains only secondhand data.

CCR Expectations:

- The CCR requires that most non-analytic cases be abstracted and submitted.
  - For definitions of non-analytic, analytic cases, and Class of Case, see Class of Case.
  - For instruction on how the case should be submitted, see Reporting.
- Report any information included in the medical record, but it is not necessary to obtain missing information, although a facility may choose to do so.
- Text information about diagnostic procedures limited to a brief statement of the patient's history and the reason for the present admission must be included.
- Enter the statement in the physical exam text area.
- Even though information for many required data items might not be available, all the data items must be completed.
- If necessary, enter the codes for UNKNOWN or NONE.
Part II. Reportable Neoplasms

Part II of Volume I contain the CCR Reportability Guide, information on how to identify primary tumors, ambiguous terminology, what to do with path or Consult Only cases, hematopoietic neoplasms, and benign/borderline and CNS tumor reporting. Additionally, abstracting accession and sequence number instructions are also included.
II.1 CCR Reportability Guide - Reportable

Refer to the reportability guide below for information on specific histologies and sites for tumors that are reportable to the CCR.

2023 ICD-O-3.2 histology coding changes: Updates include new and revised histology terms, codes, and behaviors for cases diagnosed January 1, 2023 and forward. Please see the 2023 ICD-O-3.2 Implementation Guidelines. Use of these guidelines are required for determining reportability and accurate coding.

Coding Instruction:
- Terms without reportability dates have been reportable since the region’s reference date.
- New histology codes that are reportable for 2023+ should not be used for cases diagnosed prior to 2023 because the histology was not reportable at the time of diagnosis.

Reportable Diagnoses:
- Invasive malignancies (behavior /3)
- In-situ malignancies (behavior /2)
  - The following terms indicate in-situ behavior and are reportable:

<table>
<thead>
<tr>
<th>General Reportable Terms Indicating In-situ Behavior</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bowen’s disease (excluding skin)</td>
</tr>
<tr>
<td>Confined to epithelium (does not extend beyond base membrane)</td>
</tr>
<tr>
<td>Ductal carcinoma in-situ, (DCIS) (any site)</td>
</tr>
<tr>
<td>Intracystic, 8504/2, Intraepidermal (NOS), Intrasquamous, In-situ</td>
</tr>
<tr>
<td>Intraepithelial carcinoma, NOS</td>
</tr>
<tr>
<td>Intraepithelial neoplasia grade III, not otherwise specified (NOS)</td>
</tr>
<tr>
<td>Involvement up to, but not including basement membrane</td>
</tr>
<tr>
<td>Lobular carcinoma in-situ (LCIS)</td>
</tr>
<tr>
<td>No stromal invasion</td>
</tr>
<tr>
<td>Non-infiltrating; Non-invasive</td>
</tr>
<tr>
<td>Squamous intraepithelial neoplasia grade III (SIN III) (excluding cervix and skin sites coded to C44_), 8077/2, dx 01/01/2014 +</td>
</tr>
<tr>
<td>Papillary, non-infiltrating or intraductal</td>
</tr>
<tr>
<td>Pre-invasive</td>
</tr>
</tbody>
</table>

- Site-Specific terms indicating in-situ behavior
<table>
<thead>
<tr>
<th>Site</th>
<th>Terms Indicating In-situ Behavior</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anus (C210-C211)</td>
<td>Anal Intraepithelial Neoplasia grade II (AIN II), 8077/2, dx 01/01/2022 +</td>
</tr>
<tr>
<td></td>
<td>Anal Intraepithelial Neoplasia grade III (AIN III), 8077/2, dx 01/01/2001 +</td>
</tr>
<tr>
<td></td>
<td>High grade squamous intraepithelial lesion (HGSIL or HSIL), 8077/2, dx 01/01/2018 +</td>
</tr>
<tr>
<td>Appendix (C181)</td>
<td>Low-grade appendiceal mucinous neoplasm (LAMN), 8480/2, dx 01/01/2022 +</td>
</tr>
<tr>
<td></td>
<td>High grade appendiceal mucinous neoplasm (HAMN), 8480/2, dx 01/01/2022 +</td>
</tr>
<tr>
<td>Breast (C500-C509)</td>
<td>Ductal Intraepithelial neoplasia grade III (DIN III), 8500/2, dx 01/01/2001 +</td>
</tr>
<tr>
<td></td>
<td>Lobular Intraepithelial neoplasia grade III (LIN III), 8500/2, dx 01/01/2016 +</td>
</tr>
<tr>
<td></td>
<td>Lobular neoplasia grade III (LN III), 8500/2, dx 01/01/2016 +</td>
</tr>
<tr>
<td></td>
<td>Lobular, non-infiltrating</td>
</tr>
<tr>
<td>Breast (C500-C509)</td>
<td>Stage 0 (excluding Paget's disease) confined to lamina propria</td>
</tr>
<tr>
<td>Colon (C180-C189)</td>
<td></td>
</tr>
<tr>
<td>Rectum (C209)</td>
<td></td>
</tr>
<tr>
<td>Gallbladder (C230)</td>
<td>High grade biliary intraepithelial neoplasia grade III (BiIN III), 8148/2, dx 01/01/2018 +</td>
</tr>
<tr>
<td>Larynx (C320-C329)</td>
<td>Laryngeal intraepithelial neoplasia grade III (LIN III), 8077/2, dx 01/01/2001 +</td>
</tr>
<tr>
<td>Pancreas (C250-C259)</td>
<td>Pancreatic intraepithelial neoplasia grade III (PanIN III), 8500/2, dx 01/01/2004 +</td>
</tr>
<tr>
<td>Penis (C600-C609)</td>
<td>Penile intraepithelial neoplasia grade III (PeIN III), 8077/2, dx 01/01/2001 +</td>
</tr>
<tr>
<td></td>
<td>Queyrat's erythroplasia, 8080/2</td>
</tr>
<tr>
<td>Skin (C440-C449)</td>
<td>Clark's level I (melanoma; limited to epithelium)</td>
</tr>
<tr>
<td></td>
<td>Hutchinson's melanotic freckle, not otherwise specified (NOS)</td>
</tr>
<tr>
<td></td>
<td>Lentigo maligna</td>
</tr>
<tr>
<td></td>
<td>Precancerous melanosis</td>
</tr>
<tr>
<td>Stomach and Small Intestine</td>
<td>Intestinal-Type adenoma, high grade, 8144/2, dx 01/01/2022 +</td>
</tr>
<tr>
<td>(C160-C166,</td>
<td>Adenomatous polyp, high grade dysplasia, 8210/2, dx 01/01/2022 +</td>
</tr>
<tr>
<td>C168-C169,</td>
<td>Serrated dysplasia, high grade, 8213/2, dx 01/01/2022 +</td>
</tr>
<tr>
<td>C170-C173,</td>
<td></td>
</tr>
<tr>
<td>C178, C179)</td>
<td></td>
</tr>
<tr>
<td>Vagina (C529)</td>
<td>Vaginal intraepithelial neoplasia grade II (VAIN II), 8077/2, dx 01/01/2022 +</td>
</tr>
<tr>
<td></td>
<td>Vaginal intraepithelial neoplasia grade III (VAIN III), 8077/2, dx 01/01/1992 +</td>
</tr>
<tr>
<td></td>
<td>High grade squamous intraepithelial lesion (HGSIL or HSIL), 8077/2, dx 01/01/2018 +</td>
</tr>
<tr>
<td>Vulva (C510-C519)</td>
<td>Vulvar intraepithelial neoplasia grade II (VIN II), dx 01/01/2022 +</td>
</tr>
<tr>
<td>-------------------</td>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>Vulvar intraepithelial neoplasia grade III (VIN III), 8077/2, dx 01/01/1992 +</td>
</tr>
<tr>
<td></td>
<td>High grade squamous intraepithelial lesion (HGSIL or HSIL) 8077/2, dx 01/01/2018 +</td>
</tr>
</tbody>
</table>

**NOTE:**

**Standard Setter Difference:**
- The CCR reportability date for AIN II, VAIN II, and VIN II is 01/01/2022 and forward. This differs from SEER’s requirement of 01/01/2021 and forward.

The following are reportable diagnoses that are either new or are frequently questioned.

**Reportable diagnoses that are not site-specific:**
- Lymphangioleiomyomatosis, 9173/3, dx 01/01/2023 +
- Malignant perivascular epithelioid cell tumor (PEComa), dx 01/01/2018 +
- Mesothelioma in situ, 9050/2, dx 01/01/2023 +
- Severe or high-grade dysplasia, documented as being synonymous with carcinoma.

**Site-Specific Reportability:**
- * Appendix (C181)
  - Carcinoid Tumors, NOS 8240 with malignant behavior /3, dx 01/01/2015 +
- **Bones, Joints, and Articular Cartilage** (C40-C41)
  - Chondrosarcoma, Grade 1, 9222/1, dx 01/01/2022 +
- **Gastrointestinal stromal tumors (GIST):**
  - All GIST tumors are reportable with a malignant behavior /3 in ICD-O-3.2, 8936/3, dx 01/01/2021 +
- **Hematopoietic and lymphoid neoplasms**
  - All Hematopoietic and lymphoid neoplasms as outlined in the following link: [http://seer.cancer.gov/seertools/hemelymph](http://seer.cancer.gov/seertools/hemelymph) are reportable.
- **Intracranial and/or Central Nervous System**
  - Diffuse leptomeningeal glioneuronal tumor, C71, 9509/3, dx 01/01/2023 +
- High-Grade astrocytoma with Piloid features (HGAP), C71_, 9421/3, dx 01/01/2023 +
- Benign and borderline **Intracranial and/or Central Nervous System** (CNS) tumors, dx 01/01/2001 +
  - Sites C700-C709, C710-C719, C720-C729, C751-C753, behaviors /0 or /1.
  - Diffuse astrocytoma, MYB- or MYBL1algered and diffuse low-grade glioma, MAPK pathway altered, C71_, 9421/1, dx 01/01/2023 +
  - Hemangioma, NOS 9121/0 and cavernous hemangioma, 9121/0.

**Note:** For cavernous sinus hemangioma, code site to C700 cerebral meninges.

- Lhermitte-Duclos disease is synonymous with dysplastic gangliocytoma per WHO classification of CNS tumors, C716, 9493/0, dx 01/01/2018 +
- Multinodular and vacuolating neuronal tumor 9509/0, dx 01/01/2023 +
- Juvenile xanthogranuloma 9749/1, 01/01/2023 + (C715 is the most common site)
- Pilocytic astrocytoma/juvenile pilocytic astrocytoma 9421/1, for all sites, dx 01/01/2023 +

**Standard Setter Differences:**

- CCR reportability date for benign brain tumors is 2001. This included benign schwannoma’s, 9560/0. In 2004, benign brain tumors (including schwannoma’s) became required for collection by SEER and CDC registries as well.
- Juvenile astrocytoma is coded as borderline in ICD-O-3; For dx 01/01/2001 to 12/31/2022 North America registries reported as 9421/3. (Per ICD-O-3 Errata dated 5/22/2001), with the exception of optic nerve (C723) which was reported as 9421/1. Starting with dx 01/01/2023 juvenile astrocytoma for all sites will be reported as 9421/1.

- **Kidney** (C649) – Clear cell papillary renal cell carcinoma, 8323/3, dx 01/01/2022 +
- **Liver** (C220)
  - Report liver cases stated LR-4 or LR-5 based on the American College of Radiology Liver Imaging Reporting and Data System (LI-RADS) definitions.
• **Ovary** (C569)
  - Noninvasive low grade (Micropapillary) serous carcinoma (MPSC) of ovary, dx 01/01/2018 +

  **Notes:**
  1. Assign code 8460/2, applying the ICD-O-3 matrix concept to this non-invasive carcinoma.
  2. Noninvasive can be used as a synonym for in-situ, ICD-O-3 behavior code /2. See page 66 in ICD-O-3.

• **Pancreas** (C250-C259)
  - The following diagnoses became reportable for cases diagnosed 01/01/2015 +
    - Neuroendocrine tumor of the pancreas when the diagnosis is insulinoma, 8240/3 or 8151/3.
    - Cystic pancreatic endocrine neoplasm (CPEN), 8150/3.
    - Cystic pancreatic endocrine specified as neuroendocrine tumor, grades 1 and 2, 8240/3.
    - Solid pseudopapillary neoplasm of pancreas, 8452/3
    - Non-invasive mucinous cystic neoplasm (MCN) of pancreas with high-grade dysplasia, 8470/2.

    **Note:** Term high-grade dysplasia replaces term mucinous cystadenocarcinoma, non-invasive.

• **Pituitary** (C751)
  - Rathke pouch tumor, 9350/1, dx 01/01/2001 +

    **Note:** Rathke cleft cyst and Rathke pouch tumor are different conditions. Rathke cleft cyst is not reportable.

• **Prostate** (C619)
  - Report prostate cases stated PI-RADS 4 or PI-RADS 5 based on the American College of Radiology Prostate Imaging Reporting and Data System (PI-RADS) definitions.

• **Skin** (C440-C449)
  - **Early or evolving melanoma of any type IS reportable prior to 01/01/2018 and became reportable again, dx 01/01/2021 +**

    **Note:** This includes both invasive and in-situ melanomas.
  - Basal and squamous cell carcinoma of the skin of the genital organs (vagina, clitoris, labium, vulva, prepuce, penis, and scrotum).
○ Adnexal carcinomas (e.g., carcinomas of the sweat gland, sebaceous gland, ceruminous gland, and hair follicle), adenocarcinomas, lymphomas, melanomas, sarcomas, and Merkel cell tumors are reportable regardless of site.

○ Any carcinoma arising in a hemorrhoid is reportable since hemorrhoids arise in mucosa, not in skin.

○ Reference Appendix M for a list of Q-Tips which may be related to this topic.

• **Testis** (C620-C629)
  
  ○ Mature teratoma of the testes in adult, 9080/3, dx 01/01/2015 +

  **Notes:**
  1. Adult, defined as post puberty.
  2. Do not report if it is unknown whether patient is pre- or post-pubescence.

• **Thymoma** (C379)
  
  ○ Nearly all thymomas are reportable, behavior /3 in ICD-O-3.2, dx 01/01/2021 +

  **Exceptions:**
  - Microscopic thymoma or thymoma, benign, 8580/0.
  - Micronodular thymoma with lymphoid stroma, 8580/1.
  - Ectopic hamartomatous thymoma, 8587/0.

• **Urine Cytology** - Positive for malignancy, dx 01/01/2013 +

  **Note:** Code to C689 in the absence of any other information.

* **Represents Correction** to reportability in Volume I, based on review of the SEER Program Manual. Registries are not required make changes to previous year cases based on this information.
II.1.1 CCR Reportability Guide - Non-Reportable or Historically Reportable

Refer to the reportability guide below for information on specific histologies and sites for tumors that are either not reportable or historically reportable to the CCR.

Non-Reportable or Historically Reportable Diagnoses:

- **Appendix** (C181)
  - Carcinoid tumors, NOS of the appendix, histology 8240 with borderline behavior /1, became OBsolete beginning 01/01/2015 +

- **Borderline Ovarian** (C569)
  - Histologies 8442/1, 8451/1, 8462/1, 8472/1, and 8473/1, not reportable 01/01/2016 +
    - Reportable with behavior /1 between 01/01/2001 through 12/31/2015.
    - Reportable with behavior /3 before 01/01/2001.

- **Cervix** (C530-C539)
  - Behavior /2 were reportable before 01/01/1996:
    - Carcinoma in-situ of the cervix (CIS) (including squamous cell & adenocarcinoma).
    - Cervical intraepithelial neoplasia grade III (CIN III).
    - Cervical intraepithelial neoplasia with severe dysplasia (CIN III).

- **Gastrointestinal stromal tumors (GIST)**
  - Prior to dx 01/01/2021, GIST was reportable when:
    - Documented as being in-situ.
    - Documented as NOS with multiple foci, lymph node involvement, or metastasis.
    - Patient undergoing treatment as if it is malignant.

- **Liver** (C220)
  - Do not report cases based only on an LI-RADS category LR-3.

- **Lymphoma in-situ**, behavior /2 has always been non-reportable.

- See **Historic – Newly Reportable Hematopoietic Diseases (NRHD)** for cases 01/01/2001 to 01/01/2010.

- **Prostate** (C619)
○ Prostatic intraepithelial neoplasia, grade III (PIN III), 8148/2 has always been non-reportable.

- **Renal Pelvis, ureters, urinary bladder part of urethra** – Papillary urothelial neoplasm of low malignant potential (PUNLMP) are not reportable.

- **Skin** (C440-C449) histologies 8000-8110, has always been non-reportable.
  ○ Basal cell carcinomas of the skin.
  ○ Epithelial carcinomas of the skin.
  ○ Papillary carcinomas of the skin.
  ○ Squamous cell carcinomas of the skin.
  ○ Squamous intraepithelial neoplasia III (8077) arising in the perianal skin (C445), dx 01/01/2018 +
  ○ *Early or evolving melanoma of any type was not reportable if diagnosed between 01/01/2018 – 12/31/2020.*

- **Thyroid** (C739)
  ○ Non-invasive follicular thyroid neoplasm with papillary like nuclear features is a synonym for encapsulated follicular variant of papillary thyroid carcinoma, 8343/2, was reportable if diagnosed between 01/01/2017-12/31/2020.

- **Thymoma** (C379)
  ○ Prior to dx 01/01/2021 thymoma’s were reportable when:
    - Documented as NOS with multiple foci, lymph node involvement, or metastasis.

- **Venous angioma/Venous hemangioma** - Venous angiomas are **not** reportable wherever they arise. The primary site for venous hemangioma arising in the brain is blood vessel (C490). The combination of 9122/0 (Venous hemangioma) and C490 is not reportable.

**Note:** This is a venous abnormality, previously referred to as venous angiomas and currently referred to as developmental venous anomalies (DVA).
II.2 Determining Reportability

Reportable cases are cases that the registry is required to collect and report.

Guidelines:

- Every reporting facility must report all cases, inpatient or outpatient, admitted on or after the regional registry's reference date with a neoplasm classified in the morphology section of ICD-O-3.2 (International Classification of Diseases for Oncology, Third Edition, (2000), Second Revision as malignant or in-situ, including those discovered at an autopsy.
  - The only exceptions are certain carcinomas of the skin. See the CCR Reportability Guide – Reportable.
- Neoplasms described by terms synonymous with in-situ are reportable. See In-Situ Coding for a list of these terms.
- Benign and uncertain behavior intracranial and central nervous system (CNS) tumors became reportable along with newly reportable histologies published in ICD-O-3.2. This applies to cases diagnosed January 1, 2001 and forward.
- Other benign neoplasms are not reportable.
- For a list of reportable and non-reportable neoplasms, refer to the morphology section of ICD-O-3.2.
II.2.1 Identifying the Primary Neoplasm and Single or Multiple Tumors

A primary neoplasm is the original lesion, as compared to a tumor that has developed because of metastasis or extension. A patient might have many lesions that developed from one tumor or different tumors that developed independently.

Coding Instructions:

- For cases or tumors diagnosed January 1, 2018 and forward, refer to the current Solid Tumor Rules Manual.
- Code the primary site to the location of the transplanted organ when a malignancy arises in a transplanted organ. See Appendix A - Terms and Definitions for types of transplants.
- Do not use the Solid Tumor Rules Manual to determine reportability, stage, or to assign grade.
- For hematopoietic and lymphoid cases diagnosed January 1, 2018 and forward, please refer to the SEER Hematopoietic and Lymphoid Neoplasm Database and Hematopoietic & Lymphoid Neoplasm Coding Manual.
- Kaposi's sarcoma, 9140/3 is to be reported only once.
- For additional information on historical manual references, refer to Appendix S - Historical Coding and Staging Manual Requirements for CCR.
II.2.2 Ambiguous Diagnostic Reportable Terms

Physicians sometimes use vague or ambiguous terms to describe a tumor when its behavior is uncertain. This occurs primarily when there is no histologic diagnosis.

The terms listed below are reportable when they are used with a term such as cancer, carcinoma, sarcoma, etc.

**Ambiguous Terms for Reportability**

**Ambiguous Terminology Considered as Diagnostic of Cancer**

*Exception: If the cytology is reported as “suspicious” and neither a positive biopsy nor a physician’s clinical impression supports the cytology findings, do not consider as diagnosis of cancer.*

<table>
<thead>
<tr>
<th>Reportable Terms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apparent(ly) (malignant)</td>
</tr>
<tr>
<td>Appears to</td>
</tr>
<tr>
<td>Comparable with *</td>
</tr>
<tr>
<td>Compatible with (a malignancy) *</td>
</tr>
<tr>
<td>Consistent with (a malignancy)</td>
</tr>
<tr>
<td>Favor (s) (a malignancy)</td>
</tr>
<tr>
<td>Malignant appearing *</td>
</tr>
<tr>
<td>Most likely (malignant)</td>
</tr>
<tr>
<td>Presumed (malignant)</td>
</tr>
<tr>
<td>Probable (malignancy)</td>
</tr>
<tr>
<td>Suspect (ed) (malignancy)</td>
</tr>
<tr>
<td>Suspicious (of malignancy)</td>
</tr>
<tr>
<td>Typical (of/for malignancy)</td>
</tr>
</tbody>
</table>

* Effective for cases diagnosed January 1, 1988 and forward.

**Coding Instructions:**

- Use this list as a reference of last resort.
- The only reportable ambiguous terms are those listed above. Ambiguous terms not on this list would not be considered reportable and should not be abstracted.
- The registrar should determine malignancy from the resources available for all cases where there is a clear statement of malignancy. In those cases, the ambiguous terminology list would not be applicable.
- Ambiguous terms may be located in any source document, such as pathology, operative, radiology, or clinical reports. This does not include tumor marker reports.
- Do not report a case when cytology, biopsy, excision, resection, or physician’s statement proves the ambiguous diagnosis is not reportable.
- Do not substitute synonyms such as “supposed” for “presumed” or “equal” for “comparable.” Do not substitute “likely” for “most likely.”
- There may be other ambiguous modifying words such as “mildly” suspicious. In general, ignore these modifiers and/or adjectives and accept the reportable ambiguous term.
- Report the case when there are reportable and non-reportable ambiguous terms within the medical record.
- Report the case when there is a single report, and it has a reportable term and a term not listed on the reportable list.
- Do not report if the original source document used a non-reportable ambiguous term and later documents refer to a history of cancer.
- If cytology is reported as “suspicious,” Do not interpret this as a diagnosis of cancer. Abstract the case if a positive biopsy or a physician’s clinical impression of cancer supports the cytology findings.
  - FNA “suspicious” for cancer cannot be used for the date of diagnosis without a physician statement or other indication of malignancy.
    - Text must document the physician statement of malignancy referencing the date of the suspicious cytology as date of diagnosis.
    - In the absence of a documented physician statement as outlined above, if an FNA “suspicious” for cancer is followed by a definitive procedure such as a tissue biopsy, surgery, scan or other procedure confirming the cancer, the date of the FNA would be the date of diagnosis.
  - In addition, a cytologically confirmed case with a negative biopsy must be evaluated carefully. If the biopsy rules out the presence of cancer, do not report the case. However, if a negative biopsy does not rule out the presence of cancer, the case is considered to be cytologically confirmed and is reportable. See Diagnostic Confirmation for further information.
  - A urine cytology positive for malignancy is reportable. Report these cases when they are encountered. This is effective with cases diagnosed 1/1/2013 and forward. Do not implement new/additional casefinding methods to capture these cases.
Exception: When a subsequent biopsy of a urinary site is negative, do not report the case.
  o Code the primary site to C689 in the absence of any other information.
  o As always, do not report cytology cases with ambiguous terminology.

Benign and borderline primary intracranial and CNS tumors:
  • Use the above “Ambiguous Terms for Reportability” list to identify benign and borderline primary intracranial and CNS tumors that are reportable.
  • If any of the reportable ambiguous terms precede either the word "tumor" or the word "neoplasm," report the case.
II.2.3 Pathology and Consultation Only Cases
Abstract reporting by facilities is not mandatory for reportable cases diagnosed by the pathology department based on slides or specimens submitted from outside the reporting facility and cases seen for consultation only. However, the facility must notify the regional registry about these types of cases in order to verify that all reportable cases in the population have been recorded.

It is sometimes difficult to identify a consultation only case, especially at a large teaching facility. As a guideline, the CCR recommends determination of who is ultimately responsible for treatment decisions and follow-up of the patient.

Coding Instructions:

- Consult Only abstract required: If the consulting facility is responsible for treatment decisions or follow-up, an abstract is required.
- Consult Only abstract not required: If the consulting facility is confirming a diagnosis made elsewhere, rendering a second opinion, or recommending treatment to be delivered, the regional registry must be notified.

Note: When in doubt about whether to report the case, contact your regional registry for guidance.
## II.2.4 Hematopoietic and Lymphoid Neoplasm

Reportable hematopoietic diseases diagnosed January 1, 2010 and forward, use the current Hematopoietic Database and Manual to abstract hematopoietic cases.

- Database: [https://seer.cancer.gov/seertools/hemelymph](https://seer.cancer.gov/seertools/hemelymph)

### Lymphatic & Hematopoietic Diseases – Subsequent Diagnoses

- For reportability rules of hematopoietic and lymphoid neoplasms, refer to the [Hematopoietic and Lymphoid Neoplasm Database and Coding Manual](https://seer.cancer.gov/seertools/hemelymph).

## Date of Diagnosis-Year

<table>
<thead>
<tr>
<th>1st Primary</th>
<th>2nd primary</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior to 2001</td>
<td>Prior to 2001</td>
<td>SEER Hematopoietic Manual &amp; Database</td>
</tr>
<tr>
<td>2010</td>
<td>2010</td>
<td>SEER Hematopoietic Manual &amp; Database</td>
</tr>
<tr>
<td>Prior to 2010</td>
<td>2010</td>
<td>SEER Hematopoietic Manual &amp; Database</td>
</tr>
</tbody>
</table>
II.2.5 Benign/Borderline Brain and CNS Tumors

In determining whether a Benign/Borderline Brain and CNS are reportable, the basic criterion is a diagnosis of cancer by a physician, surgeon, or dentist, even if it is not pathologically confirmed.

Reportability:

**Standard Setter Difference**

- Reportability dates for Benign/Borderline Brain and CNS Tumors.
  - California Cancer Registry began collecting the following cases January 1, 2001 and forward.
    - Benign Schwannoma:
      - Reportable for cases diagnosed January 1, 2004 and forward for sites C722-C725.
      - Expanded for cases diagnosed January 1, 2011 and forward to include site C720.
    - National implementation began with cases diagnosed on January 1, 2004 and forward.
      - In 2002, Public Law 107-260 required the National Program of Cancer Registries (NPCR) to expand their primary brain tumor data collection to include tumors of benign and uncertain behavior. This began with cases diagnosed January 1, 2004 and forward.
  - Any tumor with a behavior code of /0 or /1 will be collected for the following site codes based on ICD-O-3:
    - C700-C709 Meninges
    - C710-C719 Brain
    - C720-C720 Spinal Cord, Cranial Nerves, and Other Parts of Central Nervous System * (above)
    - C721 Cauda equina
    - C751 Pituitary gland
    - C752 Craniopharyngeal duct
    - C753 Pineal gland
  - Juvenile astrocytomas/pilocytic astrocytomas should continue to be reported as 9421/3 when the primary site is C71_.

**Exception:** The behavior is non-malignant when the primary site is optic nerve, C723.

- Only benign brain tumor cases with a diagnosis year of 2001 forward are required to be reported to the CCR.
Guidelines:

- For vague and ambiguous diagnostic terms, see [Ambiguous Diagnostic Reportable Terms](#).
- A positive pathology report takes precedence over any other report or statement in a patient's chart.
- In case of doubt about the reportability of a tumor, contact the reporting facility's regional registry for advice.
- Do not report benign brain tumor cases with an unknown year of diagnosis, unless it is known that the year of diagnosis is 2001 forward. Apply the rules under the [Vague Dates](#) section to determine a date of diagnosis if it is known that the benign brain case was diagnosed after 2001.

Reportable Terminology

- To be reportable, there must be a corresponding ICD-O-3 histology code for any CNS tumor related diagnosis.
  - The terms "tumor" and "neoplasm" are diagnostic and reportable for non-malignant brain and CNS primaries.
  - The terms "mass" and "lesion" are not reportable for non-malignant brain and CNS primaries, but may be used for initial casefinding purposes.
  - The terms "hypodense mass" or "cystic neoplasm" are not reportable even for CNS tumors.

Benign Schwannoma * (above)

- Per SEER instruction, we are to report Benign Schwannomas (9560/0) of the spinal cord (C720) and of the cranial nerves (C722 - C725); therefore, these are both reportable to the CCR. Benign Schwannomas occurring anywhere else such as the peripheral nerves or peripheral nerve roots are not reportable to the CCR.
- Report spinal (Schwannoma) tumors (C720) when the tumor arises within the spinal dura or spinal nerve roots, or when they are stated to be “intradural” or “of the nerve root.” Do not report tumors that arise in peripheral nerves. Peripheral nerves are the portion of the nerve extending beyond the spinal dura.
- The cranial nerves (C722 – C725) are composed of twelve pairs of nerves that emanate from the nervous tissue of the brain. Cranial nerves are sometimes referred to by their number, such as the 8th cranial nerve, instead of the vestibulocochlear nerve.
To assist registrars with identifying reportable benign Schwannoma tumors, the cranial nerve numbers, names and their ICD-O-3 topography codes are listed below:

<table>
<thead>
<tr>
<th>Cranial Nerve Description</th>
<th>Associated ICD-O-3 Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Olfactory (C722)</td>
</tr>
<tr>
<td>II</td>
<td>Optic (C723)</td>
</tr>
<tr>
<td>III</td>
<td>Oculomotor (C725)</td>
</tr>
<tr>
<td>IV</td>
<td>Trochlear (C725)</td>
</tr>
<tr>
<td>V</td>
<td>Trigeminal (C725)</td>
</tr>
<tr>
<td>VI</td>
<td>Abducens (C725)</td>
</tr>
<tr>
<td>VII</td>
<td>Facial (C725)</td>
</tr>
<tr>
<td>VIII</td>
<td>Vestibulocochlear (auditory and vestibular nerve, acoustic nerve) (C724)</td>
</tr>
<tr>
<td>IX</td>
<td>Glossopharyngeal (C725)</td>
</tr>
<tr>
<td>X</td>
<td>Vagus (C725)</td>
</tr>
<tr>
<td>XI</td>
<td>Accessory (C725)</td>
</tr>
<tr>
<td>XII</td>
<td>Hypoglossal (C725)</td>
</tr>
</tbody>
</table>

**Example of a reportable Schwannoma:** Vestibular Schwannoma, also known as acoustic neuroma (C724 M-9560/0).

**Note:** Registrars are not expected to go back, and review Schwannoma cases already submitted to the CCR.

**References:** SEER and CDC.

For historical information, see: [Data Collection of Primary Central Nervous System Tumors](#).
II.2.5.1 Date of Diagnosis for Benign/Borderline Brain and CNS Tumors

As the CCR began reporting benign brain and CNS tumors prior to national reporting implementation, there are two sets of rules for establishing the Date of Diagnosis for benign and malignant brain tumors.

Coding Instructions:

- Record the date a recognized medical practitioner states the patient has a reportable tumor, whether that diagnosis was made clinically or pathologically. If a clinical diagnosis, do not change the date of diagnosis/when there is a subsequent tissue diagnosis. This pertains to cases diagnosed January 1, 2004 and forward.

- For non-analytic cases (Class of Case 30-99): All attempts should be made to determine or estimate the date/year of diagnosis.
  - If no information about the date or at least year of diagnosis is available:
    - Use the date of admission /1st contact and apply the applicable coding instructions.

  **Example:** A CT scan done 4/1/20 states brain tumor. The patient has surgery on 4/5/20 and a biopsy reveal an astrocytoma. The date of diagnosis is 4/1/20.

- Use the most definitive source of diagnostic confirmation as the date of diagnosis. This pertains to cases diagnosed January 1, 2001 to December 31, 2003.

  **Example:** A CT scan done 2/1/20 states brain tumor. The patient has surgery on 2/5/20 and a biopsy reveal an astrocytoma. The date of diagnosis is 2/5/20.
II.2.5.2 Malignant Transformation - Brain and CNS Tumors
Malignant transformation occurs when a benign or borderline tumor transforms into a malignancy.

Coding Instructions:
- Create a new case abstract when a benign or borderline tumor transforms into a malignancy.
  - For cases or tumors diagnosed January 1, 2018 and forward, refer to the current Solid Tumor Rules Manual.
- Do not create a second abstract and do not change the original histology code when a benign tumor transforms to a borderline tumor.
II.2.5.3 WHO Grade – Benign/Borderline Brain and CNS Tumors

CNS WHO classifications use a grading scheme that is a “malignancy scale” ranging across a wide variety of neoplasms, rather than a strict histologic microscopic grading system, that can be applied equally to all tumor types. The WHO Grade is collected for reportable non-malignant Brain and CNS tumors in the Grade data items.

Guidelines:

- **WHO Classifications:**
  - WHO Grade I generally describe non-malignant or benign tumors.
  - WHO Grade II generally describes a malignant tumor, but it can describe a non-malignant tumor depending on histologic type.
    - Refer to the most current **Solid Tumor Rules: Non-Malignant CNS Tumors “Section 1: Behavior Code”** to determine whether WHO Grade 2 neoplasms are non-malignant or malignant. Use the appropriate set of rules.
  - WHO Grade III and IV describe malignant tumors.

Coding Instructions:

- Refer to the most current **Grade Coding Instructions and Tables** for coding instructions.

- When the WHO Grade is not documented for reportable non-malignant Brain and CNS tumors, refer to the following:
  - The WHO Grading system for selected tumors of the CNS as noted in the **AJCC Chapter 72, Brain and Spinal Cord, Table 72.2**.
  - The **Solid Tumor Rules: Non-Malignant CNS Tumors “WHO Grades of Select CNS Neoplasms.”**

- If the histology for a reportable non-malignant Brain or CNS tumor is not listed in AJCC Table 72.2, or the Non-Malignant CNS Solid Tumor Rules Table 1, code Grade to 9.

For historical information, see: **Data Collection of Primary Central Nervous System Tumors.**
II.3 Abstracting - Accession and Sequence Number

Each patient in a reporting facility's cancer registry is identified by a permanent nine-digit accession number and each of the patient's primary tumors is identified by a different two-digit sequence number. The accession number remains the same in every abstract prepared by the reporting facility for the patient, but the sequence number is different for each new tumor.
II.3.1 Year First Seen
Year first seen is the year the patient was first seen for this reportable primary.

Coding Instructions:
- Enter the four-digit year during which the patient was first seen at the reporting facility for diagnosis or treatment of the neoplasm reported in this abstract. For patients seen at the end of the year, use the year of diagnosis as the year first seen for this primary.

Example: A patient is admitted to the reporting facility in December 2019 and is diagnosed in January 2020. Assign 2020 as the year first seen for this primary.
II.3.2 Accession Number
This data item identifies the patient and the tumor. Each patient entered in a reporting facility registry is assigned a unique accession number, and each primary diagnosed for that patient is assigned a sequence number. The accession number never changes and is never reassigned, even if a patient is removed from the registry. The accession number may be auto generated by some abstracting vendors.

Coding Instructions:
- The first four digits of the accession number represent the year the patient was first seen at the reporting facility. See Year First Seen.
- The last five digits represent the approximate chronological order of the abstracts prepared for that year.
- Each facility abstract must contain an accession number and each patient can only have one accession number.
  - Check to see if there is an accession number already assigned to the patient, then use that number when it is available.
  - Assign an accession number only when the patient did not have one assigned previously.

Examples:
1. If the patient was admitted or the tumor was diagnosed on February 11, 2020, the first four digits are 2020. If the abstract for the reported tumor was the 285th prepared for 2020, the accession number is 202000285.

2. Two abstracts are being prepared for a patient with one primary tumor diagnosed in 2016 and another in 2020. The first four digits of the accession number are 2016 and the next five represent the abstract's place in the chronological order of cases reported for 2016. The same accession number must be used for the second and subsequent abstracts. (However, the year first seen for the first tumor is 2016 and for the second it is 2020).
II.3.3 Sequence Number

Sequence refers to the chronological position of a patient's primary tumor among all the reportable tumors occurring during the patient's lifetime, whether they exist at the same or separate times and whether or not they are entered in the reporting facility's registry.

Coding Instructions:

- If two or more reportable neoplasms are diagnosed at the same time, the lowest sequence number is assigned to the diagnosis with the worst prognosis.
  
  Example: A patient's medical record shows a history of three primary malignant (reportable) tumors in the past and two simultaneously diagnosed recent malignant tumors, one of which is the subject of this report, for a total of five malignancies. The stage of the tumor being reported is regional, whereas the stage of the second of the multiple tumors is localized, a better prognosis. Assign sequence number 04 to the tumor being reported. The number for the second multiple primary is 05.

- If more tumors are diagnosed before the report is submitted, the sequence number must be updated if it was originally coded as 00 or 60, designating a single tumor.

- If no difference in prognosis is evident, the decision is arbitrary.

- Use numeric sequence codes in the range of 00-35 to indicate reportable neoplasms of malignant or in-situ behavior. Cases of juvenile astrocytomas, diagnosed prior to 01/01/2001, but entered after 01/01/2003 also use a sequence code in the 00-35 range. This applies to cases diagnosed 01/01/2003 to 12/31/2022. Starting with dx 01/01/2023 juvenile astrocytoma will be reported as 9421/1 and therefore should be assigned a sequence number in the range 60-87 (see next bullet).

- A primary, non-malignant tumor of brain or CNS sites diagnosed on or after 01/01/2001 is reportable.
  
  o Sequence numbers must be in the range of 60-87

- Sequencing of non-malignant tumors does not affect sequencing of malignant tumors and vice versa.
  
  o A malignancy (sequence 00) will remain as 00 even if followed by a non-malignant tumor (sequence 60-87)

  Example: First tumor, benign meningioma, sequence 60. Second tumor, astrocytoma, sequence 00.

- For Newly Reportable Hematopoietic Diseases (NRHD):
  
  o If the original hematopoietic disease was not reportable at the time of diagnosis, do not include it in the sequencing.
**Note:** Alphabetic sequence codes are no longer allowed.

- In the remarks area, record the following information regarding subsequent reportable tumors/primary sites:
  - Enter the tumor # (first, second, third primary in relation to this one).
  - Name of site
  - Histology, and
  - Diagnosis date

**Example:** You currently abstract a breast case however the patient had a previous squamous cell cancer of the lung diagnosed January 20, 2015. Your text should state: #1 – Lt Lung SCC, dx – 1/20/2015.

### Codes for Tumors with Invasive and In-situ Behavior:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>One primary malignancy</td>
</tr>
<tr>
<td>01</td>
<td>First of two or more primaries</td>
</tr>
<tr>
<td>02</td>
<td>Second of two or more primaries</td>
</tr>
<tr>
<td>59</td>
<td>59th or higher of 59 or more primaries</td>
</tr>
<tr>
<td>99</td>
<td>Unspecified in-situ / invasive sequence number or unknown</td>
</tr>
</tbody>
</table>

### Codes for Benign and Uncertain Behavior CNS Tumors and Cases Reportable by Agreement:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>60</td>
<td>One benign or borderline tumor reportable by agreement</td>
</tr>
<tr>
<td>61</td>
<td>1st of 2 or more benign or borderline tumors</td>
</tr>
<tr>
<td>62</td>
<td>2nd of 2 or more benign or borderline tumors</td>
</tr>
<tr>
<td>87</td>
<td>27th of 27 or more tumors</td>
</tr>
<tr>
<td>88</td>
<td>Unspecified benign, borderline, tumor of uncertain behavior and reportable by agreement Sequence number</td>
</tr>
</tbody>
</table>
II.3.4 Other Tumors/Primitives
In the Text-Remarks data item, record other reportable tumors/primary sites that the patient has now or has had.

Coding Instruction:
- In the Text-Remarks area, record the following information regarding subsequent reportable tumors/primary sites:
  - Enter the tumor # (First, second, third primary in relation to this one).
  - Name of Site
  - Histology, and
  - Diagnosis date

Example: You currently abstract a breast case however the patient had a previous squamous cell cancer of the lung diagnosed January 20, 2015. Your text should state: #1 – Lt Lung SCC, dx – 1/20/2015.
Part III. Identification

Part III of Volume I is comprised of the sub-sections identifying the registry, the patient, and the case. Included in each subsection are detailed instructions on coding facility specific items, patient demographics, and case specific items such as date of diagnosis or Class of Case, to name a couple.
III.1 Registry Information
This includes reporting facility specific data items such as the reporting facility identification number, abstractor, and ACS approval flag data items. The information is used by the reporting facility and regional registries for facility specific identification purposes.
III.1.1 Abstractor
Enter the abstractor's initials, beginning in the left most space. If there are fewer than three initials, leave the trailing spaces blank.

Coding Instructions:

- Each reporting facility must submit a list of names and initials of all abstractors in their facility, including temporary staff beginning in January 2007.

- Changes to this list must be submitted to the region when specified abstractors no longer create abstracts at the facility, or when new abstractors are added.
III.1.2 Reporting Facility
Enter the reporting facility's CCR assigned reporting facility code or the facility's name.

Coding Instructions:

- Refer to the most current California Reporting Facility Codes lists, located on the CCR website https://www.ccrcal.org, Registrar Resources, Reporting Cancer in California, Volumes I-IV.
  - Lists are presented in both alphabetical and code order.
III.1.3 CoC Accredited Flag
The CoC Accredited Flag is assigned at the point and time of data abstraction to label an abstract being prepared for an analytic cancer case at a facility accredited by the Commission on Cancer (CoC). This data item is required by the CCR for cases diagnosed January 1, 2018 and forward.

Coding Instructions:
- Hospital Registries:
  - Assign the code that reflects the CoC accreditation at the time the case is abstracted.
  - The flag may be defaulted by the registry’s software or manually entered by the abstractor.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Abstract prepared at a facility WITHOUT CoC accreditation of its cancer program</td>
</tr>
<tr>
<td>1</td>
<td>ANALYTIC abstract prepared at facility WITH CoC accreditation of its cancer program (Includes Class of Case codes 10-22)</td>
</tr>
<tr>
<td>2</td>
<td>NON-ANALYTIC abstract prepared at facility WITH CoC accreditation of its cancer program (Includes Class of Case codes 30-43 and 99, plus code 00 which CoC considers analytic but does not require to be staged)</td>
</tr>
<tr>
<td>BLANK</td>
<td>Not applicable; Death Certificate Only (DCO)</td>
</tr>
</tbody>
</table>
III.2 Patient Information
This section contains instructions on how to collect patient specific demographic information.
III.2.1 Name

Follow the guidelines below for entering the patient’s name. Accurate patient information is important for matching data in the abstract with data about the patient received from other sources.

Reporting facilities must use the same rules for entering names, dates, and other information. Although reporting facility systems may have different name-related data entry requirements, the CCR requires the following information and formatting for patient name.

Coding Instructions:

- Enter the patient's last name, first name, middle name, birth surname (formerly known as maiden name), and any known alias.
- For entering alias names see, Entering Names.
- Begin at the far left of each data item.
- Avoid using only uppercase/capitals.
- Spaces, hyphens and apostrophes are allowed. Do not use any other punctuation.
- Example: A patient with the name "St. James" should be entered in either one of the following ways:
  - St James
  - St-James
  - St’James
  - Saint James
- However, you choose to enter the name, with a space, hyphen, apostrophes, or spelled out, all efforts should be made to keep all similar name entries consistent.
- Do not enter the gender or marital status-Mr., Mrs., Miss, Ms.-or similar forms of address in other languages before the name. For religious order names, see Religious Names.
- Spell out abbreviated names (e.g., Robt. = Robert).
- If the patient is a child under the age of 18, living with his/her parent(s) or guardian(s), record the name(s) of the parent(s) or guardian(s) in the Text-Remarks data item.
III.2.1.1 Entering Names
The patient's name is used by reporting facilities as a patient identifier.

Coding Instructions:

- Each name data item is 40 characters in length.
  - If more than 40 characters, enter only the first 40.
  - Spaces, hyphens and apostrophes are allowed.
  - Do not use other punctuation.

- Last Name
  - Enter the patient's entire last name.
  - If the patient has no last name, enter NLN (Examples: Prince or Madonna).
  - If the name cannot be determined or is unknown, enter “UNKNOWN” or “Unknown.”
  - If a patient's last name has changed, enter the current last name in the Last Name data item and move the original name to the Alias Name data item.

- Birth Surname
  - Enter the name given at birth, regardless of sex if it is known, even if it has been entered in the Last Name data item.
  - Note: Birth Surname, is a gender-neutral replacement for the maiden name data item.
  - Leave the data item blank if birth surname is not known or is not applicable.

- Alias Last Name
  - An alias (also known as, or AKA) surname used by the patient, certain religious order names (See Religious Names), or the first part of a Chinese name that might appear as a last name on another report. (For example, Sun Yat sen might appear elsewhere as Sun, Yat sen or Yat sen Sun).
  - The spelled-out version of a name containing the word Saint.
  - Leave the data item blank if there is no alias last name.
  - Do not enter a birth surname in the Alias Last Name data item.

- First Name
  - Enter the patient's entire first name.
If a woman uses her husband's full name (e.g., Mrs. John Smith), try to learn her first name.

- If the patient has no first name, enter NFN.
- If the name cannot be determined or is unknown, enter “UNKNOWN” or “Unknown.”

**Note:** CCR coding instructions for unknown first name differs from SEER and CoC. For this data item, CCR follows the NPCR coding instructions to pass NPCR submission edits.

- If the patient's first name is not a common male or female name or it is ambiguous with regard to gender, include a statement in the Text-Remarks data item confirming the patient's gender.

**• Alias First Name**
- Enter the alias (also known as, or AKA) first name used by the patient.
- Leave the data item blank if there is no alias first name.

**• Middle Name**
- Enter the patient's middle name or middle initial.
- Leave the space blank if there is no middle name or initial or if it is not known.
III.2.1.2 Religious Names
Please use the following instructions when entering religious names.

Coding Instructions:

- Do not enter religious designations like Sister, Brother, or Father unless the patient's secular name is unknown.
- If the secular name is known, enter the last name of the religious name under *Alias Last Name* data item.
- When the religious name only is known, enter the last name under Last Name, the designation under First Name, and the religious first name under Middle Name.

Examples:

1. Religious name: Sister Mary Anthony and Secular name: Jane Smith
   Report as:
   (last name) Smith
   (first name) Jane
   (alias) Anthony

2. Religious name: Sister Mary Anthony and secular name: Smith (first name unknown)
   Report as:
   (last name) Smith
   (first name) Sister
   (alias) Anthony

3. Religious name: Sister Mary Anthony and secular name: unknown
   Report as:
   (last name) Anthony
   (first name) Sister
   (middle name) Mary
III.2.1.3 Name Suffix
A name suffix is a title that would follow the name in a letter such as Jr, Sr, III, or IV. It is frequently a generation identifier. It helps to distinguish between patients with the same name.

**Coding Instructions:**
- Do not use punctuation.
- Leave blank if the patient does not have a name suffix.
- Do not use this data item to record suffixes such as MD or PhD.
III.2.1.4 Mother’s First Name
Enter the pediatric patient’s mother’s first name in this data item.

Coding Instructions:
- Enter up to 40 characters in the Mother’s First Name data item.
- Include the hyphen or apostrophe in a name, but do not enter any other non-alphabetic characters.
- If this name is not available, this data item may be left blank.
III.2.2 Medical Record Number

Enter the medical record number assigned to the patient at the reporting facility. For facilities using a serial numbering system, enter the latest number assigned at the time of abstracting (This will not be updated).

Coding Instructions:

- Medical record numbers can be alphanumeric.
- Do not use punctuation or leave a blank space. Enter leading zeroes that are part of the number.
- If a patient has not been assigned a medical record number at the time the abstract is prepared, certain other identifying numbers may be entered.

Examples:

1. Some facilities enter the log number assigned by the radiation therapy department, preceded by the letters RT, for patients who do not have a medical record number but are receiving radiation therapy.

2. For outpatients who are not admitted and not seen in the radiation therapy department, the assigned number can be preceded with the letters OP.

3. If a number is not assigned, enter a code meaningful to the facility. This data item should not be left blank.
III.2.3 Social Security Number

A patient's full social security number is critical for the identification of multiple reports of the same cancer so that they are not counted as separate cases.

Coding Instructions:

Two data items are provided:

- **Nine-character data item for the number:**
  
  - Enter the patient's 9-digit social security number (SSN).
  
  - Make every effort to ascertain the patient's own number. Enter it and its suffix in the data items provided.
  
  - If the patient's own number cannot be determined, enter whatever number (including its suffix) available from the medical record.
  
  - Do not combine the suffix from one number with a different number.
  
  - If the social security number is not known, enter 9’s.
  
  - Military facilities use the sponsor's social security number plus a numeric prefix as the clinic number or Medical Record Number. Disregard such a number when entering the social security number and suffix, but enter it in the **Medical Record Number** data item when appropriate.
  
  - The following values are not allowed:
    
    - First three digits cannot be 000 or 666
    
    - Fourth and fifth digits cannot be 00
    
    - Last four digits cannot be 0000
    
    - First digit cannot be 9 (except for 999999999)

**Examples:**

1. Social security number from face sheet: 111-22-3333
   Medicare claim number: 123-45-6789B
   Enter 111-22-3333

2. Social security number from face sheet: 222-33-4444D5
   No other numbers recorded in chart
   Enter 222-33-4444D5

3. Social security number from face sheet: not recorded
   Clinic record number at Air Force facility: 30-333-44-5555
   Enter 999-99-9999
• **Two-character data item for a suffix:**
  
  o The suffix for a patient's social security number was historically used to show the relationship of the patient to the bearer of the SSN entered (e.g. spouse).
  
  o If the suffix is only one character, leave a trailing blank space in the *Suffix* data item.
  
  o A Medicare claim number with a suffix indicating the patient's relationship to the wage earner or primary beneficiary/claimant, or both. (The suffix A, for example, indicates that the patient is the wage earner or primary beneficiary/claimant, and the social security number is the patient's).
  
  o When there is no suffix, leave the two-character data item blank.
III.2.4 Medicare Beneficiary Identifier (MBI)

Enter the Medicare Beneficiary Identifier assigned to the patient. The MBI is a randomly generated identifier that does not include a SSN or any personal identifiable information. The MBI is a step to minimize the risk of identity theft for Medicare beneficiaries and to reduce opportunities for fraud. The Medicare Beneficiary Identifier is required if available by the CCR (if the information is available to you for abstracting, it is required) for cases diagnosed January 1, 2018 and forward.

Coding Instructions:

- Enter the 11-character Medicare Beneficiary Identifier randomly assigned to the patient by Medicare.
- The Medicare Beneficiary Identifier:
  - Consists of numbers and upper-case letters.
  - Entered without dashes.

Codes (in addition to MBI):

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLANK</td>
<td>Not Available, Non-Medicare Patient, Not Applicable, or Unknown</td>
</tr>
</tbody>
</table>
III.2.5 Phone Number (Patient)
This data item is to be used for entering the patient's current telephone number including the area code.

Coding Instructions:
- Update this data item with the most current telephone number, when follow-up indicates that the telephone number has been changed.
- Enter all 0's, if there is no phone.
- Enter all 9’s, if the phone number is unknown.
III.2.6 Address at Diagnosis

The Address at Diagnosis data item is part of the patient’s demographic data and has multiple uses. It indicates referral patterns and allows for the analysis of cancer cluster concerns and other epidemiological studies. The main purpose of the address data item is to identify the patient's residence at the time the cancer was first diagnosed, not the patient's current address.

- Every effort should be made to determine the correct address.
- Rules for determining residency are based on those used by the U.S. Department of Commerce for the 1990 Census of Population.
- It is important to follow the rules exactly, because the Central Registry uses automated data processing methods that reject non-standard entries. The data are used for grouping cases by geographic area.

Coding Instructions:

- Enter the address of the patient's usual residence on the date of the initial diagnosis. See, Date of Diagnosis for definition of date of diagnosis.
- Usual residence is where the patient lives and sleeps most of the time and is not necessarily the same as the legal or voting residence.
- Do not record a temporary address, such as a friends or relatives.
- If both a street address and a P.O. Box are given, use the street address.
- For military personnel and their families living on base, the address is that of the base. For personnel living off base, use the residence address. For details about military personnel assigned to ships and about crews of merchant vessels, see Appendix D - Residency of Military Personnel.
- Address is that of the institution for the following:
  - Incarcerated individuals
  - Nursing home, convalescent or rest home patients
  - Physically handicapped, mentally challenged or mentally ill residents of homes, schools, hospitals or wards
  - Long-term residents of other hospitals such as Veterans Administration (VA) hospitals
- Use the current address of a college student. However, for children in boarding schools below the college level enter the parents' address.
- If the case is non-analytic (See, Class of Case for criteria), use the address at admission unless there is a documented reason to suspect that the patient resided elsewhere at the time of diagnosis. If there is such an indication, record what is known of the address at diagnosis.
- If the patient is homeless or transient with no usual residence:
- Enter the street, city and zip code as unknown but code county of residence to the county where the reporting facility is located and code the state to California.
- Document that the patient is “Homeless” or “Transient” in the Address at Diagnosis – Supplemental data item.

**Note:** Coding address information for homeless/transient patients in this manner is important from a research perspective. Attempting to code otherwise would be incorrect in California and would skew cluster investigations.

- Persons with more than one residence (snowbirds) are considered residents of the place they designate as their residence at the time of diagnosis if their usual residence cannot be determined.
III.2.6.1 Number and Street at DX
Enter the patient’s street number and street name at diagnosis.

Coding Instructions:

- Use up to 60 characters for the street address.
- The allowable character values that may be entered are:
  - Letters
  - Numbers
  - Spaces
  - The only special characters allowed are:
    - Number symbol (#)
    - Slash (/)
    - Hyphen (-)
    - Period (.)
- House numbers must precede the street name.
- Insert a single space between each component in the street address (e.g., "NEW MONTGOMERY STREET").
- Direction (e.g., North, West) and street types (e.g., Avenue, Road) may be abbreviated (e.g., N MAIN ST). However, do not abbreviate a direction that is the name of a street (e.g., 123 NORTH ST).
- Use intersection addresses (e.g., "FOURTH AND MAIN"), post office box numbers, and building names (e.g., "HOTEL NEW HAMPSHIRE") only if an exact address is not available in the medical record, business office, or elsewhere.
- Place a unit designation directly after the house number (e.g., "139A MAIN ST") or after the street name (e.g., "106 CHURCH STREET 1ST FLOOR," "36 EASTERN CIRCLE APT A").
- If the address contains more than 60 characters, omit the least essential elements, such as the apartment or space number.
  - Do not omit elements needed to locate the address in a census tract, such as house number, street, direction or quadrant, and street type.
- Abbreviate as needed, using the standard address abbreviations listed in the List of Acronyms/Abbreviations published by the U.S. Postal Service.
- If the address cannot be determined, enter the word "UNKNOWN."
- The Address at Diagnosis - Supplemental data item provides the ability to record additional address information such as the name of a place or
facility (i.e., a nursing home or name of an apartment complex) at the time of diagnosis.

- If the patient is stated to be “Homeless” or “Transient,” enter “HOMELESS” or “TRANSIENT” in this data item.
- Use up to 60 characters for this data item.
- If the patient has multiple tumors, the address may be different for subsequent primaries.
- Do not update this data item if the patient's address changes.
III.2.6.2 City at DX

Enter the patient’s city of residence.

Coding Instructions:

- Keep spaces in names consisting of more than one word, but do not use punctuation (e.g., "LOS ANGELES," "SAN FRANCISCO," "ST PAUL"). A maximum of 50 characters and spaces.
- If a patient's usual place of residence at the time of diagnosis was in a foreign country, enter the name of the city in the foreign country.
- Enter the word "UNKNOWN" if the city where the patient lived cannot be determined.
III.2.6.3 State at DX

The *State at Diagnosis* data item identifies the patient's state of residence at time of diagnosis.

**Coding Instructions:**

- For states in the U.S. and provinces in Canada, enter the standard two-letter Postal Service abbreviation.
  
  **Example:** California is CA

- For other states, U.S. Territories and Canadian provinces see, Appendix B - Postal Abbreviations for States and Territories of the United States.

- If the patient is a foreign resident, then code either XX or YY depending on the circumstance.

**Guidelines:**

- Use U.S. Postal Service abbreviations for the state, territory, commonwealth, U.S. possession, or Canadian province or territory in which the patient resides at the time the tumor is diagnosed and treated.

- If the patient has multiple tumors, the state of residence may be different for subsequent primaries.

- Do not update this data item if the patient's state or residence changes.


III.2.6.4 ZIP at DX
The data item Zip at DX identifies the postal code of the patient’s address at diagnosis.

Coding Instructions:

- Enter the five-digit or nine-digit U.S. postal zip code or the proper postal code for any other country.
  - When entering only five digits, leave the last spaces blank.
- Enter 8's in the entire data item, if the patient resided outside the U.S. or Canada at time of diagnosis and the zip code is unknown.
- To obtain an unknown zip code, consult the U.S. Postal Service National Zip Code and Post Office Directory, published by the U.S. Postal Service, or phone the local post office.
- If the code cannot be determined and it is a U.S. or Canadian resident, enter 9's in the entire data item.
III.2.6.5 County at DX

*County at DX* data item documents the county the patient lived in at the time of diagnosis.

**Coding Instructions:**

- For California residents, enter the code for the county of residence at the time of diagnosis. Some abstracting software will automatically enter the code if the county name is entered.
- Consult maps or reference works as needed to determine the correct county. If your software vendor provides FIPS codes for this data item, see Appendix H.1 and H.2 for code conversions.
- Required California county codes in Alpha or Numerical order can be accessed in the links below:
  - [Appendix H - Codes for California Counties](#)
- For foreign residents, enter the country of residence in this data item. This information will also be captured in the *Address at Diagnosis - Country* data item (see Country at DX).
- Enter code CAN for Canada, NOS, or the specific code for the known Canadian province.
  - Canadian province codes are listed in [Appendix B - Postal Abbreviations for States and Territories of the United States](#).
- For non-United States, use the country of residence.
  - [Appendix C - Codes for Countries](#).
III.2.6.6 Country at DX

*Country at DX* data item documents the country the patient lived in at the time of diagnosis.

**Coding Instructions:**

- Enter the three-digit Country code for the country in which the patient lived at the time of cancer diagnosis.
- Blanks are not allowed for this data item.
- [Appendix C](#) - Codes for Countries.
**III.2.7 Marital Status**

Incidence of cancer and sites of cancer have shown correlations to marital status. These patterns are also different among races. Thus, this data item is very important to researchers for the reportable neoplasm.

**Definition:**

Common Law Marriage: A couple living together for a period of time and declaring themselves as married to friends, family, and the community, having never gone through a formal ceremony or obtained a marriage license.

**Coding Instruction:**

- Report the patient’s marital status at the time of first diagnosis for the reportable neoplasm.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Single (never married, including only marriage annulled)</td>
</tr>
<tr>
<td>2</td>
<td>Married (including common law)</td>
</tr>
<tr>
<td>3</td>
<td>Separated</td>
</tr>
<tr>
<td>4</td>
<td>Divorced</td>
</tr>
<tr>
<td>5</td>
<td>Widowed</td>
</tr>
<tr>
<td>6</td>
<td>Unmarried or Domestic Partner (same sex or opposite sex, registered or unregistered, NOT including common law)</td>
</tr>
<tr>
<td>9</td>
<td>Unknown</td>
</tr>
</tbody>
</table>
III.2.8 Sex
This data item documents the sex (gender) of the patient.

Definitions:

**Intersex:** A person born with ambiguous reproductive or sexual anatomy; chromosomal genotype and sexual phenotype other than XY-male and XX-female.

**Transsexual:** A person who has undergone (or is in the process of) surgical alteration to achieve gender opposite to their sex at birth, i.e. surgically altered gender.

**Transgender/Transgendered person:** A person who identifies with or expresses a gender identity that differs from the one that corresponds to the person’s sex at birth.

Coding Instructions:

- Enter the appropriate code for the patient’s gender using the table below.
- Code the natal sex (sex at birth) when known over transsexual or transgender, NOS.
- Code 3 when:
  - Intersexed (persons with sex chromosome abnormalities)
  - Hermaphrodite
  
  **Note:** Hermaphrodite is an outdated term.
- Code 4 for transsexuals/transgender/transgendered with unknown natal sex and primary site is not C510-C589 or C600-C639.
- Codes 5 and 6:
  - Have priority over codes 1 and 2.
  - May be used for cases diagnosed prior to 2015.
- Code 5 for transsexuals who are natally male or transsexuals with primary site of C600-C639.
- Code 6 for transsexuals who are natally female or transsexuals with primary site of C510-C589.

When patient’s gender is unknown:

- Code 1 when primary site is C600-C639.
- Code 2 when Primary site is C510-C589.
- Code 9 for primary sites not included above.
- The CCR requires text documentation to support the sex data item.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Male</td>
</tr>
<tr>
<td>2</td>
<td>Female</td>
</tr>
<tr>
<td>3</td>
<td>Other (intersex, disorders of sexual development/DSD). The word hermaphrodite formally classified under this code is an outdated term</td>
</tr>
<tr>
<td>4</td>
<td>Transsexual/Transgender/Transgendered, NOS</td>
</tr>
<tr>
<td>5</td>
<td>Transsexual/Transgender/Transgendered, natal male</td>
</tr>
<tr>
<td>6</td>
<td>Transsexual/Transgender/Transgendered, natal female</td>
</tr>
<tr>
<td>9</td>
<td>Unknown</td>
</tr>
</tbody>
</table>
**III.2.9 Religion**

This data item captures the patient's religion or creed.

**Coding Instructions:**

- Enter the code for the patient’s identified religion.
  - [Appendix E](#) - Codes for Religions.
- Code 99 if the religion is not stated.
- These codes and definitions were added for religion, effective with cases diagnosed January 1, 1998 and forward.
- Religion codes prior to 1998 were converted.
III.2.10 Race and Ethnicity
Race and ethnicity are defined by specific physical, hereditary and cultural traditions, not necessarily by birthplace, place of residence, or citizenship. 'Origin' is defined by the Census Bureau as the heritage, nationality group, lineage, or in some cases, the country of birth of the person or the person's parents or ancestors before their arrival in the United States.

Beginning with cases diagnosed January 1, 2000, four race data items were added to the data set in addition to the existing race data item. These four data items were added so patients who belong to more than one racial category can be coded with multiple races, consistent with the 2000 Census.

Coding Resources:
- All resources in the facility, including the medical record, face-sheet, physician and nursing notes, photographs, and any other sources, must be used to determine race. If a facility does not print race in the medical record but does maintain it in electronic form, the electronic data must also be reviewed.
- Photographs of patients may be used but **only with extreme caution**. Photographs are often misleading and unreliable.
  - Use this source only when all other options are exhausted and there is no conflicting information.
  - If a photograph is used, documentation **must** be present in the abstract text explaining the use of the photograph.

Guidelines:
1. Code the patient's stated race, if possible. See Appendix O - Race and Nationality. It consists of the "Race and Nationality Descriptions from the 2000 Census and Bureau of Vital Statistics" for guidance.

   **Guideline Exception:** When the race is recorded as “Oriental,” “Mongolian,” or “Asian” (codable to 96 Other Asian, including Asian, NOS), and the place of birth is recorded as China, Japan, the Philippines, or another Asian nation, code the race based on birthplace information.

   **Exception Example:** The person's race is recorded as Asian, and the place of birth is recorded as Japan. Code race as 05 Japanese because it is more specific than 96 Other Asian, including Asian, NOS.

2. If the patient's race is determined based on the races of relatives, there is no priority for coding race, other than to list the non-white race(s) first.

3. If no race is stated in the medical record, or if the stated race cannot be coded, review the documentation for a statement of a race category.

   **Examples:**
1. Patient describes herself as multi-racial (nothing more specific) and nursing notes say "African-American" code as 02 Black or African American.

2. Patient states she has a Polynesian mother and Tahitian father. Code Race 1 as 25 Polynesian, Race 2 as 26 Tahitian and Race 3 through 5 as 88.

4. If race is unknown or not stated in the medical record and birthplace is recorded, in some cases race may be inferred from the nationality. See Appendix O - Race and Nationality. It consists of the "Race and Nationality Descriptions from the 2000 Census and Bureau of Vital Statistics" to identify nationalities from which race codes may be inferred.

**Example:** Record states: "This native of Portugal." Code race as 01 White per the Appendix O.

**Guideline Exception:** If the patient's name is incongruous with the inferred race, code Race 1 through Race 5 as 99, Unknown by patient.

**Guideline Exception Example:** Patient's name is Siddhartha Rao and birthplace listed as England. Code Race 1 through Race 5 as 99 Unknown by patient.

5. Use of patient name in determining race:
   - Do not code race from name alone, especially for females with no maiden name given.
   - In general, a name may be an indicator of a racial group, but should not be taken as the only indicator of race.
   - A patient name may be used to identify a more specific race code.
   - A patient name may be used to infer Spanish ethnicity or place of birth, but a Spanish name alone (without a statement about race or place of birth) cannot be used to determine the race code.

**Example:** Alice Gomez is a native of Indiana (implied birthplace: United States). Code Race 1 through Race 5 as 99 Unknown by patient, because we know nothing about her race.

6. Persons of Spanish or Hispanic origin may be of any race, although persons of Mexican, Central American, South American, Puerto Rican, or Cuban origin are usually white.

**Example:** Miss Sabrina Fitzsimmons is a native of Brazil. Code race as 01 White per Appendix O.

**Note:** Race and ethnicity are coded independently.

7. Code 03 should be used for any person stated to be Native American or [western hemisphere] Indian, whether from North, Central, South, or Latin America.
8. Death certificate information may be used to supplement ante mortem race information only when race is coded unknown in the patient record or when the death certificate information is more specific.

   - In the cancer record Race 1 through Race 5 are coded as 99 Unknown by patient.
   - The death certificate states race as black. Change cancer record for Race 1 to 02 Black or African American and Race 2 through Race 5 to 88.

**Coding Instructions:**

- Use [Codes for Race Data Item](#) for instructions on how to code the appropriate race of the patient.

- All race data items must be coded. This applies to cases diagnosed after January 1, 2000 and forward.

**Note:** Per 2004 SEER guidelines, races previously coded to 09 – Asian Indian were to be coded to 96 - Other Asian, including Asian, NOS. For consistency, the CCR created a new code, code 90 for Other South Asian that includes Bangladeshi, Bhutanese, Nepalese, Sikkimese, Sri Lankan (Ceylonese). Cases are converted from 90 to 96 for Calls for Data.

- Cases with conflicting information, that lack supporting text documentation, will be returned as queries and counted as discrepancies.
  
  - Outlined below are examples of when text documentation would be required.
  
  - A text statement indicating patient’s race, i.e., “Pt is Japanese,” is required for conflicting types of cases. Such remarks must be entered in either the physical exam or remarks text data items.

**Examples:**

**Note:** These examples are not intended to demonstrate all possible scenarios.

<table>
<thead>
<tr>
<th>Scenarios Demonstrating Conflicting Race Information:</th>
</tr>
</thead>
</table>
| A. **Name:** June Hashimoto  
  **Race:** White  
  **Birthplace:** Unknown  
  **Marital Status:** Single |
| B. **Name:** Bob Nguyen  
  **Race:** White  
  **Birthplace:** Mexico |
| C. **Name:** Robert Jackson  
  **Race:** Mexican |
- Codes 01 – 97 (Specific Race data items).
- Code 88 (No Further Race Documented) is not to be used for coding the first race data item (Race 1). It may only be used to document Race data items 2 through 5 when there are less than five races identified.
- Code 98 (Some other race) is not to be used if the Face Sheet states "other" or "other race." **
  - Code 98 is to be used only in the event a specified race is identified with no corresponding CCR/SEER Race code.
  - It is encouraged to use 99 before considering the use of code 98.
  - If the only information available is “other” or “other race,” carefully review the medical record in search of a specific race. If no other information is available to code a specific race, use code 99.
  - Do not code a patient stated to be Hispanic or Latino as 98 Other Race in Race 1 and 88 in Race 2 through Race 5.
- Code 99 (Unknown by patient) in the following scenarios:
  - Race code 99 is entered in the Race 1 data item ;code 99 must be entered in the remaining race data items (Race 2 through Race 5).
  - Information about the patient's race or races is not given in any portion of the medical record.
- When the patient’s race is reported differently by two or more sources within the medical record, code race using the following sources in the following priority order:
  - The patient’s self-declared identification.
  - Documentation in the medical record:
• Dictated reports
• Nurses’ notes

○ Death Certificate

• If the patient has multiple tumors, each tumor must have the same race codes assigned to each abstract.
  1. If a person's race is a combination of Hawaiian and any other race(s), code Race 1 as 07 Native Hawaiian and code the other races in Race 2, Race 3, Race 4, and Race 5 as appropriate.
  2. If a person's race is a combination of white and any other race(s), code to the appropriate other race(s) first and code white in the next race data item.
  3. Code only the specific race when both a specific race code and a non-specific race code apply (Do not code 96, 97, or 98 for “multi-racial”):
     a. Codes 04 – 17, 90 * take priority over code 96
     b. Codes 16 – 17 takes priority over code 15
     c. Codes 20 – 32 takes priority over code 97
     d. Codes 01 ** -32, 90 *, and 69-97 take priority over code 98

* California specific race code 90 (used for Other South Asian, Bangladeshi, Bhutanese, Nepalese, Sikkimese, and Sri Lankan).

** California specific race code 90 (used for Other South Asian, Bangladeshi, Bhutanese, Nepalese, Sikkimese, and Sri Lankan).

Note: Code 90 is changed to 96 for submissions.

** Unlike SEER, California gives code 01 priority over 98

Example: Patient is described as Japanese and Hawaiian. Code Race 1 as 07 Native Hawaiian, Race 2 as 05 Japanese, and Race 3 through Race 5 as 88.

• Code race in order stated when no other priority applies.

• In the absence of other more specific information, use of the parents race (if known) may be used to determine the patient’s race, with caution.
### III.2.10.1 Codes for Race Data Item

Enter the most appropriate code for a patient's race(s) or ethnicity. See Race and Ethnicity for coding instructions.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>WHITE *</td>
</tr>
<tr>
<td>02</td>
<td>BLACK OR AFRICAN AMERICAN</td>
</tr>
<tr>
<td>03</td>
<td>AMERICAN INDIAN, ALASKA NATIVE (includes all indigenous populations of the Western Hemisphere)</td>
</tr>
<tr>
<td>04</td>
<td>CHINESE</td>
</tr>
<tr>
<td>05</td>
<td>JAPANESE</td>
</tr>
<tr>
<td>06</td>
<td>FILIPINO</td>
</tr>
<tr>
<td>07</td>
<td>NATIVE HAWAIIAN</td>
</tr>
<tr>
<td>08</td>
<td>KOREAN</td>
</tr>
<tr>
<td>09</td>
<td>FORMERLY ASIAN INDIAN OR PAKISTANI, RETIRED EFFECTIVE 1/1/10. See replacement codes 15-17</td>
</tr>
<tr>
<td>10</td>
<td>VIETNAMESE</td>
</tr>
<tr>
<td>11</td>
<td>LAOTIAN</td>
</tr>
<tr>
<td>12</td>
<td>HMONG</td>
</tr>
<tr>
<td>13</td>
<td>CAMBODIAN</td>
</tr>
<tr>
<td>14</td>
<td>THAI</td>
</tr>
<tr>
<td>15</td>
<td>ASIAN INDIAN, NOS OR PAKISTANI, NOS</td>
</tr>
<tr>
<td>16</td>
<td>ASIAN INDIAN</td>
</tr>
<tr>
<td>17</td>
<td>PAKISTANI</td>
</tr>
<tr>
<td>20</td>
<td>MICRONESIAN, NOS</td>
</tr>
<tr>
<td>21</td>
<td>CHAMORRO</td>
</tr>
<tr>
<td>22</td>
<td>GUAMANIAN, NOS</td>
</tr>
<tr>
<td>25</td>
<td>POLYNESIAN, NOS</td>
</tr>
<tr>
<td>26</td>
<td>TAHITIAN</td>
</tr>
<tr>
<td>27</td>
<td>SAMOAN</td>
</tr>
<tr>
<td>28</td>
<td>TONGAN</td>
</tr>
<tr>
<td>30</td>
<td>MELANESIAN, NOS</td>
</tr>
<tr>
<td>31</td>
<td>FIJI ISLANDER</td>
</tr>
<tr>
<td>32</td>
<td>PAPUA NEW GUINEAN</td>
</tr>
<tr>
<td>88</td>
<td>NO FURTHER RACE DOCUMENTED (Do not use for coding the first race data item)</td>
</tr>
<tr>
<td>90</td>
<td>OTHER SOUTH ASIAN, INCLUDING BANGLADESHI, BHUTANESE, NEPALESE, SIKKIMESE, SRI LANKAN (CEYLONESSE)</td>
</tr>
<tr>
<td>96</td>
<td>OTHER ASIAN, INCLUDING ASIAN, NOS</td>
</tr>
<tr>
<td>97</td>
<td>PACIFIC ISLANDER, NOS</td>
</tr>
<tr>
<td>98</td>
<td>SOME OTHER RACE</td>
</tr>
<tr>
<td>99</td>
<td>UNKNOWN BY PATIENT</td>
</tr>
</tbody>
</table>

* The following are some of the ethnic groups included in the White category:

Afghan  
Albanian  
Algerian  
Arabian  
Armenian  
Australian  
Austrian  
Bulgarian  
Caucasian  
Central American *  
Cuban **  
Cypriot  
Czechoslovakian  
Dominican **  
Egyptian  
Greek  
Gypsy  
Hungarian  
Iranian  
Iraqi  
Israeli  
Italian  
Jordanian  
Latino  
Lebanese
<table>
<thead>
<tr>
<th>Mexican *</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moroccan</td>
</tr>
<tr>
<td>Palestinian</td>
</tr>
<tr>
<td>Polish</td>
</tr>
<tr>
<td>Portuguese</td>
</tr>
<tr>
<td>Puerto Rican **</td>
</tr>
<tr>
<td>Romanian</td>
</tr>
<tr>
<td>Russian</td>
</tr>
<tr>
<td>Saudi Arabian</td>
</tr>
<tr>
<td>Slavic</td>
</tr>
<tr>
<td>Slovene</td>
</tr>
<tr>
<td>South American *</td>
</tr>
<tr>
<td>Spanish</td>
</tr>
<tr>
<td>Syrian</td>
</tr>
<tr>
<td>Tunisian</td>
</tr>
<tr>
<td>Turkish</td>
</tr>
<tr>
<td>Yugoslavian</td>
</tr>
</tbody>
</table>

Unless specified as Indian (code 03)

** Unless specified as Black (code 02)
III.2.10.2 Spanish/Hispanic Origin
This data item is used to identify patients with Spanish/Hispanic surname or of Spanish origin. Persons of Spanish or Hispanic surname/origin may be of any race.

Coding Instructions:
- Coding Spanish/Hispanic Origin is independent of coding race. A person of Spanish descent might be described as white, black, or some other race.
- Use all information to determine the Spanish/Hispanic Origin, including:
  - The ethnicity stated in the medical record.
    - Self-reported information takes priority over other sources of information.
  - Death Certificate
  - Birthplace
  - Information about life history and/or language spoken.
  - Last name or birth surname (formerly known as maiden name) found on a list of Spanish/Hispanic names.
- Code 6, Spanish, NOS when:
  - There is more than one ethnicity/origin (multiple codes).
  - Example: Mexican (code 1) and Cuban (code 3).
  - There is no hierarchy among the codes 1-5 or 8.
- Code 7 for the following scenarios:
  - When the only evidence of the patient’s Hispanic origin is a surname or birth surname (formerly known as maiden name) and there is no evidence that the patient is not Hispanic.
  - See Appendix J - Spanish Surnames.
- Portuguese, Brazilians, and Filipinos are not presumed to be Spanish or non-Spanish.
  - Assign code 7 when the patient’s name is on the Spanish Surnames list and they are Portuguese, Brazilian, or Filipino.
  - Assign code 0 when the patient’s name does not appear on the Spanish Surnames list and they are Portuguese, Brazilian, or Filipino.
- Code 9 for Death Certificate Only (DCO) cases when Spanish/Hispanic origin is unknown.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>NON-SPANISH, NON-HISPANIC</td>
</tr>
<tr>
<td>1</td>
<td>MEXICAN (including Chicano, NOS)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>2</td>
<td>PUERTO RICAN</td>
</tr>
<tr>
<td>3</td>
<td>CUBAN</td>
</tr>
<tr>
<td>4</td>
<td>SOUTH OR CENTRAL AMERICAN (except Brazilian)</td>
</tr>
<tr>
<td>5</td>
<td>OTHER SPECIFIED SPANISH ORIGIN (includes European; excludes DOMINICAN REPUBLIC for cases diagnosed on or after January 1, 2005)</td>
</tr>
<tr>
<td>6</td>
<td>SPANISH, NOS; HISPANIC, NOS; LATINO, NOS (There is evidence other than surname or birth surname (formerly known as maiden name) that the person is Hispanic, but he/she cannot be assigned to any category of 1-5)</td>
</tr>
<tr>
<td>7</td>
<td>SPANISH SURNAME ONLY (only evidence of person's Hispanic origin is surname or birth surname (formerly known as maiden name), and there is no contrary evidence that the person is not Hispanic) **</td>
</tr>
<tr>
<td>8</td>
<td>DOMINICAN REPUBLIC (for cases diagnosed on or after January 1, 2005)</td>
</tr>
<tr>
<td>9</td>
<td>UNKNOWN WHETHER SPANISH OR NOT</td>
</tr>
</tbody>
</table>

** Notes: 

- ** indicates a special category for Dominican Republic cases.
- ** denotes a category for cases with only surname evidence of Hispanic origin.
III.2.11 Date of Birth
This data item captures the month, day, and year of the patient’s birth.

Coding Instructions:

- Enter the 8-digit date of birth.
  - Consult with your software vendor for specific data entry instructions.
- See Entering Dates and Date Format for additional information regarding entering dates.
- Document the patient’s age in either the Text Physical Exam or Text-Remarks data items.
  - Include text verification in the Text-Remarks data item when the patient is 100 years or older.
III.2.12 Age at Diagnosis
This data item captures the age of the patient at the time of diagnosis for this cancer or tumor. This data item is tumor specific. A patient may be a different age for each tumor diagnosis.

Coding Instructions:

- *Age at First Diagnosis* is a required data item. Usually, the Age at First Diagnosis is calculated and generated by the abstracting software.
- If the Age at First Diagnosis is not calculated and generated by the abstracting software, calculate the age and enter it into this data item.
- Document the patient’s age in either the Text Physical Exam or Text-Remarks data item.
  - Include text verification in the Text-Remarks data item when the patient is 100 years or older.
**III.2.13 Birthplace - Country**

The *Birthplace – Country* data item is intended to collect information on the patient's country of birth.

**Coding Instructions:**

- Enter the three-digit Country Code for the Country in which the patient was born.
- Blanks are not allowed for this data item.
- [Appendix C](#) - Codes for Countries.
III.2.13.1 Birthplace - State

*Birthplace - State* is a two-digit data item that is intended to collect information on the patient's birth state.

**Coding Instruction:**

- Enter the abbreviation of the State or Territory in which the patient was born.
- Refer to [Appendix B](#) - Postal Abbreviations for States and Territories of the United States.
III.2.14 Occupation and Industry
Because the identification of occupational cancer is an important aspect of cancer research, every effort should be made to record the occupation and the industry in which the patient works or worked, regardless of whether the patient was employed at the time of admission.

Guidelines:

- Ideally, the information should pertain to the longest held job (other than housework performed in the patient's home).
- Review all admissions in the patient's medical record, including those before the diagnosis of cancer, and record the best information available. It is not necessary to request parts of the medical record predating diagnosis solely to determine occupation and industry, but review all admissions in the parts pulled for abstracting.
- Good sources of information include admission and discharge summaries, face sheets, history and physical examination reports, oncology consultation reports, and health and social history questionnaires the patient has completed.
- The CCR will code the occupation and industry using the United States Bureau of the Census occupation and industry classifications.

III.2.14.1 Occupation

The usual (longest-held) occupation and industry of workers can reveal the national cancer burden by industry and occupation. Such information can also be used to help discover jobs that may have a high risk for cancer or other diseases and for which prevention efforts can be concentrated (or targeted).

**Coding Instructions:**

- Enter any available information about the kind of work performed (e.g., television repairman, chemistry teacher, bookkeeper, construction worker) associated with the longest held occupation. This data item may contain up to 100 characters.
- Avoid the use of abbreviations where possible.
- If the patient is not employed, try to determine the longest held occupation.
- Do not enter a term such as "homemaker", "student", "retired", "unemployed", or "disabled" unless no other information can be obtained.
- If no information is available, enter "NR" (not recorded). Do not leave this data item blank.

### III.2.14.2 Industry

The usual (longest-held) occupation and industry of workers can reveal the national cancer burden by industry and occupation. Such information can also be used to help discover jobs that may have a high risk for cancer or other diseases and for which prevention efforts can be concentrated (or targeted).

**Coding Instructions:**

- Enter any available information about the industry associated with the longest held occupation (e.g., automotive repair, junior high school, trucking, house construction), up to 100 characters.
- If the chart identifies the employer's name but does not describe the industry, enter the employer's name (and city if available).
- If only an abbreviation is given for the industry or employer (e.g., PERS, USD, or FDIC), record it even if it’s meaning is not known (avoid the use of abbreviations where possible).
- If no information is available, enter "NR" (not recorded). Do not leave this data item blank.

III.2.14.3 Occupation and Industry - Children

Occupation and Industry specific information is required to be entered in the abstract for children as well as adults. Follow the instructions below for Occupation and Industry if the patient is under 18 years of age.

Coding Instructions:

- Enter "Child" in the Occupation data item when the patient is a child.
  - This data item is left justified.
- Record any information available about the occupations of the parents and the industries in which they are employed.
- Record the occupation and industry of both parents if the information is in the medical record.
  - If there is not enough room, however, give priority to the father's occupation and industry.
  - Precede information about a parent with "FA" (father) or "MO" (mother).

Examples:

1. Patient is 10 years old. Father is a field engineer with an oil company. Mother is an artist (NOS). Complete the Occupation and Industry data items as follows:
   - Occupation: Child - FA: field engineer MO: artist
   - Industry: FA: oil industry

2. Patient is 14 years old. Father's occupation is not recorded. Mother is a biology professor at a university. Complete the Occupation and Industry data items as follows:
   - Occupation: Child - MO: biology professor
   - Industry: MO: University

III.2.15 No Patient Contact Flag

The No Patient Contact Flag data item is to be set to code 0 or 1 if there is documentation on the medical record or if the cancer registry has been contacted by the patient, family member, or the patient’s physician saying that they do not want to be included in research studies.

Coding Instructions:

- Assign code 0 or 1 for this data item. Regardless of the diagnosis year, blanks are not allowed.
- Assign the code that best describes whether or not the patient should or should not be contacted for research purposes.
- When consolidating records, code 1 takes precedence over code 0.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Patient may be contacted for research studies</td>
</tr>
<tr>
<td>1</td>
<td>Patient may NOT be contacted for research studies; per notification from patient, family member or physician</td>
</tr>
</tbody>
</table>
### III.2.16 Height

Document the patient’s height in this data item. This data item is required if available by the CCR (if the information is obtainable for abstracting, it is required) for cases diagnosed January 1, 2011 and forward.

**Coding Instructions:**

- Different tumors for the same patient may have different values.
- The patient’s height should be collected from source records once for each cancer.
- Height should be taken from the Nursing Interview Guide, Flow Chart, or Vital Stats section from the patient’s reporting facility medical record or physician office record.
- The height entered should be that listed at or around the time of diagnosis.
- If no height was listed on the date of diagnosis, please use the height recorded on the date closest to the date of diagnosis and before treatment was started.
- Entered as 2-digit number and measured in inches (note that 1 foot=12 inches).

**Example:** Patient is stated to be 6 feet 1 inch (6`1”) tall. Enter 73 into this data item.

- Code 98 for 98 inches or greater.
- Code 99 for unknown height.
- All inches’ values should be rounded to the nearest whole number; values with decimal place x .5 and greater should be rounded up (e.g., 62.5 inches would be 63 inches).
- Exhaust all potential sources for height before using code 99 (unknown).
- Leaving this data item blank is not permitted and code 99 should be used to reflect unknown height. The CDC will use the volume of cases coded to 99 to help determine the availability of information related to height in the medical record.

- Use the Height Conversion Table below to convert to inches:

<table>
<thead>
<tr>
<th>Feet (ft)</th>
<th>Inches (in)</th>
<th>Centimeters (cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1' 6&quot;</td>
<td>18&quot;</td>
<td>46</td>
</tr>
<tr>
<td>1' 7&quot;</td>
<td>19&quot;</td>
<td>48</td>
</tr>
<tr>
<td>1' 8&quot;</td>
<td>20&quot;</td>
<td>51</td>
</tr>
<tr>
<td>1' 9&quot;</td>
<td>21&quot;</td>
<td>53</td>
</tr>
<tr>
<td>1' 10&quot;</td>
<td>22&quot;</td>
<td>56</td>
</tr>
<tr>
<td>1' 11&quot;</td>
<td>23&quot;</td>
<td>58</td>
</tr>
<tr>
<td>2'</td>
<td>24&quot;</td>
<td>61</td>
</tr>
<tr>
<td>2' 1&quot;</td>
<td>25&quot;</td>
<td>64</td>
</tr>
<tr>
<td>2' 2&quot;</td>
<td>26&quot;</td>
<td>66</td>
</tr>
<tr>
<td>2' 3&quot;</td>
<td>27&quot;</td>
<td>69</td>
</tr>
<tr>
<td>2' 4&quot;</td>
<td>28&quot;</td>
<td>71</td>
</tr>
<tr>
<td>2' 5&quot;</td>
<td>29&quot;</td>
<td>74</td>
</tr>
<tr>
<td>2' 6&quot;</td>
<td>30&quot;</td>
<td>76</td>
</tr>
<tr>
<td>2' 7&quot;</td>
<td>31&quot;</td>
<td>79</td>
</tr>
<tr>
<td>2' 8&quot;</td>
<td>32&quot;</td>
<td>81</td>
</tr>
<tr>
<td>2' 9&quot;</td>
<td>33&quot;</td>
<td>84</td>
</tr>
<tr>
<td>2' 10&quot;</td>
<td>34&quot;</td>
<td>86</td>
</tr>
<tr>
<td>2' 11&quot;</td>
<td>35&quot;</td>
<td>89</td>
</tr>
<tr>
<td>3'</td>
<td>36&quot;</td>
<td>91</td>
</tr>
<tr>
<td>3' 1&quot;</td>
<td>37&quot;</td>
<td>94</td>
</tr>
<tr>
<td>3' 2&quot;</td>
<td>38&quot;</td>
<td>97</td>
</tr>
<tr>
<td>3' 3&quot;</td>
<td>39&quot;</td>
<td>99</td>
</tr>
<tr>
<td>3' 4&quot;</td>
<td>40&quot;</td>
<td>102</td>
</tr>
<tr>
<td>3' 5&quot;</td>
<td>41&quot;</td>
<td>104</td>
</tr>
<tr>
<td>3' 6&quot;</td>
<td>42&quot;</td>
<td>107</td>
</tr>
<tr>
<td>3' 7&quot;</td>
<td>43&quot;</td>
<td>109</td>
</tr>
<tr>
<td>3' 8&quot;</td>
<td>44&quot;</td>
<td>112</td>
</tr>
<tr>
<td>3' 9&quot;</td>
<td>45&quot;</td>
<td>114</td>
</tr>
<tr>
<td>3' 10&quot;</td>
<td>46&quot;</td>
<td>117</td>
</tr>
<tr>
<td>3' 11&quot;</td>
<td>47&quot;</td>
<td>119</td>
</tr>
<tr>
<td>4'</td>
<td>48&quot;</td>
<td>122</td>
</tr>
<tr>
<td>4' 1&quot;</td>
<td>49&quot;</td>
<td>124</td>
</tr>
<tr>
<td>4' 2&quot;</td>
<td>50&quot;</td>
<td>127</td>
</tr>
<tr>
<td>4' 3&quot;</td>
<td>51&quot;</td>
<td>130</td>
</tr>
<tr>
<td>4' 4&quot;</td>
<td>52&quot;</td>
<td>132</td>
</tr>
<tr>
<td>4' 5&quot;</td>
<td>53&quot;</td>
<td>135</td>
</tr>
<tr>
<td>4' 6&quot;</td>
<td>54&quot;</td>
<td>137</td>
</tr>
<tr>
<td>4' 7&quot;</td>
<td>55&quot;</td>
<td>140</td>
</tr>
<tr>
<td>4' 8&quot;</td>
<td>56&quot;</td>
<td>142</td>
</tr>
<tr>
<td>Height (in)</td>
<td>Width (in)</td>
<td>Length (in)</td>
</tr>
<tr>
<td>------------</td>
<td>------------</td>
<td>-------------</td>
</tr>
<tr>
<td>4' 9&quot;</td>
<td>57&quot;</td>
<td>145</td>
</tr>
<tr>
<td>4' 10&quot;</td>
<td>58&quot;</td>
<td>147</td>
</tr>
<tr>
<td>4' 11&quot;</td>
<td>59&quot;</td>
<td>150</td>
</tr>
<tr>
<td>5'</td>
<td>60&quot;</td>
<td>152</td>
</tr>
<tr>
<td>5' 1&quot;</td>
<td>61&quot;</td>
<td>155</td>
</tr>
<tr>
<td>5' 2&quot;</td>
<td>62&quot;</td>
<td>157</td>
</tr>
<tr>
<td>5' 3&quot;</td>
<td>63&quot;</td>
<td>160</td>
</tr>
<tr>
<td>5' 4&quot;</td>
<td>64&quot;</td>
<td>163</td>
</tr>
<tr>
<td>5' 5&quot;</td>
<td>65&quot;</td>
<td>165</td>
</tr>
<tr>
<td>5' 6&quot;</td>
<td>66&quot;</td>
<td>168</td>
</tr>
<tr>
<td>5' 7&quot;</td>
<td>67&quot;</td>
<td>170</td>
</tr>
<tr>
<td>5' 8&quot;</td>
<td>68&quot;</td>
<td>173</td>
</tr>
<tr>
<td>5' 9&quot;</td>
<td>69&quot;</td>
<td>175</td>
</tr>
<tr>
<td>5' 10&quot;</td>
<td>70&quot;</td>
<td>178</td>
</tr>
<tr>
<td>5' 11&quot;</td>
<td>71&quot;</td>
<td>180</td>
</tr>
<tr>
<td>6&quot;</td>
<td>72&quot;</td>
<td>183</td>
</tr>
<tr>
<td>6' 1&quot;</td>
<td>73&quot;</td>
<td>185</td>
</tr>
<tr>
<td>6' 2&quot;</td>
<td>74&quot;</td>
<td>188</td>
</tr>
<tr>
<td>6' 3&quot;</td>
<td>75&quot;</td>
<td>191</td>
</tr>
<tr>
<td>6' 4&quot;</td>
<td>76&quot;</td>
<td>193</td>
</tr>
<tr>
<td>6' 5&quot;</td>
<td>77&quot;</td>
<td>195</td>
</tr>
<tr>
<td>6' 6&quot;</td>
<td>78&quot;</td>
<td>198</td>
</tr>
<tr>
<td>6' 7&quot;</td>
<td>79&quot;</td>
<td>201</td>
</tr>
<tr>
<td>6' 8&quot;</td>
<td>80&quot;</td>
<td>203</td>
</tr>
</tbody>
</table>
### III.2.17 Weight

Document the patient’s weight at diagnosis in this data item. This data item is required if available by the CCR (if the information is obtainable for abstracting, it is required) for cases diagnosed January 1, 2011 and forward.

**Coding Instructions:**
- Entered as 3-digit numbers and measured in pounds (note that 1 kg = 2.2 pounds).
  
  **Example:** Patient is documented as 195. Enter 195 into this data item.
- Code 999 for unknown weight.
- All pound values should be rounded to the nearest whole number; values with decimal place x.5 and greater should be rounded up (e.g., 155.5 pounds would be 156 pounds).
- Patients with a weight of less than 100 pounds should be recorded with a leading 0.
- Exhaust all potential sources for weight before using code 999 (unknown).
- Leaving this data item blank is not permitted and code 999 should be used to reflect unknown weight. The CDC will use the volume of cases coded to 999 to help determine the availability of information related to weight in the medical record.

**Guidelines:**
- Different tumors for the same patient may have different values.
- The patient’s weight should be collected from source records once for each cancer.
- Weight should be taken from the Nursing Interview Guide, Flow Chart, or Vital Stats section from the patient’s reporting facility medical record or physician office record.
- The weight entered should be that listed on the date of diagnosis.
- If no weight was listed on the date of diagnosis, please use the weight recorded on the date closest to the date of diagnosis and before treatment was started.
- Use the Weight Conversion Table below to convert to pounds:

<table>
<thead>
<tr>
<th>Kilograms (kg)</th>
<th>Pounds (lb.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>147</td>
<td>324</td>
</tr>
<tr>
<td>------</td>
<td>-----</td>
</tr>
<tr>
<td>148</td>
<td>326</td>
</tr>
<tr>
<td>149</td>
<td>328</td>
</tr>
<tr>
<td>150</td>
<td>331</td>
</tr>
<tr>
<td>151</td>
<td>333</td>
</tr>
<tr>
<td>152</td>
<td>335</td>
</tr>
<tr>
<td>153</td>
<td>337</td>
</tr>
<tr>
<td>154</td>
<td>340</td>
</tr>
<tr>
<td>155</td>
<td>342</td>
</tr>
<tr>
<td>156</td>
<td>344</td>
</tr>
<tr>
<td>157</td>
<td>346</td>
</tr>
<tr>
<td>158</td>
<td>348</td>
</tr>
<tr>
<td>159</td>
<td>351</td>
</tr>
<tr>
<td>160</td>
<td>353</td>
</tr>
<tr>
<td>161</td>
<td>355</td>
</tr>
<tr>
<td>162</td>
<td>357</td>
</tr>
<tr>
<td>163</td>
<td>359</td>
</tr>
<tr>
<td>164</td>
<td>362</td>
</tr>
<tr>
<td>165</td>
<td>364</td>
</tr>
<tr>
<td>166</td>
<td>366</td>
</tr>
<tr>
<td>167</td>
<td>368</td>
</tr>
<tr>
<td>168</td>
<td>370</td>
</tr>
</tbody>
</table>


III.2.18 Tobacco Use
Records the patient's past or current use of tobacco.

Standard Setter Differences:

- The *Tobacco Use Smoking Status* is a new data item introduced with the 2022 data changes. This data item is required if available by the CCR (if the information is obtainable for abstracting, it is required) for cases diagnosed January 1, 2022 and forward.
  - The information recorded in this data item is not comparable to the information that has been historically collected in the Tobacco Use data items under the CDC Comparative Effectiveness Research (CER) and Patient Centered Outcomes Research (PCOR) project.
  - However, in an effort to alleviate double collection of Tobacco Use by the registrars, the CCR has decided to eliminate collection of Tobacco Use Cigarette and Tobacco Use Other Smoke for cases diagnosed 2022+.

- The requirement revisions are:
  - The CCR will continue to require the two data items below, if available on cases diagnosed January 1, 2011 and forward.
    1. *Tobacco Use Smokeless*
    2. *Tobacco Use NOS*
  - The CCR will **only** require the two data items below, if available for cases diagnosed January 1, 2011 through December 31, 2021.
    1. *Tobacco Use Cigarette*
    2. *Tobacco Use Other Smoke*
III.2.18.1 Tobacco Use Smokeless and Tobacco Use, NOS

*Tobacco Use Smokeless and Tobacco Use, NOS* are required if available by the CCR (if the information is obtainable for abstracting, it is required) for cases diagnosed January 1, 2011 and forward.

**Coding Instructions**

- Tobacco use should be recorded from sections such as the Nursing Interview Guide, Flow Chart, Vital Stats or Nursing Assessment section, or other available source from the patient’s reporting facility medical record or physician office record.
- Electronic cigarettes are **not** to be coded in this data item.
- *Tobacco Use Smokeless* is used to capture Smokeless tobacco products (e.g. chewing tobacco, snuff, etc.).
- *Tobacco Use, NOS* is used to capture tobacco use when there is no documentation in the medical record that indicates the type of tobacco product (smokeless, cigarettes, cigars, etc.).
- Code 0 if the medical record indicates “None,” (“Never Used”).
- Code 9 (Unknown/not stated/no smoking specifics provided) if the medical record only indicates “No,” rather than “Never used.”
- The CDC will use the volume of cases coded to “9” to help determine the availability of information related to tobacco use in the medical record.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Never used</td>
</tr>
<tr>
<td>1</td>
<td>Current user (i.e., “current user” as of date of diagnosis) <em>(added July 2011)</em></td>
</tr>
<tr>
<td>2</td>
<td>Former user, quit within one year of the date of diagnosis</td>
</tr>
<tr>
<td>3</td>
<td>Former user, quit more than one year prior to the date of diagnosis</td>
</tr>
<tr>
<td>4</td>
<td>Former user, unknown when quit</td>
</tr>
<tr>
<td>9</td>
<td>Unknown/not stated/no smoking specifics provided</td>
</tr>
</tbody>
</table>
III.2.18.2 Tobacco Use Smoking Status

This data item captures the patient's past or current use of tobacco (cigarette, cigar and/or pipe). This data item is required if available by the CCR (if the information is obtainable for abstracting, it is required) for cases diagnosed January 1, 2022 and forward.

**Coding Instructions:**

- Tobacco smoking history can be obtained from sections such as the Nursing Interview Guide, Flow Chart, Vital Stats or Nursing Assessment section, or other available sources from the patient’s hospital medical record or physician office record.
- Record the current or past use of tobacco.
  - Tobacco use includes cigarette, cigar, and/or pipe.
- Past or current use of e-cigarette vaping devices are **not** to be coded in this data item.
- Code 2 when the medical record indicates patient has smoked tobacco in the past but does not smoke now.
- If there is evidence in the medical record that the patient quit recently (within 30 days prior to diagnosis), assign code 1, current smoker. The 30 days prior information, if available, is intended to differentiate patients who may have quit recently due to symptoms that lead to a cancer diagnosis.
- Code 9 when the medical record only indicates “No”.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Never smoker</td>
</tr>
<tr>
<td>1</td>
<td>Current smoker</td>
</tr>
<tr>
<td>2</td>
<td>Former smoker</td>
</tr>
<tr>
<td>3</td>
<td>Smoker, current status unknown</td>
</tr>
<tr>
<td>9</td>
<td>Unknown if ever smoked</td>
</tr>
</tbody>
</table>
III.2.19 Source Comorbidity
This data item is intended to record the data source from which comorbidities/complications was collected.

**Note:** *Source Comorbidity* does not include data sources reflecting *Secondary Diagnosis*.

**Coding Instruction:**
- If comorbidities/complications are coded, then the source comorbidity data item must be coded.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No comorbid condition or complication identified / not applicable</td>
</tr>
<tr>
<td>1</td>
<td>Collected from facility face sheet</td>
</tr>
</tbody>
</table>
III.3 Case Identification
While some of the data reported on the Case Identification screens are only for identification and document control, the Date of Diagnosis serves as the basis for computing incidence, survival, and other statistics. Accurate recording of the date of the first diagnosis of a reportable neoplasm is especially important.
III.3.1 Date of First Contact
Per SEER Clarification, effective January 1, 2012 and forward, date of first contact is the admission date when the patient was an inpatient or an outpatient at the reporting facility for:

- Work-up of suspected cancer:
  Example: Patient has a suspected cancer. As an inpatient for work-up or first-course treatment, the date of first contact is the date of admission to the facility.

- Any part of the first-course treatment for known cancer:
  Example: A patient is diagnosed elsewhere and was seen for preliminary planning for radiation. The patient is sent elsewhere for surgery and does not return for radiation until after a lengthy recovery. The date of first contact is the date the patient returned for radiation treatment. The date of the radiation work-up is not the date of first contact.

- Class of Case change from non-analytic to analytic:
  Example: The patient comes in for a Consult Only (Class 30) and subsequently all or part of first course of treatment is given at your facility. The date of first contact is updated to the date when the case became analytic.

- Patients admitted for other causes:
  - When cancer is an incidental finding for patients admitted as an inpatient at the reporting facility for another condition, the date of first contact is the date the cancer was first suspected.
  - Autopsy Only cases
  - Date of first contact is date of death

Coding Instructions:

- Inpatient: Enter the first date of admission as an inpatient for the reportable neoplasm, or the actual date when the diagnosis of a reportable neoplasm was made during the inpatient admission to the reporting facility.

- Outpatient: Enter the date first diagnosed, treated, or seen as an outpatient for the reportable neoplasm.

See Entering Dates, Date Format and Class of Case, for further information on coding and entering dates. Consult with your software vendor for specific data entry instructions.
III.3.2 Dates of Inpatient Admission and Inpatient Discharge

Enter the dates of Inpatient Admission and Inpatient Discharge to the reporting facility for the most definitive surgery.

See Entering Dates and Date Format for additional information regarding entering dates. Consult with your software vendor for specific data entry instructions.

Coding Instructions:

- Use the inpatient admission and discharge dates for any other cancer-directed therapy when the patient does not have surgery.
- Use the dates of inpatient admission and discharge for diagnostic evaluation when the patient has not had cancer-directed therapy.
III.3.3 Date of Diagnosis

This data item captures the month day and year of the patient’s diagnosis. It serves as the basis for computing incidence, survival, and other statistics. Accurate recording of the date of the first diagnosis of a reportable neoplasm is especially important.

See Entering Dates and Date Format for additional information regarding entering dates. Consult your software vendor for specific data entry instructions.

Coding Instructions:

- Enter the date a physician, surgeon, or dentist first stated that the patient has cancer, whether the diagnosis was ever confirmed microscopically or not. The rule applies even if the cancer was confirmed at a later date and whether the diagnosis was made at the reporting facility or before admission or not.

- When the first diagnosis includes reportable ambiguous terminology, record the date of that diagnosis. See Ambiguous Diagnostic Reportable Terms for a list.

  - However, if upon clinical and/or pathologic review of a previous condition it is determined that the patient had the tumor at an earlier date, enter that date (that is, backdate the diagnosis). For cases diagnosed at autopsy, enter the date of death. If diagnosis date is not known, see Approximation for additional instructions.

- For analytic cases, a completely unknown Date of Diagnosis is no longer allowed for all analytic cases (Class of Case 00-22). Effective for all cases identified/first seen 1/1/2010 and forward.

  - At a minimum, the year of diagnosis is required for all analytic cases.
  
  - The year of diagnosis must be known or estimated and cannot be blank or unknown.
  
  - For instructions on determining a Date of diagnosis, refer to Vague Dates or Approximation, and DSQC Memo #2011-04.

  - Text documentation must be provided for the basis of the estimated date.

- For non-analytic cases (Class of Case 30-99): All attempts should be made to determine or estimate the date/year of diagnosis.

  - If no information about the date or at least year of diagnosis is available:

    - Use the date of admission /1st contact year as the date of diagnosis and apply the applicable coding instructions.
• Beginning in 2009, diagnosis and treatment dates for a fetus prior to birth are to be assigned the actual date of the event. In the past, those dates were set by rule to the date the baby was born.
III.3.3.1 Vague Dates
Vague dates refer to those occasions where incomplete or vague date information exists in the medical record. This instruction directs abstractors on how to enter vague dates.

Coding Instructions:
- Enter an approximate date when the exact date cannot be determined.
- At a minimum, a year of diagnosis is required for all analytic cases (Class of Case 00-22).
- The year of diagnosis must be known or estimated and cannot be blank or unknown.
- The date of first cancer directed therapy may be used as the date of diagnosis, if the therapy was initiated before definitive confirmation of the diagnosis.
- Text documentation must be provided for the basis of the estimated date.
III.3.3.2 Approximation

Date information is sometimes expressed in the medical record giving an idea of an approximate date. This instruction directs abstractors on how to approximate dates.

Coding Instructions:

- At a minimum, a year of diagnosis is required for all analytic cases (Class of Case 00-22).
- Use the date treatment was started if the patient receives a first course of treatment before a definitive diagnosis.
- Text documentation must be provided for the basis of the estimated date.

Estimating Year

- Use whatever information is available to calculate the year.
- Code the year of admission when there is no basis for estimation.

<table>
<thead>
<tr>
<th>Terms</th>
<th>Code To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Couple of years ago</td>
<td>Two years ago</td>
</tr>
<tr>
<td>Few years ago</td>
<td>Three years ago</td>
</tr>
</tbody>
</table>

Estimating Month

- Use whatever information is available to calculate the month.
- Leave the month blank if there is no basis for approximation.

<table>
<thead>
<tr>
<th>Terms</th>
<th>Code To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recently</td>
<td>Enter the month and year of admission, and unknown (&quot;99&quot;) for the day. If patient was admitted during the first week of a month, enter the previous month</td>
</tr>
<tr>
<td>Several months ago</td>
<td>Assume the case was first diagnosed three months before admission with the day unknown when the patient was not previously treated or if a course of treatment started elsewhere was continued at the reporting facility</td>
</tr>
<tr>
<td>Spring</td>
<td>Enter as April</td>
</tr>
<tr>
<td>Summer</td>
<td>Enter as July</td>
</tr>
<tr>
<td>Fall or Autumn</td>
<td>Enter as October</td>
</tr>
<tr>
<td>Winter</td>
<td>Enter as December or January based on available information i.e. end/beginning of year</td>
</tr>
<tr>
<td>Early in the year</td>
<td>Enter as January</td>
</tr>
<tr>
<td>Middle of the year</td>
<td>Enter as July</td>
</tr>
<tr>
<td>End of the year</td>
<td>Enter as December</td>
</tr>
</tbody>
</table>
**III.3.4 Place of Diagnosis**
If the case was not first diagnosed at the reporting facility, enter whatever is known about the place of diagnosis:

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Instruction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Another Reporting Facility</td>
<td>Enter the facility’s name, the city, and the state</td>
</tr>
<tr>
<td>Physician Only</td>
<td>Enter physician’s name and address. If the physician is on the reporting facility’s medical staff, also enter &quot;Staff Physician&quot;</td>
</tr>
<tr>
<td>Reporting Facility and Physician Unknown</td>
<td>Enter name of city, state, or country where diagnosis was first made</td>
</tr>
<tr>
<td>No Information Available</td>
<td>Enter &quot;unknown&quot;</td>
</tr>
</tbody>
</table>
III.3.5 Class of Case

Class of Case is divided into two basic categories: Analytic and Nonanalytic.

- **Analytic cases** (codes 00-22) are grouped according to the location of diagnosis and first course of treatment. Analytic cases are required to be reported to the CCR by all facilities. These cases are included in treatment and survival analyses.

- **Nonanalytic cases** include codes 30-49 and 99. The CCR requires that specific non-analytic cases be abstracted by the reporting facility.
  
  - Non-analytic class of cases which always require reporting to CCR via an abstract are 32, 34-38.
  
  - Non-analytic class of case 30 requires reporting to CCR via an abstract under most, but not all scenarios (see details below).

- **Class of Case change from non-analytic to analytic:**

  **Example:** The patient had diagnoses elsewhere and comes to your facility for treatment planning only (Class 30) and the case is abstracted as Class 30. If a decision is made for the patient to receive all or part of first course of treatment at your facility, the case is now analytic (Class 20-22). The date of first contact is updated to the date when the case became analytic.

For specific reportability requirements, see Reporting.

A facility's Cancer Committee may also direct reporting of non-analytic cases. Nonanalytic cases are not required to be abstracted by the CoC and are not included in treatment and survival analyses.

**Analytic Classes of Case**

**Initial Diagnosis at Reporting Facility**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
</table>
| 00   | Initial diagnosis at the reporting facility AND all treatment or a decision not to treat was done elsewhere  
**Example:** Patient was diagnosed with squamous cell carcinoma of the tonsil by biopsy at reporting facility; underwent surgical resection at another facility  
**Note:** Beginning in 2010, Class of Case 00 includes cases diagnosed by the facility that are treated in staff or non-staff physician’ offices, as well as cases when it is known that the patient went elsewhere for treatment. Facility Referred To, **MUST** be documented  
**Note:** Use Class of Case 10 if there is no information about whether or where the patient was treated  
**Note:** Use Class of Case 14 if the patient received no treatment, either because the patient refused recommended treatment, or a decision was made not to treat |
| 10   | Initial diagnosis at the reporting facility or in an office of a physician with admitting privileges AND part or all of first course treatment or a decision not to treat was at the reporting facility, NOS |
**Initial Diagnosis Elsewhere, Facility Involved in First Course Therapy**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>Initial diagnosis elsewhere AND part or all of first course treatment was done at the reporting facility, NOS</td>
</tr>
</tbody>
</table>
| 21   | Initial diagnosis elsewhere AND part of first course treatment was done at the reporting facility; part of the first course treatment was done elsewhere  
*Example: Definitive or repeat biopsy following initial FNA or biopsy performed elsewhere.* |
| 22   | Initial diagnosis elsewhere AND all first course treatment or a decision not to treat was done at the reporting facility |

**Non-Analytic Classes of Case**

**Patient Appears in Person at Reporting Facility; Both Initial Diagnosis and Treatment Elsewhere**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
</table>
| 30   | Initial diagnosis and all first course treatment elsewhere AND reporting facility participated in diagnostic workup  
*Examples: Consult Only; Treatment planning only; Staging workup after initial diagnosis elsewhere  
Reporting required to CCR* |
<table>
<thead>
<tr>
<th>Case</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>31</td>
<td>Initial diagnosis and all first course treatment provided elsewhere AND reporting facility provided in-transit care or facility provided care that facilitated treatment elsewhere. <strong>Examples:</strong> Patient receiving transient care to avoid interrupting therapy initiated elsewhere (equipment failure at the reporting facility or while vacationing); Catheter placement for cancer therapy. <strong>Reporting not required to CCR</strong></td>
</tr>
<tr>
<td>32</td>
<td>Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease recurrence or persistence. <strong>Examples:</strong> Patient with active disease admitted for other medical condition(s); Patient expires in the ER with lung metastases; After treatment failure, patient is admitted for supportive care. <strong>Reporting required to CCR</strong></td>
</tr>
<tr>
<td>33</td>
<td>Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease history only. <strong>Example:</strong> A patient admitted that does not have active disease. <strong>Reporting not required to CCR</strong></td>
</tr>
</tbody>
</table>
| 34   | Applicable to CoC-Accredited facilities ONLY. Type of case not required by CoC to be accessioned AND initial diagnosis AND part or all of first course treatment by reporting facility. Non CoC-Accredited facilities report these as analytic cases. **Reporting required to CCR** in this category include:  
  - Benign and borderline intracranial/CNS tumors diagnosed 1/1/2001 - 12/31/2003 only. **Note:** For cases diagnosed on or after 1/1/04 when these diagnoses became nationally reportable, use Class of Case codes 00-22.  
  - Intraepithelial neoplasia grade II and III tumors as follows:  
    - Anal intraepithelial neoplasia grade II (AIN II), dx 01/01/2022+  
    - Anus (AIN III) cases, dx 01/01/2001+  
    - Vaginal intraepithelial neoplasia grade II (VAIN II) dx 01/01/2022+  
    - Vagina (VAIN III) cases, dx 01/01/1992+  
    - Vulvar intraepithelial neoplasia grade II (VIN II), dx 01/01/2022+  
    - Vulva (VIN III) cases, dx 01/01/1992+  
  - Borderline ovarian tumors diagnosed 1/1/2001 through 12/31/2015. **Note:** Effective 1/1/2010, active follow-up is no longer required for borderline ovarian cases diagnosed 1/1/2001 forward. |
| 35   | Cases diagnosed before program’s Reference Date AND initial diagnosis AND part or all of first course treatment by reporting facility. |
Reporting required to CCR for cases diagnosed on or after 1/1/1988, or the regional registry reference date if earlier. See Reporting for additional instructions.

Applicable to CoC-Accredited facilities ONLY. Type of case not required by CoC to be accessioned AND initial diagnosis elsewhere AND part or all of first course treatment by reporting facility. Non CoC-Accredited facilities report these as analytic cases.

Reporting required to CCR in this category include:

- Benign and borderline intracranial/CNS tumors diagnosed 1/1/2001 - 12/31/2003 only
  
  Note: For cases diagnosed on or after 1/1/04 when these diagnoses became nationally reportable, use Class of Case codes 00-22

- Intraepithelial neoplasia grade II and III tumors as follows:
  - Anal intraepithelial neoplasia grade II (AIN II), dx 01/01/2022+
  - Anus (AIN III) cases, dx 01/01/2001+
  - Vaginal intraepithelial neoplasia grade II (VAIN II), dx 01/01/2022+
  - Vagina (VAIN III) cases, dx 01/01/1992+
  - Vulvar intraepithelial neoplasia grade II (VIN II), dx 01/01/2022+
  - Vulva (VIN III) cases, dx 01/01/1992+

- Borderline ovarian tumors diagnosed 1/1/2001 through 12/31/2015
  
  Note: Effective 1/1/2010, active follow-up is no longer required for borderline ovarian cases diagnosed 1/1/2001 forward.

Cases diagnosed before program’s Reference Date AND initial diagnosis elsewhere AND part or all of first course treatment by reporting facility

Reporting required to CCR for cases diagnosed on or after 1/1/1988, or the regional registry reference date if earlier. See Reporting for additional instructions.

Initial diagnosis established by autopsy at the reporting facility, cancer not suspected prior to death

Reporting required to CCR

Note: If the patient is suspected to have a malignancy, confirmed at autopsy, code to Class of Case 14

Patient Does Not Appear in Person at Reporting Facility

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>Diagnosis AND all first course treatment given at the same staff physician’s* office</td>
</tr>
<tr>
<td>41</td>
<td>Diagnosis AND all first course treatment given in two or more different offices of physicians with admitting privileges.</td>
</tr>
<tr>
<td>42</td>
<td>Non-staff physician, clinic or other facility, not part of reporting facility, accessioned by reporting facility for diagnosis and/or treatment by that entity</td>
</tr>
<tr>
<td></td>
<td>Example: Reporting facility abstracts cases from an independent radiation facility.</td>
</tr>
<tr>
<td>43</td>
<td>Pathology or other lab specimens only</td>
</tr>
<tr>
<td></td>
<td>Note: If a pathology specimen is submitted by a physician’s office to be read at the reporting facility, notification to the regional registry is required</td>
</tr>
<tr>
<td></td>
<td>Class 43 is to be Used by CCR/ Regional registries only</td>
</tr>
</tbody>
</table>
Unknown Relationship to Reporting Facility

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>99</td>
<td>Nonanalytic case of unknown relationship to facility</td>
</tr>
</tbody>
</table>

* A staff physician is a physician who is employed by the reporting facility, under contract with it, or a physician who has routine practice privileges there.

For further information, please see the current STORE Manual.
III.3.6 Type of Reporting Source

*Type of Reporting Source* data item records the source documents used to abstract the majority of information on the tumor being reported.

**Coding Instructions:**

- Codes 3, 6 and 7 are only used with the following *Class of Case* codes:
  - Class 43 (Path Only) – code 3
  - Class 38 (Autopsy Only) – code 6
  - Class 49 (Death Certificate Only) – code 7
- Codes 4 and 5 must be used with the following reporting facilities:
  - 0000999996, 0000000803 or specific Physician# – code 4
  - 0000000804 or specific Nursing Home# – code 5
- Codes are arranged in the order of the precedence of the sources, with a hospital record first.
- Code this data item in the following priority order: 1, 2, 8, 4, 3, 5, 6, and 7.
- Enter code 1 for reporting source and code 2, for type of admission for Class 40 and 41 cases.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>HOSPITAL INPATIENT/Managed health plans with comprehensive, unified medical records</td>
</tr>
<tr>
<td>2</td>
<td>RADIATION TREATMENT CENTERS OR MEDICAL ONCOLOGY CENTERS (HOSPITAL-AFFILIATED OR INDEPENDENT)</td>
</tr>
<tr>
<td>3</td>
<td>LABORATORY, hospital or private (e.g., pathology specimen only)</td>
</tr>
<tr>
<td>4</td>
<td>PRIVATE MEDICAL PRACTITIONER</td>
</tr>
<tr>
<td>5</td>
<td>NURSING HOME, CONVALESCENT HOSPITAL, OR HOSPICE</td>
</tr>
<tr>
<td>6</td>
<td>AUTOPSY ONLY (neoplasm discovered and diagnosed for the first time as a result of an autopsy - see <em>Class of Case</em>)</td>
</tr>
<tr>
<td>7</td>
<td>DEATH CERTIFICATE ONLY (DCO)</td>
</tr>
<tr>
<td>8</td>
<td>OTHER HOSPITAL OUTPATIENT UNITS/SURGERY CENTERS</td>
</tr>
</tbody>
</table>
**III.3.7 Type of Admission**

This data item represents the type(s) of admission the patient had at the reporting facility.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Inpatient Only</td>
</tr>
<tr>
<td>2</td>
<td>Outpatient Only</td>
</tr>
<tr>
<td>3 *</td>
<td>Tumor Board Only</td>
</tr>
<tr>
<td>4 *</td>
<td>Pathology Specimen Only</td>
</tr>
<tr>
<td>5</td>
<td>Inpatient and Outpatient</td>
</tr>
<tr>
<td>6</td>
<td>Inpatient and Tumor Board</td>
</tr>
<tr>
<td>7</td>
<td>Outpatient and Tumor board</td>
</tr>
<tr>
<td>8</td>
<td>Inpatient, Outpatient and Tumor Board</td>
</tr>
<tr>
<td>9</td>
<td>Unknown (may appear in archival files but is not entered by hospitals)</td>
</tr>
</tbody>
</table>

* See [Reporting, Required Method of Reporting Guide](#)
III.3.8 Casefinding Source
This two-digit data item indicates the source that identified the case.

Coding Instructions:
- Determine where the case was first identified, and enter the appropriate code. However, if a hospital and a non-hospital source identified the case independently of each other, enter the code for the non-hospital source (i.e., codes 30-95 have priority over codes 10-29).
- If the case was first identified at a cancer reporting facility (codes 10-29), code the earliest source of identifying information.
- If a death certificate, private pathology laboratory report, consultation only report from a hospital, or other report was used to identify a case that was then abstracted from a different source, enter the code for the source that first identified the case, not the source from which it was abstracted.
- If the regional registry or CCR identifies a case and asks a reporting facility to abstract it, the regional registry or CCR must specify the appropriate code to be used in the data item.
- If a case was identified through the Death Clearance process at the regional registry, the hospital must use code 80 when abstracting the case.

Case First Identified at Cancer Reporting Facility

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>REPORTING HOSPITAL, NOS</td>
</tr>
<tr>
<td>20</td>
<td>PATHOLOGY DEPARTMENT REVIEW (surgical pathology reports, autopsies, or cytology reports)</td>
</tr>
<tr>
<td>21</td>
<td>DAILY DISCHARGE REVIEW (daily screening of charts of discharged patients in the medical records department)</td>
</tr>
<tr>
<td>22</td>
<td>DISEASE INDEX REVIEW (review of disease index in the medical records department)</td>
</tr>
<tr>
<td>23</td>
<td>RADIATION THERAPY DEPARTMENT/CENTER</td>
</tr>
<tr>
<td>24</td>
<td>LABORATORY REPORTS (other than pathology reports, code 20)</td>
</tr>
<tr>
<td>25</td>
<td>OUTPATIENT CHEMOTHERAPY</td>
</tr>
<tr>
<td>26</td>
<td>DIAGNOSTIC IMAGING/RADIOLOGY (other than radiation therapy, code 23; includes nuclear medicine)</td>
</tr>
<tr>
<td>27</td>
<td>TUMOR BOARD</td>
</tr>
<tr>
<td>28</td>
<td>HOSPITAL REHABILITATION SERVICE OR CLINIC</td>
</tr>
<tr>
<td>29</td>
<td>OTHER HOSPITAL SOURCE (including clinic, NOS or outpatient department, NOS)</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>30</td>
<td>PHYSICIAN INITIATED CASE</td>
</tr>
<tr>
<td>40</td>
<td>CONSULTATION ONLY OR PATHOLOGY ONLY REPORT (not abstracted by reporting hospital)</td>
</tr>
<tr>
<td>50</td>
<td>PRIVATE PATHOLOGY LABORATORY REPORT</td>
</tr>
<tr>
<td>60</td>
<td>NURSING HOME INITIATED CASE</td>
</tr>
<tr>
<td>70</td>
<td>CORONER'S OFFICE RECORDS REVIEW</td>
</tr>
<tr>
<td>75</td>
<td>MANAGED CARE ORGANIZATION (MCO) OR INSURANCE RECORDS</td>
</tr>
<tr>
<td>80</td>
<td>DEATH CERTIFICATE FOLLOW BACK (case identified through death clearance)</td>
</tr>
<tr>
<td>85</td>
<td>OUT-OF-STATE CASE SHARING</td>
</tr>
<tr>
<td>90</td>
<td>OTHER NON-REPORTING HOSPITAL SOURCE</td>
</tr>
<tr>
<td>95</td>
<td>QUALITY CONTROL REVIEW (case initially identified through quality control activities of a regional registry or the CCR)</td>
</tr>
<tr>
<td>99</td>
<td>UNKNOWN</td>
</tr>
</tbody>
</table>
III.3.9 Payment Source (Primary and Secondary) and Payment Source Text

These data items identify the patient’s insurance status at the time of initial diagnosis. It consists of three data items:

- *Primary source of payment*
- *Secondary source of payment*
- 40-character alphanumeric text data item for collecting the specific name of the payment source (i.e., Foundation Health Plan, Blue Shield, etc.).

**Coding Instructions:**

- The primary payment source and text data items are required and may not be left blank.
- Record the primary payer from the information available at diagnosis.
- Enter the secondary payment source if it is available in the medical record.
- When multiple insurances are listed:
  - Code the first mentioned as the primary, and the second as secondary.
  - Code the closest to the date of diagnosis when there are multiple admissions and/or multiple physician encounters.
- When the primary payer at diagnosis is unknown, record the information available during the initial treatment period.
- Code 02 when the only information is “self-pay.”
- Code 10 for prisoners when no further information is available.
- Codes 28-HMO and 29-PPO are California specific codes that are converted to code 20-Managed Care for submission to standard setting agencies. This was effective with 2004 cases.
- Code 89-County Funded, NOS is a California specific code that is converted to code 31-Medicaid for submission to standard setting agencies. This was effective with 2006 cases.

<table>
<thead>
<tr>
<th>Code</th>
<th>Label</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>NOT INSURED</td>
<td>Patient has no insurance and is declared a charity write-off</td>
</tr>
<tr>
<td>02</td>
<td>NOT INSURED, SELF PAY</td>
<td>Patient has no insurance and is declared responsible for charges</td>
</tr>
<tr>
<td>10</td>
<td>INSURANCE, NOS</td>
<td>Type of insurance unknown or other than the types listed in codes 20, 21, 31, 35, 60–68</td>
</tr>
<tr>
<td>20</td>
<td>PRIVATE INSURANCE: MANAGED CARE, HMO,</td>
<td>An organized system of prepaid care for a group of enrollees usually within a defined geographic area. Generally formed as one of four types: a group</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Details</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>144</td>
<td>OR PPO</td>
<td>Model, an independent physician association (IPA), a network, or a staff model. “Gate-keeper model” is another term for describing this type of insurance.</td>
</tr>
<tr>
<td>21</td>
<td>PRIVATE INSURANCE: FEE-FOR SERVICE</td>
<td>An insurance plan that does not have a negotiated fee structure with the participating reporting facility. Type of insurance plan not coded as 20.</td>
</tr>
<tr>
<td>28</td>
<td>HMO</td>
<td>California specific code.</td>
</tr>
<tr>
<td>29</td>
<td>PPO</td>
<td>California specific code.</td>
</tr>
<tr>
<td>31</td>
<td>MEDICAID</td>
<td>State government administered insurance for persons who are uninsured, below the poverty level, or covered under entitlement programs. Medicaid other than described in code 35.</td>
</tr>
<tr>
<td>35</td>
<td>MEDICAID ADMINISTERED THROUGH A MANAGED CARE PLAN</td>
<td>Patient is enrolled in Medicaid through a Managed Care program (for example, HMO or PPO). The Managed Care plan pays for all incurred costs.</td>
</tr>
<tr>
<td>60</td>
<td>MEDICARE WITHOUT SUPPLEMENT, MEDICARE, NOS</td>
<td>Federal government funded insurance for persons who are 65 years of age or older, or are chronically disabled (Social Security insurance eligible), or are dialysis patients. Not described in codes 61, 62, or 63.</td>
</tr>
<tr>
<td>61</td>
<td>MEDICARE WITH SUPPLEMENT, NOS</td>
<td>Patient has Medicare and another type of unspecified insurance to pay costs not covered by Medicare.</td>
</tr>
<tr>
<td>62</td>
<td>MEDICARE – ADMINISTERED THROUGH A MANAGED CARE PLAN</td>
<td>Patient is enrolled in Medicare through a Managed Care plan (for example, HMO or PPO). The Managed Care plan pays for all incurred costs.</td>
</tr>
<tr>
<td>63</td>
<td>MEDICARE WITH PRIVATE SUPPLEMENT</td>
<td>Patient has Medicare and private insurance to pay costs not covered by Medicare.</td>
</tr>
<tr>
<td>64</td>
<td>MEDICARE WITH MEDICAID ELIGIBILITY</td>
<td>Federal government Medicare insurance with State Medicaid administered supplement.</td>
</tr>
<tr>
<td>65</td>
<td>TRICARE</td>
<td>Department of Defense program providing supplementary civilian-sector reporting facility and medical services beyond a military treatment facility to military dependents, retirees, and their dependents. Formally CHAMPUS (Civilian Health and Medical Program of the Uniformed Services).</td>
</tr>
<tr>
<td>66</td>
<td>MILITARY</td>
<td>Military personnel or their dependents who are treated at a military facility.</td>
</tr>
<tr>
<td>67</td>
<td>VETERANS AFFAIRS</td>
<td>Veterans who are treated in Veterans Affairs facilities.</td>
</tr>
<tr>
<td>68</td>
<td>INDIAN/PUBLIC HEALTH SERVICES</td>
<td>Patient who receives care at an Indian Health Service facility or at another facility, and the medical costs are reimbursed by the Indian Health Service. Patient receives care at a Public Health Service facility or at another facility, and medical costs are reimbursed by the Public Health Service.</td>
</tr>
<tr>
<td>89</td>
<td>COUNTY FUNDED, NOS</td>
<td>California specific code</td>
</tr>
<tr>
<td>----</td>
<td>------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>99</td>
<td>INSURANCE STATUS UNKNOWN</td>
<td>It is unknown from the patient’s medical record whether or not the patient is insured</td>
</tr>
</tbody>
</table>
III.3.10 Reporting Facility Referred From
The CCR assigned reporting facility code for the facility or agency that has referred the patient to your facility.

Coding Instructions:

- Refer to the most current California Reporting Facility Codes lists, located on the CCR website https://www.ccrcal.org, Registrar Resources, Reporting Cancer in California, Volumes I-IV.
  - Lists are presented in both alphabetical and code order.
- Code Facility Referred From to 0000999994 UNSPEC NONCAL HOSP, when out of state patient is seen at your facility for further workup or treatment.
- If the diagnosis was made before admission (diagnosed PTA), enter the CCR assigned reporting facility code for the other facility at which the patient was previously seen for the disease.
III.3.11 Reporting Facility Referred To
The CCR assigned reporting facility code for the facility or agency that your reporting facility has referred the patient to.

Coding Instructions:
- Refer to the most current California Reporting Facility Codes lists, located on the CCR website https://www.ccrcal.org/, Reporting Cancer in California, Volumes I-IV.
  - Lists are presented in both alphabetical and code order.
- If the patient is seen at another reporting facility or other facility for specialized cancer treatment or any other cancer-related reason after admission to the reporting facility, enter the facility's name or CCR assigned reporting facility code.
III.3.12 Physicians
Each reporting facility must maintain its own roster of physicians and their code or NPI numbers. The non-NPI numbers codes are based on the physicians' California license numbers.

As physicians who treat cancer patients join the reporting facility's staff, they must be added to the roster with their license or NPI numbers. If the license number is unavailable, assign a temporary number, beginning it with the letter X to differentiate it from regular codes. When the license number becomes available, update the files as soon as possible.
III.3.12.1 Physician License Numbers
Enter the physician’s license number.

Coding Instructions:

- Enter the California State physician's license number.
  - These are eight characters in length and the first character is always an alpha character.
  - License numbers less than eight characters insert zero(s) after the first alpha character.
    
    **Example:** Physician - A23456 would be entered A0023456
  - For dentists, the same instructions apply.
    
    **Example:** Dentist - D0056789 would be entered D0056789

- For osteopaths, add a leading O (alpha character) and then enter the entire eight-character code.
  - It is important to note that the first character of the osteopath license is an alpha character, and the third character is a zero.
  - For handling a nine-character number, drop the first zero after O2.
    
    **Example:** Osteopath - O20A4422 would be entered O20A4422 or for nine-digit O20A44222 would be entered O2A44222

- **Out-of-state license numbers:**
  - The first character must be an X.
  - If this number is less than seven characters, insert zeros between the X and the license number.
III.3.12.2 Entering Physician NPI Codes

Enter the physician NPI code in the respective data item, if available. This data item is required if available by the CCR (if the information is obtainable for abstracting, it is required) for cases diagnosed January 1, 2007 and forward. See Appendix P - National Provider Identifier (NPI) codes for further details.

Coding Instructions:

- The Managing Physician data item may not be blank.
- Use the following codes for surgeon, radiation oncologist, and medical oncologist.
- Additional physicians are designated by their role in the case, i.e. referring, consulting, and other. See Follow-Up Physician for further instructions.
- If there is no managing physician, or the managing physician cannot be determined, the code for "unknown physician" or "license number not assigned" (99999999) must be entered.
- If the managing physician is the same as another physician, (i.e., the medical oncologist) the license number must be entered in both places.

### Surgeon

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00000000</td>
<td>No surgery and no surgical consultation performed</td>
</tr>
<tr>
<td>88888888</td>
<td>Non-surgeon performed procedure</td>
</tr>
<tr>
<td>99999999</td>
<td>Physician is unknown, or an identification number is not assigned</td>
</tr>
</tbody>
</table>

### Radiation Oncologist

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00000000</td>
<td>No radiation therapy or radiation therapy consult performed</td>
</tr>
<tr>
<td>99999999</td>
<td>Physician is unknown, or an identification number is not assigned</td>
</tr>
</tbody>
</table>

### Medical Oncologist

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00000000</td>
<td>No chemotherapy or chemotherapy consult was performed</td>
</tr>
<tr>
<td>99999999</td>
<td>Physician is unknown, or an identification number is not assigned</td>
</tr>
</tbody>
</table>
III.3.13 Secondary Diagnosis 1-10

Secondary Diagnosis 1-10 data items are designed to capture the patient’s preexisting or secondary diagnosis, factors influencing health status, and/or complications during the admission to the reporting facility for the treatment of cancer using ICD-10-CM codes. These factors may affect treatment decisions and influence outcomes. These data items were developed to capture ICD-10-CM, which can be up to 7 characters in length and have a different structure than ICD-9-CM.

**Note: ICD-10-CM were implemented October 1, 2015.**

**Coding Instructions:**

- Use the *Secondary Diagnosis 1–10* data items when your facility begins using ICD-10-CM. Only ICD-10-CM codes are allowed in these data items.

- Data collection of *Secondary Diagnosis 1-10* data items are required if available by the CCR (if the information is obtainable for abstracting, it is required), and is required from CoC facilities.

- These data items are left justified. Do **not** add additional characters, such as 0’s if the ICD-10-CM code is less than 7-characters.

- If ICD-9-CM was initially used in the patient record for a case and then the ICD-10-CM was subsequently used, code the relevant ICD-9-CM codes in *Comorbidities and Complications* and the relevant ICD-10-CM codes in Secondary Diagnoses. Do not attempt to convert between versions.

- If multiple ICD-10-CM codes are available to enter into these data items, use the Secondary Diagnosis data items in order beginning with Secondary Diagnosis 1 and use the other nine (9) data items in order, using as many as needed.

- If there is a secondary diagnosis that is stated in the medical record but is not coded, do not attempt to code the condition.

  **Example:** If diabetes is mentioned in the medical record and it is not coded in the medical record do not attempt to code the condition in ICD-10-CM or fill in these data items.

- Code the secondary diagnoses in the sequence in which they appear in the discharge summary or recorded by the billing department.

- Report the secondary diagnoses for this cancer using the following priority rules:
  1. Surgically treated patients:
     a. Following the most definitive surgery of the primary site.
     b. Following other non-primary site surgeries.
  2. Non-surgically treated patients:
a. Following the first treatment encounter/episode.

3. In cases of non-treatment:
   a. Following the last diagnostic/evaluative encounter.

   - If no ICD-10-CM secondary diagnoses were documented, code 0000000 in the data item Secondary Diagnosis #1 and leave the remaining data items blank.
   - If fewer than 10 ICD-10-CM secondary diagnoses are listed, then code the diagnoses listed, and leave the remaining blank.
   - For cases or tumors diagnosed January 1, 2018 and forward, refer to the most current STAndards for Oncology Registry Entry (STORE) Manual for coding instructions.

   Note: For ICD-10-CM codes there is an assumed decimal between the third and fourth characters.
III.3.14 Comorbidities and Complications

Comorbidities and Complications 1-10 data items are designated to capture the patient's preexisting medical conditions, factors influencing health status, and/or complications during the patient's admission to the reporting facility for the treatment of the cancer using ICD-9-CM codes. These factors may affect treatment decisions and influence outcomes.

Note: ICD-10-CM were implemented October 1, 2015.

Coding Instructions:

- **Only** ICD-9-CM codes are allowed in this data item. ICD-10-CM codes are to be coded in the data item Secondary Diagnosis 1-10. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.

- Although data collection for these data items is required by the CCR if available (if the information is obtainable for abstracting, it is required), Comorbidity/Complications 1-10 will be collected from CoC facilities.

- If a comorbid condition is stated in the medical record but is not coded, do not attempt to code the condition in ICD-9-CM or ICD-10-CM.

  **Example:** If diabetes is mentioned in the medical record and it is not coded in the medical record do not attempt to code the condition in ICD-10-CM or fill in these data items.

- Code the comorbid conditions in the sequence in which they appear in the discharge summary or recorded by the billing department.

- Report the comorbid conditions for this cancer using the following priority rules:
  1. Surgically treated patients:
     a. Following the most definitive surgery of the primary site
     b. Following other non-primary site surgeries
  2. Non-surgically treated patients:
     a. Following the first treatment encounter/episode
  3. In cases of non-treatment:
     a. Following the last diagnostic/evaluative encounter

- If no ICD-9-CM comorbid conditions were documented, then code 00000 in the data item Comorbidities and Complications #1 and leave the remaining data items blank.

- If fewer than 10 ICD-9-CM comorbid conditions are listed, then code the diagnoses listed, and leave the remaining data items blank.
For cases or tumors diagnosed January 1, 2018 and forward, refer to the STAndards for Oncology Registry Entry (STORE) Manual for coding instructions.

Note: For comorbid conditions (ICD-9-CM codes 00100-13980 and 24000-99990), there is an assumed decimal point between the third and fourth characters. For complications (ICD-9-CM codes E8700-E8799 and E9300-E9499), there is an assumed decimal point between the fourth and fifth characters. For conditions influencing health status and contact with health services (ICD-9-CM codes V0720-V0739, V1000-V1590, V2220- V2310, V2540, V4400-V4589, and V5041-V5049), there is an assumed decimal point between the third and fourth characters. For ICD-10-CM codes, there is an assumed decimal between the third and fourth characters.
III.3.15 ICD Revision - Comorbidities and Complications

This item indicates the coding system from which the Comorbidities and Complications codes are provided. This data item is not required by the CCR, but it is required for CoC approved facilities.

Coding Instructions:

- *ICD Revision Comorbidities and Complications* are to be recorded for patients diagnosed January 1, 2006 and forward.
  - ICD-10-CM is allowable for cases diagnosed 2011 and 2012 only.
  - For cases diagnosed January 1, 2013 and forward, code 1 is no longer allowed.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No secondary diagnosis reported</td>
</tr>
<tr>
<td>1</td>
<td>ICD - 10</td>
</tr>
<tr>
<td>9</td>
<td>ICD - 9</td>
</tr>
<tr>
<td>Blank</td>
<td>Comorbidities and Complications not collected</td>
</tr>
</tbody>
</table>
III.3.16 Discovered by Screening

This data item tracks which cancer cases were first diagnosed via screening programs. This item is required if available by the CCR (if the information is obtainable for abstracting, it is required).

Coding Instructions:

- If this information is not available, the data item may be left blank.
- It is an existing optional data item as part of the Department of Defense Data Set and will be collected and transmitted from facilities completing the Department of Defense Data Set.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No (discovered by some other method such as symptomatic patient)</td>
</tr>
<tr>
<td>1</td>
<td>Routine screening exam (e.g. routine screening mammogram in asymptomatic patient)</td>
</tr>
<tr>
<td>2</td>
<td>Reporting facility screening program (targeted to a particular cancer)</td>
</tr>
<tr>
<td>3</td>
<td>State-sponsored screening program</td>
</tr>
<tr>
<td>4</td>
<td>Nationally sponsored screening program</td>
</tr>
<tr>
<td>5</td>
<td>Other type of screening (e.g., American Cancer Society screening project)</td>
</tr>
<tr>
<td>9</td>
<td>Unknown if via screening (default)</td>
</tr>
</tbody>
</table>
Part IV. Diagnostic Procedures
Part IV of Volume I contain coding instructions for diagnostic procedures. This includes physical examination, x-rays and scans, scopes, laboratory results, operative and pathologic findings and staging procedures. This section also includes directions regarding diagnostic confirmation.
IV.1 Text - Diagnostic Procedures Performed

Text documentation is an essential component of a complete electronic abstract and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

Text Documentation Instructions:

- Report results for all analytic cases and for autopsy only (Class 38) cases.
- Reporting diagnostic procedures is optional for non-analytic cases; but if they are coded, then they must be supported by text.
- Record text in a consistent, organized manner.
- Use standard medical abbreviations when possible. See Appendix I - Common Acceptable Symbols and Abbreviations.
- Use phrases not complete sentences. Separate phrases using either periods (.) or semi-colons (;).
- Avoid using only uppercase/capitals in text documentation.
- Include where the diagnostic exam/procedure was performed when not at the reporting facility.
  - If exam occurred at another facility prior to admission, begin the exam findings with ‘PTA.’
- Do not leave data item blank. Record “None,” NR, or NA when information is missing from the medical record or there is not pertinent information.
- When entering dates, use either a slash (/) or hyphen (-) to separate month, day, and year.
- Coded data items must be supported by text documentation on the abstract.
  - Information which does not require supporting text:
    - Date of Birth (DOB) (unless the patient is 100 years of age or older) See Age at Diagnosis.
    - Social Security Number (SSN)
    - Medical Record Number (MRN)
    - Comorbidities
    - Secondary Diagnosis
- Demographics may be entered in either the Text-Physical Exam or Text-Remarks data items, but it is preferred to enter the information in the Text-Remarks. See Text - Remarks for Instructions.
- Reference Appendix M for a list of Q-Tips which may be related to this topic.
**IV.1.1 Text - Physical Examination**
Enter findings from the physical examination performed by the physician.

**Text Documentation Instructions:**

- **For Analytic cases**, include the following information in the Physical Exam text:
  - Date of the first physical exam reported for the cancer at your facility.
  - Chief complaint/reason for the admission.
  - Brief statement of the patient’s history of the cancer (if applicable) including any relevant treatment and staging information.
  - Findings in the physical exam that are **pertinent** to the cancer.
    - Primary site location (include laterality)
    - Tumor size/extension to surrounding tissue/structures
    - Lymph Node status
    - Spread to distant sites
  - Physician impression: anything relevant which provides physician’s impression to support the diagnosis, extent of disease, stage, or planned treatment.

- **For Non-Analytic cases**, include the following information in the Physical Exam text:
  - Date of admission to your facility
  - Reason for the admission
  - Patient’s history of the cancer including all relevant staging information and 1st course treatment.

- Do not record planned work-up.
- Do not record findings from exams that are recorded in other text fields on the abstract (X-Rays/Scans, Scopes, etc.).
- Record the Managing/Treating physician’s impression/statement of the patient’s overall **clinical** response to neoadjuvant therapy.
- Record required patient demographics if not recorded in **Text – Remarks**.
IV.1.2 Text - X-Ray/Scans

Document X-Ray/Scan findings in this text data item to capture relevant positive and negative findings on imaging or scans performed.

Text Documentation Instructions:

- Enter findings from X-rays, computerized axial tomography (CT or CAT scans), magnetic resonance imaging (MRI), echosonography, and other imaging used to diagnose or stage the cancer.
  - Document findings from the original diagnostic workup only. Do not record findings for follow-up, recurrence, or progression of disease.
- Record:
  - Date of exam(s) in chronological order.
    - For multiple exams performed on the same date, record the date once and separate exams with a period (.) or semi-colon (;).
  - Type of exam/body part examined (CT Chest; MRI Brain).
  - Where the exam was performed (if not at the reporting facility).
  - Pertinent findings, both positive and negative, that identify:
    - Primary site location (include subsite/lobe/quadrant/laterality/whether it is multi-focal)
    - Tumor size/extension to surrounding tissue/structures
    - Lymph Node status
    - Spread to distant sites
    - Capture any other clinical information needed to support site-specific data items
  - Diagnostic statement/impression of the radiologist or endoscopist, including response to neoadjuvant therapy.
IV.1.3 Text - Scopes

In the Scopes section of the abstract, record information for all scopes performed as part of the initial work-up of diagnosis.

Text Documentation Instructions:

- Enter the date and type of procedure performed, such as laryngoscopies, sigmoidoscopies, mediastinoscopies, colonoscopies, and other endoscopic procedures.
- Record:
  - Date of exam(s) in chronological order.
  - Type of exam/body part examined.
  - Where the exam was performed (if not at the reporting facility).
  - Pertinent findings, both positive and negative, that identify:
    - Primary site location (include subsite/lobe/quadrant/laterality/whether it is multi-focal)
    - Tumor size/extension to surrounding tissue/structures
    - Lymph Node status
    - Spread to distant sites
    - Capture any other clinical information needed to support site-specific data items.
- Diagnostic statement/impression and/or stage of the endoscopist, including response to neoadjuvant therapy.
- Include mention of biopsies, washings, and other procedures performed during the examination. All results obtained from these procedures must be entered in the Text – Pathology Section.
IV.1.4 Text - Laboratory Tests
Enter the findings from the laboratory tests or procedures used in establishing the diagnoses of neoplasms or metastases, such as serum protein electrophoresis for multiple myeloma or Waldenstrom's macroglobulinemia, serum alpha-fetoprotein (AFP) for liver cancer, and other tumor marker studies.

Text Documentation Instructions:
- Text must support every lab result and/or tumor marker that is used to code data items on the abstract.
- Record:
  - Lab results pertinent to primary site being reported
    - Pertinent labs prior to surgery or treatment
    - Pertinent labs post OP for certain primary sites
  - Date of test(s) in chronological order
  - Name of test
  - Where the exam was performed (if not at the reporting facility).
  - Test Results
    - Normal test value/range and/or interpretation recorded in parenthesis.
    - If only the test result or interpretation is stated by the physician and there is no lab report in the chart, document results as per MD.
- Record T- and B-cell marker studies on leukemia’s and lymphomas, but enter hematology reports for leukemia and myeloma under Pathology.
- In leukemia cases where both bone marrow and chromosomes are analyzed, the bone marrow results take precedence in coding histologic type, unless more specific information is given in the cytogenetic report. See Diagnostic Confirmation for additional information.
- Subcategories of acute myeloid leukemia are described according to cytogenetic abnormalities. If these abnormalities are included in a laboratory report, they take precedence in coding histologic type.
- Record chromosome study or cytogenetic and molecular biological data results here. Enter "none" if no pertinent laboratory tests were performed.
IV.1.5 Text - Operative Findings

Enter findings from operative procedures performed during the diagnosis or treatment of the cancer.

Text Documentation Instructions:

- Record pertinent observations of the surgeon (what is seen/felt/palpated) during the surgical procedure.
- Record pertinent positive and negative results of diagnostic surgical procedures, such as biopsies, dilation and curettage (D & C), and laparotomy, as well as definitive surgery findings.
- Findings may be listed in the formal operative report (heading labeled “operative findings”), within the body of the operative report, or in the “op notes” (progress notes).
- Do not report what the surgeon did (step by step procedure) or path findings.
- Record:
  - Date of procedure(s) in chronological order.
  - Type of procedure/body part(s) biopsied/resected/removed.
    - Provide enough information to support staging/diagnostic procedure and surgery codes
  - Where the procedure was performed (if not at the reporting facility).
  - Pertinent findings, both positive and negative, that identify:
    - Primary site location (include subsite/lobe/quadrant/laterality/whether it is multi-focal)
    - Tumor size/extension to surrounding tissue/structures
    - Lymph Node status
    - Spread to distant sites
    - Tumor tissue that was not/could not be removed
    - Residual tumor status/size
    - Surgical Margins/Measurements
  - Record “technique only” if no findings are documented or NSF when there are no significant findings.
IV.1.6 Text - Pathology Findings

In this text data item, enter the details needed to describe the information from the pathology or cytology reports.

Pathology reports that are consultation only are typically requested from a more experienced or specialized pathologist/lab and are generally thought to be more accurate. The CCR recommends that information from consult pathology reports be preferred over the original pathology report.

Text Documentation Instructions:

- If there is a pathology report, all the Path Report Identifier Data Item fields must be completed. See Pathology Report Identifier Data Items for further instructions.
  - If the medical record only includes "hearsay" information or the physician only refers to a report finding, but there is no report in the medical record, do not complete the Path Report Data Items, but include the information in the text data item.
- Include information from all pertinent pathology-autopsy reports for procedures performed at your facility and any outside slide information that may be available.
- Record reports in chronological order as follows:
  - Date specimen collected
  - Primary cancer site/tissue specimen source
  - Clearly describe what is sampled/removed (FNA, Core Bx, organ resection)
  - Histology/Behavior/Grade
  - Tumor size (record greatest dimension only, unless other dimensions are required to support codes)
  - Extent of disease within and beyond the primary site
  - Lymphovascular Invasion status
  - Status of Margins
    - Including any site-specific margins
  - Lymph node involvement stated as number of positive/number examined and name of lymph node chain if stated (6/12 AxLN).
  - Other tissue/organs examined and findings
  - Treatment effect to neoadjuvant therapy as stated in the pathology report, including the treatment response score
  - TNM Staging by the pathologist
- Pertinent biomarker results (recorded in SSDIs, used for staging, evaluate response to neoadjuvant therapy, etc.)
- Comments or reports from outside consultants (review of outside slides)
- Addendums
- Capture any other information needed to support site-specific data items

- If additional space is needed, continue the pathology text in any other available text data item and indicate which text data item the text is extending to (e.g. * Text - Remarks*).
### IV.1.6.1 Pathology Report Identifier Data Items

The following data items have replaced the *DXRX Report Identifiers* as of January 1, 2010.

#### Coding Instructions:

- **Path Reporting Facility ID (1-5)**
  - This data item identifies the pathology facility that produced the report.

- Refer to the most current *California Reporting Facility Codes* lists, located on the CCR website [https://www.ccrical.org/](https://www.ccrical.org/), Registrar Resources, Reporting Cancer in California, Volumes I-IV.
  - Lists are presented in both alphabetical and code order.
  - Enter the reporting facility's CCR assigned reporting facility code.
  - This data item replaces CCR data item, *DXRX Report Facility ID*, and is required.

- **Path Report Numbers (1-5)**
  - This data item is a unique sequential number assigned by a laboratory to the corresponding pathology report for the case.
  - This data item replaces CCR data item, *DXRX Report Number*, and is required.

- **Path Date Specimen Collected (1-5)**
  - This data item collects the date and time of the specimen collection for the cancer being reported, not the date read or date the report was typed.
  - This data item replaces CCR data item, *DXRX Report Date*, and is required.
  - Enter the date and, if available, the time the specimen was collected.

- **Path Report Type (1-5)**
  - This data item describes the type of report transmitted to the cancer registry and may need to be classified at the Central Cancer Registry.
  - This data item accommodates information for only one path report.
  - If additional path reports were prepared, enter the path report type(s) in *Path Report Type 2* through *Path Report Type 5*.
  - This data item is required by the CCR.

- Consult your software vendor for specific data entry instructions.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>Pathology</td>
</tr>
</tbody>
</table>

166
<table>
<thead>
<tr>
<th></th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>02</td>
<td>Cytology</td>
</tr>
<tr>
<td>03</td>
<td>Gyn Cytology</td>
</tr>
<tr>
<td>04</td>
<td>Bone Marrow (biopsy/aspirate)</td>
</tr>
<tr>
<td>05</td>
<td>Autopsy</td>
</tr>
<tr>
<td>06</td>
<td>Clinical Laboratory Blood Work, NOS</td>
</tr>
<tr>
<td>07</td>
<td>Tumor Marker (p53, CD’s Ki, CEA, HER2/neu, etc.)</td>
</tr>
<tr>
<td>08</td>
<td>Cytogenetics</td>
</tr>
<tr>
<td>09</td>
<td>Immunohistochemical Stains</td>
</tr>
<tr>
<td>10</td>
<td>Molecular Studies</td>
</tr>
<tr>
<td>11</td>
<td>Flow Cytometry, Immunophenotype</td>
</tr>
<tr>
<td>98</td>
<td>Other</td>
</tr>
<tr>
<td>99</td>
<td>Unknown</td>
</tr>
</tbody>
</table>
IV.1.7 Text - Staging
The text data item for staging is used to document additional staging and diagnostic workup information not already entered in other text data items.

Text Documentation Instructions:
- Staging by physicians (other than the pathologist) may be recorded in this data item.
  - Record the type of physician recording the stage (Managing MD, Radiation Oncologist, Registrar and MD, etc.).
  - Staging by pathologist should be recorded in the Text-Pathology Findings date Item.
- Examples of information that can be recorded in this data item:
  - Diagnostic workup (date/procedure/findings), or other information(outpatient progress notes/consults/treatment summaries) which provided information for assigning stage.

Example:
- Per MD Oncology Note, completion staging workup Pos for bone mets.
- Staging by MD’s (other than the pathologist) or other info on who staged the case may be recorded here.

Example:
- Per Surgeon, pre-op clinical stage was T2N0M0 Stage 1.
- Per ROC report 5/1/16 TNM stage cT3cN1cM0 Stage 3 (Larynx)
- Clinical Stage per Registrar, Pathologic stage per Managing
- MD and Registrar
- Clinical and Path stage per Tumor Board consensus.
- Staging conflicts: useful for times when QC of registry abstract is compared to the source medical record or to explain any circumstance where text documentation and TNM stage recorded may conflict.

Example:
- Conflict between MD stage and Registrar documentation. Only partial/limited records available to Registrar – MD stage recorded.
- Conflict between MD staging and Registrar review of complete records- Registrar stage coded. MD stage was (document original MD stage).
IV.2 Diagnostic Confirmation
Records the best method used to confirm the presence of the cancer being reported. The best method could occur at any time throughout the entire course of the disease. It is not limited to the confirmation at the time of initial diagnosis. The most conclusive method should be coded in the Diagnostic Confirmation data item.

Coding Instructions:
- Medical records must be studied to determine what methods were used to confirm the diagnosis of cancer.
- As the Diagnostic Confirmation data item covers the patient's entire medical history, the best method could occur at any time throughout the entire course of the disease. It is not limited to the confirmation at the time of initial diagnosis.
- Coding for the Diagnostic Confirmation data item is in the order of the conclusiveness of the method with the lowest number taking precedence over other codes even when there are multiple diagnostic methods.
  - Change to a lower code:
    - If at ANY TIME during the course of disease the patient has a diagnostic confirmation of a higher priority.
    - If a higher priority diagnostic confirmation code is based on the result of subsequent treatment.
- Code 1 if the microscopic diagnosis is based on:
  - Tissue specimens from fine needle aspirate, biopsy, surgery, autopsy, or D&C
  - Bone marrow aspiration and/or biopsy
- Code 2 if the microscopic diagnosis is based on:
  - Examination of cells (instead of tissue)

Examples:
1. Include but is not limited to sputum, vaginal, and cervical smears; bronchial washings or brushings; prostatic or breast secretions; gastric, spinal, peritoneal or pleural fluid; urinary sediment.
2. Paraffin block specimens from concentrated spinal, pleural, or peritoneal fluid.
- Code 4 if the diagnosis is documented as microscopically confirmed, but the type of confirmation is not known.
- Code 5 if the diagnosis is based on laboratory tests or tumor marker studies that are clinically diagnostic for the specific cancer and there is no other diagnostic workup (e.g., imaging).
- Code 6 if the diagnosis is only based on:
  - Surgeons operative report from a surgical exploration or endoscopy, when no tissue was examined.
  - **Examples**: Mediastinoscopy, peritoneoscopy, or colonoscopy.
  - Gross autopsy findings, without cytologic or tissue confirmation.

- Code 7 when the only confirmation of malignancy is diagnostic imaging.
  - **Examples**: CT or MRI scans.

- Code 8 when the diagnosis is made by any clinical method not mentioned in the previous codes.
  - This code is used when the only confirmation of disease is the physician’s clinical diagnosis.

- Code 9 if it is unknown if the diagnosis was confirmed microscopically.

### Microscopic Confirmation

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>POSITIVE HISTOLOGY</td>
</tr>
<tr>
<td></td>
<td>Use for microscopic confirmation based on biopsy, including punch biopsy, needle biopsy, bone marrow aspiration, curettage, and conization</td>
</tr>
<tr>
<td></td>
<td>Code 1 includes:</td>
</tr>
<tr>
<td></td>
<td>1. Microscopic examination of frozen section specimens and surgically removed tumor tissue, whether taken from the primary or a metastatic site</td>
</tr>
<tr>
<td></td>
<td>2. Leukemia only: Records a positive blood count (CBC or peripheral blood)</td>
</tr>
<tr>
<td></td>
<td>3. Cancers first diagnosed as a result of an autopsy or previously suspected and confirmed in an autopsy if microscopic examination is performed on the autopsy specimens</td>
</tr>
</tbody>
</table>

| 2    | POSITIVE CYTOLOGY, NO POSITIVE HISTOLOGY |
|      | Cytologic diagnoses based on microscopic examination of cells, rather than tissue |
|      | 1. Do not use code 2 if cancer is ruled out by a histologic examination |
|      | 2. Included is sputum, cervical, and vaginal smears; fine needle aspiration from breast or other organs; bronchial brushings and washings; tracheal washings; prostatic secretions; gastric, spinal, or peritoneal fluid; and urinary sediment, or urine cytology |
|      | Also, include diagnoses based on paraffin block specimens from concentrated spinal, pleural, or peritoneal fluid |

**CODE 3 is ONLY used for Hematopoietic and Lymphoid Neoplasms (9590/3-9993/3)**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>POSITIVE HISTOLOGY PLUS</td>
</tr>
<tr>
<td></td>
<td>Positive immunophenotyping AND/OR positive genetic studies</td>
</tr>
</tbody>
</table>
Code 3 is used when the following conditions are met:
1. Genetic testing and/or immunophenotyping are described in the Hematopoietic Database "Definitive Diagnostic Method", AND
2. Genetic testing and/or immunophenotyping were done, AND
3. Genetic testing and/or immunophenotyping were positive (proved the type of neoplasm being coded)

Flow cytometry is a test for immunophenotyping and also for genetic testing. It is coded for hematopoietic and lymphoid neoplasms using the directions above.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>POSITIVE MICROSCOPIC CONFIRMATION, METHOD NOT SPECIFIED</td>
</tr>
<tr>
<td></td>
<td>Cases with a history of microscopic confirmation, but no information about whether based on examination of tissue or cells</td>
</tr>
</tbody>
</table>

### No Microscopic Confirmation

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>POSITIVE LABORATORY TEST OR MARKER STUDY</td>
</tr>
<tr>
<td></td>
<td>Clinical diagnosis of cancer based on certain laboratory tests or marker studies that are clinically diagnostic for cancer</td>
</tr>
<tr>
<td></td>
<td>Examples are the presence of alpha-fetoprotein (AFP) for liver cancer and an abnormal electrophoretic spike for multiple myeloma or Waldenstrom’s macroglobulinemia</td>
</tr>
<tr>
<td></td>
<td>Although an elevated PSA is nondiagnostic of cancer, if the physician uses the PSA as a basis for diagnosing prostate cancer with no other workup, record as code 5</td>
</tr>
<tr>
<td>6</td>
<td>DIRECT VISUALIZATION WITHOUT MICROSCOPIC CONFIRMATION</td>
</tr>
<tr>
<td></td>
<td>Includes diagnoses by visualization and/or palpation during surgical or endoscopic exploration, or by gross autopsy</td>
</tr>
<tr>
<td></td>
<td>Do not use code 6 if visualization or palpation during surgery or endoscopy is confirmed by a positive histology or cytology report</td>
</tr>
<tr>
<td>7</td>
<td>RADIOGRAPHY WITHOUT MICROSCOPIC CONFIRMATION</td>
</tr>
<tr>
<td></td>
<td>Includes all diagnostic radiology, scans, ultrasound, and other imaging technologies not confirmed by a positive histologic or cytologic report or by direct visualization</td>
</tr>
<tr>
<td>8</td>
<td>CLINICAL DIAGNOSIS ONLY (Other than 5, 6, or 7)</td>
</tr>
<tr>
<td></td>
<td>Cases diagnosed by clinical methods other than direct visualization and/or palpation during surgery, endoscopy, or gross autopsy, if not confirmed microscopically</td>
</tr>
<tr>
<td>9</td>
<td>UNKNOWN WHETHER OR NOT MICROSCOPICALLY CONFIRMED</td>
</tr>
<tr>
<td></td>
<td>Death Certificate Only (DCO)</td>
</tr>
</tbody>
</table>
Part V. Tumor Data

Part V of Volume I contain instructions and guidelines on coding tumor related data items. Items included in this section are *Primary Site, Laterality, Histology*, coding and staging systems, and pediatric staging.
V.1 Primary Site
Primary site is the anatomic position of where the primary tumor developed. It is essential to identify the original (primary) site of a tumor rather than a metastatic (secondary) site.

Coding Instructions:
- Resources for coding primary site are:
    - The Primary Site data item codes are found in the Topography section. In the Index, the site is indicated by a four-character code. The first character is always a “C,” followed by three numbers.
    - The first two numerical digits stand for the primary site (organ, tissue, or structure). The third digit identifies the subsite of the primary site.
  - The current Solid Tumor Rules are used for selected primary site coding instructions.
  - Identify the primary site by careful scrutiny of all reports in the patient's medical record.
    - Where information in the record is conflicting, statements in the pathology report generally take precedence over other statements.
    - If the record does not provide a clear answer, ask the patient's physician.
  - If the only information available is the secondary site, then it should be reported in accordance with the instructions in Section Primary Site – Site-Specific Special Conditions.
  - Record the site in which the primary tumor originated, including Gastrointestinal Stromal Tumors (GIST) tumors, even if it extends onto/into an adjacent subsite.

Examples:
1. A computerized axial tomographic (CT or CAT) scan of a patient's chest revealed a large malignancy in the upper lobe of the left lung. The correct ICD-O-3 code is therefore C34.1, which should be entered C341.
2. The site cardia of the stomach (the part of the stomach at the opening of the esophagus) is listed in the Index for the ICD-O-3 under "cardia" or "stomach, cardia" as T-C16.0, which should be entered C160.
   - The current Solid Tumor Rules are used for selected primary site coding instructions.
• Code the site of the invasive tumor when there is an invasive and an in-situ tumor in different subsites of the same anatomic site.

• Code a transplanted organ to the primary site the organ is grafted to.

• When the medical record does not contain enough information to assign a primary site:
  o Consult a physician advisor to assign the code.
  o Use the NOS code for the organ system or Ill-Defined site (C760-C768) when the physician cannot identify the primary site.

  ▪ Occult Tumors of the Head and Neck:
    • Assign C119 (Nasopharynx) for occult head and neck tumors with cervical node mets in Levels I-VII, and other group nodes positive for Epstein-Barr virus (EBV+) (regardless of p16 status) encoded small RNAs (EBER) identified by in-situ hybridization.
    • Assign C109 (Oropharynx) for occult head and neck tumors with cervical node mets in Levels I-VII, and other group nodes, p16 positive with histology consistent with HPV-mediated oropharyngeal carcinoma (OPC).
    • Assign C760 (Head, Neck, Face NOS) for occult head and neck tumors with positive cervical nodes. Schema Discriminator 1, is used to discriminate between these cases and other uses of C760. See the SSDI Manual, Appendix A for additional information.
      o Assign the NOS code for the body system when there are two or more possible primary sites documented and they are within the same system.
      o Assign C449 (Skin, NOS) for Merkel cell carcinoma presenting in a nodal or distant site and the site of origin is unknown.
      o Code unknown primary (C809) in the absence of any information when the physician is not able to identify a primary site and none of the instructions above apply.

• Reference Appendix M for a list of Q-Tips which may be related to this topic.

• Code the last digit of the primary site code to '8' when a single tumor overlaps an adjacent subsite(s) of an organ, and the point of origin cannot be determined.

  Exception: Skin Cancers – Assign the site code for where the bulk of the tumor is or where the epicenter is. Do not use code C448.

• Code the last digit of the primary site to ‘9’ for single primaries, when multiple tumors arise in different subsites of the same anatomic site and the point of origin cannot be determined.
In the absence of any additional information, assign the codes listed for these primary sites:

<table>
<thead>
<tr>
<th>Primary Site</th>
<th>ICD-O-3 Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ampullary/peri-ampullary</td>
<td>C241</td>
</tr>
<tr>
<td>Anal margin</td>
<td>C445</td>
</tr>
<tr>
<td>Anal verge</td>
<td>C211</td>
</tr>
<tr>
<td>Angle of the stomach</td>
<td>C162</td>
</tr>
<tr>
<td>Angular incisura of stomach</td>
<td>C163</td>
</tr>
<tr>
<td>Book-leaf lesion (mouth)</td>
<td>C068</td>
</tr>
<tr>
<td>Clavicular skin</td>
<td>C445</td>
</tr>
<tr>
<td>Colored / lipstick portion of the upper lip</td>
<td>C000</td>
</tr>
<tr>
<td>Cutaneous leiomyosarcoma</td>
<td>C44_</td>
</tr>
<tr>
<td>Distal conus</td>
<td>C720</td>
</tr>
<tr>
<td>Edge of tongue</td>
<td>C021</td>
</tr>
<tr>
<td>Frontoparietal (brain)</td>
<td>C718</td>
</tr>
<tr>
<td>Gastric angular notch (incisura)</td>
<td>C163</td>
</tr>
<tr>
<td>Gastrohepatic ligament</td>
<td>C481</td>
</tr>
<tr>
<td>Genu of pancreas</td>
<td>C250</td>
</tr>
<tr>
<td>Glossotonsillar sulcus</td>
<td>C109</td>
</tr>
<tr>
<td>Infrahilar area of lung</td>
<td>C349</td>
</tr>
<tr>
<td>Incisura, incisura angularis</td>
<td>C163</td>
</tr>
<tr>
<td>Interhemispheric fissure (cerebrum)</td>
<td>C710</td>
</tr>
<tr>
<td>Lateral tongue</td>
<td>C023</td>
</tr>
<tr>
<td>Leptomeninges</td>
<td>C709</td>
</tr>
<tr>
<td>Masticator space</td>
<td>C069</td>
</tr>
<tr>
<td>Melanoma, NOS</td>
<td>C449</td>
</tr>
<tr>
<td>Nail bed. Thumb</td>
<td>C446</td>
</tr>
<tr>
<td>Pancreatobiliary space</td>
<td>C269</td>
</tr>
<tr>
<td>Parapharyngeal space</td>
<td>C490</td>
</tr>
<tr>
<td>Perihilar bile duct</td>
<td>C240</td>
</tr>
<tr>
<td>Testis, descended post orchiopex</td>
<td>C621</td>
</tr>
<tr>
<td>Uncinate of pancreas</td>
<td>C250</td>
</tr>
</tbody>
</table>
V.1.1 Identification of Separate Sites
For cases or tumors diagnosed January 1, 2018 and forward, refer to the current Solid Tumor Rules Manual.

Coding Instructions:

- Tumor recurrences only relate to the organ of origin. Metastatic tumors in regional and distant sites are not considered tumor recurrences when applying the Solid Tumor Rules.
- When determining multiple primaries for solid tumors, do not use a physician's statement to decide whether the patient has a recurrence of a previous cancer or a new primary.
- Use the Solid Tumor Rules as written unless a pathologist compares (slide review) the present tumor to the "original" tumor and states that this tumor is a recurrence of a cancer from the previous primary.
V.1.2 Indefinite and Metastatic Sites
This instruction discusses how to code specific categories in instances where a specific primary site cannot be identified.

Coding Instructions:

- Assign codes from the following categories **only** when the primary site cannot be identified exactly:
  - **NOS** (not otherwise specified) subcategory when a subsite or tissue of an organ is not specifically listed in ICD-O-3.
    - Do not use NOS if a more descriptive term is available.
  - **Codes C760 - C768** when diagnoses referring to regions and ill-defined sites of the body, such as "head", "thorax", "abdomen", "pelvis", "upper limb," and "lower limb."
    - These sites typically contain several types of tissue (e.g., bone, skin, soft tissue), which might not be specified on the diagnostic statement.
    - If the tissue in which the tumor originated can be identified, use a more specific site code.
  - **Code C809** when the primary site is not known and the only information available is the metastatic or secondary site.
V.1.3 Primary Site - Site-Specific Special Conditions

For cases or tumors diagnosed January 1, 2018 and forward, refer to the current Solid Tumor Rules Manual.

For hematopoietic and lymphoid cases diagnosed January 1, 2018 and forward, please refer to the SEER Hematopoietic and Lymphoid Neoplasm Database and coding Manual.

Site-Specific Special Conditions Coding Instructions:

SKIN:

- Assign the site code for where the bulk of the tumor is or where the epicenter is. Do **not** use code C448.

  **Melanoma**
  - If the primary site is unknown, assume the primary site is the skin and enter C449.
  - Unless it is stated to be a recurrent or metastatic melanoma, record each melanoma as a separate primary when any of the following apply:
    - The occurrences are more than two months apart.
    - The fourth character of the ICD-O topography code for skin (C44_) is different.
    - The first three digits of the ICD-O-3 morphology code are different.
    - An in-situ melanoma is followed by an invasive melanoma.
    - The occurrences are within the same sub-site code, but have a different laterality or a different trunk side, such as chest and back.

  **Kaposi's Sarcoma**
  - Code the primary site as the site in which the tumor arises. If Kaposi's sarcoma arises in the skin and another site simultaneously, or if no primary site is stated, code the primary site as skin (C44_).

BREAST:

**Subareolar/Retroareolar Tumor**
- Code as the central portion of the breast (C501), which indicates that the tumor arose in the breast tissue beneath the nipple, but not in the nipple itself.

COLON:
Determining Subsite

- If there is no other information given regarding subsite except for the measurement given in the colonoscopy, the measurement may be used to assign subsite. If the colonoscopy measurement is used to assign a specific subsite, the CCR’s standard reference is the colon diagram:

![Colonoscopy Measurements Diagram]

Solid Tumor Rules Manual

- If there is conflicting information in the medical record with regard to subsite and there is no surgical resection, code the subsite as stated by the physician. If there is a surgical resection, code the subsite as stated in the operative report or a combination of the operative report and the pathology report.

Familial Polyposis

- When multiple carcinomas arising in familial polyposis involve multiple segments of the colon or the colon and rectum, code the primary site as colon, NOS (C189).

OTHER:

Neuroblastoma

- Code neuroblastomas of ill-defined sites for the most likely site in each case. (Adrenal medulla is a common site). If the location of the primary tumor is unknown, code as connective, subcutaneous, and other soft tissue, NOS (C499).
**Angiosarcoma**

- Code C422 (spleen) for angiosarcoma of the spleen
- Code C50_ (breast) for angiosarcoma of the breast. Although angiosarcoma originates in the lining of the blood vessels, when it arises in the breast, there is a poorer prognosis than many other breast tumors.
V.1.4 Uncertain Primary Site
Vague or ambiguous terms are sometimes used by physicians when indicating the primary site of a tumor. Interpretation of terms in this context is like their interpretation in a diagnosis of cancer itself. See Ambiguous Diagnostic Reportable Terms for additional information.

Interpret the following list of terms as an indication of the primary site:

<table>
<thead>
<tr>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apparently (malignant)</td>
</tr>
<tr>
<td>Appears to</td>
</tr>
<tr>
<td>Comparable with</td>
</tr>
<tr>
<td>Compatible with (a malignancy)</td>
</tr>
<tr>
<td>Consistent with (a malignancy)</td>
</tr>
<tr>
<td>Favor (a malignancy)</td>
</tr>
<tr>
<td>Malignant appearing</td>
</tr>
<tr>
<td>Most likely (malignant)</td>
</tr>
<tr>
<td>Presumed (malignant)</td>
</tr>
<tr>
<td>Probable (malignancy)</td>
</tr>
<tr>
<td>Suspect or suspected (malignancy)</td>
</tr>
<tr>
<td>Suspicious (of malignancy)</td>
</tr>
<tr>
<td>Typical (of/for malignancy)</td>
</tr>
</tbody>
</table>

Coding Instructions:

- Ambiguous terms not listed above are not considered indication of primary site.
- Ambiguous terms may be located in any source document, such as pathology, operative, radiology, or clinical reports. This does not include tumor marker reports.
- Do not substitute synonyms such as “supposed” for presumed or “equal” for comparable. Do not substitute “likely” for “most likely.”

Benign and borderline primary intracranial and CNS tumors:

- Use the above terms list to identify benign and borderline primary intracranial and CNS primary tumors.
- Ambiguous terms not listed above are not considered indication of primary site.
- If any of the reportable ambiguous terms precede either the word “tumor” or the word “neoplasm,” it is considered an indication of a primary site.
V.2 Laterality

Laterality describes the side of a paired organ or the side of the body on which the reportable tumor originated, which is not captured in topographic codes. The Laterality data item applies only to the primary site. Its main purpose is to identify the origin of the tumor.

Coding Instructions:

- Laterality must be coded for all paired sites. See Laterality - Paired Sites for additional information.
  - Laterality may be coded for non-paired sites other than those required: for example, thyroid.
- Code 0 when:
  - Non-paired sites, not otherwise specified
  - Primary Site is unknown (C809)
- Metastatic bilateral involvement is not coded for laterality.
- Code 3 if the laterality is not known but the tumor is confined to a single side of the paired organ.
- Code 4 should not be used for bilateral primaries for which separate abstracts are prepared or when the side of origin is known, and the tumor has spread to the other side.
  
  Example: A left ovarian primary with metastases to the right ovary is code 2, rather than code 4.

- Code 5 when the tumor originates in the midline of a paired organ or site (effective with 1/1/2010 dx).
  
  Example: Patient has an excision of a melanoma located above the umbilicus.

- All primary brain and CNS tumors diagnosed prior to January 1, 2004 are coded: Laterality 0 (not a paired site).

- Site code C700, C710-C714, C722 diagnosed January 1, 2004 and forward require a laterality codes 1-5, or 9.

- All other CNS/brain subsites of C70, C71, and C72 are coded: Laterality 0 (not a paired organ) regardless of the date of diagnosis. All pituitary and pineal gland and craniopharyngeal duct tumors (C751-3) are coded Laterality = 0 (not a paired site).

- Code 9 when the neoplasm originated in a paired site and the laterality is unknown and there is no statement that only one side of the paired organ is involved.

- The CCR requires text documentation to support the laterality code.
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Not a paired site</td>
</tr>
<tr>
<td>1</td>
<td>Right side origin of primary</td>
</tr>
<tr>
<td>2</td>
<td>Left side origin of primary</td>
</tr>
<tr>
<td>3</td>
<td>One side only involved, but right or left side origin not specified</td>
</tr>
<tr>
<td>4</td>
<td>Both sides involved, but origin unknown (including bilateral ovarian primaries of the same histologic type, diagnosed within two months of each other; bilateral retinoblastomas; and bilateral Wilms' tumors)</td>
</tr>
<tr>
<td>5</td>
<td>Paired site, midline tumor (effective with 1/1/2010 dx)</td>
</tr>
<tr>
<td>9</td>
<td>Paired site, but no information available concerning laterality</td>
</tr>
</tbody>
</table>
## V.2.1 Laterality - Paired Sites

This section identifies the sites that are considered paired. The ICD-O-3 site codes listed below are sites for which laterality must be entered. The requirement includes any subsite, except those specifically noted. See [Laterality](#) for specific laterality coding.

<table>
<thead>
<tr>
<th>Site Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C079</td>
<td>Parotid gland</td>
</tr>
<tr>
<td>C080</td>
<td>Submandibular gland</td>
</tr>
<tr>
<td>C081</td>
<td>Sublingual gland</td>
</tr>
<tr>
<td>C098</td>
<td>Overlapping lesion of tonsil</td>
</tr>
<tr>
<td>C099</td>
<td>Tonsil, NOS</td>
</tr>
<tr>
<td>C301</td>
<td>Middle ear</td>
</tr>
<tr>
<td>C310</td>
<td>Maxillary sinus</td>
</tr>
<tr>
<td>C312</td>
<td>Frontal sinus</td>
</tr>
<tr>
<td>C341-C349</td>
<td>Lung</td>
</tr>
<tr>
<td>C384</td>
<td>Pleura, NOS</td>
</tr>
<tr>
<td>C400</td>
<td>Upper limb long bones, scapula</td>
</tr>
<tr>
<td>C401</td>
<td>Upper limb short bones</td>
</tr>
<tr>
<td>C402</td>
<td>Lower limb long bones</td>
</tr>
<tr>
<td>C403</td>
<td>Lower limb short bones</td>
</tr>
<tr>
<td>C441</td>
<td>Eyelid skin</td>
</tr>
<tr>
<td>C442</td>
<td>External ear skin</td>
</tr>
<tr>
<td>C443</td>
<td>Skin of other and unspecified parts of face</td>
</tr>
<tr>
<td>C444</td>
<td>Skin of scalp and neck</td>
</tr>
<tr>
<td>C445</td>
<td>Trunk skin</td>
</tr>
<tr>
<td>C446</td>
<td>Upper limb and shoulder skin</td>
</tr>
<tr>
<td>C447</td>
<td>Lower limb and hip skin</td>
</tr>
<tr>
<td>C471</td>
<td>Peripheral nerves and autonomic nervous system of upper limb and shoulder</td>
</tr>
<tr>
<td>C472</td>
<td>Peripheral nerves and autonomic nervous system of lower limb and hip</td>
</tr>
<tr>
<td>C491</td>
<td>Connective, subcutaneous, and other soft tissues of upper limb and shoulder</td>
</tr>
<tr>
<td>C492</td>
<td>Connective, subcutaneous, and other soft tissues of lower limb and hip</td>
</tr>
<tr>
<td>C500-C509</td>
<td>Breast</td>
</tr>
<tr>
<td>C569</td>
<td>Ovary</td>
</tr>
<tr>
<td>C570</td>
<td>Fallopian tube</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------</td>
</tr>
<tr>
<td>C620 C629</td>
<td>Testis</td>
</tr>
<tr>
<td>C630</td>
<td>Epididymis</td>
</tr>
<tr>
<td>C631</td>
<td>Spermatic cord</td>
</tr>
<tr>
<td>C649</td>
<td>Kidney, NOS</td>
</tr>
<tr>
<td>C659</td>
<td>Renal pelvis</td>
</tr>
<tr>
<td>C669</td>
<td>Ureter</td>
</tr>
<tr>
<td>C690-C699</td>
<td>Eye and adnexa</td>
</tr>
<tr>
<td>C700</td>
<td>Cerebral meninges, NOS (excluding diagnoses prior to 2004)</td>
</tr>
<tr>
<td>C710</td>
<td>Cerebrum (excluding diagnoses prior to 2004)</td>
</tr>
<tr>
<td>C711</td>
<td>Frontal lobe (excluding diagnoses prior to 2004)</td>
</tr>
<tr>
<td>C712</td>
<td>Temporal lobe (excluding diagnoses prior to 2004)</td>
</tr>
<tr>
<td>C713</td>
<td>Parietal lobe (excluding diagnoses prior to 2004)</td>
</tr>
<tr>
<td>C714</td>
<td>Occipital lobe (excluding diagnoses prior to 2004)</td>
</tr>
<tr>
<td>C722</td>
<td>Olfactory nerve (excluding diagnoses prior to 2004)</td>
</tr>
<tr>
<td>C723</td>
<td>Optic nerve (excluding diagnoses prior to 2004)</td>
</tr>
<tr>
<td>C724</td>
<td>Acoustic nerve (excluding diagnoses prior to 2004)</td>
</tr>
<tr>
<td>C725</td>
<td>Cranial nerve, NOS (excluding diagnoses prior to 2004)</td>
</tr>
<tr>
<td>C740-C749</td>
<td>Adrenal gland</td>
</tr>
<tr>
<td>C754</td>
<td>Carotid body</td>
</tr>
</tbody>
</table>
**V.3 ICD-O Morphology - Histology and Behavior**

The morphology code indicates the type of cell that has become neoplastic (histology) and its biologic activity (behavior).

**2022 ICD-O-3.2 histology coding changes:** Updates include new and revised histology terms, codes, and behaviors for cases diagnosed January 1, 2022 and forward. Please see the [2022 ICD-O-3.2 Implementation Guidelines](#). Use of these guidelines is required for determining reportability and accurate coding.

**Definitions:**

- **Histology** identifies the specific cell type of the tumor. Specific cell lines come from different tissues and are extremely important information for the diagnosis and treatment of the disease. For cases or tumors diagnosed January 1, 2018 and forward, refer to the current [Solid Tumor Rules Manual](#).

**Examples:**

- **Adenocarcinoma:** is typically a cancer that begins in glandular (secretory) cells. Glandular cells are found in tissue that lines certain internal organs and makes and releases substances in the body, such as mucus, digestive juices, or other fluids. Most cancers of the breast, pancreas, lung, prostate, and colon are adenocarcinomas.

- **Squamous cell carcinoma:** Cancer that begins in squamous cells. Squamous cells are thin, flat cells that look like fish scales, and are found in the tissue that forms the surface of the skin, the lining of the hollow organs of the body, and the lining of the respiratory and digestive tracts. Most cancers of the anus, cervix, head and neck, and vagina are squamous cell carcinomas (also called epidermoid carcinoma).

- **Melanoma:** A form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or in the intestines.

- **Sources for Determining Histology:**
  - For solid tumors diagnosed January 1, 2018 and forward, refer to the current [Solid Tumor Rules Manual](#).
  - For hematopoietic and lymphoid cases diagnosed January 1, 2018 and forward, please refer to the [SEER Hematopoietic and Lymphoid Neoplasm Database and Hematopoietic & Lymphoid Neoplasm Coding Manual](#).

- Reference [Appendix M](#) for a list of Q-Tips which may be related to this topic.

- **Behavior** indicates whether a tumor is malignant or benign, or uncertain whether benign or malignant.
**Coding Instructions:**

- The CCR has adopted the ICD-O-3.2 (*International Classification of Diseases for Oncology, Third Edition, Second Revision*) as its official morphology code system for all cases diagnosed January 1, 2001 forward.
- Enter the appropriate morphology code.
**V.3.1 Histologic Type**

Histology is the study of the minute structure of cells, tissues, and organs in relation to their functions. It is primarily through histological analysis that neoplasms are identified. Determination of the correct histology code can be one of the most difficult aspects of abstracting. Training and experience are essential for development of the ability to assign the correct code. The rules are taken from the SEER Program Manual. They provide guidance, but no set of rules can cover all situations.

**Coding Instructions:**

- For cases or tumors diagnosed January 1, 2018 and forward, refer to the current [Solid Tumor Rules Manual](#) and/or the SEER Hematopoietic and Lymphoid Neoplasm Database and Hematopoietic & Lymphoid Neoplasm Coding Manual and the 2022 ICD-O-3.2 Implementation Guidelines.
V.3.2 Unspecified Malignancies
Unspecified malignancies are those malignancies in which a specific histologic type has not been identified.

Coding Instructions:
- Enter the code for neoplasm (8000) for unspecific terms such as "malignant tumor," "malignant neoplasm", and "cancer."
- Code 8001 (malignant cells, NOS), if a diagnosis is based only on a cytology report stating, "malignant cells."
See Diagnostic Confirmation for additional information.
V.3.3 Behavior
The Behavior Code describes the malignant potential of the tumor. Codes range from /0-benign to /3-malignant (invasive). The fifth digit of the morphology code is the Behavior Code.

Coding Instructions:
- Intracranial and CNS tumor with behavior codes /0-benign or /1-borderline are reportable for cases diagnosed 01/01/2001 forward.
- Code behavior from CT scan, MRI or PET scans when there is no tissue diagnosis (no pathology or cytology report). Code the behavior as indicated on the scan.
  - Do not use WHO grade to code behavior.
- Clinical evidence alone is not sufficient to identify behavior as in-situ. A behavior code of /2-in-situ must be based on pathologic examination.
  Note: If Diagnostic Confirmation is Clinical (8), then behavior cannot be /2-in-situ.
- Code /3-malignant when malignant metastasis is identified.
  Example shown below is representative and is not intended to represent all possible scenarios:
    - Adenocarcinoma in-situ with lymph nodes positive for malignancy. Code the behavior /3.
    Exception: For in-situ breast cancer, code as non-invasive in the presence of isolated tumor cells or if cells are artifactually displaced from a previous procedure.
- Code /3-malignant if any portion of the primary tumor is invasive, regardless of how limited (i.e., microinvasion).
  Example below is representative and not intended to represent all possible scenarios:
    - Intraductal carcinoma of the breast with focal areas of invasion.
- The pathologist has the final decision on the behavior of the tumor. The applicable ICD-O-3 code may indicate /3-malignant behavior, however, the pathologist may indicate the specimen is /2-in-situ. Code the /2 behavior per the pathologist’s findings. The reverse scenario also applies.
- Re-Code the behavior as malignant /3 when metastases are attributed to a tumor originally thought to be in-situ.
- Do not code in-situ behavior with a primary site that is unknown or ill-defined. A behavior code of /2-in-situ combined with any of the following primary sites will result in an error:
  - C269 Gastrointestinal tract, NOS
- C399 Ill-Defined sites within respiratory system
- C559 Uterus, NOS
- C579 Female genital tract, NOS
- C639 Male genital organs, NOS
- C689 Urinary system, NOS
- C729 Nervous system, NOS
- C759 Endocrine gland, NOS
- C76 Other and ill-defined sites
- C809 Unknown primary site

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>/0 *</td>
<td>Benign</td>
</tr>
<tr>
<td>/1 *</td>
<td>Uncertain whether benign or malignant Borderline Malignancy (except cystadenomas in the range 844-849) Low Malignant Potential</td>
</tr>
<tr>
<td>/2</td>
<td>Carcinoma in-situ (see In-situ Coding for synonyms)</td>
</tr>
<tr>
<td>/3</td>
<td>Malignant, Primary Site (includes microinvasion **)</td>
</tr>
<tr>
<td>/6 **</td>
<td>Malignant, Metastatic Site, Malignant, secondary site -- Reportable behavior but enter code 3 (Code 6 NOT Used by Cancer Registries) Malignant, Secondary Site</td>
</tr>
<tr>
<td>/9 **</td>
<td>Malignant, uncertain whether primary or metastatic site</td>
</tr>
</tbody>
</table>

* Benign and borderline Brain and CNS tumors are reportable to CCR for cases diagnosed 1/1/2001 forward.

** Behavior codes of /6 or /9 per ICD-O-3 are not reportable. An edit error will be received when attempting to enter /6 or /9 for behavior.
V.3.3.1 In-Situ Coding

The term "in-situ" means a tumor that meets all microscopic criteria for malignancy, except invasion of basement membrane. For further discussion of "in-situ", see Terms Indicating In-Situ for Staging.

"In-situ" behavior can be determined only by pathologic examination and not by clinical evidence alone. If a tumor is classifiable as "in-situ" according to the time period rules for stage at diagnosis, code the tumor as "in-situ." In other words, a behavior code of 2, "in-situ" corresponds to a stage code of 0, "in-situ" and vice versa. Computer and visual edits will verify that the codes in these two data items correspond. Do not interpret terms like "approaching in-situ" or "very close to in-situ" as "in-situ."

<table>
<thead>
<tr>
<th>General Reportable Terms Indicating In-situ Behavior</th>
</tr>
</thead>
<tbody>
<tr>
<td>Behavior code /2</td>
</tr>
<tr>
<td>Bowen's disease (excluding skin)</td>
</tr>
<tr>
<td>Confined to epithelium (does not extend beyond base membrane)</td>
</tr>
<tr>
<td>Ductal carcinoma in-situ, (DCIS) (any site)</td>
</tr>
<tr>
<td>Intracystic, Intraepidermal (NOS), Intrasquamous, In-situ</td>
</tr>
<tr>
<td>Intraepithelial carcinoma, (NOS)</td>
</tr>
<tr>
<td>Intraepithelial neoplasia grade III, not otherwise specified (NOS)</td>
</tr>
<tr>
<td>Involvement up to, but not including basement membrane</td>
</tr>
<tr>
<td>Lobular carcinoma in-situ (LCIS)</td>
</tr>
<tr>
<td>No stromal invasion</td>
</tr>
<tr>
<td>Non-infiltrating; Non-invasive</td>
</tr>
<tr>
<td>Squamous intraepithelial neoplasia grade III (SIN III) (excluding cervix and skin sites coded to C44_), dx 01/01/2014 +</td>
</tr>
<tr>
<td>Papillary, non-infiltrating or intraductal</td>
</tr>
<tr>
<td>Pre-invasive</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Site</th>
<th>Terms Indicating In-situ Behavior</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anus</td>
<td>Anal Intraepithelial Neoplasia grade III (AIN III), dx 01/01/2001 +</td>
</tr>
<tr>
<td></td>
<td>Anal Intraepithelial Neoplasia grade II (AIN II), dx 01/01/2022 +</td>
</tr>
<tr>
<td></td>
<td>High grade squamous intraepithelial lesion (HGSIL or HSIL), dx 01/01/2018 +</td>
</tr>
<tr>
<td>Appendix</td>
<td>Low-grade appendiceal mucinous neoplasm (LAMN), 8480/2, dx 01/01/2022 +</td>
</tr>
<tr>
<td></td>
<td>High grade appendiceal mucinous neoplasm (HAMN), 8480/2, dx 01/01/2022 +</td>
</tr>
<tr>
<td>Breast</td>
<td>Ductal intraepithelial neoplasia grade III (DIN III), dx 01/01/2001+</td>
</tr>
<tr>
<td></td>
<td>Lobular intraepithelial neoplasia grade III (LIN III), dx 01/01/2016 +</td>
</tr>
<tr>
<td></td>
<td>Lobular neoplasia grade III (LN III), dx 01/01/2016 +</td>
</tr>
<tr>
<td>Organ</td>
<td>Description</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Breast, Colon, Rectum</td>
<td>Stage 0 (excluding Paget’s disease) confined to lamina propria</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>High grade biliary intraepithelial neoplasia grade III (BiIN III), 01/01/2018 +</td>
</tr>
<tr>
<td>Larynx</td>
<td>Laryngeal intraepithelial neoplasia grade III (LIN III), dx 01/01/2001 +</td>
</tr>
<tr>
<td>Pancreas</td>
<td>Pancreatic intraepithelial neoplasia grade III (PanIN III), dx 01/01/2004 +</td>
</tr>
<tr>
<td>Penis</td>
<td>Penile intraepithelial neoplasia grade III (PeIN III), dx 01/01/2001 +</td>
</tr>
<tr>
<td>Skin</td>
<td>Clark’s level I (melanoma; limited to epithelium)</td>
</tr>
<tr>
<td>Skin</td>
<td>Hutchinson’s melanotic freckle, not otherwise specified (NOS)</td>
</tr>
<tr>
<td>Skin</td>
<td>Lentigo maligna</td>
</tr>
<tr>
<td>Skin</td>
<td>Precancerous melanosis</td>
</tr>
<tr>
<td>Stomach, Small Intestine</td>
<td>Intestinal-Type adenoma, high grade, 8144/2, dx 01/01/2022 +</td>
</tr>
<tr>
<td>Stomach, Small Intestine</td>
<td>Adenomatous polyp, high grade dysplasia, 8210/2, dx 01/01/2022 +</td>
</tr>
<tr>
<td>Stomach, Small Intestine</td>
<td>Serrated dysplasia, high grade, 8213/2, dx 01/01/2022 +</td>
</tr>
<tr>
<td>Vagina</td>
<td>Vaginal intraepithelial neoplasia grade III (VAIN III), dx 01/01/1992 +</td>
</tr>
<tr>
<td>Vagina</td>
<td>Vaginal intraepithelial neoplasia grade II (VAIN II), dx 01/01/2022 +</td>
</tr>
<tr>
<td>Vagina</td>
<td>High grade squamous intraepithelial lesion (HGSIL or HSIL), dx 01/01/2018 +</td>
</tr>
<tr>
<td>Vulva</td>
<td>Vulvar intraepithelial neoplasia grade III (VIN III), dx 01/01/1992 +</td>
</tr>
<tr>
<td>Vulva</td>
<td>Vulvar intraepithelial neoplasia grade II (VIN II), dx 01/01/2022 +</td>
</tr>
<tr>
<td>Vulva</td>
<td>High grade squamous intraepithelial lesion (HGSIL or HSIL), dx 01/01/2018 +</td>
</tr>
</tbody>
</table>

**Note:** Terms without reportability dates have been reportable since the region’s reference date.

**Not Reportable (Reminder)**

As a reminder, carcinoma "in-situ" (including squamous cell and adenocarcinoma) of the cervix and Cervical Intraepithelial Neoplasia, CIN III, are not reportable effective with cases diagnosed January 1, 1996 and forward.

Prostatic Intraepithelial Neoplasia (PIN III), morphology code 8148/2 is also not reportable to the CCR.
V.4 Grade and Differentiation
Grade is a measurement of how closely the tumor cells resemble the parent tissue (organ of origin).

**Grade is coded in separate, specific data items as follows:**

- **Grade Clinical** (2018 +)
- **Grade Pathological** (2018 +)
- **Grade Post Therapy Clin (yc)** (2021 +)
- **Grade Post Therapy Path (yp)** (2018 +)

- For cases diagnosed 2021 +, the data item *Grade Post Therapy* has been divided into two. The new *Grade Post Therapy Clin (yc)* will be collected for cases diagnosed 2021 +. *Grade Post Therapy* was renamed to *Grade Post Therapy Path (yp)* and along with *Grade Clinical* and *Grade Pathological*, will continue to be collected for cases diagnosed 2018 +.

- See [Archived Volume I](#) for coding cases diagnosed prior to 2018.
  - Use case year of diagnosis to determine which Volume I to choose.

- Cell lineage indicator/grade for hematopoietic lymphoid neoplasms are NO LONGER COLLECTED for cases with DX date 2018 +.

See [Grade - General Information](#) for further grade coding guidelines.

Grade questions should be directed to CAnswer Forum at: [http://cancerbulletin.facs.org/forums/](http://cancerbulletin.facs.org/forums/).

Refer to the most current [Grade Coding Instructions and Tables](#) for coding instructions.
V.4.1 Grade - General Information

For cases diagnosed 2021+, the data item *Grade Post Therapy* has been divided into two. *Grade Post Therapy Clin (yc)* will be collected for cases diagnosed 2021+. *Grade Post Therapy was renamed to Grade Post Therapy Path (yp)* and along with *Grade Clinical* and *Grade Pathological*, will continue to be collected for cases diagnosed 2018+.

For additional information on historical manual references, refer to Appendix S – Historical Coding and Staging Manual Requirements for CCR.

Guidelines:

- Refer to the most current Grade Coding Instructions for coding.
- Cell lineage indicator/grade for hematopoietic lymphoid neoplasms are NO LONGER COLLECTED for cases with DX date 2018+.
  
  **ONLY EXCEPTION:** Ocular Adnexa Lymphoma AJCC Chapter 71. AJCC has defined a grading system for the follicular histologies.

  - Applicable sites: C441, C690, C695, C696
  - Applicable histologies for above: 9690/3, 9691/3, 9595/3, 9698/3
  - Grade for all other histologies collected in AJCC Chapter 71 is coded as 9

- Classification of grade now varies by tumor site and/or histology.
- Four grade data items reflect the points in time in the patient’s work-up care when grade may be assessed:

  - **Grade Clinical** – Record the grade of a solid primary tumor before any treatment, including surgical resection, systemic therapy, radiation therapy or neoadjuvant therapy.
    
    **Note:** Not all surgical procedures are treatment.
    
    **Examples:** Grade determined from a TURBT, TURB, or endoscopic biopsies would be collected as clinical grade.

  - **Grade Pathological** – Record the grade of a solid primary tumor that has been surgically resected, and patient has **not** had neoadjuvant treatment.
    
    - The tumor must meet the surgical resection requirements in the AJCC Manual for pathological stage.
    
    - Pathological grade may include the grade from clinical workup, as all information from diagnosis (clinical staging) through the surgical resection is used for pathological grade.

  **Note:** Not all surgical procedures meet the requirements for pathological grade or pathological stage (i.e., TURB or TURP).
- **Grade Post Therapy Clin (yc)** – Record the grade of a solid primary tumor that has been microscopically sampled following neoadjuvant therapy or primary systemic/radiation therapy.

- **Grade Post Therapy Path (yp)** – Record the grade of a solid primary tumor that has been resected following neoadjuvant therapy.
  - The tumor must meet the surgical resection requirements for yp pathological stage in the AJCC Manual to assign the post therapy grade.
  - Neoadjuvant therapy **must** meet applicable guidelines or standards, and not be that given for variable or unconventional reasons as noted in the AJCC Manual.
  - This data item corresponds to the yp staging period only.
**V.4.1.1 Grade - Clinical**

*Grade Clinical* records the grade of a solid tumor before any treatment (surgical resection or initiation of any treatment including neoadjuvant). This data item is required by the CCR for cases diagnosed January 1, 2018 and forward.

**Coding Instructions:**

- Refer to the most current [Grade Coding Instructions](#) for coding.
  - **Always** check the site-specific Clinical Grade tables (in the document link above) for additional information.
- Clinical grade is recorded for cases where a histological (microscopic) exam is done and tissue is available, and grade is recorded.
  - Includes: FNA, biopsy, needle core biopsy, etc.
- *Clinical Grade* data item must not be blank.
- Code the highest grade from the primary tumor assessed during the clinical time frame.
  - Assign the highest grade when there are multiple tumors with different grades abstracted as one primary.
- Code 9 (unknown) when:
  - Grade is not documented
  - Clinical grade/staging is not applicable
    - **Example:** cancer is an incidental finding during surgery for another condition
  - Grade checked “not applicable” on CAP Protocol (if available) and no other grade information is available.
  - If there is only one grade available and it cannot be determined if it is clinical or pathological, assign it as a clinical grade and code unknown (9) for pathological grade, and blank for post therapy grade clin (yc) and post therapy grade path (yp).
V.4.1.2 Grade - Pathological

Grade Pathological records the grade of a solid tumor that has been resected and for which no neoadjuvant therapy was administered. This data item is required by the CCR for cases diagnosed January 1, 2018 and forward.

Coding Instructions:

- Refer to the most current Grade Coding Instructions for coding.
  - *Always* check the site-specific Pathological Grade tables (in the document linked above) for additional information.
- Pathological grade is recorded for cases where a surgical resection has been done.
- *Pathological Grade* data item **must not** be blank.
- Assign the highest grade from the primary tumor.
  - Use the grade that was identified during the clinical time frame for both clinical grade and pathological grade if the clinical grade is higher than the grade identified on the surgical resection specimen.
  - Assign the highest grade when there are multiple tumors with different grades abstracted as one primary.
- Code 9 (unknown) when:
  - Grade is not documented
  - No resection of the primary site performed
  - Neoadjuvant therapy followed by a resection. See Grade - Post Therapy Path (yp).
  - Clinical case only. See Grade - Clinical.
  - Grade checked “not applicable” on CAP Protocol (if available) and no other grade information is available.
  - There is only one grade available, and it cannot be determined if it is clinical or pathological.
V.4.1.3 Grade - Post Therapy Clin (yc)

*Grade Post Therapy Clin (yc)* records the grade of a solid primary tumor that has been microscopically sampled following neoadjuvant therapy or primary systemic/radiation therapy. This data item is required by the CCR for cases diagnosed January 1, 2021 and forward.

**Coding Instructions:**

- Refer to the most current [Grade Coding Instructions](#) for coding.
  - **Always** check the site-specific Post Therapy Grade tables (in the document linked above) for additional information.

- Leave **BLANK** when:
  - No neoadjuvant therapy given
  - Clinical or pathological case only
  - Neoadjuvant therapy completed, no microscopic exam done prior to surgery/resection of the primary tumor.
  - There is only one grade available, and it cannot be determined if it is clinical, pathological, or post therapy path.

- Assign the highest grade from the microscopically sampled specimen of the primary tumor assessed **after** the completion of neoadjuvant therapy or primary systemic/radiation therapy.
  - Assign the highest grade when there are multiple tumors with different grades abstracted as one primary.

- Code 9 (unknown) when:
  - Microscopic exam is done after neoadjuvant therapy and grade from the primary site is not documented.
  - Microscopic exam is done after neoadjuvant therapy and there is no residual cancer.
  - Grade checked “not applicable” on CAP Protocol (if available) and no other grade information is available.
**V.4.1.4 Grade - Post Therapy Path (yp)**

*Grade Post Therapy (yp)* records the grade of a solid tumor that has been resected following neoadjuvant therapy. This data item is required by the CCR for cases diagnosed January 1, 2018 and forward.

**Coding Instructions:**

- Refer to the most current [Grade Coding Instructions](#) for coding.
  - **Always** check the site-specific Post Therapy Grade tables (in the document linked above) for additional information.

- Leave **BLANK** when:
  - No neoadjuvant therapy given
  - Clinical or pathological case only
  - Neoadjuvant therapy completed; surgical resection not done.
  - There is only one grade available, and it cannot be determined if it is clinical, pathological, or post therapy.

- Assign the highest grade from the resected primary tumor assessed **after** the completion of neoadjuvant therapy only.
  - Assign the highest grade when there are multiple tumors with different grades abstracted as one primary.

- Code 9 (unknown) when:
  - Surgical resection is done after neoadjuvant therapy and grade is not documented.
  - Surgical resection is done after neoadjuvant therapy and there is no residual cancer.
  - Grade checked “not applicable” on CAP Protocol (if available) and no other grade information is available.
V.5 Tumor Size

Three data items were added in 2016 to collect information on tumor size of the solid, primary tumor at various points in the diagnosis and treatment of the reportable neoplasm. These data items are *Tumor Size-Clinical*, *Tumor Size-Pathological* and *Tumor Size-Summary*. These data items are independent from one another and have specific, unique coding instructions. Refer to each separate tumor size data item for the specific corresponding coding instructions.
V.5.1 Tumor Size Clinical

This data item records the size of a solid primary tumor before any treatment (surgical resection or initiation of any treatment including neoadjuvant) and is essential for treatment decision making and prognosis determination for many types of cancer. This data item is required by the CCR for cases diagnosed January 1, 2016 and forward.

Coding Instructions:

- Code this data item for all solid tumors.
- Code the largest tumor size from all information:
  - During the detection and diagnostic confirmation of the tumor. Information prior to the date of diagnosis may be used when it is part of the workup for this primary tumor.
    *Exception:* Use the measurements (size) closest to the day of diagnoses for coding clinical size when there is progression of disease.
  - Within four months of the date of diagnosis, in the absence of disease progression when no treatment is administered.
- Code the tumor size before any form of treatment using the following priority order:
  - Operative report from surgical exploration without resection.
  - Image-guided tissue biopsy (i.e., incisional biopsy done under image guidance).
    - Code the size that corresponds to the tumor, not the specimen size.
  - Diagnostic imaging: Use the largest size from available diagnostic imaging procedures in no priority order unless the physician specifies the imaging that is most accurate.
  - Physical exam: Use the physical exam in the absence of any of the above preferred diagnostic procedures.
    *Note:* Tumor size found by endoscopic procedures such as colonoscopy are included in physical exam.
- Timing Rules: Tumor Size Clinical follows the timing rules for AJCC clinical staging. For clinical tumor size, take into consideration what the physician would use to assign clinical stage. Refer to AJCC TNM guidelines to determine the sources of information that pertain to the clinical staging timeframe.
  *Example:* TURBT for a bladder primary pertains to clinical staging. A size from a TURBT would be a clinical size.
  *Note:* Do not use the classification in the T category to infer the tumor size.
• Code the size of the primary tumor before neoadjuvant (preoperative) treatment.

**Example:** Patient has a 2.8 cm mass in the hypopharynx; fine needle aspiration of mass confirms squamous cell carcinoma. Patient receives a course of neoadjuvant combination chemotherapy. Pathological size of tumor after total resection is 3.2 cm. Record clinical tumor size as 028 (28mm).

• Code the size of the largest invasive tumor, or the largest in-situ tumor if all tumors are in-situ, when the tumor is multi-focal or when multiple tumors are reported as a single primary.

• Code the size of the largest invasive tumor, even if smaller, when an in-situ and invasive tumor are present, and the invasive component has been measured.

• Tumor size is the largest dimension of the tumor, not the depth or thickness of the tumor.

• Code the size of the primary tumor, including contiguous tumor tissue extension, at the time of diagnosis.

• Code the size of the primary tumor, not the size of the polyp, ulcer, cyst, or distant metastasis.
  o However, if the tumor is described as a “cystic mass,” and only the size of the entire mass is given, code the size of the entire mass, since the cysts are part of the tumor itself.

• **Breast tumors:** Clinical size may be recorded based on the size of a non-mass enhancement (NME). See Appendix A for definition.

• Code the size of the largest focus when there is microinvasion.
  o Code 990 when there is microinvasion and no size stated.

• Record tumor size only in millimeters (mm). Convert to millimeters when the size of tumor is measured in centimeters.

• Tumor size is the largest dimension of the tumor, not necessarily the depth or thickness of the tumor.

• Tumor size noted in a resection operative report is a clinical tumor size, and not a pathologic tumor size.

• Check the Clinical History/Clinical Impression/Clinical Information section of the pathology report for information on the clinical size of the tumor.

• Record the size stated when tumor is described as “at least” a certain size.
  o Record 004 for a tumor size of at least 4mm.

• Record the higher tumor size when stated as a range.

**Tumor Size Less than or Greater than:**
o Record the tumor size as 1mm less when tumor size is reported as “less than Xmm” or “less than x cm.”

Examples:
1. Code as 009 when stated <10 mm; or 009 when stated as <1 cm.
2. Code 001 when stated as less than 1mm.

o Record the tumor size as 1mm more when tumor size is reported as “more than Xmm” or “more than x cm.”

Example: Code as 010 when stated > 9 mm; or 011 when stated as > 1 cm.

o When size stated is between 2 sizes, for example, “between 3 and 4 cm”, code to the midpoint: 3.5.

Rounding:

o Round tenths of millimeters in the 1-4 range down to the nearest whole millimeter.

o Round tenths of millimeters in the 5-9 range up to the nearest whole millimeter when tumor size is greater than 1 millimeter.

Examples:
1. Lung cancer described as 4.5 millimeters in size. Round up to 5mm and code as 005.
2. Cancer in a polyp described as 2.3 millimeters in size. Round down to 2mm and code as 002.

EXCEPTION FOR BREAST PRIMARIES ONLY

o Rounding rules for Breast Primaries

  ▪ Round tumor sizes greater than 1.0mm and up to 2.4mm to 2mm (002).

Notes:

1. The purpose of this exception is so that the size recorded in the Tumor Size data item will derive to the correct AJCC TNM Primary Tumor (T) category for breast primaries.

2. Do not apply this to any other site.

• Code 000 when:
  o Schema is 00060 Cervical Lymph nodes and Unknown Primary.
  o EOD Primary Tumor for any schema is coded 800 (no evidence of primary tumor).

• Assign a tumor size for benign or borderline tumor in the schemas Brain, CNS other, and Intracranial Gland when provided. Do not default to 999.

• Code 999 when size is unknown and for the following Schema ID/Schemas:
- Any case code to Primary C420, C421, C423, C424, C770-C779, or C809.
- 00830 Heme Retic (excluding Spleen (C422))
- 00458 Kaposi Sarcoma
- 00790 Lymphoma (excluding CLL/SLL)
- 00795 Lymphoma (CLL/SLL)
- 00672 Melanoma Choroid and Ciliary Body
- 00671 Melanoma Iris
- 00822 Plasma Cell Disorders
- 00821 Plasma cell Myeloma

- **The CCR requires text documentation to support the Tumor Size Clinical code.**

- Tumor size is important for staging of tumors in specific schemas. For more information about schemas and schema IDs, see the [SSDI Manual, Appendix A](#) for additional information.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>000</td>
<td>No mass/tumor found</td>
</tr>
<tr>
<td>001</td>
<td>1mm or described as <strong>less than</strong> 1mm (0.1 cm or less than 0.1 cm)</td>
</tr>
<tr>
<td>002-988</td>
<td>Exact size in millimeters (2mm to 988mm) (0.2 cm to 98.8 cm)</td>
</tr>
<tr>
<td>989</td>
<td>989 millimeters or larger (98.9 cm or larger)</td>
</tr>
<tr>
<td>990</td>
<td>Microscopic focus or foci only and no size of focus is given</td>
</tr>
</tbody>
</table>

| 998-Site-Specific Codes | Alternate descriptions of tumor size for specific sites:  
Familial/multiple polyposis:  
Rectosigmoid and rectum (C199, C209)  
Colon (C180, C182-C189)  
**If no size is documented**  
Circumferential:  
Esophagus (C150-C155, C158-C159)  
Diffuse; widespread: 3/4s or more; linitis plastica  
Stomach and Esophagus GE Junction (C160-C166, C168-C169)  
Diffuse, entire lung or NOS:  
Lung and main stem bronchus (C340-C343, C348-C349)  
Diffuse:  
Breast (C500-C506, C508-C509) |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>999</td>
<td>Unknown; size not stated; Not documented in patient record; Size of tumor cannot be assessed; The only measurement(s) describes pieces or chips; Not applicable</td>
</tr>
</tbody>
</table>
V.5.2 Tumor Size Pathologic

This data item records the size of a solid primary tumor that has been resected. It is an important prognostic indicator and is valuable for both clinical practice and for research on surgically treated patients for most cancers. This data item is required by the CCR for cases diagnosed January 1, 2016 and forward.

Coding Instructions:

- Code this data item for **all** solid tumors.
- Record the size of the resected or excised **tumor**.

**Notes:**

1. The tumor size may differ from the size of the specimen.
2. An incisional biopsy that removes the whole tumor is actually an excisional biopsy.

- Record the size of the invasive component, even if it is smaller, when both in-situ and invasive components are measured.
- Record the size of the entire tumor from the operative report or pathology report when the size of the invasive component is not given.
- Record the size of the primary tumor, including contiguous tumor tissue extension, at the time of diagnosis.
- Code the largest size of the primary tumor measured on surgical resection specimen, when surgery is administered as first course treatment.
  - Code the size from the synoptic report (CAP protocol) when there is a discrepancy among the various sections of the pathology report.
    - **Example:** Chest x-ray shows 2.5 cm mass; the pathology report from the surgery states that the same mass is malignant and measures 1.8 cm. Record tumor size as 018 (18mm).
  - Use final diagnosis, microscopic or gross examination, in that order, when only a pathology report is available.

- **Timing Rules:** Pathologic tumor size follows the timing rules for AJCC pathological staging.
  - For pathologic tumor size, take into consideration what the physician would use to assign pathological stage. Refer to AJCC TNM guidelines to determine the sources of information that pertain to the pathological staging timeframe.
    - **Example:** Lumpectomy and mastectomy pertain to the pathological timeframe. A size from lumpectomy or mastectomy would be used for the pathologic tumor size.

**Notes:**
1. Do **not** infer the tumor size from the T category

2. If neoadjuvant therapy has been administered, do not record the pathologic tumor size from surgery. See further instructions under code 000 and 999.

- Tumor size noted in a resection operative report is a clinical tumor size, not a pathologic tumor size.
- Tumor size is the largest dimension of the tumor, not necessarily the depth or thickness of the tumor.
- Record the largest dimension or diameter of tumor, whether it is from an excisional biopsy specimen or the complete resection of the primary tumor.
- Code the size of the primary tumor, not the size of the polyp, ulcer, cyst, or distant metastasis. Tumor size may differ from the size of the specimen.
  - However, if the tumor is described as a “cystic mass,” and only the size of the entire mass is given, code the size of the entire mass, since the cysts are part of the tumor itself.
- Code the size of the largest focus when there is microinvasion.
  - Code 990 when there is microinvasion and no size stated.
- Record the size as stated for purely in-situ lesions.
- Disregard microscopic residual or positive margins when coding tumor size.
- Code the size of the largest invasive tumor, or the largest in-situ tumor if all tumors are in-situ, when the tumor is multi-focal or multiple tumors are reported as a single primary.
- Record tumor size only in millimeters (mm). Convert to millimeters when the size of tumor is measured in centimeters.
- Record the size stated when tumor is described as “at least” a certain size.
  - Record 004 for a tumor size of at least 4mm.
- Record the higher tumor size when stated as a range.

**Tumor Size Less than or Greater than:**

- Record the tumor size as 1mm less when tumor size is reported as “less than Xmm” or “less than x cm.”

**Examples:**

1. Code as 009 when stated <10mm; or 009 when stated as < 1 cm.
2. Code 001 when stated as less than 1mm.

- Record the tumor size as 1mm more when tumor size is reported as “more than Xmm” or “more than x cm.”
Example: Code as 010 when stated > 9mm; or 011 when stated as > 1 cm.

- When size stated is between two sizes, for example, “between 3 and 4 cm”, code to the midpoint: 3.5.

Rounding:

- Round tenths of millimeters in the 1-4 range down to the nearest whole millimeter.
- Round tenths of millimeters in the 5-9 range up to the nearest whole millimeter when tumor size is greater than 1 millimeter.

Examples:

1. Lung cancer described as 6.5 millimeters in size. Round up to 7mm and code as 007.
2. Cancer in a polyp described as 1.3 millimeters in size. Round down to 1mm and code as 001.

EXCEPTION FOR BREAST PRIMARIES ONLY

- Rounding rules for Breast Primaries.
  - Round tumor sizes greater than 1.0mm and up to 2.4mm to 2mm (002).

Notes:

1. The purpose of this exception is so that the size recorded in the Tumor Size data item will derive to the correct AJCC TNM Primary Tumor (T) category for breast primaries.
2. Do not apply this to any other site.

- Code 000 when:
  - No residual tumor found in resected surgical specimen.
    - This includes when neoadjuvant therapy has been administered and the resection shows no residual tumor. For all other scenarios where neoadjuvant has been given, see code 999.
  - Schema is 00060 Cervical Lymph nodes and Unknown Primary.
  - EOD Primary Tumor for any schema is coded 800 (no evidence of primary tumor).

- Assign a tumor size for benign or borderline tumor in the schemas Brain, CNS other, and Intracranial Gland when provided. Do not default to 999.

- Code 999 when:
  - Pathologic tumor size is unknown.
  - No excisional biopsy or tumor resection performed.
- The only measurement describes pieces or chips. Do not add the size of pieces or chips together to create a whole; they may not be from the same location, or they may represent a very small portion of a large tumor.

**Exception:** Code the size of tumor when the pathologist states an aggregate or composite size (determined by fitting the tumor pieces together and measuring the total size).

- The patient receives neoadjuvant treatment.

- For the following schema ID/schemas:
  - Any case code to Primary C420, C421, C423, C424, C770-C779, or C809.
  - 00830 Heme Retic (excluding Spleen (C422))
  - 00458 Kaposi Sarcoma
  - 00790 Lymphoma (excluding CLL/SLL)
  - 00795 Lymphoma (CLL/SLL)
  - 00672 Melanoma Choroid and Ciliary Body
  - 00671 Melanoma Iris
  - 00822 Plasma Cell Disorders
  - 00821 Plasma cell Myeloma

- **The CCR requires text documentation to support the Tumor Size Pathologic code.**

- Tumor size is important for staging of tumors in specific schemas. For more information about schemas and schema IDs, see the SSDI Manual, Appendix A for additional information.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>000</td>
<td>No mass/tumor found</td>
</tr>
<tr>
<td>001</td>
<td>1mm or described as <strong>less than</strong> 1mm (0.1 cm or less than 0.1 cm)</td>
</tr>
<tr>
<td>002-988</td>
<td>Exact size in millimeters (2mm to 988mm) (0.2 cm to 98.8 cm)</td>
</tr>
<tr>
<td>989</td>
<td>989 millimeters or larger (98.9 cm or larger)</td>
</tr>
<tr>
<td>990</td>
<td>Microscopic focus or foci only and no size of focus is given</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>998-Site-Specific Codes</th>
<th>Alternate descriptions of tumor size for specific sites:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Familial/multiple polyposis:</td>
</tr>
<tr>
<td></td>
<td>Rectosigmoid and rectum (C199, C209)</td>
</tr>
<tr>
<td></td>
<td>Colon (C180, C182-C189)</td>
</tr>
<tr>
<td><strong>If no size is documented</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Circumferential:</td>
</tr>
<tr>
<td></td>
<td>Esophagus (C150-C155, C158-C159)</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
</tr>
</tbody>
</table>
| 210  | Diffuse; widespread: 3/4s or more; linitis plastica  
Stomach and Esophagus GE Junction (C160-C166, C168-C169)  
Diffuse, entire lung or NOS:  
Lung and main stem bronchus (C340-C343, C348-C349)  
Diffuse:  
Breast (C500-C506, C508-C509) |
| 999  | Unknown; size not stated; Not documented in patient record; Size of tumor cannot be assessed; The only measurement(s) describes pieces or chips; Not applicable |
V.5.3 Tumor Size Summary
This data item records the most accurate measurement of a solid primary tumor, usually measured on the surgical resection specimen. Tumor size is one indication of the extent of disease and is therefore used by clinicians and researchers. Tumor size that is independent of stage is also useful for quality assurance efforts. This data item is required by the CCR for cases diagnosed January 1, 2016 and forward.

Coding Instructions:

- Tumor size is the diameter of the tumor, not the depth or thickness of the tumor.
- All measurements should be in millimeters (mm).
- Use tumor size measurement from the surgical resection specimen, when no pre-surgical treatment is administered.
  - If there is a discrepancy among tumor size measurements in the various sections of the pathology report, code the size from the synoptic report.
  - If only a path text report is available, use: final diagnosis, microscopic, or gross examination, in that order.
  - Microscopic residual or positive surgical margins should be disregarded when coding tumor size. The status of primary tumor margins may be recorded in a separate data item.
- If neoadjuvant therapy was followed by surgical resection, do not record the size from the pathological specimen. Instead code the largest tumor size prior to neoadjuvant treatment.
- If no surgical resection, record the size prior to any other form of treatment.
  - Code the largest tumor measurement in the following priority order:
    - Imaging
    - Physical exam
    - Other diagnostic procedures
  - Priority of imaging/radiographic techniques should be taken as a lower priority, but over a physical exam.
    - If there is a difference in reported tumor size among imaging and radiographic techniques, unless the physician specifies which imaging is most accurate, record the largest size in the record, regardless of which imaging technique reports it.
- Always code the size of the primary tumor, not the size of the polyp, ulcer, cyst, or distant metastasis.
However, if the tumor is described as a "cystic mass," and only the size of the entire mass is given, code the size of the entire mass, since the cysts are part of the tumor itself.

- Record the size of the invasive component, if given.
  - If the size of the invasive component is not given, record the size of the entire tumor from the surgical report, pathology report, radiology report or clinical examination.
  - If both an in-situ and an invasive component are present and the invasive component is measured, record the size of the invasive component even if it is smaller.

- Record the largest dimension or diameter of tumor, whether it is from an excisional biopsy specimen or the complete resection of the primary tumor.
- Record the size as stated for purely in-situ lesions.
- Multifocal/multicentric tumors: If the tumor is multi-focal or if multiple tumors are reported as a single primary, code the size of the largest invasive tumor or if all the tumors are in-situ, code the size of the largest in-situ tumor.
- Code 999 in the following situations:
  - Neoadjuvant (preoperative) therapy was administered, and pretreatment tumor size is unknown.
  - For the following schema ID/schemas:
    - Any case code to Primary C420, C421, C423, C424, C770-C779, or C809.
    - 00830 Heme Retic (excluding Spleen (C422))
    - 00458 Kaposi Sarcoma
    - 00790 Lymphoma (excluding CLL/SLL)
    - 00795 Lymphoma (CLL/SLL)
    - 00672 Melanoma Choroid and Ciliary Body
    - 00671 Melanoma Iris
    - 00822 Plasma Cell Disorders
    - 00821 Plasma cell Myeloma
  - Pieces or chips are the only measurement provided.

- Recording 'less than'/'greater than' Tumor Size:
  - If tumor size is reported as less than Xmm or less than x cm, the reported tumor size should be 1mm less; for example, if size is < 10mm, code size as 009.
If tumor size is reported as more than Xmm or more than x cm, code size as 1mm more; for example, if size is > 10mm, size should be coded as 011.

If tumor size is reported to be between two sizes, record tumor size as the midpoint between the two: i.e., add the two sizes together and then divide by two.

- Rounding decimals: Round the tumor size only if it is described in fractions (decimals) of millimeters.
  - If the largest dimension of a tumor is less than 1 millimeter (between 0.1 and 0.9mm), record size as 001 (do not round down to 000).
  - If tumor size is greater than 1-millimeter, round tenths of millimeters in the 1-4 range down to the nearest whole millimeter.
  - Round tenths of millimeters in the 5-9 range up to the nearest whole millimeter.
  - Do not round tumor size expressed in centimeters to the nearest whole centimeter (rather, move the decimal point one space to the right, converting the measurement to millimeters).

**Examples:**
1. Breast tumor described as 6.5 millimeters in size. Round up Tumor Size as 007.
2. Cancer in polyp described as 2.3 millimeters in size. Round down Tumor Size as 002.
3. Focus of cancer described as 1.4mm in size. Round down as 001.

- **The CCR requires text documentation to support the Tumor Size Summary code.**
- Tumor size is important for staging of tumors in specific schemas. For more information about schemas and schema IDs, see the SSDI Manual, Appendix A for additional information.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>000</td>
<td>No mass/tumor found</td>
</tr>
<tr>
<td>001</td>
<td>1mm or described as less than 1mm (0.1 cm or less than 0.1 cm)</td>
</tr>
<tr>
<td>002-988</td>
<td>Exact size in millimeters (2mm to 988mm) (0.2 cm to 98.8 cm)</td>
</tr>
<tr>
<td>989</td>
<td>989 millimeters or larger (98.9 cm or larger)</td>
</tr>
<tr>
<td>990</td>
<td>Microscopic focus or foci only and no size of focus is given</td>
</tr>
<tr>
<td>998</td>
<td>Alternate descriptions of tumor size for specific sites:</td>
</tr>
<tr>
<td></td>
<td>Familial/multiple polyposis:</td>
</tr>
<tr>
<td></td>
<td>Rectosigmoid and rectum (C199, C209)</td>
</tr>
<tr>
<td></td>
<td>Colon (C180, C182-C189)</td>
</tr>
<tr>
<td><strong>If no size is documented</strong></td>
<td></td>
</tr>
<tr>
<td>----------------------------</td>
<td></td>
</tr>
<tr>
<td>Circumferential:</td>
<td></td>
</tr>
<tr>
<td>Esophagus (C150-C155, C158-C159)</td>
<td></td>
</tr>
<tr>
<td>Diffuse; widespread: 3/4s or more; linitis plastica</td>
<td></td>
</tr>
<tr>
<td>Stomach and Esophagus GE Junction (C160-C166, C168-C169)</td>
<td></td>
</tr>
<tr>
<td>Diffuse, entire lung or NOS:</td>
<td></td>
</tr>
<tr>
<td>Lung and main stem bronchus (C340-C343, C348-C349)</td>
<td></td>
</tr>
<tr>
<td>Diffuse:</td>
<td></td>
</tr>
<tr>
<td>Breast (C500-C506, C508-C509)</td>
<td></td>
</tr>
</tbody>
</table>

| 999 | Unknown; size not stated; Not documented in patient record; Size of tumor cannot be assessed; The only measurement(s) describes pieces or chips; Not applicable |
V.6 Mets at Diagnosis Bone, Brain, Liver, Lung, Distant Lymph Nodes, and Other

The following data items record the specific site(s) of metastatic disease present at diagnosis. Each data item identifies whether bone, brain, distant lymph nodes, liver, lung or other discontinuous or distant metastatic site(s) are involved.

**Coding Instructions:**

- Metastatic involvement may be single (one focus of metastatic disease) or multiple (multiple foci of metastatic disease in the same site or multiple sites). Information may be clinical or pathologic.
- Code these data items for metastasis even if the patient had neoadjuvant (preoperative) systemic therapy, unless it is determined to be disease progression.
- These data items are to be coded for all solid tumors, Kaposi’s sarcoma, Lymphoma’s, Unknown primary site and Ill-Defined Other primary sites.
- In the data item for each site, enter the code that demonstrates involvement of that site.
V.6.1 Mets at Diagnosis - Bone

The Mets at Diagnosis – Bone data item captures whether bone is an involved metastatic site at the time of diagnosis.

Coding Instructions:

- Code information about bone metastasis only (discontinuous or distant) to the bone identified at the time of diagnosis.

  **Note:** Bone marrow involvement is **not** coded in this data item. See Mets at Diagnosis – Other.

- Metastatic involvement may be single (one focus of metastatic disease) or multiple (multiple foci of metastatic disease in the same site or multiple sites).

- Information regarding bone involvement may be clinical or pathologic.

- Code this data item for bone metastasis even if the patient had neoadjuvant (preoperative) systemic therapy, unless it is determined to be disease progression.

- Code bone involvement in this data item for all solid tumors, including Kaposi’s sarcoma and Ill-Defined Other primary sites (includes unknown primary site) and the following hematopoietic schemas.
  
  o 00710 Lymphoma Ocular Adnexe
  o 00790 Lymphoma (excluding CLL/SLL)
  o 00795 Lymphoma (CLL/SLL)
  o 00811 Mycosis Fungoides (MF)
  o 00812 Primary Cutaneous Lymphoma (excluding MF and SS)
  o 00830 HemeRetic (excluding sites C420, C421, C423, and C424)

- Assign the code that best describes whether the case has bone metastasis at diagnosis.
  
  o Code 0 when the medical record indicates:
    
    ▪ No distant (discontinuous) metastases at all.
    ▪ The tumor is benign /0, borderline /1, or in-situ /2.
    ▪ Clinical or pathological statement that there is no bone metastasis.
    ▪ Imaging reports that are negative for bone metastasis.
    ▪ The patient has distant (discontinuous) metastasis, but bone is not mentioned as an involved site.
  
  o Code 1 when the medical record confirms:
- The patient has distant (discontinuous) metastasis, and the bone is mentioned as involved.
- Bone is the primary and there is metastasis in a different bone(s).

**Note:** Do not code as 1 when bone is the primary with multifocal bone involvement of the same bone.
- The patient is diagnosed with an unknown primary (C809) and bone is mentioned as a distant metastatic site.
  - Code 8 (not applicable) for the following:
    - Any case coded to primary site C420, C421, C423, or C424.
    - 00822 Plasma cell Disorders
  - Code 9 when the patient is known to have distant metastasis, but it cannot be determined whether the distant metastasis include bone.

**Note:** For additional information on schemas and schema IDs, see the SSDI Manual, Appendix A for additional information.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None; no bone involvement</td>
</tr>
<tr>
<td>1</td>
<td>Yes, distant bone metastasis</td>
</tr>
<tr>
<td>8</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>9</td>
<td>Unknown whether bone is an involved metastatic site Not documented in patient record</td>
</tr>
</tbody>
</table>
V.6.2 Mets at Diagnosis - Brain
The Mets at Diagnosis – Brain data item captures whether the brain is an involved metastatic site at the time of diagnosis.

Coding Instructions:

- Code information about brain metastasis only (discontinuous or distant) to the brain identified at the time of diagnosis.

  **Note:** Spinal cord involvement is not coded in this data item. See Mets at Diagnosis – Other.

- Metastatic involvement may be single (one focus of metastatic disease) or multiple (multiple foci of metastatic disease in the same site or multiple sites).

- Information regarding brain involvement may be clinical or pathologic.

- Code this data item for brain metastasis even if the patient had neoadjuvant (preoperative) systemic therapy, unless it is determined to be disease progression.

- Code brain involvement in this data item for all solid tumors, including Kaposi’s sarcoma and Ill-Defined Other primary sites (includes unknown primary site) and the following hematopoietic schemas.
  - 00710 Lymphoma Ocular Adnexa
  - 00790 Lymphoma (excluding CLL/SLL)
  - 00795 Lymphoma (CLL/SLL)
  - 00811 Mycosis Fungoides (MF)
  - 00812 Primary Cutaneous Lymphoma (excluding MF and SS)
  - 00830 HemeRetic (excluding sites C420, C421, C423, or C424)

- Assign the code that best describes whether the case has brain metastasis at diagnosis.
  - Code 0 when the medical record indicates:
    - No distant (discontinuous) metastases at all.
    - The tumor is benign /0, borderline /1, or in-situ /2.
    - Clinical or pathological statement that there is no brain metastasis.
    - Imaging reports that are negative for brain metastasis.
    - The patient has distant (discontinuous) metastasis, but brain is not mentioned as an involved site.
  - Code 1 when the medical record confirms:
- The patient has distant (discontinuous) metastasis, and the brain is mentioned as involved.
- The patient is diagnosed with an unknown primary (C809) and brain is mentioned as a distant metastatic site.
  - Code 8 (not applicable) for the following:
    - Any case coded to primary site C420, C421, C423, or C424.
    - 00822 Plasma cell Disorders
  - Code 9 when the patient is known to have distant metastasis, but it cannot be determined whether the distant metastasis include brain.

**Note:** For additional information on schemas and schema IDs, see the SSDI Manual, Appendix A for additional information.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None; no brain involvement</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Yes, distant brain metastasis</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Not Applicable</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Unknown whether brain is an involved metastatic site</td>
<td>Not documented in patient record</td>
</tr>
</tbody>
</table>
V.6.3 Mets at Diagnosis - Liver

The Mets at Diagnosis – Liver data item captures whether the liver is an involved metastatic site at the time of diagnosis.

Coding Instructions:

- Code information about liver metastasis only (discontinuous or distant) to the liver identified at the time of diagnosis.
- Metastatic involvement may be single (one focus of metastatic disease) or multiple (multiple foci of metastatic disease in the same site or multiple sites).
- Information regarding liver involvement may be clinical or pathologic.
- Code this data item for liver metastasis even if the patient had neoadjuvant (preoperative) systemic therapy, unless it is determined to be disease progression.
- Code liver involvement in this data item for all solid tumors, including Kaposi’s sarcoma and Ill-Defined Other primary sites (includes unknown primary site) and the following hematopoietic schemas.
  - 00710 Lymphoma Ocular Adnexa
  - 00790 Lymphoma (excluding CLL/SLL)
  - 00795 Lymphoma (CLL/SLL)
  - 00811 Mycosis Fungoides (MF)
  - 00812 Primary Cutaneous Lymphoma (excluding MF and SS)
  - 00830 HemeRetic (excluding sites C420, C421, C423, or C424)
- Assign the code that best describes whether the case has liver metastasis at diagnosis.
  - Code 0 when the medical record indicates:
    - No distant (discontinuous) metastases at all.
    - The tumor is benign /0, borderline /1, or in-situ /2.
    - Clinical or pathological statement that there is no liver metastasis.
    - Imaging reports that are negative for liver metastasis.
    - The patient has distant (discontinuous) metastasis, but liver is not mentioned as an involved site.
  - Code 1 when the medical record confirms:
    - The patient has distant (discontinuous) metastasis, and the liver is mentioned as involved.
The patient is diagnosed with an unknown primary (C809) and liver is mentioned as a distant metastatic site.

- Code 8 (not applicable) for the following:
  - Any case coded to primary site C420, C421, C423 or C424.
  - 00822 Plasma cell Disorders
- Code 9 when the patient is known to have distant metastasis, but it cannot be determined whether the distant metastasis include liver.

**Note:** For additional information on schemas and schema IDs, see the SSDI Manual, Appendix A for additional information.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None; no liver involvement</td>
</tr>
<tr>
<td>1</td>
<td>Yes, distant liver metastasis</td>
</tr>
<tr>
<td>8</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>9</td>
<td>Unknown whether liver is an involved metastatic site</td>
</tr>
<tr>
<td></td>
<td>Not documented in patient record</td>
</tr>
</tbody>
</table>
**V.6.4 Mets at Diagnosis - Lung**

The *Mets at Diagnosis – Lung* data item captures whether lung is an involved metastatic site at the time of diagnosis.

**Coding Instructions:**

- Code information about lung metastasis only (discontinuous or distant) to the lung identified at the time of diagnosis.
  
  **Note:** Pleural or pleural fluid involvement is not coded in this data item. See [Mets at Diagnosis – Other](#).

- Metastatic involvement may be single (one focus of metastatic disease) or multiple (multiple foci of metastatic disease in the same site or multiple sites).

- Information regarding lung involvement may be clinical or pathologic.

- Code this data item for lung metastasis even if the patient had neoadjuvant (preoperative) systemic therapy, unless it is determined to be disease progression.

- Code lung involvement in this data item for all solid tumors, including Kaposi’s sarcoma and Ill-Defined Other primary sites (includes unknown primary site) and the following hematopoietic schemas.
  
  - 00710 Lymphoma Ocular Adnexa
  - 00790) Lymphoma (excluding CLL/SLL)
  - 00795) Lymphoma (CLL/SLL)
  - 00811 Mycosis Fungoides (MF)
  - 00812 Primary Cutaneous Lymphoma (excluding MF and SS)
  - 00830 HemeRetic (excluding sites C420, C421, C423, or C424)

- Assign the code that best describes whether the case has lung metastasis at diagnosis.
  
  - Code 0 when the medical record indicates:
    - No distant (discontinuous) metastases at all.
    - The tumor is benign /0, borderline /1, or in-situ /2.
    - Clinical or pathological statement that there is no lung metastasis.
    - Imaging reports that are negative for lung metastasis.
    - The patient has distant (discontinuous) metastasis, but lung is not mentioned as an involved site.
  
  - Code 1 when the medical record confirms:
- The patient has distant (discontinuous) metastasis, and the lung is mentioned as involved.
- Lung is the primary and there is metastasis in the contralateral lung.

**Note:** Do not code as 1 when lung is the primary with multifocal lung involvement of the same lung.
- The patient is diagnosed with an unknown primary (C809) and lung is mentioned as a distant metastatic site.
  - Code 8 (not applicable) for the following:
    - Any case coded to primary site C420, C421, C423, or C424.
    - 00822 Plasma cell Disorders
  - Code 9 when the patient is known to have distant metastasis, but it cannot be determined whether the distant metastasis include lung.

**Note:** For additional information on schemas and schema IDs, see the [SSDI Manual, Appendix A](#).

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None; no lung involvement</td>
</tr>
<tr>
<td>1</td>
<td>Yes, distant lung metastasis</td>
</tr>
<tr>
<td>8</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>9</td>
<td>Unknown whether lung is an involved metastatic site</td>
</tr>
<tr>
<td></td>
<td>Not documented in patient record</td>
</tr>
</tbody>
</table>
V.6.5 Mets at Diagnosis - Distant Lymph Node(s)

The Mets at Diagnosis – Distant Lymph Node(s) data item captures whether distant lymph node(s) are an involved metastatic site at the time of diagnosis.

Coding Instructions:

- Use AJCC TNM to determine regional versus distant lymph nodes.  
  **Note:** Regional lymph nodes are **not** coded in this data item.
- Code information about distant lymph node(s) metastasis only (discontinuous or distant) to distant lymph node(s) identified at the time of diagnosis.
- Metastatic involvement may be single (one focus of metastatic disease) or multiple (multiple foci of metastatic disease in the same site or multiple sites).
- Information regarding distant lymph node involvement may be clinical or pathologic.
- Code this data item for distant lymph node metastasis even if the patient had neoadjuvant (preoperative) systemic therapy, unless it is determined to be disease progression.
- Code distant lymph node involvement in this data item for all solid tumors, including Kaposi’s sarcoma and Ill-Defined Other primary sites (includes unknown primary site) and the following hematopoietic schemas.
  - 00710 Lymphoma Ocular Adnexa
  - 00790) Lymphoma (excluding CLL/SLL)
  - 00795 Lymphoma (CLL/SLL)
  - 00811 Mycosis Fungoides (MF)
  - 00812 Primary Cutaneous Lymphoma (excluding MF and SS)
  - 00830 HemeRetic (excluding sites C420, C421, C423, or C424)
- Assign the code that best describes whether the case has distant lymph node metastasis at diagnosis.
  - Code 0 when the medical record indicates:
    - No distant (discontinuous) metastases at all.
    - The tumor is benign /0, borderline /1, or in-situ /2.
    - Clinical or pathological statement that there is no distant lymph node metastasis.
    - Imaging reports that are negative for distant lymph node metastasis.
- Lymph nodes are involved, but there is no indication they are regional or distant.
- The patient has distant (discontinuous) metastasis, but distant lymph node(s) are not mentioned as an involved site.

  - Code 1 when the medical record confirms:
    - The patient has distant (discontinuous) metastasis and the distant lymph node(s) are mentioned as involved.

  - Code 8 (not applicable) for the following:
    - Any case coded to primary site C420, C421, C423, or C424.
    - 00822 Plasma cell Disorders

  - Code 9 when the patient is known to have distant metastasis, but it cannot be determined whether the distant metastasis include distant lymph node.

**Note:** For additional information on schemas and schema IDs, see the SSDI Manual, Appendix A for additional information.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None; no distant lymph node involvement</td>
</tr>
<tr>
<td>1</td>
<td>Yes, distant lymph node metastasis</td>
</tr>
<tr>
<td>8</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>9</td>
<td>Unknown whether distant lymph node(s) are involved metastatic site Not documented in patient record</td>
</tr>
</tbody>
</table>
V.6.6 Mets at Diagnosis - Other

The Mets at Diagnosis – Other data item captures any type of distant involvement not captured in the bone, brain, liver, lung, and distant lymph node data items where metastasis has occurred at the time of diagnosis.

Coding Instructions:

- Code information about other metastasis only (discontinuous or distant) to other sites identified at the time of diagnosis.
  
  **Note:** Do not code this data item for bone, brain, liver, lung, or distant lymph node metastasis.

- Metastatic involvement may be single (one focus of metastatic disease) or multiple (multiple foci of metastatic disease in the same site or multiple sites).

- Information regarding other involvement may be clinical or pathologic.

- Code this data item for other metastasis even if the patient had neoadjuvant (preoperative) systemic therapy, unless it is determined to be disease progression.

- Code other involvement in this data item for all solid tumors, including Kaposi’s sarcoma and III-Defined Other primary sites (includes unknown primary site) and the following hematopoietic schemas.
  
  - 00710 Lymphoma Ocular Adnexa
  - 00790 Lymphoma (excluding CLL/SLL)
  - 00795 Lymphoma (CLL/SLL)
  - 00811 Mycosis Fungoides (MF)
  - 00812 Primary Cutaneous Lymphoma (excluding MF and SS)
  - 00830 HemeRetic (excluding sites C420, C421, C423, or C424)

- Assign the code that best describes whether the case has other metastasis at diagnosis.
  
  - Code 0 when the medical record indicates:
    - No distant (discontinuous) metastases at all.
    - The tumor is benign /0, borderline /1, or in-situ /2.
    - Clinical or pathological statement that there is no other metastasis.
    - Imaging reports that are negative for other metastasis.
    - The patient has distant (discontinuous) metastasis, but other sites are not mentioned as an involved site.
  
  - Code 1 when the medical record confirms:
- The patient has distant (discontinuous) metastasis in any sites (other than bone, brain, liver, lung, or distant lymph node(s)).
- Lymphomas with bone marrow involvement (Stage IV disease).
  **Note:** Do not include lymphomas or lymphoma/leukemias where the primary site is coded to C421 (bone marrow).
- The patient is diagnosed with an unknown primary (C809) and other is mentioned as a distant metastatic site.
  - Code 2 when the medical record confirms:
    - The patient has carcinomatosis (carcinomatosis is a condition in which cancer is spread widely throughout the body, or, in some cases, to a relatively large region of the body).
    **Note:** It is possible to have carcinomatosis and have metastatic disease to a specific organ.
    - If a patient has metastatic disease to a site other than bone, brain, liver, lung, or distant nodes and carcinomatosis, assign code 2 for carcinomatosis. Code 2 for carcinomatosis takes priority.
  - Code 8 (not applicable) for the following:
    - Any case coded to primary site C420, C421, C423, or C424.
    - 00822 Plasma cell Disorders
  - Code 9 when the patient is known to have distant metastasis, but it cannot be determined whether the distant metastasis include other.
  **Note:** For additional information on schemas and schema IDs, see the [SSDI Manual, Appendix A](#) for additional information.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None; no other metastasis</td>
</tr>
</tbody>
</table>
| 1    | Yes, distant metastasis in known site(s), other than bone, brain, liver, lung, or distant lymph nodes  
  **Note:** Includes bone marrow involvement for lymphoma |
| 2    | Generalized metastasis such as carcinomatosis |
| 8    | Not Applicable |
| 9    | Unknown whether any other metastatic site or generalized metastasis  
  Not documented in patient record |
V.7 Lymphovascular Invasion

The *Lymphovascular Invasion* data item identifies the presence or absence of tumor cells within blood vessels, lymphatic channels (not lymph nodes) or surrounding tissue within the primary tumor as noted microscopically by the pathologist. Lymphovascular invasion (LVI) includes lymphatic, vascular, and lympho-vascular invasion is an indicator of prognosis.

**Coding Instructions:**

- Lymphovascular invasion status is required by the CCR for all sites when available.
  - LVI is required by the CCR for primary sites penis (C600; C608-C609) and testis (C620-C621) for cases diagnosed 1/1/2010 and forward.
- Code from pathology report(s). If not available, code the absence or presence of lymphovascular invasion as described in the medical record.
  - The primary source of this information is the College of American Pathologists (CAP) synoptic report or checklist. If the CAP is not available, code this data item from the pathology report or a physician’s statement within the medical record, in that order of priority.
  - Code 0, 2, 3, 4, or 9 in lymphovascular invasion for the following Schema IDs
    - 00730 Thyroid
    - 00740 Thyroid Medullary
    - 00760 Adrenal Gland
  - Perineural invasion is **not** coded in this data item.
  - Use the pathology report for any specimen (biopsy or resection) from the primary tumor.
  - Use the table below for cases treated with neoadjuvant (preoperative) therapy. Code LVI based on the medical record when medical record conflicts with this table.

<table>
<thead>
<tr>
<th>LVI on pathology report PRIOR to neoadjuvant therapy</th>
<th>LVI on pathology report AFTER neoadjuvant therapy</th>
<th>Code LVI to:</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 - Not present/Not identified</td>
<td>0 - Not present/Not identified</td>
<td>0 - Not present/Not identified</td>
</tr>
<tr>
<td>0 - Not present/Not identified</td>
<td>1 - Present/Identified</td>
<td>1 - Present/Identified</td>
</tr>
<tr>
<td>0 - Not present/Not identified</td>
<td>9 - Unknown/Indeterminate</td>
<td>9 - Unknown/Indeterminate</td>
</tr>
<tr>
<td>1 - Present/Identified</td>
<td>0 - Not present/Not identified</td>
<td>1 - Present/Identified</td>
</tr>
<tr>
<td>1 - Present/Identified</td>
<td>1 - Present/Identified</td>
<td>1 - Present/Identified</td>
</tr>
</tbody>
</table>
• Code 0:
  o When the pathology report indicates no lymphovascular invasion.
  o Purely in-situ carcinoma, which biologically has no access to lymphatic or vascular channels below the basement membrane.

• Code 1, when the pathology report indicates lymphovascular invasion (or one of its synonyms) is present.

**Synonyms for Lymphovascular Invasion**

<table>
<thead>
<tr>
<th>Angiolympathic invasion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood vessel invasion</td>
</tr>
<tr>
<td>Lymph vascular emboli</td>
</tr>
<tr>
<td>Lymphatic invasion</td>
</tr>
<tr>
<td>Lymphvascular invasion</td>
</tr>
<tr>
<td>Vascular invasion</td>
</tr>
</tbody>
</table>

• Code 8 for the following Schema ID/Schemas:
  o 00430 GIST
  o 00830 HemeRetic
  o 00790 Lymphoma
  o 00795 Lymphoma (CLL/SLL)
  o 00710 Lymphoma Ocular Adnexa
  o 00811 Mycosis Fungoides (MF)
  o 00822 Plasma Cell Disorder
  o 00821 Plasma Cell Myeloma
  o 00812 Primary Cutaneous Lymphoma (excluding MF and SS)

**Note:** For additional information on schemas and schema IDs, see the SSDI Manual, Appendix A for additional information.

• Code 9 when:
  o There is no microscopic examination of a primary tissue specimen.
  o The primary site specimen is a cytology or fine needle aspiration.
- The biopsy is only a very small tissue sample.
- It is not possible to determine whether lymphovascular invasion is present.
- The pathologist states the specimen is insufficient to determine lymphovascular invasion.
- Lymphovascular invasion is not mentioned in the pathology report.
- There is no information/documentation from the pathology report or other sources.
- Primary site is unknown.
- Ambiguous terminology is used

**Example:** suspicious LVI

- This data item is to be left blank for cases diagnosed before 2010.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Lymphovascular invasion stated as not present (absent)/Not identified</td>
</tr>
<tr>
<td>1</td>
<td>Lymphovascular invasion present/identified (NOT used for thyroid and adrenal)</td>
</tr>
<tr>
<td>2</td>
<td>Lymphatic and small vessel invasion only (L) OR Lymphatic invasion only (thyroid and adrenal only)</td>
</tr>
<tr>
<td>3</td>
<td>Venous (large vessel) invasion only (V) OR Angioinvasion (thyroid and adrenal only)</td>
</tr>
<tr>
<td>4</td>
<td>BOTH lymphatic and small vessel AND venous (large vessel) invasion OR BOTH lymphatic AND angioinvasion (thyroid and adrenal only)</td>
</tr>
<tr>
<td>8</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>9</td>
<td>Unknown if lymphovascular invasion present; Indeterminate; not mentioned in path report; Ambiguous terminology used</td>
</tr>
</tbody>
</table>
## V.8 Terms Indicating In-situ for Staging

Certain terms indicate an in-situ stage. Also, see [In-Situ Coding](#) for Reportable terms indicating “in-situ” behavior.

### General Terms Indicating In-situ Behavior

<table>
<thead>
<tr>
<th>Term</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bowen’s disease (excluding skin)</td>
<td></td>
</tr>
<tr>
<td>Confined to epithelium (does not extend beyond base membrane)</td>
<td></td>
</tr>
<tr>
<td>Ductal carcinoma in-situ, (DCIS) (any site)</td>
<td></td>
</tr>
<tr>
<td>Intracystic 8504/2, Intraepidermal (NOS), Intrasquamous, In-situ</td>
<td></td>
</tr>
<tr>
<td>Intraepithelial carcinoma, NOS</td>
<td></td>
</tr>
<tr>
<td>Intraepithelial neoplasia grade III, not otherwise specified (NOS)</td>
<td></td>
</tr>
<tr>
<td>Involvement up to, but not including basement membrane</td>
<td></td>
</tr>
<tr>
<td>Lobular carcinoma in-situ (LCIS) **</td>
<td></td>
</tr>
<tr>
<td>No stromal invasion</td>
<td></td>
</tr>
<tr>
<td>Non-infiltrating; Non-invasive</td>
<td></td>
</tr>
<tr>
<td>Squamous intraepithelial neoplasia grade III (SIN III) (excluding cervix and skin sites coded to C44_), 8077/2, dx 01/01/2014</td>
<td></td>
</tr>
<tr>
<td>Papillary, non-infiltrating or intraductal</td>
<td></td>
</tr>
<tr>
<td>Pre-invasive</td>
<td></td>
</tr>
</tbody>
</table>

### Site-Specific Terms Indicating In-situ Behavior

<table>
<thead>
<tr>
<th>Site</th>
<th>Terms Indicating In-situ Behavior</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anus</td>
<td>Anal Intraepithelial Neoplasia grade II (AIN II), 8077/2, dx 01/01/2022 +</td>
</tr>
<tr>
<td></td>
<td>Anal Intraepithelial Neoplasia grade III (AIN III), 8077/2, dx 01/01/2001 +</td>
</tr>
<tr>
<td></td>
<td>High grade squamous intraepithelial lesion (HGSIL or HSIL), 8077/2, dx 01/01/2018 +</td>
</tr>
<tr>
<td>Appendix</td>
<td>Low-grade appendiceal mucinous neoplasm (LAMN), 8480/2, dx 01/01/2022 +</td>
</tr>
<tr>
<td></td>
<td>High grade appendiceal mucinous neoplasm (HAMN), 8480/2, dx 01/01/2022 +</td>
</tr>
<tr>
<td>Breast</td>
<td>Ductal intraepithelial neoplasia grade III (DIN III), 8500/2, dx 01/01/2001 +</td>
</tr>
<tr>
<td></td>
<td>Lobular intraepithelial neoplasia grade III (LIN III), 8500/2, dx 01/01/2016 + (LCIS) **</td>
</tr>
<tr>
<td></td>
<td>Lobular neoplasia grade III (LN III), 8500/2, dx 01/01/2016 + **</td>
</tr>
<tr>
<td></td>
<td>Lobular, non-infiltrating</td>
</tr>
<tr>
<td>Breast</td>
<td>Stage 0 (excluding Paget’s disease) confined to lamina propria</td>
</tr>
<tr>
<td>Colon</td>
<td></td>
</tr>
<tr>
<td>Rectum</td>
<td></td>
</tr>
<tr>
<td>Gallbladder</td>
<td>High grade biliary intraepithelial neoplasia grade III (BilN III), 8148/2, dx 01/01/2018 +</td>
</tr>
<tr>
<td>Larynx</td>
<td>Laryngeal intraepithelial neoplasia grade III (LIN III), 8077/2, dx 01/01/2001 +</td>
</tr>
<tr>
<td>Organ</td>
<td>Description</td>
</tr>
<tr>
<td>-------------</td>
<td>------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Pancreas</td>
<td>Pancreatic intraepithelial neoplasia grade III (PanIN III), 8500/2, dx 01/01/2004 +</td>
</tr>
<tr>
<td>Penis</td>
<td>Penile intraepithelial neoplasia grade III (PeIN III), 8077/2, dx 01/01/2001 + Queyrat’s erythroplasia, 8080/2</td>
</tr>
<tr>
<td>Skin</td>
<td>✓ Clark’s level I (melanoma; limited to epithelium)</td>
</tr>
<tr>
<td></td>
<td>✓ Hutchinson’s melanotic freckle, not otherwise specified (NOS)</td>
</tr>
<tr>
<td></td>
<td>✓ Lentigo maligna</td>
</tr>
<tr>
<td></td>
<td>✓ Precancerous melanosis</td>
</tr>
<tr>
<td>Stomach</td>
<td>Intestinal-Type adenoma, high grade, 8144/2, dx 01/01/2022 +</td>
</tr>
<tr>
<td>Small Intestine</td>
<td>Adenomatous polyp, high grade dysplasia, 8210/2, dx 01/01/2022 +</td>
</tr>
<tr>
<td></td>
<td>Serrated dysplasia, high grade, 8213/2, dx 01/01/2022 +</td>
</tr>
<tr>
<td>Vagina</td>
<td>Vaginal intraepithelial neoplasia grade III (VAIN III), dx 01/01/1992 +</td>
</tr>
<tr>
<td></td>
<td>Vaginal intraepithelial neoplasia grade II (VAIN II), dx 01/01/2022 +</td>
</tr>
<tr>
<td></td>
<td>High grade squamous intraepithelial lesion (HGSIL or HSIL), dx 01/01/2018 +</td>
</tr>
<tr>
<td>Vulva</td>
<td>Vaginal intraepithelial neoplasia grade III (VAIN III), dx 01/01/1992 +</td>
</tr>
<tr>
<td></td>
<td>Vaginal intraepithelial neoplasia grade II (VAIN II), dx 01/01/2022 +</td>
</tr>
<tr>
<td></td>
<td>High grade squamous intraepithelial lesion (HGSIL or HSIL), dx 01/01/2018 +</td>
</tr>
</tbody>
</table>

**Staging of these data items differ by standard setter.** Please see:
- [AJCC Cancer Staging Manual](#) for TNM staging clarifications.
- [Extent of Disease 2018 General Instructions](#) for staging instructions.
- [Summary Stage 2018 Manual](#) for staging instructions.
V.9 Stage at Diagnosis
Stage at Diagnosis is the established extent of disease determined after the diagnostic/staging workup for a new cancer.

Guidelines:

- Include pertinent findings from autopsy reports if the patient dies within four months of the diagnosis of cancer.
- Exclude data about progression of disease since the time of the original diagnosis.
  - **Progression of Disease:** Any regional or distant metastasis known to have developed after the stage at diagnosis was established.

Examples:

1. Prostate biopsy 1/10/20 is diagnostic of Adenocarcinoma. There is no suspicion of and/or evidence of disease beyond the prostate. On 2/28/20 the patient underwent a Radical prostatectomy. He was seen again on 4/28/20 complaining of hip pain. On 5/1/20 Bone scan reveals bony metastases. The subsequent findings of bony mets, even though within four months from diagnosis would be excluded when coding stage at diagnosis.

2. A patient is undergoing first course treatment and then develops new symptoms or is not responding to treatment, and upon investigation is found to have disease progression. The progression of disease would be excluded when coding the stage at diagnosis.

- Documentation of treatment failure and/or disease progression signifies the end of the first course of treatment.

- Sometimes stage may be stated incorrectly in the medical record due to a typographical, transcription, or similar error. If the stage recorded in one report is clearly contradicted in another, query the physician or the registry's medical consultant. Do not code stage based on information that appears to be inaccurate.

- See, Appendix Q – For additional staging information related to Site-Specific Data Items (SSDIs).
V.9.1 Staging Requirements
Staging requirements have evolved over the years. This page provides a view of the changes over the last few years at a glance.

Guidelines:

- Methods commonly used to determine stage are the American Joint Committee on Cancer (AJCC) TNM staging system, SEER Summary Stage, SEER Extent of Disease, Site-Specific Data Items, and Collaborative Stage:
  - **AJCC TNM:** Used in the clinical setting by physicians to define spread of disease to make appropriate treatment decisions, determine prognosis, and measure end results. Refer to the most current [AJCC Cancer Staging Manual](#) for coding instructions.
    - The Version 9 Cancer Staging System is an update to the AJCC 8th Edition replacing selected disease site(s) on an annual basis. All 8th Edition disease sites remain in effect unless replaced by a new Version 9 protocol.
  - **SEER Summary Stage:** Used by Epidemiologists and researchers where cases are grouped into standardized and simplified broad categories to ensure consistent definitions over time. Refer to the most current [SEER Summary Stage 2018 Manual](#) for coding instructions.
  - **SEER Extent of Disease:** Reflects a combination of clinical and pathologic information. Permits staging of all cancer types. Allows calculation of a combined “best” stage. Refer to the most current [SEER Extent of Disease General Instructions](#) for coding.
  - **Site-Specific Data Items:** Consist of additional prognostic factors or schema discriminators, which are cancer site-specific. Some are used in combination with staging systems variables to determine or derive a stage.
    - Refer to the most current [Site-Specific Data Items Manual](#) for coding instructions.
    - See, Appendix Q – Site-Specific Data Items (SSDIs) for the CCR requirement for Schema Discriminators 1-3.
  - For staging requirements prior to 2018, please see [Archived Volume I](#) – Use case year of diagnosis to determine which Volume I to choose.

**Staging Requirements 2018-2023**

<p>| Staging System Data/Collection | 2018-2023 |</p>
<table>
<thead>
<tr>
<th>Description</th>
<th>Requirement</th>
</tr>
</thead>
<tbody>
<tr>
<td>AJCC TNM 8th Edition Clinical &amp; Path Stage Directly Coded</td>
<td>Required from CoC facilities only, for cases diagnosed 2018 +</td>
</tr>
<tr>
<td>AJCC Version 9 Cancer Staging System; Clinical &amp; Path Stage Directly Coded</td>
<td>Required from CoC facilities only; Cervix diagnosed 2021 +; Anus, Appendix, Brain &amp; Spinal Cord/Medulloblastoma diagnosed 2023+</td>
</tr>
<tr>
<td>SEER 2018 Extent of Disease (EOD) Directly Coded</td>
<td>Required from ALL facilities for cases diagnosed 2018 +</td>
</tr>
<tr>
<td>Summary Stage 2018 Directly Coded</td>
<td>Required from ALL facilities for cases diagnosed 2018 +</td>
</tr>
<tr>
<td>Site-Specific Data Items (SSDIs) only per CCR Appendix Q</td>
<td>Required from ALL facilities as required by CCR Appendix Q</td>
</tr>
</tbody>
</table>
V.10 AJCC TNM Staging
The American Joint Committee on Cancer (AJCC) released the AJCC Cancer Staging Manual, 8th Edition in October 2016. AJCC has started rolling updates, which began in 2021 with the release of Cervix 9th Version. Additional sites are being rolled out annually. AJCC Staging is required by CoC-accredited facilities for all cases diagnosed January 1, 2018 and forward.

Guidelines:
- Refer to the most current AJCC Cancer Staging Manual for specific disease site chapters and staging instructions.
- AJCC Cancer Staging questions should be directed to the CAnswer Forum at: http://cancerbulletin.facs.org/forums.
V.10.1 AJCC TNM Staging General Information

The 2018 AJCC TNM staging data items are separate from the pre-2018 TNM clinical and pathological stage items.

The CCR requires AJCC TNM Staging by CoC-accredited facilities for:

- AJCC TNM Clinical and Pathologic stage for all cases diagnosed January 1, 2018 and forward.
- AJCC TNM Post Therapy Path (yp) stage (renamed from AJCC TNM Post Therapy) for cases diagnosed January 1, 2018 and forward.
- AJCC TNM Post Therapy Clin (yc) stage for cases diagnosed January 1, 2021 and forward.

For additional information on historical manual references, refer to Appendix S – Historical Coding and Staging Manual Requirements for CCR.

Guidelines:

- Refer to the most current AJCC Cancer Staging Manual for specific disease site chapters and staging instructions.
- Four stage classifications are defined by AJCC TNM staging and include:
  - **AJCC TNM Clinical Stage** classification includes the following data items:
    - Clinical Stage
      - AJCC TNM Clin T
      - AJCC TNM Clin T Suffix
      - AJCC TNM Clin N
      - AJCC TNM Clin N Suffix
      - AJCC TNM Clin M
      - AJCC TNM Clin Stage Group
  - **AJCC TNM Pathological Stage** classification includes the following data items:
    - Pathological Stage
      - AJCC TNM Path T
      - AJCC TNM Path T Suffix
      - AJCC TNM Path N
      - AJCC TNM Path N Suffix
      - AJCC TNM Path M
      - AJCC TNM Path Stage Group
- **Post Therapy Clin (yc) Stage** classification includes the following data items:

<table>
<thead>
<tr>
<th>Post Therapy Clin (yc) Stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>AJCC TNM Post Therapy Clin (yc) T</td>
</tr>
<tr>
<td>AJCC TNM Post Therapy Clin (yc) T Suffix</td>
</tr>
<tr>
<td>AJCC TNM Post Therapy Clin (yc) N</td>
</tr>
<tr>
<td>AJCC TNM Post Therapy Clin (yc) N Suffix</td>
</tr>
<tr>
<td>AJCC TNM Post Therapy Clin (yc) M</td>
</tr>
<tr>
<td>AJCC TNM Post Therapy Clin (yc) Stage Group</td>
</tr>
</tbody>
</table>

- **Post Therapy Path (yp) Stage** classification includes the following data items:

<table>
<thead>
<tr>
<th>Post Therapy Path (yp) Stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>AJCC TNM Post Therapy Path (yp) T</td>
</tr>
<tr>
<td>AJCC TNM Post Therapy Path (yp) T Suffix</td>
</tr>
<tr>
<td>AJCC TNM Post Therapy Path (yp) N</td>
</tr>
<tr>
<td>AJCC TNM Post Therapy Path (yp) N Suffix</td>
</tr>
<tr>
<td>AJCC TNM Post Therapy Path (yp) M</td>
</tr>
<tr>
<td>AJCC TNM Post Therapy Path (yp) Stage Group</td>
</tr>
</tbody>
</table>
V.10.2 AJCC TNM Edition Number
AJCC TNM Edition Number identifies the Cancer Staging Manual edition used to code the AJCC TNM Stage.

- There will no longer be a single edition or version number applicable to every disease site for the diagnosis year.
  
  **Note:** The AJCC has started rolling updates, which began in 2021 with the release of Cervix 9th Version. As warranted by medical practice, additional disease sites will be updated in the future as necessary, while the other disease sites will remain unchanged, and the 8th Edition will be used.

- While references will be made to the 9th Version, the registry data item will continue to reference *TNM Edition Number*.

**Coding Instructions:**

- Record the edition of the [AJCC Cancer Staging Manual](#) that was used for TNM staging.

- The TNM Edition data item may not be left blank.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>Not staged</td>
</tr>
<tr>
<td>01</td>
<td>First edition</td>
</tr>
<tr>
<td>02</td>
<td>Second edition</td>
</tr>
<tr>
<td>03</td>
<td>Third edition</td>
</tr>
<tr>
<td>04</td>
<td>Fourth edition</td>
</tr>
<tr>
<td>05</td>
<td>Fifth edition</td>
</tr>
<tr>
<td>06</td>
<td>Sixth edition</td>
</tr>
<tr>
<td>07</td>
<td>Seventh edition</td>
</tr>
<tr>
<td>08</td>
<td>Eighth edition</td>
</tr>
<tr>
<td>09</td>
<td>Ninth edition</td>
</tr>
<tr>
<td>88</td>
<td>Not applicable (cases do not have an AJCC staging scheme and staging was not done)</td>
</tr>
<tr>
<td>99</td>
<td>Unknown</td>
</tr>
</tbody>
</table>
V.10.3 AJCC - Ambiguous Terms for Disease Extension
AJCC TNM staging does not define ambiguous terminology nor mandate how words should be interpreted.

Guidelines:
How to interpret words for cancer involvement:
- Review clinician’s statements.
- Treatment choices may indicate clinician’s impression.
- Review and analyze entire case:
  - Physical exam
  - Medical history of all other disease
  - Symptoms
  - Imaging
  - Lab tests
  - Diagnostic procedures
  - All other variable information
- Judgement call based on all aspects of patient’s care.

Note: For CoC facilities as a reference of last resort with respect to tumor spread for staging purposes, please see STORE - Ambiguous Terms Describing Tumor Spread.
V.11 Extent of Disease (EOD)

Extent of Disease (EOD) 2018 is a data collection system which has three data items: EOD Primary Tumor, EOD Regional Nodes, and EOD Mets. EOD 2018 is required by the CCR to be collected for every site and histology combination for cases diagnosed January 1, 2018 and forward.

Guidelines:

- Refer to the most current Extent of Disease 2018 General Instructions for coding instructions and SEER*RSA for rules and site-specific codes and coding structures.
- Extent of Disease questions should be directed to ask a SEER Registrar at: https://seer.cancer.gov/registrars/contact.html.
V.11.1 EOD General Information

The 2018 Extent of Disease is separate from the previous version. *EOD Primary Tumor, EOD Regional Nodes, and EOD Mets* are required by the CCR for cases diagnosed January 1, 2018 and forward.

For additional information on historical manual references, refer to Appendix S - Historical Coding and Staging Manual Requirements for CCR.

**Guidelines:**

- Refer to the most current *Extent of Disease 2018 General Instructions* for coding instructions and **SEER***RSA* for rules and site-specific codes and coding structures.

- Three main EOD data items:
  - *EOD Primary Tumor*
  - *EOD Regional Nodes*
  - *EOD Mets*

- **Always** check the site-specific EOD 2018 schemas for exceptions and/or additional information.

- EOD is based on a combined clinical and operative/pathological assessment for all sites.
  - Gross observations at surgery are particularly important when all malignant tissue cannot be, or was not removed.
    - In the event of a disagreement between pathology and operative reports regarding excised tissue, priority is given to the pathology report.

- EOD should include all available information within four months of diagnosis in the absence of disease progression or upon completion of surgery(ies) during the first course of treatment, whichever is longer.

- Review clinical information carefully to accurately determine the extent of disease. Clinical information such as description of skin involvement for breast cancer and lymph nodes for any site, can change the EOD Stage.
  - If the operative/pathological information disproves the clinical information, use the operative/pathological information.

- Information for EOD from a surgical resection after neoadjuvant treatment may only be used if the extent of disease is greater than the pre-treatment clinical stage.

- Exclude disease progression, including metastatic involvement, known to have developed after the initial stage workup, when coding EOD data items.
• Autopsy reports are used in coding EOD just as pathology reports. Apply the same rules for inclusion and exclusion.

• Death Certificate Only (DCO) cases
  o Code the following for DCO’s, unless more specific codes can be assigned
    ▪ *EOD Primary Tumor*: 999
    ▪ *EOD Regional Nodes*: 999
    ▪ *EOD Mets*: 99

• TNM information may be used to code EOD 2018 when it is the only information available.

• When there is a discrepancy between the T, N, M information and the documentation in the medical record.
  o Access the physician to resolve the discrepancy, when possible. Otherwise, use the medical record documentation to assign EOD.

• EOD schema-specific guidelines take precedence over the general guidelines. Always read the information pertaining to the specific primary site or histology schema.
V.11.1.1 EOD - Primary Tumor

*EOD-Primary Tumor* is part of the EOD 2018 data collection system and is used to classify contiguous growth (extension) of the primary tumor within the organ of origin or its direct extension into neighboring organs at the time of diagnosis. This data item is required by the CCR for cases diagnosed January 1, 2018 and forward.

**Coding Instructions:**

- Refer to the most current [Extent of Disease 2018 General Instructions](#) for coding instructions and [SEER*RSA](#) for rules and site-specific codes and coding structures.

- **Always** check the site-specific EOD 2018 schemas for exceptions and/or additional information.

- Enter the code for farthest documented direct contiguous extension of the primary tumor.

  - If an involved organ or tissue is not specifically mentioned in the code descriptions, approximate the location from listed structures in the same anatomic area and assign the appropriate code based on that information.

- **EOD-Primary Tumor codes are hierarchical** except for code 800.

- Clinical vs Pathological codes:

  - Some schemas have EOD extension codes that are noted as “clinical assessment only” or “pathological assessment only.”

    - Use clinical assessment codes when there is a workup only (physical exam, imaging, and biopsy) and no surgical resection of the primary tumor or site has been done.
    
    - Use pathological assessment when there is a surgical resection of the tumor or site.

- The “localized, NOS” code is **only** to be used after an exhaustive search for more specific information.

- Pathological findings take priority over clinical findings.

  - Assign the highest code representing the greatest extension pathologically.

  - Assign the highest code representing the greatest extension clinically, when there is no pathology.

    - Imaging takes precedence over physical examination.

  - If the extension is positive based on the imaging and/or physical exam, but is confirmed to be negative on the pathological exam, code the *EOD-Primary Tumor* based on the pathological findings.
Neoadjuvant therapy - When a patient receives preoperative systemic therapy (chemotherapy/immunotherapy) or radiation:
  - Code the clinical information if that is the furthest documented extension or
  - Code the post-neoadjuvant extension if the post-neoadjuvant surgery shows a more extensive disease (i.e., disease was greater than at clinical presentation) or
  - Code the extension based on the clinical information when the clinical and pathological information are the same.

Code 000 when:
  - Medical record indicates tumor is in-situ.
    Exception: For some schemas, e.g., Breast, there may be multiple categories of in-situ codes. Use the schema-specific instructions and codes.
  - In-situ tumors which have nodal or metastatic involvement:
    - In the event of an in-situ tumor with nodal or metastatic involvement, assign EOD-Primary tumor as in-situ and code the EOD-Regional Nodes and/or EOD-Mets appropriately. This is a change from previous version of EOD and Summary Stage.
    Note: Behavior would be /3 for these tumors. The primary tumor is in-situ; however, there is evidence of and invasive component due to the positive lymph nodes or metastatic involvement.

Discontinuous or distant mets: Discontinuous/distant metastasis are usually coded in the EOD-Mets data item.
  - Some exceptions include Mucinous carcinoma of the appendix, corpus uteri, ovary, fallopian tube and female peritoneum, where discontinuous mets in the pelvis or abdomen are coded in EOD-Primary Tumor.
    - For some schemas, such as breast, lung, and kidney, direct (contiguous) extension to certain specific sites is listed under EOD-Mets.
      - If the structure involved by direct extension is not listed in the EOD-Primary Tumor categories, look for it in the EOD-Mets.
      - If the specific structure involved by direct extension is not listed in either data item, assign the highest known contiguous extension code in EOD-Primary Tumor.
• Code 800 when there is no evidence of the primary tumor (occult primary).

**Note:** This does not apply to those cases where a biopsy removes all of the tumor and there is not residual tumor on the surgical resection.

  o When *EOD-Primary Tumor* is coded to 800:
    ▪ *Tumor Size Clinical* should be coded to 000 when there is no surgical resection for the primary tumor or site, but clinically no primary tumor was identified.
    ▪ *Tumor Size Pathologic* should be coded to 000 when the suspected tumor or site is resected, but no tumor is found. If surgical resection is done, code 999.

• Code 999:
  o When there is no information on primary tumor extent.
  o By default, for Death Certificate Only (DCO) cases; however, assign the appropriate *EOD-Primary Tumor* code when specific primary tumor extension information is available on a DCO.

• Document choice of *EOD-Primary Tumor* code in text. It is strongly recommended that the assessment of the primary tumor extension be documented, as well as the choice of the *EOD-Primary Tumor* code in a related STAGE text data item on the abstract. While primary tumor extension can be found in a variety of places, it is most commonly found in a pathology and/or operative report.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>000</td>
<td>In-situ, intraepithelial, noninvasive, non-infiltrating</td>
</tr>
<tr>
<td></td>
<td><strong>SCHEMA-SPECIFIC CODES WHERE NEEDED</strong></td>
</tr>
<tr>
<td>800</td>
<td>No evidence of primary tumor</td>
</tr>
<tr>
<td>999</td>
<td>Unknown; primary tumor not stated</td>
</tr>
<tr>
<td></td>
<td>Not documented in patient record</td>
</tr>
<tr>
<td></td>
<td>Primary tumor cannot be assessed</td>
</tr>
<tr>
<td></td>
<td>Death Certificate Only (DCO)</td>
</tr>
</tbody>
</table>
V.11.1.2 EOD - Regional Nodes

*EOD-Regional Nodes* is part of the EOD 2018 data collection system and is used to classify the regional lymph nodes involved at the time of diagnosis. This data item is required by the CCR for cases diagnosed January 1, 2018 and forward.

**Coding Instructions:**

- Refer to the most current *Extent of Disease 2018 General Instructions* for coding instructions and *SEER*RSA for rules and site-specific codes and coding structures.

- **Always** check the site-specific EOD 2018 schemas for exceptions and/or additional information.

- Regional lymph nodes are listed for each schema.

- Enter the code for the specific involved regional lymph node chain(s) farthest from the primary site.

- **EOD-Regional Nodes are hierarchical** except for code 800.
  - Usually, regional lymph nodes in the chain(s) closest to the primary site typically have lower codes, while nodes further away from the primary or in a further lymph node chain have higher codes. Although, there are some exceptions due to lymph node drainage patterns.

  - If a lymph node chain is not listed, check:
    - *SEER*RSA – Abstracter Notes
    - Hematopoietic Manual, Appendix C
    - An anatomy textbook
    - ICD-O-3
    - Medical Dictionary

  - If the named lymph node chain or its synonym cannot be found in the above resources and are not listed in regional nodes, code involved node(s) in EOD-Mets.

**Coding tip for lymph nodes:** If it is not possible to determine if a lymph node is regional or distant, check the scheme for a site that is nearby.

**Example:** If the site is esophagus and you are unable to determine if a listed regional node is regional or distant, check the stomach *EOD-Regional nodes*. If the lymph node chain is listed as regional for stomach, assume the named lymph node is not an obscure name for a lymph node chain and that it is probably distant for the esophagus.

- Clinical vs pathological codes:
Some schemas have EOD extension codes that are noted as “clinical assessment only” or “pathological assessment only.”

- Use clinical assessment codes when there is a workup only (physical exam, FNA, needle core biopsy, sentinel node biopsy, or lymph node excision) and no surgical resection of the primary tumor or site has been done.

- Use pathological assessment when there is a surgical resection of the tumor or site, when there is an FNA done in conjunction with surgery, or a sentinel lymph node biopsy or lymph node dissection has been performed.

  **Note:** The FNA or sentinel lymph node biopsy can be done during the clinical workup and then followed by a negative lymph node dissection.

**Pathological findings take priority over clinical findings.**

- Assign the highest applicable code for lymph node involvement at diagnosis, whether determination was clinical or pathological.

- If there is a discrepancy between clinical and pathologic information about the same lymph nodes, pathologic information takes precedence (provided no preoperative treatment was administered).

  **Note:** Biopsy of every suspicious lymph node is not necessary to disprove involvement.

- Assign the code representing lymph node involvement at diagnosis pathologically.

- Assign the code representing lymph node involvement at diagnosis clinically, when there is no pathology.

- If the lymph nodes are positive based on the imaging, but are confirmed to be negative on the pathological exam, code the EOD-Regional Nodes based on the pathological findings.

  **Exception:** Assign code 800 only when there is lymph node involvement but no available information regarding the specific nodal chain involved.

**Solid Tumors – Terms indicating lymph node involvement** (when no specific information as to tissue involved) are recorded as lymph node involvement:

- Fixed

- Matted

- Mass in the hilum, mediastinum, retroperitoneum, and/or mesentery

- The following terms should be ignored for solid tumors unless there is a statement of involvement by the clinician, or the patient was treated as though regional lymph nodes were involved.
• Palpable
• Enlarged
• Visible swelling
• Shotty
• Lymphadenopathy
  o “Ipsilateral,” “homolateral,” and “same side’ are used interchangeably.

• **Accessible lymph nodes** – Lymph nodes that can be observed, palpated, or examined without instruments such as the regional lymph nodes for breast, oral cavity, salivary gland, skin, thyroid and other organs are considered accessible lymph nodes.
  o Look for the description of the accessible lymph nodes.
  o Code 000 (negative regional lymph nodes) when:
    ▪ A statement such as “remainder of examination negative” is made.
    ▪ Clinical evaluation IS mentioned but no mention of positive nodes.

• **Inaccessible lymph nodes** – Lymph nodes within body cavities that in most situations are **not** easily examined by clinical methods such as observation, palpation and physical exam are considered inaccessible.

  **Examples**: Bladder, colon, corpus uteri, esophagus, kidney, liver, lung, ovary, prostate, and stomach (not an all-inclusive list).

• Code 000 over 999 when **all** the following conditions are met:
  o No mention of regional nodes involved in the physical exam, the pre-treatment diagnostic testing, or the surgical exploration.
  o The patient has localized disease.
  o Patient receives (or is offered but refused) standard treatment to the primary site as determined appropriate to the stage of disease by the physician.

• Code 000 when:
  o Medical record indicates tumor is in-situ (behavior /2).
    ▪ For breast and thyroid, there are multiple lymph node codes indicating no regional lymph node involvement (depending on whether lymph nodes were pathologically examined or not).
  o In-situ tumors which have nodal metastatic involvement:
    ▪ In the event of an in-situ tumor with metastatic nodal involvement, assign **EOD-Primary Tumor** as in-situ and code the **EOD-Regional Nodes** appropriately positive.

  **Note**: Behavior for these tumors would be /3. The primary is in-situ; however, there is evidence of an invasive component due to the positive lymph nodes.
• Direct extension of tumor into regional lymph node is coded as an involved node(s) in *EOD-Regional Nodes*.

• Code as positive regional nodes, when involved nodes are found during sentinel lymph node procedures.
  o The sentinel lymph nodes are the first to receive lymphatic drainage from the primary tumor.
  o If the sentinel lymph node contains metastatic tumor, this indicates other lymph nodes may contain tumor. If it does not contain metastatic tumor, the other lymph nodes are not likely to contain tumor.

• **Isolated Tumor Cells (ITCs)** – ITCs are counted as positive regional nodes (for some schemas). Other schemas count them as negative. See individual schemas to determine how to code ITCs.

• Discontinuous (satellite) tumor deposits (peritumoral nodules) for colon, appendix, rectosigmoid, and rectum: These can occur WITH or WITHOUT regional lymph node involvement.
  o Enter the code according to guidelines in the individual schemas.
  o Tumor nodules in pericolic or perirectal fat without evidence of residual lymph node structures can have one of several aspects of the primary cancer: discontinuous spread, venous invasion with extravascular spread, or a totally replaced lymph node.
  o When there are Tumor Deposits and lymph node involvement:
    ▪ Code only the lymph node involvement in *EOD-Regional Nodes*.
    ▪ Code the presence of Tumor Deposits in the SSDI item, Tumor Deposits.

• Code 800 in the following situations:
  o Lymph node assignment for the EOD schema is based on location (specifically listed lymph nodes) and the only documentation available is that lymph nodes are involved.
  o Lymph node assignment for the EOD schema is based on number and/or size and the only documentation available is that lymph nodes are involved.
  o Stated as “Regional lymph nodes involved,” with no further information on location, number and size.
  o Undefined nodes included with the resected primary site.
    ▪ Nodes may be identified in the operative/pathology report (including the final diagnosis), microscopic or gross description.
  o Lymph nodes that are not specified as regional or distant (LN chain/name and location unknown) should be assumed to be regional nodes.

• Code 888 for the following schemas:
- 00721 Brain
- 00722 CNS Other
- 00830 HemeRetic
- 99999 Ill-Defined Other (includes unknown primary site)
- 00723 Intracranial Gland
- 00790 Lymphoma
  - Primary 00812 Cutaneous and 00710 Ocular Adnexal Lymphomas have separate schemas from Lymphoma. Code 888 is invalid for these schemas. Code the EOD-Regional Nodes appropriately per medical record findings.
- 00795 Lymphoma CLL/SLL
- 00821 Plasma Cell Myeloma
- Code 999 when the medical record:
  - Has no information on regional lymph node involvement and the primary tumor is not localized.
  - By default, for Death Certificate Only (DCO) cases; however, assign the appropriate EOD-Regional Nodes code when specific regional lymph node involvement information is available on a DCO.
- Document choice of EOD-Regional Nodes code in text. It is strongly recommended that the assessment of regional nodes be documented, as well as the choice of the EOD-Regional Nodes code in a related STAGE text data item on the abstract. While regional node status can be found in a variety of places, it is most commonly found in physical exam, scans, and pathology reports.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>000</td>
<td>No regional lymph node involvement</td>
</tr>
<tr>
<td></td>
<td><strong>SCHEMA-SPECIFIC CODES WHERE NEEDED</strong></td>
</tr>
<tr>
<td>800</td>
<td>Regional lymph node(s), NOS</td>
</tr>
<tr>
<td></td>
<td>Lymph node(s), NOS</td>
</tr>
<tr>
<td>888</td>
<td>Use for these sites only: Brain; CNS Other; HemeRetic; Ill-Defined Other (includes unknown primary site); Intracranial Gland; Lymphoma; Lymphoma-CLL/SLL, Plasma Cell Myeloma</td>
</tr>
<tr>
<td>999</td>
<td>Unknown; regional lymph node(s) not stated</td>
</tr>
<tr>
<td></td>
<td>Regional lymph node(s) cannot be assessed</td>
</tr>
<tr>
<td></td>
<td>Not documented in patient record</td>
</tr>
<tr>
<td></td>
<td>Death Certificate Only (DCO)</td>
</tr>
</tbody>
</table>
V.11.1.3 EOD - Mets

*EOD-Mets* is part of the EOD 2018 data collection system and is used to classify the distant site(s) of metastatic involvement at the time of diagnosis. This data item is required by the CCR for cases diagnosed January 1, 2018 and forward.

**Coding Instructions:**

- Refer to the most current *Extent of Disease 2018 General Instructions* for coding instructions and *SEER*RSA for rules and site-specific codes and coding structures.
- **Always** check the site-specific EOD 2018 schemas for exceptions and/or additional information.
- Determination of *EOD-Mets* requires **only** history and physical examination.
- Imaging of distant organs is not required. The registrar can infer solely from the PE, that there is no distant metastasis when there is a lack of extensive workup.
- Code 00 when:
  - There is no distant metastasis as determined by clinical, radiographic and/or pathological methods.
  - No physical exam, imaging or pathology information is available.
  - There is reasonable doubt that the tumor is no longer localized and there is no documentation of distant metastasis.
- Enter the appropriate *EOD-Mets* codes for cases with one or more distant metastasis identified clinically, radiographically, and/or pathologically.
- **EOD-Mets are hierarchical** except for code 70.
- The *EOD-Mets* category may include direct extension of the primary tumor into distant organs or tissues for a few schemas, such as breast, lung, kidney, and ovary.
  - If the structure involved by direct extension is **not** listed in the *EOD-Primary Tumor* categories, look for it in the *EOD-Mets*.
  - If the specific structure involved by contiguous mets is not listed in either data item, assign the highest available code in *EOD-Primary Tumor*.
- **Discontinuous or hematogenous metastasis:** Tumor metastasis known at the time of diagnosis to have indirectly spread (through vascular or lymph channels) to distant nodes or site(s) from the primary site, are coded in the *EOD-Mets* data item. Refer to individual schemas for detailed instructions.
- Positive pathological findings **take priority over** clinical findings.

**Exception:** Not every metastatic site may be biopsied; however, for purposes of coding this data item, each metastatic site, whether confirmed clinically or pathologically, should be included, which may mean that clinical evidence would take priority over pathological.
o Assign the highest code for metastasis at diagnosis pathologically.

o Assign the highest code for metastasis at diagnosis clinically, with imaging taking priority, when there is no pathology, or the pathology report does not show metastasis.

- Not all possible metastatic sites are listed in each of the schemas. If there is confirmed metastasis that is not listed, assign the highest code as described below:
  o Code 70 is used for all mets (except distant lymph nodes only), for schemas that have only codes 10 (distant lymph nodes) and 70 (all other mets).
  o For schemas where there are additional codes:
    ▪ Use the highest code before code 70, when mets are present that are not specified in any of the other codes.
    ▪ Code 70 in these cases should only be used when the only information is “distant metastasis, NOS,” and there is no documentation regarding the specific metastases.

- Neoadjuvant therapy - When a patient receives preoperative systemic therapy (chemotherapy/immunotherapy) or radiation:
  o Code the clinical information description that identifies the most extensive metastasis.
  o or if the post-neoadjuvant surgery reveals additional or more extensive disease, code EOD-Mets based on the post-neoadjuvant information.
  o or code the metastasis based on the clinical information when the clinical and pathological information are the same.

- Isolated Tumor Cells (ITCs), Circulating Tumor Cells (CTCs), and Disseminated Tumor Cells (DTCs) – Are small clusters of cells not greater than 0.2 mm in largest dimension found in distant sites such as bone, circulating blood, or bone marrow and have uncertain prognostic significance.
  o Breast – Code 5 when a biopsy of distant nodes shows ITCs, CTCs or DTCs detected by IHC or molecular techniques.
  o Other sites – ITCs, CTCs or DTCs are coded to 00.

- In-situ tumors with metastatic involvement:
  o In the event of an in-situ tumor with metastatic involvement, assign EOD-Primary Tumor as in-situ and code the EOD-Mets as positive.
    Note: Behavior for these tumors would be /3. The primary is in-situ; however, there is evidence of an invasive component due to the metastatic involvement.

- Code 88 for the following schemas:
  o 00830 HemeRetic
99999 Ill-Defined Other (includes unknown primary site)
00458 Kaposi Sarcoma
00790 Lymphoma
  - Primary 00812 Cutaneous and 00710 Ocular Adnexal Lymphomas have separate schemas from Lymphoma. **EOD-Mets code 88 is invalid for these sites.** Code EOD-Mets appropriately per medical record findings.
00795 Lymphoma-CLL/SLL
00822 Plasma Cell Myeloma
00821 Plasmacytosis
- Code 99 only for Death Certificate Only (DCO) cases; however, assign the appropriate EOD-Mets code when specific metastatic information is available on a DCO.
  - Code 00 when it is unknown if there are distant metastasis.
- Document choice of EOD-Mets code in text. It is strongly recommended that the assessment of distant lymph nodes and/or distant metastasis be documented, as well as the choice of the EOD-Mets code in a related STAGE text data item on the abstract. While information on met status can be found in a variety of places, it is most commonly found in physical exam and scans.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>No distant metastasis</td>
</tr>
<tr>
<td></td>
<td>Unknown if distant metastasis</td>
</tr>
<tr>
<td></td>
<td><strong>SCHEMA-SPECIFIC CODES WHERE NEEDED</strong></td>
</tr>
<tr>
<td>70</td>
<td>Distant Metastasis, NOS</td>
</tr>
<tr>
<td>88</td>
<td>Not applicable: Information not collected for this schema Use for these sites only: HemeRetic; Ill-Defined Other (includes unknown primary site); Kaposi Sarcoma; Lymphoma; Lymphoma-CLL/SLL, Plasma Cell Disorder; Plasma Cell Myeloma</td>
</tr>
<tr>
<td>99</td>
<td>Death Certificate Only (DCO)</td>
</tr>
</tbody>
</table>
**V.11.2 EOD Prostate Pathological Extension**

This data item is used in EOD staging and was previously collected as Prostate, CS SSF#3. The *Prostate Pathological Extension* is used to assign pT category for prostate cancer based on the radical prostatectomy specimens. This data item is required by the CCR for cases diagnosed January 1, 2018 and forward.

**Guidelines:**

- Refer to the Schema-specific [Summary Stage 2018](#) and [Extent of Disease (EOD)](#) codes/coding instructions and [SEER*RSA](#) for rules and site-specific codes and coding structures for coding instructions on this data item.
  - Always check the site-specific EOD 2018 schemas for exceptions and/or additional information.
- Only use histologic information from prostatectomy, including simple prostatectomy with negative margins, and autopsy in this data item.
  - Information from biopsy of extraprostatic sites are coded in [EOD - Primary Tumor](#).
- Code 900 when there is not prostatectomy performed within the first course of treatment.
- Limit information in this data item to first course of treatment in the absence of disease progression.
- If prostate cancer is an incidental finding during a prostatectomy for other reasons (such as, cystoprostatectomy for bladder cancer), use the appropriate code for the extent of disease found.
- Involvement of the prostatic urethra does not alter the extension code.
- The clinical term which means tumor extends to pelvic sidewall(s) is “Frozen Pelvis.”
  - Code 700 in the absence of a more detailed statement of involvement.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>000</td>
<td>In-situ: noninvasive; intraepithelial</td>
</tr>
<tr>
<td>250</td>
<td>Invasion into (but not beyond) prostatic capsule&lt;br&gt;Intracapsular involvement only&lt;br&gt;No extracapsular extension</td>
</tr>
<tr>
<td>300</td>
<td>Confined to prostate, NOS&lt;br&gt;Localized, NOS</td>
</tr>
<tr>
<td>350</td>
<td>Bladder neck, microscopic invasion&lt;br&gt;Extraprostatic extension (beyond prostatic capsule), unilateral, bilateral, or NOS&lt;br&gt;WITHOUT invasion of the seminal vesicles&lt;br&gt;Extension to periprostatic tissue WITHOUT invasion of the seminal vesicles</td>
</tr>
<tr>
<td>400</td>
<td>Tumor invades seminal vesicle(s)</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td>500</td>
<td>Extraprostatic tumor that is not fixed WITHOUT invasion of adjacent structures Periprostatic extension, NOS (unknown if seminal vesicle(s) involved) Extraprostatic extension, NOS (unknown if seminal vesicle(s) involved) Through capsule, NOS</td>
</tr>
<tr>
<td>600</td>
<td>Bladder neck, except microscopic bladder neck involvement Bladder, NOS External sphincter Extraprostatic urethra (membranous urethra) Fixation, NOS Levator muscles Rectovesical (Denonvillier’s) fascia Rectum Skeletal muscle Ureter(s)</td>
</tr>
<tr>
<td>700</td>
<td>Extension to or fixation to pelvic wall or pelvic bone &quot;Frozen pelvis&quot;, NOS Further contiguous extension including: • Bone • Other organs • Penis • Sigmoid colon • Soft tissue other than periprostatic</td>
</tr>
<tr>
<td>800</td>
<td>No evidence of primary tumor</td>
</tr>
<tr>
<td>900</td>
<td>No prostatectomy or autopsy performed</td>
</tr>
<tr>
<td>950</td>
<td>Prostatectomy performed, but not first course of treatment (for example performed after disease progression)</td>
</tr>
<tr>
<td>999</td>
<td>Unknown; extension not stated Unknown if prostatectomy done Primary tumor cannot be assessed Not documented in patient record</td>
</tr>
</tbody>
</table>
V.11.3 EOD - Ambiguous Terms for Extent of Disease

Registrars will find definitive statements of involvement, most of the time; however, for those situations where involvement is described with non-definitive (ambiguous) terminology, use the guidelines below to interpret and determine the appropriate assignment of EOD 2018.

Guidelines:

- Refer to the most current Extent of Disease 2018 General Instructions for coding instructions and SEER*RSA for rules and site-specific codes and coding structures.

- Always check the site-specific EOD 2018 schemas for exceptions and/or additional information.

- Determination of the cancer stage is both a subjective and objective assessment by the physician(s) of how far the cancer has spread.
  
  o Look at the documentation that the physician used to make informed decisions on how the patient is being treated when it is not possible to determine the extent of involvement because terminology is ambiguous.

  Example: Assign EOD data items based on involvement when the patient was treated as though adjacent organs or nodes were involved.

- Use the following lists to interpret the intent of the clinician only when further documentation is not available and/or there is no specific statement of involvement in the medical record.
  
  o The physician’s definitions/descriptions and choice of therapy have priority over these lists because individual clinicians may use these terms differently.

- Terminology in the chapter takes priority over this list:
  
  o Some chapters interpret certain words as involvement; such as ‘encasing’ the carotid artery for a head and neck site or “abutment,” “encases,” or “encasement” for pancreas primaries.

- Use the following list only for EOD 2018 or Summary Stage 2018.
  
  o This is not the same list used for determining reportability as published in the SEER Program Manual, Hematopoietic Manual or in Section 1 of the STandards for Oncology Registry Entry (STORE) Manual.

  o This is not the same list of ambiguous terminology provided in the current Solid Tumor Rules Manual published and maintained by the SEER Program.

  o Use the following list of terms as a guide ONLY when no other information is available.
## Involved

<table>
<thead>
<tr>
<th>Adherent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apparent(ly)</td>
</tr>
<tr>
<td>Appears to</td>
</tr>
<tr>
<td>Comparable with</td>
</tr>
<tr>
<td>Compatible with</td>
</tr>
<tr>
<td>Consistent with</td>
</tr>
<tr>
<td>Contiguous/continuous with</td>
</tr>
<tr>
<td>Encroaching upon*</td>
</tr>
<tr>
<td>Extension to, into, onto, out onto</td>
</tr>
<tr>
<td>Features of</td>
</tr>
<tr>
<td>Fixation to a structure other than primary**</td>
</tr>
<tr>
<td>Fixed to another structure**</td>
</tr>
<tr>
<td>Impending perforation of</td>
</tr>
<tr>
<td>Impinging upon</td>
</tr>
<tr>
<td>Impose/imposing on</td>
</tr>
<tr>
<td>Incipient invasion</td>
</tr>
<tr>
<td>Induration</td>
</tr>
<tr>
<td>Infringe/infringing</td>
</tr>
<tr>
<td>Into*</td>
</tr>
<tr>
<td>Intrude</td>
</tr>
<tr>
<td>Most likely</td>
</tr>
<tr>
<td>Onto*</td>
</tr>
<tr>
<td>Overstep</td>
</tr>
<tr>
<td>Presumed</td>
</tr>
<tr>
<td>Probable</td>
</tr>
<tr>
<td>Protruding into (unless encapsulated)</td>
</tr>
<tr>
<td>Suspected</td>
</tr>
<tr>
<td>Suspicious</td>
</tr>
<tr>
<td>To*</td>
</tr>
<tr>
<td>Up to</td>
</tr>
</tbody>
</table>

## Not Involved

<p>| Abuts                          |
| Approaching                    |</p>
<table>
<thead>
<tr>
<th>Approximates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Attached</td>
</tr>
<tr>
<td>Cannot be excluded/ruled out</td>
</tr>
<tr>
<td>Efface/effacing/effacement</td>
</tr>
<tr>
<td>Encased/encasing</td>
</tr>
<tr>
<td>Encompass(ed)</td>
</tr>
<tr>
<td>Entrapped</td>
</tr>
<tr>
<td>Equivocal</td>
</tr>
<tr>
<td>Extension to without invasion/involvement</td>
</tr>
<tr>
<td>Kiss/kissing</td>
</tr>
<tr>
<td>Matted (except for lymph nodes)</td>
</tr>
<tr>
<td>Possible</td>
</tr>
<tr>
<td>Questionable</td>
</tr>
<tr>
<td>Reaching</td>
</tr>
<tr>
<td>Rule out</td>
</tr>
<tr>
<td>Suggests</td>
</tr>
<tr>
<td>Very Close to</td>
</tr>
<tr>
<td>Worrisome</td>
</tr>
</tbody>
</table>

* interpret as involvement whether the description is clinical or operative/ pathological
** interpret as involvement of other organ or tissue
V.12 Site-Specific Data Items (SSDIs)

Site-Specific Data Items (SSDIs) are based on primary site, AJCC chapter, the EOD schema, or the Summary Stage schema. SSDIs have their own data item name and number and can be collected for as many sites, chapters, and/or schemas as needed. Each Site-Specific Data Item (SSDI) applies only to selected site-specific schemas.

Site-Specific Data Item SSDI questions should be directed to CAnswer Forum at: http://cancerbulletin.facs.org/forums.

Refer to the most current Site-Specific Data Item (SSDI) Manual for coding instructions and the SSDI Schema List for site-specific codes and coding structures.
V.12.1 SSDI General Information
The Site-Specific Data Items are separate from the pre-2018 Collaborative Stage items. Each Site-Specific Data Item (SSDI) applies only to selected site-specific schemas. SSDIs are to be used for cases diagnosed January 1, 2018 and forward.

Resources:
• Please see, Appendix Q – Site Specific Data Items (SSDIs) for CCR requirements.
• Refer to the most current Site-Specific Data Item (SSDI) Manual for coding instructions and the SSDI Schema List for site-specific codes and coding structures.
• For additional information on historical manual references, refer to Appendix S - Historical Coding and Staging Manual Requirements for CCR.

Guidelines:
• SSDIs are to be collected during the initial diagnosis, workup and first course treatment.
• Code SSDIs based on date of diagnosis, not the date the case was abstracted.
• SSDI data items should be blank for schemas where they do not apply.
• Schema ID is derived based on coded values for primary site, histology, and schema discriminator when needed.
• The association between site/histologies and SSDIs are based on:
  o Schema discriminators when needed to determine the correct SSDIs, AJCC chapter, EOD schema, or Summary Stage schema.
    ▪ See, Appendix Q – Site-Specific Data Items (SSDIs) for the CCR requirement for Schema Discriminators 1-3.
  o Data items required to assign stage.
  o Data items currently required by at least one standard setter and listed as registry collection data items in at least one AJCC 8th Edition/9th Version.
  o Certain data items are required by standard setters and not necessarily stage related.
• SSDIs follow the standard definitions of rounding.
  o All SSDIs that have lab values, percentages or measurements are set up to record in the 10ths (one digit after the decimal point).
  o If a lab value, percentage, or measurement is recorded in 100ths (two digits after the decimal point), then the last digit must be rounded.
  o The general rounding rules are:
    ▪ If digit is 0-4, round down
- If digit is 5-9, round up
- Currently, the only SSDIs that have exceptions to the general rounding rules are:
  - HER2 ISH Single Probe Copy Number
  - HER2 ISH Dual Probe Copy Number
  - HER2 ISH Dual Probe Ratio
- Unless instructions for a specific laboratory test state otherwise, record only test results obtained.
  - Before any cancer-directed treatment is given (neoadjuvant therapy or surgical), and
  - No earlier than approximately three months before diagnosis and
  - If multiple lab tests are available, record the highest value
- SSDI format:
  - The character length for each SSDI code is dependent on the highest value recommended by AJCC 8th Edition/9th Version.
  - SSDI data items for lab values and percentages may include the decimal point in the code.
  - “Not applicable” and “unknown” codes differ based on length of the specific data item.
    - Not applicable codes ALWAYS end in “8”
    - Unknown codes ALWAYS end in “9”

Note: It is important to reference the SSDI Manual when completing the SSDI data items. Do not rely on registry software coding notes alone. Additional guidelines as well as updated notes and clarifications will only be available in the online manual.
V.13 SEER Site-Specific Factor 1

SEER Site-Specific Factor 1 is reserved for capturing information on human papilloma virus (HPV) status. There is evidence that HPV plays a role in pathogenesis of some cancers. HPV testing may be performed for prognostic purposes; testing may be performed on metastatic sites to aid in determination of the primary site. This data item is required by the CCR for cases diagnosed January 1, 2018 and forward.

**NOTE:** For information on coding Site-Specific Data Items, see Site-Specific Data Items (SSDIs) and Appendix Q - Site-Specific Data Items (SSDIs).

This data item only applies to the schemas:

- Buccal Mucosa: C060, C061
- Floor of Mouth: C040-C041, C048-C049
- Gum: C030, C031, C039, C062
- Hypopharynx: C129, C130-C132, C138-C139
- Lip: C003-C005, C008, C009
- Mouth Other: C058-C059, C068-C069
- Oropharynx (p16-): C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109, C111
- Oropharynx HPV-Mediated (p16+): C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109, C111
- Palate Hard: C050
- Tongue Anterior: C020-C023, C028-C029

**Coding Instructions:**

- Codes 0-7 are hierarchical
  - Use the highest code that applies (0 is highest, 7 is lowest)
- **This data item is only for HPV** status determined by tests designed to detect viral DNA or RNA. Tests based on ISH, PCR, RT-PCR technologies detect the viral DNA or RNA.
- **Do not record the results of IHC p16 expression in this data item.**
  - There are several methods for determination of HPV status. The most frequently used test is IHC for p16 expression which is a surrogate marker for HPV infection and is not to be recorded in this data item.
  - HPV-type 16 refers to **virus type** and is different from p16 overexpression (p16+).
- Record the results of HPV testing performed on pathologic specimens including surgical and cytological (from cell blocks) tissue from the primary tumor or a metastatic site, including lymph nodes.
- Do not record the results of blood tests or serology.
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>HPV negative for viral DNA by ISH test</td>
</tr>
<tr>
<td>1</td>
<td>HPV positive for viral DNA by ISH test</td>
</tr>
<tr>
<td>2</td>
<td>HPV negative for viral DNA by PC test</td>
</tr>
<tr>
<td>3</td>
<td>HPV positive for viral DNA by PCR test</td>
</tr>
<tr>
<td>4</td>
<td>HPV negative by ISH E6/E7 RNA test</td>
</tr>
<tr>
<td>5</td>
<td>HPV positive by ISH E6/E7 RNA test</td>
</tr>
<tr>
<td>6</td>
<td>HPV negative by RT-PCR E6/E7 RNA test</td>
</tr>
<tr>
<td>7</td>
<td>HPV positive by RT-PCR E6/E7 RNA test</td>
</tr>
<tr>
<td>8</td>
<td>HPV status reported in medical records as positive or negative, but test type is unknown</td>
</tr>
<tr>
<td>9</td>
<td>Not documented in medical record</td>
</tr>
<tr>
<td></td>
<td>Unknown if HPV test detecting viral DNA and/or RNA not performed, or unknown if assessed</td>
</tr>
</tbody>
</table>
V.14 STandards for Oncology Registry Entry (STORE)
The American College of Surgeons Cancer (ACS), Commission on Cancer (CoC) releases the STandards for Oncology Registry Entry (STORE) annually. The STORE Manual is required for CoC Accredited facilities for cases diagnosed January 1, 2018 and forward.
V.14.1 STORE General Information

The American College of Surgeons Cancer (ACS), Commission on Cancer (CoC) releases the STandards for Oncology Registry Entry (STORE) annually. The STORE Manual is required for CoC Accredited facilities for cases diagnosed January 1, 2018 and forward. If non-CoC facilities are collecting data items outlined in the STORE Manual as available, then the STORE Manual should be referenced for coding instructions, particularly in the event coding clarification is not included in Volume I for those data items.

For additional information on historical manual references, to Appendix S - Historical Coding and Staging Manual Requirements for CCR.

Guidelines:

- Refer to the most current STandards for Oncology Registry Entry (STORE) Manual for coding instructions.
- STORE Manual questions should be directed to the CAnswer Forum at: http://cancerbulletin.facs.org/forums.
V.14.2 STORE - Ambiguous Terms Describing Tumor Spread

The purpose of the Ambiguous Terminology list for tumor spread is to help registrars make consistent decisions when wording in the patient record is ambiguous with respect to tumor spread and there is no further information is available from any source.

Guidelines:

- **The first and foremost resource for the registrar for questionable cases is the physician who staged the tumor.** The ideal way to approach abstracting situations when the medical record is not clear is to follow up with the physician.
- When the record is not clear, and the physician is unavailable:
  - Review the medical record closely for the required information.
  - Only use the Ambiguous Terms Describing Tumor Spread list when **no** other information is available from any resource.
    - If tumor spread can be determined from the resources available, **do not** use the Ambiguous Terms Describing Tumor Spread list.
  - If the wording in the patient record is ambiguous with respect to tumor spread for stating purposes, **use the following table as a reference of last resort**:

### Ambiguous Terms Describing Tumor Spread

**Terms that Constitute Tumor Involvement or Extension**

<table>
<thead>
<tr>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adherent</td>
</tr>
<tr>
<td>Apparent</td>
</tr>
<tr>
<td>Compatible with</td>
</tr>
<tr>
<td>Consistent with</td>
</tr>
<tr>
<td>Encroaching upon</td>
</tr>
<tr>
<td>Fixation, fixed</td>
</tr>
<tr>
<td>Induration</td>
</tr>
<tr>
<td>Into</td>
</tr>
<tr>
<td>Onto</td>
</tr>
<tr>
<td>Out onto</td>
</tr>
<tr>
<td>Probable</td>
</tr>
<tr>
<td>Suspect</td>
</tr>
<tr>
<td>Suspicious</td>
</tr>
<tr>
<td>To</td>
</tr>
</tbody>
</table>
## Terms that *DO NOT* Constitute Involvement or Extension

<table>
<thead>
<tr>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approaching</td>
</tr>
<tr>
<td>Equivocal</td>
</tr>
<tr>
<td>Possible</td>
</tr>
<tr>
<td>Questionable</td>
</tr>
<tr>
<td>Suggests</td>
</tr>
<tr>
<td>Very Close to</td>
</tr>
</tbody>
</table>
**V.15 Summary Stage 2018 (SS2018)**

Summary Stage is the most basic way of classifying how far a cancer has spread from its point of origin. *Summary Stage 2018* is collected for every site and histology combination and is required by the CCR for cases diagnosed January 1, 2018 and forward.

**Guidelines:**

- Refer to the most current [Summary Stage 2018 Manual](https://seer.cancer.gov/) for general coding instructions, site-specific coding instructions, and the Complete Summary Stage 2018 manual.

- Summary Stage 2018 questions should be directed to ask a SEER Registrar at: [https://seer.cancer.gov/registrars/contact.html](https://seer.cancer.gov/registrars/contact.html).

- See [Archived Volume I](https://seer.cancer.gov/) – Use case year of diagnosis to determine which Volume I to choose.

- Summary Stage is very important for researchers and data use. However, the versioning of the item has changed over the years. Here is a quick guide for which data item (and corresponding manual) to use while coding.

<table>
<thead>
<tr>
<th>Year(s) of Diagnosis</th>
<th>Data Item to Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018 and forward</td>
<td>SEER Summary Stage 2018</td>
</tr>
<tr>
<td>2015 - 2017</td>
<td>SEER Summary Stage 2000</td>
</tr>
<tr>
<td>2004 - 2014</td>
<td>SEER Summary Stage 2000 (Derived from Collaborative Stage)</td>
</tr>
<tr>
<td>2001 - 2003</td>
<td>SEER Summary Stage 2000</td>
</tr>
<tr>
<td>Prior to 2001</td>
<td>SEER Summary Stage 1977</td>
</tr>
</tbody>
</table>
**V.15.1 SS2018 General Information**
Summary Stage 2018 uses all available information in the medical record; a combination of the most precise clinical and pathological information of the extent of disease. SS2018 is required by the CCR for cases diagnosed January 1, 2018 and forward.

For additional information on historical manual references, refer to Appendix S - Historical Coding and Staging Manual Requirements for CCR.

**Guidelines:**
- Refer to the most current Summary Stage 2018 Manual for general coding instructions, site-specific coding instructions, and the complete Summary Stage 2018 manual.
- Six main categories in Summary Stage 2018:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>In-situ</td>
</tr>
<tr>
<td>1</td>
<td>Localized only</td>
</tr>
<tr>
<td>2</td>
<td>Regional by direct extension only</td>
</tr>
<tr>
<td>3</td>
<td>Regional lymph nodes only</td>
</tr>
<tr>
<td>4</td>
<td>Regional by BOTH direct extension AND lymph node involvement</td>
</tr>
<tr>
<td>7</td>
<td>Distant site(s)/node(s) involved</td>
</tr>
<tr>
<td>8</td>
<td>Benign/borderline *</td>
</tr>
<tr>
<td>9</td>
<td>Unknown if extension or metastasis (unstaged, unknown, or unspecified)</td>
</tr>
<tr>
<td></td>
<td>Death Certificate Only (DCO)</td>
</tr>
</tbody>
</table>

*Applicable for the following SS2018 chapters: Brain, CNS Other, Intracranial Gland.

- Summary Stage chapters apply to all primary sites and histologies.
- Chapter-specific guidelines take precedence over general guidelines.
  - **Always** check the information pertaining to a specific primary site or histology chapter.
- For all primary sites and histologies, Summary Stage is based on a combined clinical and operative/pathological assessment.
  - Gross observations at surgery are particularly important when all malignant tissue cannot be, or was not removed.
    - In the event of a disagreement between pathology and operative reports regarding excised tissue, priority is given to the pathology report.
- Summary Stage should include all available information within four months of diagnosis in the absence of disease progression or upon completion of surgery(ies) during the first course of treatment, whichever is longer.
• Review clinical information carefully to accurately determine the extent of disease. Clinical information such as description of skin involvement for breast cancer and lymph nodes for any site, can change the Summary Stage.
  
  o If the operative/pathological information disproves the clinical information, use the operative/pathological information.

• Assign the greatest Summary Stage from any tumor when multiple tumors are reported as a single primary.

• Information for Summary Stage from a surgical resection after neoadjuvant treatment may only be used if the extent of disease is greater than the pre-treatment clinical stage.

• Exclude disease progression, including metastatic involvement, known to have developed after the initial stage workup, when coding Summary Stage data items.

• Autopsy reports are used in coding Summary Stage just as pathology reports. Apply the same rules for inclusion and exclusion.

• TNM information may be used to code Summary Stage when it is the only information available.

• If there is a discrepancy between the T, N, M information and the documentation in the medical record.
  
  o Access the physician to resolve the discrepancy, when possible.
  Otherwise, use the medical record documentation to assign Summary Stage.

• Document choice of Summary Stage assignment in text. It is strongly recommended that the assessment of Summary Stage be documented, as well as the choice of the Summary Stage code in a related STAGE text data item on the abstract.

• Death Certificate Only (DCO) cases and unknown primaries are coded to “9” for Summary Stage cases; however, assign the appropriate Summary Stage code when specific staging information IS available on a DCO.
**V.15.1.1 SS2018 - In-situ (Code 0)**

In-situ is the presence of malignant cells within the cell group from which they arose. There is no penetration of the basement membrane of the tissue and no stromal invasion. Generally, a cancer begins in the rapidly dividing cells of the epithelium or lining of an organ and grows from the inside to the outside of the organ. An In-situ cancer fulfills all pathological criteria for malignancy except that it has not invaded the supporting structure of the organ or tissue in which it arose.

**Coding Instructions:**

- Refer to the most current [Summary Stage 2018 Manual](#) for general coding instructions, and site-specific coding instructions.
- Chapter-specific guidelines take precedence over general guidelines.
  - **Always** check the information pertaining to a specific primary site or histology chapter.
- In-Situ diagnosis can only be diagnosed microscopically.
  - If the pathology report indicates an in-situ tumor but there is evidence of positive lymph nodes or distant metastases, code to the regional nodes/distant metastases.
- Organs and tissues that have no epithelial layer cannot be staged as in-situ, since they do not have a basement membrane.
- Descriptions pathologists use to describe in-situ cancer:
  - Intracystic
  - Intra-epithelial
  - No penetration below the basement membrane
  - No stromal invasion
  - Non-infiltrating
  - Noninvasive
  - Pre-invasive
- **Code 0** is not applicable for the following Summary Stage chapters:
  - Bone
  - Brain
  - Cervical Lymph Nodes, Occult Head and Neck
  - CNS Other
  - Corpus Sarcoma
  - Heart, Mediastinum and Pleura
  - HemeRetic
  - Ill-Defined Other
• Kaposi Sarcoma
• Lymphoma
• Lymphoma Ocular Adnexa
• Mycosis Fungoides
• Myeloma Plasma Cell Disorder
• Pleural Mesothelioma
• Primary Cutaneous Lymphoma (non-MF and SS)
• Retinoblastoma
• Retroperitoneum
• Soft Tissue
A localized cancer is defined as a malignancy limited to the site of origin, that has not spread farther than the site of origin in which it started. It has infiltrated basement membrane of the epithelium into parenchyma (the functional part of the organ), but there is no spread beyond the boundaries of the organ.

**Coding Instructions:**

- Refer to the most current [Summary Stage 2018 Manual](#) for general coding instructions, site-specific coding instructions, and the Complete Summary Stage 2018 manual.
- Chapter-specific guidelines take precedence over general guidelines.
  - **Always** check the information pertaining to a specific primary site or histology chapter.
- It is typically straightforward to determine if the cancer is localized when:
  - Organs have definite boundaries (such as prostate, testis, or stomach).
  - Sites have a clear line between the organ of origin and the surrounding region (such as breast or bladder).
    - **Exception:** Skin, because it is sometimes difficult to determine where the dermis ends, and subcutaneous tissue begins.
  - It is possible for imaging to determine if the cancer is localized or regional without surgery. However, for many internal organs, it is difficult to determine whether the tumor is localized without surgery.
- It is imperative to know and recognize the names of different structures within the organ (such as lamina propria, myometrium, and muscularis) so invasion or involvement of these structures is interpreted correctly. Misinterpretation can lead to over or under staging.
- **Summary Stage** uses both clinical and pathological information:
  - Review and read the pathology and operative report(s) for comments on gross evidence of spread, microscopic extension, and metastases, as well as physical exam and diagnostic imaging reports for mention of regional or distant disease.
    - The case is not localized if any of these reports provide evidence that the cancer has spread beyond the boundaries of the organ of origin.
    - The case is assumed to be localized if the pathology report, operative report, and other investigations show no evidence of spread.
• Code 1 is **not** applicable for the following Summary Stage chapters:
  o Cervical Lymph Nodes and Unknown Primary
  o Ill-Defined Other
V.15.1.3 SS2018 - Regional (Codes 2-4)
Regional stage can be described as direct extension only, regional lymph node(s) involvement only, or regional by both direct extension and regional lymph node(s) involvement. There are several codes to describe the different methods of regional tumor spread.

Coding Instructions:
- Refer to the most current Summary Stage 2018 Manual for general coding instructions, site-specific coding instructions, and the Complete Summary Stage 2018 manual.
- Chapter-specific guidelines take precedence over general guidelines.
  - Always check the information pertaining to a specific primary site or histology chapter.
- It is important to understand the words used to describe the spread of the cancer and how they are used in staging because clinicians may use some terms differently than cancer registrars.

Examples:
1. “Local” as in “carcinoma of the stomach with involvement of the local lymph nodes.” Local nodes are the first group of nodes to drain the primary site and often are referred to as “regional” nodes. Unless evidence of distant or regional spread is present, such a case should be staged as regional lymph node(s) involved only, assign 3.
2. “Metastases” as in “carcinoma of lung with peribronchial lymph node metastases.” Metastases in this sense means involvement by tumor. The name of the involved lymph node will determine whether it is a regional node or distant node. In this case, it would be a regional node. It is important to learn the names of regional nodes for each primary site.
V.15.1.3.1 SS2018 - Regional by Direct Extension Only (Code 2)
Regional by direct extension means there is direct tumor extension beyond the limits of the site of origin. Regional stage by direct extension is perhaps the broadest category as well as the most difficult to properly identify. Although the boundary between localized and regional tumor extension is usually well identified, the boundary between regional and distant spread is not always clear and can be defined differently by physicians in various specialties.

Coding Instructions:

- Refer to the most current Summary Stage 2018 Manual for general coding instructions, site-specific coding instructions, and the Complete Summary Stage 2018 manual.

- Chapter-specific guidelines take precedence over general guidelines.
  - **Always** check the information pertaining to a specific primary site or histology chapter.

- Once there is potential for cancer spread by more than one vascular supply route, cancer becomes regional by direct extension. For example, if the tumor goes outside of the wall and invades another organ, it is regional by direct extension.

- Definitions of “regional” differ among specialists:
  - Surgeons define regional as:
    - The area extending from the periphery of an involved organ that lends itself to removal en bloc with a portion of, or an entire organ with outer limits to include at least the first level nodal basin. However, en bloc resection (removal of multiple organs or tissues in one piece at the same time) is not always feasible or may have been shown not to be necessary.

    **Example:** Many clinical trials have shown that lumpectomy or modified radical mastectomy has equivalent survival to the very disfiguring radical mastectomy for treatment of breast cancer.

  - Radiation Oncologists define regional as:
    - Including any organs or tissues encompassed in the radiation data item used to treat the primary site and regional lymph nodes.

- Regional by direct extension in:
  - Primary sites which have “walls” such as the colon or rectum, means there is invasion or extension through the entire wall of the primary organ into surrounding organs and/or adjacent tissue, direct extension, or contiguous spread.
• Primary sites without defined walls, means the tumor has spread beyond the primary site or capsule into adjacent structures.

• Code 2 is **not** to be used when there is both direct extension and regional nodes positive (see code 4).

• Code 2 is not applicable for the following Summary Stage chapters:
  o Cervical Lymph Nodes and Unknown Primary
  o HemeRetic
  o Ill-Defined Other
  o Myeloma Plasma Cell Disorder
V.15.1.3.2 SS2018 - Regional Lymph Nodes Only (Code 3)
Regional lymph nodes only include nodes that are regional to the primary site. Please see the specific chapter/site in the Summary Stage 2018 Manual for site-specific regional lymph nodes.

Coding Instructions:

- Refer to the most current Summary Stage 2018 Manual for general coding instructions, site-specific coding instructions, and the Complete Summary Stage 2018 manual.
- Chapter-specific guidelines take precedence over general guidelines.
  - Always check the information pertaining to a specific primary site or histology chapter.
    - Regional lymph nodes are listed for each chapter/site.
    - Use the following resources to help identify regional lymph nodes when a lymph node chain is not listed in code 3:
      - Appendix I
      - Anatomy textbook
      - ICD-O manual
      - Medical dictionary (synonym)
- If preoperative treatment was not administered and there is a discrepancy between clinical and pathological information about the same lymph nodes, pathological information takes precedence.
  - It is not necessary to biopsy every lymph node in the suspicious area to disprove involvement. Use the following priority order:
    - Pathology report
    - Imaging
      - If nodes are determined positive based on imaging and then confirmed to be negative on pathological exam, treat the regional nodes as negative when assigning Summary Stage.
    - Physical exam
      - If nodes are determined positive based on physical exam and then confirmed to be negative on pathological exam, treat the regional nodes as negative when assigning Summary Stage.
- Neoadjuvant (preoperative) treatment as in systemic therapy (chemotherapy, immunotherapy) or radiation therapy:
Code the clinical information if that is the most extensive lymph node involvement documented.

Code the regional nodes based on the post-neoadjuvant information when the post-neoadjuvant surgery shows more extensive lymph node involvement.

- **Solid Tumors – Terms indicating lymph node involvement** (when no specific information as to tissue involved) are recorded as lymph node involvement:
  - Fixed
  - Matted
  - Mass in the hilum, mediastinum, retroperitoneum, and/or mesentery

- The following terms should be ignored for solid tumors unless there is a statement of involvement by the clinician, or the patient was treated as though regional lymph nodes were involved.
  - Palpable
  - Enlarged
  - Visible swelling
  - Shotty
  - Lymphadenopathy

- “Ipsilateral,” “homolateral,” and “same side;” these terms are used interchangeably.

- **Accessible lymph nodes** – Lymph nodes that can be observed, palpated, or examined without instruments such as the regional lymph nodes for breast, oral cavity, salivary gland, skin, thyroid and other organs are considered accessible lymph nodes. It is sufficient to determine lymph nodes as negative when:
  - A statement such as “remainder of examination negative” is made.

- **Inaccessible lymph nodes** – Lymph nodes within body cavities that in most situations are not easily examined by clinical methods such as observation, palpation and physical exam are considered inaccessible. Bladder, colon, corpus uteri, esophagus, kidney, liver, lung, ovary, prostate, and stomach (not an all-inclusive list). It is sufficient to determine lymph nodes as negative when:
  - The tumor is localized and standard treatment for a localized site is done.
• Code as positive regional nodes, when involved nodes are found during sentinel lymph node procedures.
  o The sentinel lymph nodes are the first to receive lymphatic drainage from the primary tumor.
  o If the sentinel lymph node contains metastatic tumor, this indicates other lymph nodes may contain tumor. If it does not contain metastatic tumor, the other lymph nodes are not likely to contain tumor.
• **Isolated Tumor Cells (ITCs)** – ITCs are counted as positive regional nodes (for some schemas). Other schemas count them as negative. See individual schemas to determine how to code ITCs.
• Discontinuous (satellite) tumor deposits (peritumoral nodules) for colon, appendix, rectosigmoid, and rectum: These can occur WITH or WITHOUT regional lymph node involvement.
  o Enter the appropriate code according to guidelines in the individual schemas.
  o Tumor nodules in pericolic or perirectal fat without evidence of residual lymph node structures can have one of several aspects of the primary cancer: discontinuous spread, venous invasion with extravascular spread, or a totally replaced lymph node.
  o When there are Tumor Deposits **and** lymph node involvement:
    ▪ Code only the lymph node involvement in Summary Stage.
• Code as involved regional nodes when there is direct extension of the primary tumor into a regional lymph node.
• Code as “Regional Lymph Nodes, NOS” when any positive unidentified nodes are included with the resected primary site specimen.
• If the only indication of positive regional lymph node involvement in the record is the physician’s statement of a positive N category from the TNM staging system or a stage from a site-specific staging system, use that information to code regional lymph node involvement.
• Assume distant lymph node(s) are involved when a specific chain of lymph nodes is named, but not listed as regional.
  o Determine if the name is synonymous with a listed lymph node.
• Code 3 is **not** to be used when there is both regional nodes positive **and** direct extension (see code 4).
• Code 3 is **not** applicable for the following Summary Stage chapters:
  o Brain
- CNS Other
- HemeRetic
- Ill-Defined Other (includes unknown primary site)
- Intracranial Gland
- Lymphoma
  - Primary Cutaneous Lymphoma and Ocular Adnexal Lymphoma have separate chapters from Lymphoma and regional lymph node involvement is assigned in these chapters.
V.15.1.3.3 SS2018 - Regional by BOTH Direct Extension AND Regional Lymph Node(s) Involved (Code 4)
Regional by BOTH Direct Extension and Regional lymph node(s) include direct tumor extension beyond the limits of the site of origin as well as nodes that are regional to the primary site only. Please see the specific chapter/site in the Summary Stage 2018 Manual for site-specific regional lymph nodes.

Coding Instructions:
- Refer to the most current Summary Stage 2018 Manual for general coding instructions, site-specific coding instructions, and the Complete Summary Stage 2018 manual.
- Chapter-specific guidelines take precedence over general guidelines.
  - **Always** check the information pertaining to a specific primary site or histology chapter.
- Code 4 when tumors have BOTH regional direct extension and have regional lymph node involvement.
- Code 4 is not applicable for the following Summary Stage chapters:
  - Brain
  - Cervical Lymph Nodes and Unknown Primary
  - CNS Other
  - HemeRetic
  - Ill-Defined Other (includes unknown primary site)
  - Intracranial Gland
  - Lymphoma
    - Primary Cutaneous Lymphoma and Ocular Adnexal Lymphoma have separate chapters from Lymphoma and regional lymph node involvement is assigned in these chapters.
  - Myeloma Plasma Cell Disorder
Distant metastases are tumor cells that have broken away from the primary tumor, have travelled to other parts of the body, and have begun to grow at the new location. Distant stage is also called remote, diffuse, disseminated, metastatic, or secondary disease.

**Coding Instructions:**

- Refer to the most current [Summary Stage 2018 Manual](#) for general coding instructions, site-specific coding instructions, and the Complete Summary Stage 2018 manual.
- Chapter-specific guidelines take precedence over general guidelines.
  - **Always** check the information pertaining to a specific primary site or histology chapter.
- Cancer cells can travel from the primary site in any of four ways:
  - Extension from the primary organ beyond adjacent tissue into next organ.
    - **Example:** From the lung through the pleura into bone or nerve.
  - Travel in lymph channels beyond the first (regional) drainage area.
  - Hematogenous or blood-borne metastases.
  - Spread through fluids in a body cavity.
    - This type of spread is also called implantation or seeding metastases.
- Common sites of distant spread are:
  - Liver, lung, brain, and bones, but they are not listed specifically for each chapter.
    - **Example:** Liver involvement from a primary in the gallbladder. It is likely that this is regional by direct extension rather than distant stage, since the gallbladder is adjacent to the liver.
- Read the diagnostic imaging reports to determine:
  - Involvement of the surface of the secondary organ, which could either be regional by direct (contiguous) extension or distant (if determined to be a discontiguous surface implant).
    - If the tumor is identified growing from one organ onto/through the surface of the secondary organ, then it is contiguous extension.
    - However, if the tumor is only found in the parenchyma of the secondary organ well away from the primary organ, then it is
discontinuous mets.

- Hematopoietic, immunoproliferative, and myeloproliferative neoplasms are distant except as noted in the Summary Stage chapter.
- Code 7 is not applicable for the following Summary Stage chapters:
  - Ill-Defined Other
V.15.1.5 SS2018 - Benign/Borderline (Code 8)
Benign, borderline, and uncertain behavior intracranial and central nervous system (CNS) tumors.

Coding Instructions:

- Refer to the most current Summary Stage 2018 Manual for general coding instructions, site-specific coding instructions, and the Complete Summary Stage 2018 manual.

- Code 8 is for Benign/borderline neoplasms.
  - Benign/borderline neoplasms are collected only for the following chapters:
    - Brain
    - CNS Other
    - Intracranial Gland

- Code 9 for Summary Stage 2018 when a registry collects other benign/borderline tumors that are not reportable.

  **Note:** Code 8 (at this time) will not be allowed for other sites.
Unstaged, Unknown, or Unspecified) (Code 9)

Unknown extension or metastatic involvement is unknown.

**Coding Instructions:**

- Refer to the most current [Summary Stage 2018 Manual](#) for general coding instructions, site-specific coding instructions, and the Complete Summary Stage 2018 manual.
- Chapter-specific guidelines take precedence over general guidelines.
  - Always check the information pertaining to a specific primary site or histology chapter.
- Summary Stage must be unknown when the primary site is unknown (C809).
- Assign 9 very sparingly.
  - If possible, contact the physician to see if there is more information about the case.
- There will be cases for which sufficient evidence is not available to adequately assign a stage.

**Examples:**

1. The patient expires before workup is completed
2. A patient refuses a diagnostic or treatment procedure
3. There is limited workup due to the patient’s age or a simultaneous comorbid or contraindicating condition
4. Only a biopsy is done and does not provide enough information to assign stage

**Code 9:**

- By default, for Death Certificate Only (DCO) cases; however, assign the appropriate Summary Stage when specific staging information is available on a DCO.
V.15.2 SS2018 Ambiguous Terms for Disease Extension

Registrars will find definitive statements of involvement, most of the time; however, for those situations where involvement is described with non-definitive (ambiguous) terminology, use the guidelines below to interpret and determine the appropriate assignment of Summary Stage 2018.

Guidelines:

- Refer to the most current Summary Stage 2018 Manual for general coding instructions, site-specific coding instructions, and the Complete Summary Stage 2018 manual.
- Chapter-specific guidelines take precedence over general guidelines.
  - Always check the information pertaining to a specific primary site or histology chapter.
- Determination of the cancer stage is both a subjective and objective assessment by the physician(s) of how far the cancer has spread.
  - Look at the documentation that the physician used to make informed decisions on how the patient is being treated when it is not possible to determine the extent of involvement because terminology is ambiguous.
  - Example: Assign Summary Stage 2018 based on involvement when the patient was treated as though adjacent organs or nodes were involved.
- Use the following lists to interpret the intent of the clinician only when further documentation is not available and/or there is no specific statement of involvement in the medical record.
  - The physician’s definitions/descriptions and choice of therapy have priority over these lists because individual clinicians may use these terms differently.
- Terminology in the chapter takes priority over this list:
  - Some chapters interpret certain words as involvement; such as “encasing” the carotid artery for a head and neck site or “abutment,” “encases,” or “encasement” for pancreas primaries.
- Use this list only for Summary Stage 2018 or EOD 2018.
  - This is not the same list used for determining reportability as published in the SEER Program Manual, Hematopoietic Manual or in Section 1 of the STandards for Oncology Registry Entry (STORE) Manual.
- This is not the same list of ambiguous terminology provided in the Solid Tumors Rules published and maintained by the SEER Program.
- Use the following list of terms as a guide **ONLY when no other information is available.**

<table>
<thead>
<tr>
<th>Involved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adherent</td>
</tr>
<tr>
<td>Apparent(ly)</td>
</tr>
<tr>
<td>Appears to</td>
</tr>
<tr>
<td>Comparable with</td>
</tr>
<tr>
<td>Compatible with</td>
</tr>
<tr>
<td>Consistent with</td>
</tr>
<tr>
<td>Contiguous/continuous with</td>
</tr>
<tr>
<td>Encroaching upon*</td>
</tr>
<tr>
<td>Extension to, into, onto, out onto</td>
</tr>
<tr>
<td>Features of</td>
</tr>
<tr>
<td>Fixation to a structure other than primary**</td>
</tr>
<tr>
<td>Fixed to another structure**</td>
</tr>
<tr>
<td>Impending perforation of</td>
</tr>
<tr>
<td>Impinging upon</td>
</tr>
<tr>
<td>Impose/imposing on</td>
</tr>
<tr>
<td>Incipient invasion</td>
</tr>
<tr>
<td>Induration</td>
</tr>
<tr>
<td>Infringe/infringing</td>
</tr>
<tr>
<td>Into*</td>
</tr>
<tr>
<td>Intrude</td>
</tr>
<tr>
<td>Most likely</td>
</tr>
<tr>
<td>Onto*</td>
</tr>
<tr>
<td>Overstep</td>
</tr>
<tr>
<td>Presumed</td>
</tr>
<tr>
<td>Probable</td>
</tr>
<tr>
<td>Protruding into (unless encapsulated)</td>
</tr>
<tr>
<td>Suspected</td>
</tr>
<tr>
<td>Suspicious</td>
</tr>
<tr>
<td>To*</td>
</tr>
<tr>
<td>Up to</td>
</tr>
</tbody>
</table>
**Not Involved**

<table>
<thead>
<tr>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abuts</td>
</tr>
<tr>
<td>Approaching</td>
</tr>
<tr>
<td>Approximates</td>
</tr>
<tr>
<td>Attached</td>
</tr>
<tr>
<td>Cannot be excluded/ruled out</td>
</tr>
<tr>
<td>Efface/effacing/effacement</td>
</tr>
<tr>
<td>Encased/encasing</td>
</tr>
<tr>
<td>Encompass(ed)</td>
</tr>
<tr>
<td>Entrapped</td>
</tr>
<tr>
<td>Equivocal</td>
</tr>
<tr>
<td>Extension to without invasion/involvement</td>
</tr>
<tr>
<td>Kiss/kissing</td>
</tr>
<tr>
<td>Matted (except for lymph nodes)</td>
</tr>
<tr>
<td>Possible Questionable</td>
</tr>
<tr>
<td>Reaching</td>
</tr>
<tr>
<td>Rule out</td>
</tr>
<tr>
<td>Suggests</td>
</tr>
<tr>
<td>Very Close to</td>
</tr>
<tr>
<td>Worrisome</td>
</tr>
</tbody>
</table>

* Interpret as involvement whether the description is clinical or operative/pathological.

** Interpret as involvement of other organ or tissue.
V.16 Pediatric Stage

Pediatric staging refers to cancer staging that is specific to pediatric patients, which may differ in some instances from staging of adult cancers. Pediatric Stage includes patients who are younger than twenty (20) years of age.

Common pediatric cancers are often managed using clinical protocols and are treated in pediatric centers. Many pediatric cancers are staged using specialized systems which are histology and tumor site driven per clinical trials.

However, some pediatric cancers can be staged using the AJCC TNM staging system.

**Example:** Lymphoma in pediatric patients is staged using the same scheme as that for adults.

**Coding Instructions:**

- If AJCC staging is used to stage a pediatric case, refer to the most current [AJCC Cancer Staging Manual](https://www.cancerstaging.org) for coding instructions.

- When Summary Stage is used, for cases or tumors diagnosed January 1, 2018 and forward, refer to the [SEER Summary Stage 2018 Manual](https://seer.cancer.gov/summarystage/2018/) for coding instructions.

- In the event another staging system is used, please specify the staging method used.

- Document the stage and method used in the stage text data item.
**V.16.1 Pediatric Stage Group**

Pediatric stage group refers to the stage group assigned for the pediatric cancer. This scheme is to be used for entering the stage for pediatric patients only.

**Coding Instructions:**

- Pediatric stage includes patients who are younger than twenty (20) years of age and diagnosed January 1, 1996 or later.
- Record the stage assigned by the managing provider.
- This scheme is to be used for entering the stage for pediatric patients only.
- Code 88 (not applicable) for patients twenty years of age and older.
- Code 99 for pediatric leukemia cases.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Stage I</td>
</tr>
<tr>
<td>1A</td>
<td>Stage IA (rhabdomyosarcomas &amp; related sarcomas)</td>
</tr>
<tr>
<td>1B</td>
<td>Stage IB (rhabdomyosarcomas &amp; related sarcomas)</td>
</tr>
<tr>
<td>2</td>
<td>Stage II</td>
</tr>
<tr>
<td>2A</td>
<td>Stage IIA (rhabdomyosarcomas &amp; related sarcomas)</td>
</tr>
<tr>
<td>2B</td>
<td>Stage IIB (rhabdomyosarcomas &amp; related sarcomas)</td>
</tr>
<tr>
<td>2C</td>
<td>Stage IIC (rhabdomyosarcomas &amp; related sarcomas)</td>
</tr>
<tr>
<td>3</td>
<td>Stage III</td>
</tr>
<tr>
<td>3A</td>
<td>Stage IIIA (liver, rhabdo. &amp; related sarcomas, Wilms')</td>
</tr>
<tr>
<td>3B</td>
<td>Stage IIIB (liver, rhabdo. &amp; related sarcomas, Wilms')</td>
</tr>
<tr>
<td>3C</td>
<td>Stage IIIC (Wilms' tumor)</td>
</tr>
<tr>
<td>3D</td>
<td>Stage IIID (Wilms' tumor)</td>
</tr>
<tr>
<td>3E</td>
<td>Stage IIIE (Wilms' tumor)</td>
</tr>
<tr>
<td>4</td>
<td>Stage IV</td>
</tr>
<tr>
<td>4A</td>
<td>Stage IVA (bone)</td>
</tr>
<tr>
<td>4B</td>
<td>Stage IVB (bone)</td>
</tr>
<tr>
<td>4S</td>
<td>Stage IVS (neuroblastoma)</td>
</tr>
<tr>
<td>5</td>
<td>Stage V (Wilms' tumor/retinoblastoma)</td>
</tr>
<tr>
<td>A</td>
<td>Stage A (neuroblastoma)</td>
</tr>
<tr>
<td>B</td>
<td>Stage B (neuroblastoma)</td>
</tr>
<tr>
<td>C</td>
<td>Stage C (neuroblastoma)</td>
</tr>
<tr>
<td>D</td>
<td>Stage D (neuroblastoma)</td>
</tr>
<tr>
<td></td>
<td>Stage DS (neuroblastoma)</td>
</tr>
<tr>
<td>----</td>
<td>--------------------------------------------------------------</td>
</tr>
<tr>
<td>88</td>
<td>Not Applicable (not a pediatric case)</td>
</tr>
<tr>
<td>99</td>
<td>Unstaged, Unknown</td>
</tr>
</tbody>
</table>
**V.16.2 Pediatric Protocols**

Pediatric protocols refer to the specialized systems used to stage pediatric cancers. These systems are based on histologic type and/or primary site.

**Coding Instructions:**
- Use for pediatric patients **only**.
- Record the staging system used by the managing provider.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>None</td>
</tr>
<tr>
<td>01</td>
<td>American Joint Committee on Cancer (AJCC)</td>
</tr>
<tr>
<td>02</td>
<td>Ann Arbor</td>
</tr>
<tr>
<td>03</td>
<td>Children's Cancer Group (CCG)</td>
</tr>
<tr>
<td>04</td>
<td>Evans</td>
</tr>
<tr>
<td>05</td>
<td>General Summary</td>
</tr>
<tr>
<td>06</td>
<td>Intergroup Ewing's</td>
</tr>
<tr>
<td>07</td>
<td>Intergroup Hepatoblastoma</td>
</tr>
<tr>
<td>08</td>
<td>Intergroup Rhabdomyosarcoma</td>
</tr>
<tr>
<td>09</td>
<td>International System</td>
</tr>
<tr>
<td>10</td>
<td>Murphy</td>
</tr>
<tr>
<td>11</td>
<td>National Cancer Institute (Pediatric Oncology)</td>
</tr>
<tr>
<td>12</td>
<td>National Wilms Tumor Study</td>
</tr>
<tr>
<td>13</td>
<td>Pediatric Oncology Group (POG)</td>
</tr>
<tr>
<td>14</td>
<td>Reese Ellsworth</td>
</tr>
<tr>
<td>15</td>
<td>SEER Extent of Disease</td>
</tr>
<tr>
<td>16</td>
<td>Children's Oncology Group (COG)</td>
</tr>
<tr>
<td>88</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>97</td>
<td>Other</td>
</tr>
<tr>
<td>99</td>
<td>Unknown</td>
</tr>
</tbody>
</table>
V.16.3 Staged by - Pediatric Stage
This data item identifies the person who assigned the cancer stage.

Coding Instructions:
- This data item is to be used for pediatric cases only diagnosed January 1, 1996 and forward. It identifies the person who staged the case.
- The ACS states that the managing provider is responsible for staging analytical cases.
  - The CCR concurs and feels that this applies to non-analytic cases, also.
- If the staging has not been done by the provider, the registrar does not have to stage the case.
  - Enter 0 for not staged.
- Code 0 for patients older than twenty (20).

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Not staged</td>
</tr>
<tr>
<td>1</td>
<td>Managing physician</td>
</tr>
<tr>
<td>2</td>
<td>Pathologist</td>
</tr>
<tr>
<td>3</td>
<td>Other physician</td>
</tr>
<tr>
<td>4</td>
<td>Any combination of 1, 2, or 3</td>
</tr>
<tr>
<td>5</td>
<td>Registrar</td>
</tr>
<tr>
<td>6</td>
<td>Any combination of 5 with 1, 2, or 3</td>
</tr>
<tr>
<td>7</td>
<td>Other</td>
</tr>
<tr>
<td>8</td>
<td>Staged, individual not specified</td>
</tr>
<tr>
<td>9</td>
<td>Unknown if staged</td>
</tr>
</tbody>
</table>
Part VI First Course of Treatment

Part VI of Volume I consists of first course of treatment. Instructions included in this section range from surgery, radiation, chemotherapy, hormone therapy, immunotherapy, transplant/endocrine therapy and other therapy, to the summary of treatment status and protocol participation.
VI.1 Definitions and Guidelines - First Course of Treatment

First course treatment is all treatments administered to the patient after the original diagnosis of cancer in an attempt to destroy or modify the cancer tissue.

**IMPORTANT Note:** This section applies to all neoplasms (including benign and borderline intracranial and CNS tumors) except hematopoietic and neoplasms. For hematopoietic and lymphoid cases diagnosed January 1, 2018 and forward, please refer to the [SEER Hematopoietic and Lymphoid Neoplasm Database and Hematopoietic & Lymphoid Neoplasm Coding Manual](http://www.seer.cancer.gov) for information on coding first course treatment for these cases.

Record all cancer directed therapeutic procedures (surgery, radiation, systemic, or other therapy) administered at any facility, whether in a primary or metastatic site, whatever the mode of treatment, and regardless of the sequence and degree of completion of any component part.

**Coding Instructions:**

These instructions are in hierarchical order:

1. Use the documented first course of therapy (treatment plan) from the medical record. First course of therapy ends when the treatment is completed (no matter how long it takes to complete the plan).

2. First course ends when there is documentation of disease progression, recurrence, or treatment failure.

3. When there is no documentation of a treatment plan or progression, recurrence or a treatment failure, first course therapy ends one year after the date of diagnosis. Any treatment given after one year is second course therapy in the absence of a documented treatment plan or a standard of treatment.

**CCR Expectations:**

- The CCR expects every reporting facility that has a tumor registry to obtain information about the entire first course therapy from the medical record and, if necessary, the physicians themselves, regardless of where the treatment was administered.

- Reporting facilities preparing initial case reports for the sole purpose of meeting state mandatory reporting requirements may elect to record only the treatment documented in their medical records.

- Abstractors are provided with two data items to record first course of treatment information.
o The first treatment data item for each modality (except surgery) is known as "Treatment Summary." This data item should include any first course treatment administered for that modality, regardless of where it was administered, including treatment administered at the reporting facility.

o The second treatment data item for each modality (except surgery) is known as "Treatment at this reporting facility." This data item should only include first course treatment administered at the reporting facility, respective to each modality.

o Treatment given by a physician on the medical staff of a facility should not be recorded as treatment given at that reporting facility, effective with cases diagnosed January 1, 1998 and forward.

• Referral to an oncologist is considered a recommendation. Registry personnel should follow-up on these cases to determine whether chemotherapy was administered or not, and code accordingly. This applies to cases diagnosed January 1, 2010 and forward. Prior to January 1, 2010, referral did not equal a recommendation.
VI.1.1 First Course of Treatment - Special Situations
Listed below are special conditions that may occur and must be considered when coding first course of treatment.

In Utero Diagnoses and Treatment
- Beginning in 2009, the dates of diagnosis and treatment for tumors developed while in utero should reflect the dates on which they occur. In the past, these dates were assigned to the date the baby was born.
- Diagnoses made in utero are reportable if the pregnancy results in a live birth. When a reportable diagnosis is confirmed prior to birth and disease is not evident at birth due to regression, accession the case based on the pre-birth diagnosis.
- In the absence of documentation of stillbirth, abortion or fetal death, assume there was a live birth and report the case.

Treatment Performed Elsewhere
- Record any part of the first course of treatment administered at another facility before the patient was admitted to the reporting facility or after discharge. Also, record the name of the facility where the treatment was administered.

Coding Instructions:
Leukemia and Hematopoietic Diseases
- For hematopoietic and lymphoid cases diagnosed January 1, 2018 and forward, please refer to the SEER Hematopoietic and Lymphoid Neoplasm Database and Hematopoietic & Lymphoid Neoplasm Coding Manual.

Treatment – Refused
- The first course of therapy is no treatment when the patient refuses treatment. Code the treatment data items to refused.
  - Keep the refused codes, even if the patient later changes his/her mind and decides to have the prescribed treatment in the following scenario:
    - More than one year after diagnosis, or when there is evidence of disease progression before treatment is implemented.
  - Code 87 in the respective treatment data item if the patient or patient's guardian refuses that modality and record the fact in the text data item.
If the patient or patient's guardian refuses surgery to the primary site, enter code 7 in the Reason for No Surgery data item.

**Note:** Prior to January 1, 2010, referral does not equal a recommendation.

**No Treatment**
- If a patient did not receive any of the treatments described in sections VI.2-VI.8:
  - The surgery summary code would be A000 or B000 and all the other treatment summary data items would contain a 00.
  
  **Example:** The case might be Autopsy Only, or the patient might have received only symptomatic or supportive therapy. Explain briefly, why no definitive treatment was given (for example, "terminal," "deferred").
  - If definitive treatment was refused, see Treatment – Refused (above) for coding instructions. A facility that is preparing initial case reports to only meet state mandatory reporting requirements may also use 00 if no treatment is documented in its medical records (code 99 should not be used in this situation).
  - The data item RX-Summ Treatment Status was added to summarize the status of all treatment modalities. This data item is a summary of whether treatment was given, including an option that identifies active surveillance or watchful waiting.

  **Note:** Referral to an oncology specialist is considered a recommendation. Registry personnel should follow up on these cases to determine whether treatment was administered or not, and code accordingly. This applies to cases diagnosed January 1, 2010 and forward.

**Treatment – Unknown**
- If it is unknown whether or not the patient had treatment:
  - Code 9, 99, A990 or B990 (unknown) should generally be used only for cases in which the first course of treatment is unknown.
  - Enter 99 or 9 for each modality of treatment, leave the treatment date data items blank, **and state briefly, why the information is not available.**
  - Do not use code 99 or 9 for a component part of the treatment summary.
**Example:** If surgical resection was performed and it is not known whether chemotherapy was administered, do not enter a 99 in the *Chemotherapy* data item -- use code 00.

- If specific treatment is recommended, but it is not known whether it was administered, enter a statement to this effect and code the appropriate summary code (8,88 or 99) which applies to the specific treatment type data item and code At this Hospital data to 00.

**Note:** Referral to a specialist is considered a recommendation. Registry personnel should follow up on these cases to determine whether treatment was administered or not, and code accordingly. This applies to cases diagnosed January 1, 2010 and forward.
VI.1.2 First Course of Treatment - Data Entry

Enter codes, dates, and written summaries to reflect the first course of treatment.

Dates

Enter the date treatment was started for each modality.

Coding Instructions:

• For instructions about entering dates, see Entering Dates.

• If the treatment was administered in courses (as in a radiation therapy series) or included different procedures (for example, excisional biopsy and a resection), enter the date the first procedure was performed.

• The Date of Systemic Therapy will be generated from Date of Chemotherapy, Date of Hormone, Date of Immunotherapy, and Date of Transplant/Endocrine Procedures, effective with cases diagnosed 1/1/2003 and forward.

Text

Text is the abstractor’s supporting documentation obtained from the medical record that validates codes entered in the abstract.

Priority Order for Entering Text:

• Date treatment started.

• Location of treatment (at this facility, elsewhere).

• Type of treatment (surgical procedure/treatment volume/modality/agent(s)/protocol/regimen) and all information needed to support the coded data items for the treatment.

• If more than one procedure/treatment performed, describe each one in chronological order.

• Discontinued treatment – enter the reason treatment discontinued in the appropriate treatment text field.

• Treatment not given – enter the reason no treatment given in the appropriate text field.

• Unknown if treatment given - If it cannot be determined whether an intended therapy was performed, record that it was recommended but is not known if the procedure was administered.

Example: Record “Chemotherapy” recommended; unknown if given.”

• Treatment planned - If the MD has documented a treatment plan, but treatment has not yet been initiated, enter the “planned treatment”
specifics in the respective treatment text field, including MD or facility where treatment will be delivered.

- Treatment delayed - If there is a delay in planned treatment and the treatment has not been initiated, enter the “planned treatment” specifics in the respective treatment text field and the reason for the delay.

Notes:
1. Do not leave a text data item blank when information is missing or unknown -Record None, NR, or NA.
2. There is no text data item for bone marrow transplant and endocrine procedures. Record text information regarding bone marrow transplants and endocrine procedures in the immunotherapy text data item.

- For additional information regarding recording text, please see Appendix T -Text Documentation Guidelines.
- Alphanumeric codes summarize each modality of treatment (surgery, radiation, chemotherapy, etc.). For each modality except summary, code a summary of the entire first course of treatment. See Surgery Introduction – First Course of Treatment for coding the surgery data items.

Coding Instructions:
- In the data item provided, assign a separate code to that portion of the treatment administered at the reporting facility.
- The codes for the reason no surgery, reason no radiation, reason no chemotherapy and reason no hormone therapy have been incorporated into each respective treatment modality data item.
- The codes for surgical procedures are alphanumeric, beginning with cases diagnosed 1/1/2023 and forward. See Archived Volume I. Use year of diagnosis to determine which Volume I to choose.
- Other codes have two digits, with a 00 always meaning no procedure performed for that type of treatment.
- Code all treatment data items to 00 (not done) when physician decides to do active surveillance (aka watchful waiting). The first course of therapy is no treatment. When the disease progresses or the patient becomes symptomatic, any prescribed treatment is second course.
- Cases coded to 00 based on active surveillance must also be coded to 2 in the RX Summ-Treatment Status data item.
• Code all treatment that was started and administered, whether completed or not.

• Code the treatment on both abstracts when a patient has multiple primaries and the treatment given for one primary also affects/treats the other primary.

• Code the treatments only for the site that is affected when a patient has multiple primaries, and the treatment affects only one of the primaries.

• Code the treatment given as first course even if the correct primary is identified later when a patient is diagnosed with an unknown primary.

• Do not code treatment added to the plan when the primary site is discovered as first course. This is a change in the treatment plan.

  **Example:** The patient is diagnosed with metastatic carcinoma, unknown primary site. After a full course of chemotherapy, the primary site is identified as prostate. Hormonal treatment is started. Code the chemotherapy as first course of treatment. The hormone therapy is second course because it was not part of the initial treatment plan.
VI.1.3 Neoadjuvant Treatment - First Course of Treatment

Systemic treatment (chemotherapy, endocrine/hormone therapy, targeted therapy, immunotherapy, or biological therapy) and/or radiation treatment given prior to surgical resection to improve outcomes. This treatment is also sometimes referred to as pre-surgical or preoperative treatment.

• The following Neoadjuvant Therapy data items are required by the CCR to be collected for cases diagnosed January 1, 2021 and forward:
  o Neoadjuvant Therapy
  o Neoadjuvant Therapy – Clinical Response
  o Neoadjuvant Therapy – Treatment Effect

Guidelines:
• See Appendix A - Terms and Definitions for therapy definitions.
• Neoadjuvant therapy may be given to:
  o Reduce the disease burden, which may allow for surgical resection for previously unresectable disease or allow for less extensive surgery, organ preservation or function, or quality of life.
  o Eradicate or control undiscovered metastases and improve outcomes of overall survival and disease-free survival.
  o Provide prognostic information based on response. A clinical response to neoadjuvant therapy is associated with length of disease-free survival and overall survival in some cancers.

Note: Limited systemic therapy may be given prior to surgery, or may also occur in clinical trials with no expectation of the above-mentioned benefits.

• Additional benefits for the use of neoadjuvant therapy information:
  o Allow direct observation of therapeutic efficacy.
  o Allow time for appropriate genetic testing, if applicable.
  o Test novel therapies and predictive biomarkers by providing tumor specimens and blood samples prior to and during systemic treatment.
  o Assist in determining the next steps for treatment.
  o Compare survival, rates of successful optimal reductive surgical resection, postoperative complications and quality of life.

• For Site-Specific coding instructions of Neoadjuvant Therapy -Treatment Effect, see Appendix C of the current SEER Program and Staging Manual.
VI.1.3.1 Neoadjuvant Therapy
This data item is used to capture whether the patient has had neoadjuvant therapy prior to planned definitive surgical resection of the primary site. This data item is required by the CCR for cases diagnosed January 1, 2021 and forward.

Coding Instructions:

- For the purposes of this data item, neoadjuvant therapy is defined as systemic treatment (chemotherapy, endocrine/hormone therapy, targeted therapy, immunotherapy, or biological therapy) and/or radiation therapy before intended or performed surgical resection to improve local therapy and long-term outcomes.

- Criteria must be followed when coding this data item:
  - Have/use a physician’s treatment plan/statement of patient completing neoadjuvant therapy.
  - Treatment must follow the recommended treatment guidelines for the type and duration of treatment for that primary site and/or histology.
    - Length of full course of neoadjuvant systemic therapy may vary depending on site and/or histology. Often from 4-6 months, but could be shorter.
  - Neoadjuvant treatment may include systemic or radiation alone, or combinations of radiation and systemic therapy.

- Code the following data items even when neoadjuvant therapy is partial treatment, less than a full course, or limited.
  - Radiation Sequence with Surgery, when radiation is given prior to surgical resection as part of limited neoadjuvant therapy.
  - Systemic Treatment/Surgery Sequence, when systemic therapy is given prior to surgical resection as part of limited neoadjuvant therapy.
  - The appropriate treatment data items (chemotherapy, immunotherapy, hematologic transplant and endocrine procedures, radiation modality – phases I, II, and III), as well as the associated date and text field items.

- Document in the corresponding treatment text field(s) (e.g. Text-Chemotherapy, Text-Radiation Therapy):
  - If therapy is considered neoadjuvant per the treatment plan.
  - If neoadjuvant treatment is started, but not completed, as prescribed.
  - For additional information regarding recording text, please see Appendix T -Text Documentation Guidelines.
• Code 0 when:
  o Neoadjuvant therapy or tumor-directed treatment prior to surgical resection is not part of the treatment plan.
  o Surgical resection is not part of the planned first course of treatment.
  o Patient did not have neoadjuvant therapy based on the sequence of treatment.
  o Autopsy Only cases.
  o Cases where neoadjuvant therapy is not part of standard treatment.
    ▪ Sites C420, C421, C423, C424, and C809.
    ▪ Schemas:
      • 00830 HemeRetic
      • 99999 Ill-Defined Other
      • 00790 Lymphoma
      • 00795 Lymphoma (CLL/SLL)
      • 00811 Mycosis Fungoides (MF)
      • 00822 Plasma Cell Disorders
      • 00821 Plasma Cell Myeloma
      • 00812 Primary Cutaneous Lymphoma (excluding MF and SS)
• Code 1 for:
  o Any tumor-direct therapy meeting the definition of neoadjuvant therapy. See Appendix A - Terms and Definitions for neoadjuvant treatment definitions.
    ▪ Occurring prior to or performed definitive surgical resection, and
    ▪ Documented as neoadjuvant therapy by a treating physician or it is part of the patient’s documented treatment regimen/protocol.
  o Patient who completed the full course of neoadjuvant therapy with or without planned surgical resection.
• Code 2 when tumor-direct therapy (excluding surgical resection) meeting the definition of neoadjuvant therapy whose intent was neoadjuvant, was begun and the patient did not complete the full course of neoadjuvant therapy.
• Code 3 when:
- Any tumor-direct therapy (excluding surgical resection) not documented as neoadjuvant in the treatment plan and not meeting treatment guideline.
- The patient receives some therapy prior to surgical resection, but not enough to qualify for a full course of neoadjuvant therapy.

**Note:** For the purposes of coding the neoadjuvant data item, both scenarios below are to be coded as hormone therapy and not in the neoadjuvant data item.

- One shot of Lupron does **not** qualify as neoadjuvant therapy.
- A short course of Tamoxifen does **not** qualify as neoadjuvant therapy.

- Code 9 when:
  - It is unknown if neoadjuvant therapy was administered.
    - Planned, but unknown if given
    - Death Certificate Only (DCO)

- **Note:** Code 9 should rarely be used. Use code 0 when it is clear that the patient did not have neoadjuvant therapy based on the sequence of diagnosis and treatment.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No neoadjuvant therapy; no treatment before surgery; surgical resection not part of first course of treatment plan; autopsy only</td>
</tr>
<tr>
<td>1</td>
<td>Neoadjuvant therapy completed according to treatment plan and guidelines</td>
</tr>
<tr>
<td>2</td>
<td>Neoadjuvant therapy started, but not completed or unknown if completed</td>
</tr>
<tr>
<td>3</td>
<td>Limited systemic exposure when the intent was not neoadjuvant; treatment did not meet the definition of neoadjuvant therapy</td>
</tr>
</tbody>
</table>
| 9    | Unknown if neoadjuvant therapy performed  
Death Certificate Only (DCO) |
VI.1.3.2 Neoadjuvant Therapy - Clinical Response
This data item is used to capture the clinical outcomes of neoadjuvant therapy prior to planned surgical resection. This data item is required by the CCR for cases diagnosed January 1, 2021 and forward.

Coding Instructions:

- Records the clinical outcomes of neoadjuvant therapy as determined by the managing physician (oncologic surgeon, radiation oncologist, or medical oncologist).

- For the purposes of this data item, neoadjuvant therapy is defined as systemic treatment (chemotherapy, endocrine/hormone therapy, targeted therapy, immunotherapy, or biological therapy) and/or radiation therapy given to shrink a tumor before surgical resection.

- Neoadjuvant Therapy – Clinical Response is evaluated after primary systemic and/or radiation therapy is completed and prior to surgical resection.
  - It is based on clinical history, physical examination, biopsies, imaging studies, and other diagnostic workup. Therefore, surgical pathology report is not used to code this item.

- Have/use the managing/treating physician’s interpretation/statement of the response to neoadjuvant therapy, whenever this interpretation/statement is available.

- Document information in text to support the clinical response that is coded:
  - Record in Text-Physical Examination the managing/treating physician’s interpretation/statement of response to neoadjuvant therapy, when available (codes 1-5).
  - Record in Text-Scopes and Text-Scans the radiologist or endoscopist statement/impression of the response to neoadjuvant therapy when post-neoadjuvant therapy scopes/scans are done prior to resection (code 6).
  - Record in Text-Pathology any post-neoadjuvant biopsy and/or biomarker results used to infer a clinical response (codes 6 and 7).
  - For additional information regarding recording text, please see Appendix T -Text Documentation Guidelines.

- Code 0 when:
  - Neoadjuvant therapy is not administered.
  - Therapy administered does not qualify as neoadjuvant therapy (presurgical treatment) because surgical resection not planned.
- Patient did not have neoadjuvant therapy based on the sequence of treatment.
- Autopsy Only cases.
- Cases where neoadjuvant therapy is not part of standard treatment.
  - Sites C420, C421, C423, C424, and C809.
  - Schemas:
    - 00830 HemeRetic
    - 99999 Ill-Defined Other
    - 00790 Lymphoma
    - 00795 Lymphoma (CLL/SLL)
    - 00811 Mycosis Fungoides (MF)
    - 00822 Plasma Cell Disorders
    - 00821 Plasma Cell Myeloma
    - 00812 Primary Cutaneous Lymphoma (excluding MF and SS)
- A managing/treating physician statement is required to assign codes 1-5.
- Code 1 when managing/treating physician documents complete (or total) response (CR) based on clinical findings.
- Code 2 when:
  - Managing/treating physician documents partial response (PR) based on clinical findings or
  - Documented as not being either complete response (CR) or progressive disease (PD).
- Code 3 when the managing/treating physician documents:
  - Progressive disease (PD) based on clinical findings.
  - “Progression” or that the size/extent of the tumor and/or presence of lymph nodes or metastatic disease has increased.
  - There is evidence of new metastasis.
- Code 4 when the managing/treating physician documents:
  - No clinical response based on clinical findings due to stable disease (SD) or
  - States there is no change in size/extent of tumor and/or the presence of lymph nodes or metastatic disease.
• Code 5 when the evaluation after neoadjuvant therapy is done and the managing/treating physician documents no response (NR); and does not indicate:
  o The tumor progressed (code 3).
  o The was change in the tumor size/extent.
  o Tumor was stable (see code 4).
• Code 6 when neoadjuvant therapy was completed, there is no statement from the managing/treating physician based on clinical evaluation documented or available, and the clinical response is inferred from imaging impression, changes in biomarkers or yc stage.
• Code 7 when there is a biopsy done of the primary site, the pathology report indicates complete response, and there is no statement regarding clinical response from the managing physician.
• Code 8 when neoadjuvant therapy is done, and the clinical response is not documented or is unknown.
• Code 9 when:
  o It is unknown if neoadjuvant therapy was administered.
    ▪ Planned, but unknown if given
    ▪ Death Certificate Only (DCO)

Note: Code 9 should rarely be used. Use code 0 when it is clear that the patient did not have neoadjuvant therapy based on the sequence of diagnosis and treatment.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Neoadjuvant therapy not given</td>
</tr>
<tr>
<td>1</td>
<td>Complete clinical response (CR) (per managing/treating physician statement)</td>
</tr>
<tr>
<td>2</td>
<td>Partial clinical response (PR) (per managing/treating physician statement)</td>
</tr>
<tr>
<td>3</td>
<td>Progressive disease (PD) (per managing/treating physician statement)</td>
</tr>
<tr>
<td>4</td>
<td>Stable disease (SD) (per managing/treating physician statement)</td>
</tr>
<tr>
<td>5</td>
<td>No response (NR) (per managing/treating physician statement) Not stated as progressive disease (PD) or stable disease (SD)</td>
</tr>
<tr>
<td>6</td>
<td>Neoadjuvant therapy done, managing/treating physician interpretation not available, treatment response inferred from imaging, biomarkers, or yc stage</td>
</tr>
<tr>
<td>7</td>
<td>Complete clinical response based on biopsy results from a pathology report (per pathologist assessment)</td>
</tr>
<tr>
<td>8</td>
<td>Neoadjuvant therapy done, response not documented or unknown</td>
</tr>
<tr>
<td>9</td>
<td>Unknown if neoadjuvant therapy performed</td>
</tr>
<tr>
<td>Death Certificate Only (DCO)</td>
<td></td>
</tr>
</tbody>
</table>
**VI.1.3.3 Neoadjuvant Therapy - Treatment Effect**

This data item is used to capture the pathologist’s statement of neoadjuvant treatment effect on the primary tumor site, with or without lymph nodes and/or distant metastasis, from the pathology report. This data item is required by the CCR for cases diagnosed January 1, 2021 and forward.

**Coding Instructions:**

- For the purposes of this data item:
  - Neoadjuvant therapy is defined as systemic treatment (chemotherapy, endocrine/hormone therapy, targeted therapy, immunotherapy, or biological therapy) and/or radiation therapy given to shrink the tumor prior to surgical resection.
  - Surgical resection is defined as the most definitive surgical procedure that removes some or all of the primary tumor or site, with or without lymph nodes and/or distant mets.
    - For many sites, this would be surgical codes 30-80; however, there are some sites where surgical codes less than 30 could be used.

  **Example:** Code 22 for breast (excisional biopsy or lumpectomy).

**Note:** This data item is not the same as AJCC’s *Post Therapy Path (yp) Pathological Response*, which is based on the managing/treating physician’s evaluation from the surgical pathology report and clinical evaluation after neoadjuvant therapy. **This data item only addresses response based on the surgical path report.**

- This data item follows the CAP definitions indicating presence or absence of effect.
  - When site-specific CAP definitions are not available, use the treatment effect codes for all other schemas, in the SEER Program Manual, appendix C (link below).

- For Site-Specific coding instructions of *Neoadjuvant Therapy -Treatment Effect*, see Appendix C of the current SEER Program and Staging Manual.

- Code 9 when the only information available is the managing/treating physician’s evaluation.

- Document in Text-Pathology the treatment effect as stated in the path report, including the treatment response score.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Neoadjuvant therapy not given/no known presurgical therapy</td>
</tr>
<tr>
<td>1-4</td>
<td>Site-specific code; type of response</td>
</tr>
</tbody>
</table>
|   | Neoadjuvant therapy completed, and surgical resection performed, response not documented or unknown  
|   | Cannot be determined  
| 6 | Neoadjuvant therapy completed and planned surgical resection not preformed  
| 7 | Unknown if neoadjuvant therapy performed  
|   | Unknown if planned surgical procedure performed after completion of neoadjuvant therapy  
|   | Death Certificate Only (DCO)  
| 9 |   


VI.2 Surgery Introduction - First Course of Treatment

In abstracting surgical treatment, the total or partial removal (except an incisional biopsy) of tumor tissue must be recorded in the text data item, whether from a primary or metastatic site.

Coding Instructions:

- Surgical procedures are coded in four-character alphanumeric codes, beginning with cases diagnosed January 1, 2023. For cases diagnosed prior to 2023, see Archived Volume I Use case year of diagnosis to determine which Volume I to choose.

- Record procedures that remove normal tissue.

  **Example:** Dissection of non-cancerous lymph nodes if they are part of the first course of treatment.

- Shave or punch biopsies are most often diagnostic. Code as a surgical procedure **only** when the entire tumor is removed, and margins are clear.

- Brushings, washings, aspiration of cells and peripheral blood smears are not considered surgical procedures, but they might have to be recorded as diagnostic procedures.

- In the appropriate text field, enter the following information:
  - Date and name of surgical procedure. Be sure to review the operative report and verify the stated procedure(s) was performed.
  - Avoid recording non-pertinent information such as incidental appendectomy.

For additional information regarding recording text, please see Appendix T - Text Documentation Guidelines.
VI.2.1 Treatment Facility Number
The CCR assigned reporting facility code for the reporting facility or agency that provided first course treatment.

Coding Instructions:

- Refer to the most current California [California Reporting Facility Codes](https://www.ccrcal.org/), located on the CCR website. Registrar Resources, Reporting Cancer in California, Volumes I-IV.
  - Lists are presented in both alphabetical and code order.
- The data items are to be left blank if no cancer-directed surgery was performed.
- These data items are used in conjunction with each surgical procedure performed.
- If the procedure was performed at the reporting facility, the CCR assigned reporting facility code should be entered.
VI.2.2 Sources for Information (Surgery)
To capture all aspects of a patient’s surgical treatment, it is necessary to review multiple sources. This instruction directs abstractors on where to obtain information regarding surgery.

Coding Instructions:

- To ascertain exactly what procedures were performed, read the operative and pathology reports thoroughly. Do not depend on the title of an operative report, because it might be incomplete.

- If the operative report is unclear about what tissue was excised or the operative and pathology reports contain different information, use the pathology report unless there is reason to doubt its accuracy.
VI.2.3 Diagnostic or Staging Procedures

Record surgical procedures performed solely for establishing a diagnosis and/or determining stage of disease. If more than one surgical diagnostic or staging procedure was done, record the first one performed.

Surgical diagnostic or staging procedures include:

- Biopsy, incisional or NOS (if a specimen is less than or equal to 1 cm, assume the biopsy to have been incisional unless otherwise specified).
- Only record positive procedures.
  
  **Note:** If a lymph node is biopsied or removed to diagnose or stage lymphoma, and that node is not the only node involved with lymphoma, use code 02. If there is only a single lymph node involved with lymphoma, use the data item *Surgery of Primary Site* 2023 to code these procedures.

- Dilation and curettage for invasive cervical cancer.
- Dilation and curettage for invasive or in-situ cancers of the corpus uteri, including choriocarcinoma.
- Surgery in which tumor tissue is not removed:
  
  **Examples:**

     **Note:** Removal of fluid (paracentesis or thoracentesis) even if cancer cells are present is not a surgical procedure. Do not code brushings, washings, or hematologic findings (peripheral blood smears). These are not considered surgical procedures.

  2. Exploratory surgery—celiotomy, cystotomy, gastrotomy, laparotomy, nephrotomy, thoracotomy.

     **Note:** If both an incisional biopsy of the primary site and an incisional biopsy of a metastatic site are done, use code 02 (Incisional biopsy of primary site).

Coding Instructions:

- This data item does not include palliative treatment/procedures. Palliative treatment/procedures are recorded in a separate data item. The CCR does not require that palliative treatment/procedures be recorded but the CoC does require this data item. Please consult the *STANDARDS FOR ONCOLOGY REGISTRY ENTRY (STORE) MANUAL* for instructions regarding the palliative procedure data item. This applies to cases diagnosed January 1, 2003 forward.
• Give priority to:
  o Codes 01-07 over code 09
  o Codes 01-06 over code 07
  o Codes in the range 01-06 are hierarchical
  o Code microscopic residual disease or no residual disease as Surgery of Primary Site 2023.

  **Note:** The CCR follows SEER guidelines for assigning surgery codes

**COC Facilities:** Please make note in your user defined data items when standards between CoC and CCR differ.

---

**Do Not Code the following information:**

• Brushings, washings, cell aspirations and hematologic findings (peripheral smears), as they are **not** considered surgical procedures and should not be coded in the *Diagnostic or Staging Procedures* data item. Code positive brushings, washings and cell aspirations, and hematologic findings (peripheral smears) as cytologic diagnostic confirmation in the *Diagnostic Confirmation* data item.

• Surgical procedures which aspirate, biopsy, or remove regional lymph nodes in effort to diagnose and/or stage disease in this data item. Use the data item *Scope of Regional Lymph Node Surgery* to code these procedures. Do not record the date of surgical procedures which aspirate, biopsy, or remove regional lymph nodes in the data item *Date of Surgical Diagnostic and Staging Procedure*.

• Excisional biopsies with clear or microscopic margins in this data item. Use the data item *Surgical of Primary Site 2023* to code these procedures.

• Palliative surgical procedures in this data item.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>No surgical diagnostic or staging procedure</td>
</tr>
<tr>
<td>01</td>
<td>Incisional, needle, or aspiration biopsy of other than primary site (code microscopic residual disease or no residual disease as surgery of other regional site[s], distant site[s], or distant lymph nodes[s])</td>
</tr>
<tr>
<td>02</td>
<td>Incisional, needle, or aspiration biopsy of primary site</td>
</tr>
<tr>
<td>03</td>
<td>Exploratory surgery only (no biopsy)</td>
</tr>
<tr>
<td>04</td>
<td>Bypass surgery or ostomy only (no biopsy)</td>
</tr>
<tr>
<td>05</td>
<td>Combination of 03 plus 01 or 02</td>
</tr>
<tr>
<td>06</td>
<td>Combination of 04 plus 01 or 02</td>
</tr>
<tr>
<td>07</td>
<td>Diagnostic or staging procedure, NOS</td>
</tr>
<tr>
<td></td>
<td>Unknown if diagnostic or staging procedure done</td>
</tr>
<tr>
<td>---</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>09</td>
<td></td>
</tr>
</tbody>
</table>
VI.2.3.1 Date of Diagnostic or Staging Surgical Procedures
Enter the date of the earliest surgical diagnostic and/or staging procedure in this data item.

See Entering Dates and Date Format for additional information regarding entering dates.

Coding Instructions:
- Enter the earliest date in which the diagnostic or staging surgical procedure was administered.
- Record only first course of treatment dates in this data item.
- Record the date, diagnostic or staging procedure, and results in the associated text data item.
VI.2.4 Surgery of Primary Site 2023

*Surgery of Primary Site 2023* describes a surgical procedure that removes and/or destroys tissue of the primary site that is performed as part of the initial diagnostic and staging work-up or first course of therapy. This data item is required by the CCR for cases diagnosed January 1, 2023 and forward.

See Appendix K.2 - STORE Surgery Codes for Site-Specific Surgery Codes.

For cases diagnosed prior to 2023, this data item is to be left blank. Code cases to Surgery of Primary Site 03-2022. See Archived Volume I – Use case year of diagnosis to determine which Volume I to choose.

Generally, cancer-directed surgery includes most procedures that involve removal of a structure (those with the suffix "ectomy") and such procedures as:

- Biopsy, excisional (which has microscopic residual disease or no residual disease)
- Biopsy, NOS, which removes all tumor tissue
- Chemosurgery (Moh’s technique)
- Conization
- Cryosurgery
- Desiccation and Curettage for bladder and skin tumors
- Electrocautery
- Fulguration for bladder, skin, and rectal neoplasms
- Laser therapy
- Local excision with removal of cancer tissue (including excisional biopsy but excluding incisional biopsy)
- Photocoagulation
- Splenectomy for lymphoma or leukemia
- Surgery removing metastatic malignant tissue
- Transurethral resection (TUR) with removal of tumor tissue of bladder or prostatic tumors

**Coding Instructions:**

- **Operative report takes precedence.** Use the entire operative report as the primary source document to determine the best Surgery of Primary Site 2023 code. The body of the operative report will designate the surgeon’s planned procedure as well as a description of the procedure that was actually performed. The pathology report may complement the information.
documented in the operative report, but the operative report takes precedence.

- Record the site-specific coding scheme corresponding to the primary site or histology. See Appendix K.2 - STORE Surgery Codes for Site-Specific Surgery Codes.

- Enter the procedures in chronological order. If more than three surgical procedures are performed on a patient, the earliest surgery and the most definitive surgery must be included. For codes A000 or B000 through A790 or B790, the response positions are hierarchical.
  - Code A980 or B980 takes precedence over code A000 or B000.
  - Codes A800 or B000 and A990 or B990 only if more precise information about the surgery is unavailable.

- Surgery to remove regional tissue or organs is coded in this item only if the tissue/organs are removed in continuity with the primary site, except where noted in Appendix K.2 - Surgery Codes for Site-Specific Surgery Codes.

- Do not code pre-surgical embolization of hypervascular tumors with particles, coils, or alcohol. These pre-surgical embolizations are typically performed to make the resection of the primary tumor easier.
  
  **Example:** Where pre-surgical embolization is used include meningiomas, hemangiomas, paragangliomas, and renal cell metastases in the brain.

- Surgery of Primary Site 2023 consists of three alphanumeric data items which are to be used to record surgeries of the primary site only. If an en bloc resection is performed which removes regional tissue or organs with the primary site(s) is part of a specific code definition, it should be coded. An en bloc resection is the removal of organs in one piece at one time. Specimens from an en bloc resection may be submitted to pathology separately.
  
  **Example:** Patient undergoes a modified radical mastectomy. The breast and auxiliary contents are removed in one piece (en bloc). Surgery would be coded A500 for modified radical mastectomy regardless of whether nodes were found by pathology in the specimen.

- For non-en bloc resections, record the resection of a secondary or metastatic site in the Surgery of Other Regional Site(s), Distant Site(s), or Distant Lymph Node(s).

- Refer to Appendix K.2 – STORE Surgery Codes for Site-Specific Surgery Codes. They are hierarchical with less specific (NOS) terms followed by more specific terms.

  **Examples:**

  1. A500 Gastrectomy, NOS WITH removal of a portion of esophagus
2. A510 Partial or subtotal gastrectomy
3. A520 Near total or total gastrectomy

- Codes A100-A900 or B100-B900 have priority over code A990 or B990.
- Codes A000-A790 or B000-B790 have priority over codes A800 or B800, A900 or B900 and A990 or B990, where A800 or B800 is site-specific surgery, not otherwise specified.
- If surgery removes the remaining portion of an organ, code the total removal of the organ.

**Example:** Patient undergoes left thyroid lobectomy (code A210) for goiter and is found to have thyroid cancer on pathologic review. The patient then returns to have the right thyroid lobe removed. The removal of the right lobe results in a total thyroidectomy, therefore code to A500, total thyroidectomy, (not a second lobectomy code A210).

- Biopsies, NOS, which remove all gross tumor or leave only microscopic margins, should be coded to *Surgery of Primary Site 2023*. If there is no statement that the initial biopsy was excisional, yet no residual tumor was found at a later resection, assume that the biopsy was excisional.

**Examples:**
1. The patient had a resection of a stomach remnant and portion of the esophagus at the time of their second procedure.
2. The first procedure was a partial gastrectomy, NOS – code A300 or B300.

- **Excisional Biopsy:**
  - Record an excisional biopsy as first surgical treatment, whether followed by further definitive surgery or not and whether or not residual tumor was found in a later resection.

**Note:** The CCR follows SEER guidelines for assigning surgery codes.

**COC Facilities:** Please make note in your user defined data items when standards between CoC and CCR differ.

- **Aborted Procedure:**
  - Assign the surgery code(s) that actually represents the extent of the surgical procedure that was carried out when surgery is aborted. If the procedure was cancelled or discontinued before anything took place, assign code A000 or B000.

- **Extranodal Lymphomas:**
When coding surgery for extranodal lymphomas, use the appropriate code for the extranodal site. For example, use a code for the stomach to code a lymphoma of the stomach.

- Code A000 or B000 when:
  - No surgery performed on the primary site, or
  - First course is active surveillance/watchful waiting, or
  - Case was diagnosed at autopsy.

**Exception:** All sites and histologies that would be coded as A980 or B980.

- Code A980 or B980 when:
  - Primary site is C420, C421, C423, C424, C760-C768, or C809.
    **Exception:** If case is a Death Certificate Only case (DCO), code A990 or B990.
  - When Surgery of Primary Site 2023 is coded A980 or B980, code:
    - Surgical Margins of the Primary Site to 9.
    - Reason for No Surgery of Primary Site to 1.

- Code A990 or B990 for:
  - Death Certificate Only (DCO).
  - Not documented, unknown if surgical procedure of the primary site has been performed (i.e., is unknown).

**Notes:**

1. If the only information available is that the patient was referred to a surgeon, medical oncologist, or radiation oncologist, with no confirmation that treatment was administered, code no treatment given.

2. Referral to a specialist is considered a recommendation. Registry personnel should follow-up on these cases to determine whether treatment was administered or not and code accordingly. This applies to cases diagnosed January 1, 2010 and forward.
VI.2.4.1 Date of Surgery
Enter the date of surgery performed for each surgical procedure. There are three date data items available to be used in conjunction with each definitive procedure performed.

- Procedures for this date data item include:
  - *Surgery of the Primary Site* 2023
  - Scope of Regional Lymph Node Surgery
    - Do not count *Scope of Regional Lymph Node Surgery* code 1 as surgery for coding the date of first surgical procedure data item.
  - *Surgery of Other Regional/Distant Sites*
- Record the date, surgical procedure, and results in the associated text data item.

**Note:** Surgery must be entered in chronological order.

See [Entering Dates](#) and [Date Format](#) for additional information regarding entering dates.
**VI.2.4.2 Surgical Margins of the Primary Site**
This data item describes the final status of the surgical margins after resection of the primary tumor. It is used in staging, for quality assurance measures, and may be a prognostic factor in recurrence. Surgical margins are required by the CCR to be coded for all primary sites. This applies to cases diagnosed January 1, 2016 and forward.

**Coding Instructions:**
- Record the margin status as it appears in the pathology report.
- Codes 0-3 are hierarchical.
  - If two codes describe the margin status, use the numerically higher code.
- Code 0 when all margins are negative both microscopically and macroscopically.
- Code 1 for involved margins not otherwise specified.
- Code 2 for involved margins seen microscopically but not grossly (cannot be seen by the naked eye).
  - To identify microscopic findings, use the margins section of the CAP protocol or the microscopic description from the pathology report.
- Code 3 for involved margins seen macroscopically (grossly, with the naked eye).
  - To identify macroscopic findings, use the margins section of the CAP protocol or the gross description from the pathology report.
- Code 7 if the pathology report indicates the margin could not be determined.
- Code 8 when no surgery is performed on the primary site.
- Code 9 in the following scenarios:
  - Pathology report makes no mention of the margins.
  - No tissue was sent to pathology.
  - When *Surgery of Primary Site 2023* is coded to A980 or B980.
  - Primary site is C420, C421, C423, C424, C760-C768, C770-C779, or C809.
  - Not documented, unknown if surgical procedure of the primary site has been performed.
  - Death Certificate Only (DCO).

<table>
<thead>
<tr>
<th>Code</th>
<th>Label</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

328
<table>
<thead>
<tr>
<th>No.</th>
<th>Description</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No residual tumor</td>
<td>All margins are grossly and microscopically negative</td>
</tr>
<tr>
<td>1</td>
<td>Residual tumor, NOS</td>
<td>Involvement is indicated, but not otherwise specified</td>
</tr>
<tr>
<td>2</td>
<td>Microscopic residual tumor</td>
<td>Cannot be seen by the naked eye</td>
</tr>
<tr>
<td>3</td>
<td>Macroscopic residual tumor</td>
<td>Gross tumor of the primary site which is visible to the naked eye</td>
</tr>
<tr>
<td>7</td>
<td>Margins not evaluable</td>
<td>Cannot be assessed (indeterminate)</td>
</tr>
<tr>
<td>8</td>
<td>No primary surgery site</td>
<td>No surgical procedure of the primary site. Diagnosed at autopsy</td>
</tr>
<tr>
<td>9</td>
<td>Unknown of not applicable</td>
<td>It is unknown whether a surgical procedure to the primary site was performed; death certificate-only; for lymphomas with lymph node primary site; an unknown or ill-defined primary; or for Hematopoietic, Reticuloendothelial, Immunoproliferative, or Myeloproliferative disease</td>
</tr>
</tbody>
</table>
**VI.2.4.3 Macroscopic Evaluation of the Mesorectum**

This data item records whether a total mesorectal excision (TME) was performed and the macroscopic evaluation of the completeness of the excision. **This applies to rectal cases only.** This data item is required by CoC-accredited facilities for all cases diagnosed January 1, 2022 and forward.

**Coding Instructions:**

- Use information from the pathology report and/or the CAP protocol for this data item.
- When the primary site is other than rectum (C20.9), leave this field blank.
- Neoadjuvant therapy does not alter coding of this data item.
- Code 00 when a total mesorectal excision is not performed.
- Codes 10, 20, and 30 are based on pathology report and/or CAP protocol.
  - Do not attempt to apply the pathologist’s criteria to assess completeness status.
- Code 40 when the pathologist does not indicate incomplete, nearly complete, or complete for a TME specimen.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>Patient did not receive TME</td>
</tr>
<tr>
<td>10</td>
<td>Incomplete</td>
</tr>
<tr>
<td>20</td>
<td>Nearly complete</td>
</tr>
<tr>
<td>30</td>
<td>Complete</td>
</tr>
</tbody>
</table>
| 40   | TME performed not specified on pathology report as incomplete, nearly complete, or complete
  TME performed but pathology report not available
  Physician statement that TME performed, no mention of incomplete, nearly complete or complete status |
| 99   | Unknown if TME performed |
| Blank| Site not rectum (C209) |
VI.2.5 Sentinel Lymph Node Biopsy

It is a known fact that sentinel lymph node biopsies have been under-reported. Additionally, the timing and results of sentinel lymph node biopsy procedures are used in quality of care measures. This data item can be used to more accurately assess the date of regional node dissection separate from the date of sentinel lymph node biopsy if performed.

Guidelines:

- Sentinel lymph nodes (SLNs) are the first lymph nodes (LNs) to which cancer cells are most likely to spread from the primary tumor.
- Sentinel lymph node biopsy (SLNBx) is a procedure in which a sentinel LN is identified, removed, and examined.
  - By injection of a radioactive tracer substance and/or blue dye near the tumor, sentinel lymph nodes can be identified when they “map” or are described as “hot” from radiotracer uptake, or described “blue” resulting from dye uptake.
  - Usually 1-3 sentinel LNs will be identified, however, non-sentinel LNs may be in very close proximity to SLNs and may need to be excised in the process of dissecting the SLNs.
    - All LNs removed in this bundle during the sentinel lymph node procedure are counted and coded in the number of sentinel LNs examined even if the node(s) were described as “non-sentinel,” “failed to map,” and/or did not contain dye or radio tracer.
    - All LNs removed in this bundle during the sentinel lymph node procedure and identified as positive by the pathologist, are counted and coded as positive even if the node(s) were described as “non-sentinel,” “failed to map,” and/or did not contain dye or radio tracer.
- A SLN biopsy is performed when lymph nodes (LNs) are clinically negative and may be followed by a full regional lymph node (LN) dissection when:
  - Nodes “fail to map” or
  - SLNs are found to be positive
- Failure to map occurs when no nodes will uptake either the radiotracer substance or the blue dye.
- If a relatively large number of LNs (>5) are removed, more investigation needs to be done.
• READ the operative report to clarify that the procedure was limited to a SLNBx and did not include a full regional LN dissection. This cannot be determined from the path report.

• Generally performed for breast and cutaneous melanoma cancers.
VI.2.5.1 Date of Sentinel Lymph Node Biopsy
Enter the date of the sentinel lymph node(s) biopsy procedure. This data item is required by the CCR for breast and cutaneous melanoma cases only diagnosed January 1, 2018 and forward.

Coding Instructions:

- Enter the date of the sentinel lymph node(s) biopsy procedure performed, and documented in the Sentinel Lymph Node Examined data item.
- Record must definitively state that the procedure is a sentinel lymph node (SLN) procedure.
  - Dates for lymph node aspiration, fine needle aspiration, fine needle aspiration biopsy, core needle biopsies, and core biopsies are not to be coded in this data item.
- If the SLNBx is either the first or only surgical procedure performed, also record this date in the Date First Surgical Procedure data item.
- If a regional lymph node dissection (RLND) is also performed in addition to/or subsequent to the SLNBx, also record the date of the RLND in the Date Regional Lymph Node Dissection data item.
  - If a SLNBx and a RLND are performed on the same date, the dates should be equal/the same.
  - If the RLND is done subsequently (on a later date), after the SLNBx, then dates for each procedure will differ.
- Record the date, procedure, and results in the associated text data item(s).
- Leave date blank when:
  - SLNBx attempted but “failed to map”
  - Cases other than breast or cutaneous melanoma

See Entering Dates and Date Format for additional information regarding entering dates.
VI.2.5.2 Sentinel Lymph Nodes Positive
This data item records the exact number of sentinel lymph nodes found to contain metastases. This data item is required by the CCR for breast and cutaneous melanoma cases only diagnosed January 1, 2018 and forward.

Coding Instructions:

• Data item may be left blank for cases other than breast and cutaneous melanoma.

• Record information only about sentinel lymph node procedure in this data item.

• If a positive aspiration of sentinel lymph node(s) and a positive sentinel node biopsy are done on the same patient, record the results of the sentinel node biopsy procedure.

• Enter the exact number of sentinel lymph nodes biopsied/dissected and found to contain metastasis by the pathologist.
  o If “non-sentinel” lymph nodes are removed by chance during the sentinel lymph node procedure, which are positive on exam by the pathologist, record the total number of positive nodes from the sentinel lymph node procedure regardless of whether the positive node(s) contained any dye or radiotracer.

• Record the number of positive sentinel lymph nodes identified in this data item, and record the total number of positive regional nodes (which includes sentinel LNs), in the Regional Lymph Nodes Positive data item.

• Sentinel lymph nodes with mi (Microscopic or micro mets) are considered positive.

Breast carcinoma only:
  o If only positive isolated tumor cells (ITCs) are identified, the sentinel lymph nodes are negative.
  o Code 97 in this data item when a sentinel lymph node biopsy and a regional node dissection are performed during the same procedure, and positive sentinel lymph nodes are documented as present, and record the total number of positive regional nodes (which includes any positive sentinel nodes) in the Regional Lymph Nodes Positive data item.
  o The CAP Protocol for Breast is designed to capture information from the resection (there is no diagnostic protocol for breast). As a result, when the sentinel lymph node biopsy is performed during the same procedure as the regional node dissection, only the overall total
number of positive regional nodes (both sentinel and regional) is recorded. The number of sentinel nodes is not captured.

**Cutaneous Melanoma only:**

- If only positive isolated tumor cells (ITCs) are identified, the sentinel lymph nodes are **positive**.
- If both a sentinel lymph node biopsy procedure and a regional lymph node dissection are performed during the same procedure record the total number of positive sentinel nodes identified in the sentinel procedure in this data item, and record the total number of positive regional lymph nodes biopsied/dissected (which includes the number of sentinel nodes documented in this data item) in the *Regional Lymph Nodes Positive* data item.

- The number of positive sentinel lymph nodes should be less than or equal to the total number of regional nodes positive.
- The number of positive sentinel lymph nodes will typically be found in the:
  - Pathology report
  - Radiology Report
  - Documented by the physician
- Determination of the exact number of positive sentinel lymph nodes may require assistance from the managing physician.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>All sentinel nodes examined negative</td>
</tr>
<tr>
<td>01-90</td>
<td>Sentinel nodes are positive (code exact number of nodes positive)</td>
</tr>
<tr>
<td>95</td>
<td>Positive aspiration of sentinel lymph node(s) was performed</td>
</tr>
<tr>
<td>97</td>
<td>Positive sentinel nodes are documented, but the number is unspecified; For breast ONLY: SLN and RLND occurred during the same procedure</td>
</tr>
<tr>
<td>98</td>
<td>No sentinel nodes were biopsied</td>
</tr>
<tr>
<td>99</td>
<td>It is unknown whether sentinel nodes are positive; not applicable; not stated in patient record</td>
</tr>
</tbody>
</table>
VI.2.5.3 Sentinel Lymph Nodes Examined
This data item records the total number of lymph nodes sampled during the sentinel node biopsy and examined by the pathologist. This data item is required by the CCR for breast and cutaneous melanoma cases only diagnosed January 1, 2018 and forward.

Coding Instructions:

- This data item may be left blank for cases other than breast and cutaneous melanoma.
- Record the total number of nodes sampled during the sentinel node biopsy procedure and examined by the pathologist.
  - Includes aspiration of SLNs.
  - If both sentinel and non-sentinel LNS were sampled during the SLNBx procedure:
    - Record total number of node(s) examined regardless of status; sentinel, "non-sentinel," positive or negative.
- Sentinel lymph nodes are also regional nodes. Therefore, if both a sentinel lymph node biopsy procedure is performed and a regional lymph node dissection (whether on the same date or a subsequent date) is performed, record the total number of sentinel nodes examined in the sentinel procedure in this data item, and record the total number of regional lymph nodes biopsied/dissected (which includes the number of sentinel nodes documented in this data item) in the Regional Lymph Nodes Examined data item.
- If both an aspiration of sentinel lymph node(s) is done, and a sentinel node biopsy is done on the same patient, record the results of the sentinel node biopsy procedure.
- The number of sentinel nodes examined should be equal to or less than the number of regional lymph nodes examined recorded in the Regional Lymph Nodes Examined data item.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>No sentinel nodes were examined</td>
</tr>
<tr>
<td>01-90</td>
<td>Sentinel nodes were examined (code the exact number of sentinel lymph nodes examined)</td>
</tr>
<tr>
<td>95</td>
<td>No sentinel nodes were removed, but aspiration of sentinel node(s) was performed</td>
</tr>
<tr>
<td>98</td>
<td>Sentinel lymph nodes were biopsied, but the number is unknown</td>
</tr>
<tr>
<td>99</td>
<td>Unknown whether sentinel nodes were examined; not stated in patient record</td>
</tr>
</tbody>
</table>
VI.2.6 Scope of Regional Lymph Node Surgery

This data item is used to record the procedures performed to remove, biopsy, or aspirate regional lymph nodes during the initial work-up or first course of therapy.

Guidelines:

- See Appendix A - Terms and Definitions for types of surgery and their definitions.
- **Operative report takes precedence.** Use the entire operative report as the primary coding source to determine if a sentinel lymph node biopsy (SLNBx) or regional lymph node dissection was performed.
  - The body of the operative report will designate the surgeon’s planned procedure as well as a description of the procedure that was actually performed.
  - The pathology report may complement the information documented in the operative report, but the operative report takes precedence.

  **Note:** Do not use the number of lymph nodes removed and pathologically examined as the sole means of distinguishing between a SLNBx and a regional lymph node dissection.

- Record the removal of distant lymph node(s) in the data item: *Surgical Procedure of Other Reg/Dis Site*.
- Refer to the most current AJCC Staging or EOD 2018 Manuals for lymph nodes identified as regional.
- Record all surgical procedures that remove, biopsy, or aspirate regional lymph node(s) regardless of whether a procedure of the primary site was performed.
  - The regional lymph node surgical procedure(s) may be done to **diagnose** cancer, **stage** the disease, or as a part of the initial **treatment**.
- Removal of intra-organ lymph nodes are coded in *Scope of Regional Lymph Node Surgery*.
- Do not use the number of lymph nodes removed/examined to determine SLNBx vs RLND.
- When two primaries share a common regional lymph node, code regional node removal for both primaries.

**Coding Instructions All Sites (excluding Breast):**

- See Coding Instructions for (SLNBx) Breast (C500-C509) are described at the end of this page, following the tables for all other sites.
Effective January 1, 2012 and forward the following instructions apply:

- There is no minimum number of nodes that must be removed.
  - Record the **cumulative** total of lymph nodes during each first course surgical procedure.
  - If a regional lymph node was aspirated or biopsied, code regional lymph node(s) removed, NOS (1).
    - For counting regional lymph nodes for a core needle biopsy or aspiration followed by a dissection, see Section **Special Rules for Counting Lymph Nodes**.
- Assign the appropriate code for occult primaries of the head and neck with positive cervical lymph nodes (Schema 00060), do not default to 9.

- Code 0 when any of the following scenarios apply:
  - Regional lymph node procedure was not performed.
  - Regional lymph node procedure performed but **no** lymph nodes were found by the pathologist.
  - Patient is on active surveillance or watchful waiting.
- Code 2 when the **operative report**:
  - SLNBx was performed.
  - Describes procedure involving radio label and/or dye to identify lymph nodes for removal (also see references to “hot” and/or “blue” lymph nodes).
  - SLNBx attempted but “failed to map” and **NO** lymph nodes removed (no RLND performed).
  - SLN and additional incidental non-sentinel lymph nodes are removed as part of the SLNBx procedure.
- Code 3 when the number of regional lymph nodes removed is unknown, not stated, or are stated as regional lymph nodes removed NOS.
- Code 4 for 1-3 regional lymph node(s) removed.
- Code 5 for 4 or more regional lymph nodes removed.
- Code 6 for SLNBx and regional lymph node dissection (codes 3, 4, or 5) during the same surgical procedure, or the timing is not known.
  - SLNBx attempted but “failed to map” and lymph nodes removed (regional lymph node dissection performed). **Code these cases as 6.**
- Code 7 when SLNBx and regional lymph node dissection (code 3, 4, or 5) during a separate surgical procedure.
• Code 9 when:
  o Primary site is C420, C421, C423, C424, C589, C700-C709, C710-C729, C751-C753, C761-C768, C770-C779, or C809.
  o 00790 Lymphoma (Excluding CLL/SLL)
  o 00795 Lymphoma (CLL/SLL)
  o 00822 Plasma Cell Disorders (excluding 9734/3)

Note: Applies to All Sites

Use the operative report as the primary source document to determine whether the operative procedure was a sentinel lymph node biopsy (SLNBx), or a more extensive dissection of regional lymph nodes, or a combination of both SLNBx and regional lymph node dissection. The operative report will designate the surgeon’s planned procedure as well as a description of the procedure that was actually performed. The pathology report may be used to complement the information appearing in the operative report, but the operative report takes precedence when attempting to distinguish between SLNBx and regional lymph node dissection or a combination of these two procedures. Do not use the number of lymph nodes removed and pathologically examined as the sole means of distinguishing between a SLNBx and a regional lymph node dissection.

Codes (all sites excluding Breast):

For breast sites see, Codes (Breast Only)

<table>
<thead>
<tr>
<th>Code</th>
<th>Label</th>
<th>All Sites (except Breast, see table below)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No regional lymph node surgery</td>
<td>No regional lymph node surgery</td>
</tr>
<tr>
<td>1</td>
<td>Biopsy or aspiration of regional lymph node(s)</td>
<td>Review the operative report to confirm whether an excisional biopsy or aspiration of regional lymph nodes was actually performed. If additional procedures were performed on the lymph nodes, use the appropriate code 2-7</td>
</tr>
<tr>
<td>2</td>
<td>Sentinel Lymph Node Biopsy</td>
<td>The operative report states that a SLNBx was performed. Code 2 SLNBx when the operative report describes a procedure using injection of a dye, radio label, or combination to identify a lymph node (possibly more than one) for removal/examination. When a SLNBx is performed, additional non-sentinel nodes can be taken during the same operative procedure. These additional non-sentinel nodes may be discovered by the pathologist or selectively removed (or harvested) as part of the SLNBx procedure by the surgeon. Code this as a SLNBx (code 2). If review of the operative report confirms that a</td>
</tr>
<tr>
<td></td>
<td>Regional lymph node dissection followed the SLNBx, code these cases as 6</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>The operative report states that a regional lymph node dissection was performed (a SLNBx was not done during this procedure or in a prior procedure). Code 3 (Number of regional lymph nodes removed unknown, not stated; regional lymph nodes removed, NOS). Check the operative report to ensure this procedure is not a SLNBx only (code 2), or a SLNBx with a regional lymph node dissection (code 6 or 7). Code 4 (1-3 regional lymph nodes removed) should be used infrequently. Review the operative report to ensure the procedure was not a SLNBx only. Code 5 (4 or more regional lymph nodes removed). If a relatively small number of nodes were examined pathologically, review the operative report to confirm the procedure was not a SLNBx only (code 2). If a relatively large number of nodes were examined pathologically, review the operative report to confirm that there was not a SLNBx in addition to a more extensive regional lymph node dissection during the same, or separate, procedure (code 6 or 7). Infrequently, a SLNBx is attempted, and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection). When mapping fails, surgeons usually perform a more extensive dissection of regional lymph nodes. Code these cases as 2 if no further dissection of regional lymph nodes was undertaken, or 6 when regional lymph nodes were dissected during the same operative event.</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>The operative report states that a regional lymph node dissection was performed (a SLNBx was not done during this procedure or in a prior procedure). Code 3 (Number of regional lymph nodes removed unknown, not stated; regional lymph nodes removed, NOS). Check the operative report to ensure this procedure is not a SLNBx only (code 2), or a SLNBx with a regional lymph node dissection (code 6 or 7). Code 4 (1-3 regional lymph nodes removed) should be used infrequently. Review the operative report to ensure the procedure was not a SLNBx only. Code 5 (4 or more regional lymph nodes removed). If a relatively small number of nodes were examined pathologically, review the operative report to confirm the procedure was not a SLNBx only (code 2). If a relatively large number of nodes were examined pathologically, review the operative report to confirm that there was not a SLNBx in addition to a more extensive regional lymph node dissection during the same, or separate, procedure (code 6 or 7).</td>
<td></td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Details</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>2</td>
<td>No further dissection of regional lymph nodes was undertaken</td>
<td>Infrequently, a SLNBx is attempted, and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection). When mapping fails, surgeons usually perform a more extensive dissection of regional lymph nodes. Code these cases as 2 if no further dissection of regional lymph nodes was undertaken, or 6 when regional lymph nodes were dissected during the same operative event.</td>
</tr>
<tr>
<td>6</td>
<td>Regional lymph nodes were dissected during the same operative event</td>
<td>The operative report states that a regional lymph node dissection was performed (a SLNBx was not done during this procedure or in a prior procedure). Code 3 (Number of regional lymph nodes removed unknown, not stated; regional lymph nodes removed, NOS). Check the operative report to ensure this procedure is not a SLNBx only (code 2), or a SLNBx with a regional lymph node dissection (code 6 or 7). Code 4 (1-3 regional lymph nodes removed) should be used infrequently. Review the operative report to ensure the procedure was not a SLNBx only. Code 5 (4 or more regional lymph nodes removed). If a relatively small number of nodes were examined pathologically, review the operative report to confirm the procedure was not a SLNBx only. If a relatively large number of nodes were examined pathologically, review the operative report to confirm that there was not a SLNBx in addition to a more extensive regional lymph node dissection during the same, or separate, procedure (code 6 or 7). Infrequently, a SLNBx is attempted, and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection). When mapping fails, surgeons usually perform a more extensive dissection of regional lymph nodes. Code these cases as 2 if no further dissection of regional lymph nodes was undertaken, or 6 when regional lymph nodes were dissected during the same operative event.</td>
</tr>
<tr>
<td>4</td>
<td>1-3 regional lymph nodes removed</td>
<td>Code 3 (Number of regional lymph nodes removed unknown, not stated; regional lymph nodes removed, NOS). Check the operative report to ensure this procedure is not a SLNBx only (code 2), or a SLNBx with a regional lymph node dissection (code 6 or 7). Code 4 (1-3 regional lymph nodes removed) should be used infrequently. Review the operative report to ensure the procedure was not a SLNBx only. Code 5 (4 or more regional lymph nodes removed). If a relatively small number of nodes were examined pathologically, review the operative report to confirm the procedure was not a SLNBx only. If a relatively large number of nodes were examined pathologically, review the operative report to confirm that there was not a SLNBx in addition to a more extensive regional lymph node dissection during the same, or separate, procedure (code 6 or 7). Infrequently, a SLNBx is attempted, and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection). When mapping fails, surgeons usually perform a more extensive dissection of regional lymph nodes. Code these cases as 2 if no further dissection of regional lymph nodes was undertaken, or 6 when regional lymph nodes were dissected during the same operative event.</td>
</tr>
<tr>
<td>5</td>
<td>4 or more regional lymph nodes removed</td>
<td>Code 3 (Number of regional lymph nodes removed unknown, not stated; regional lymph nodes removed, NOS). Check the operative report to ensure this procedure is not a SLNBx only (code 2), or a SLNBx with a regional lymph node dissection (code 6 or 7). Code 4 (1-3 regional lymph nodes removed) should be used infrequently. Review the operative report to ensure the procedure was not a SLNBx only. Code 5 (4 or more regional lymph nodes removed). If a relatively small number of nodes were examined pathologically, review the operative report to confirm the procedure was not a SLNBx only. If a relatively large number of nodes were examined pathologically, review the operative report to confirm that there was not a SLNBx in addition to a more extensive regional lymph node dissection during the same, or separate, procedure (code 6 or 7). Infrequently, a SLNBx is attempted, and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection). When mapping fails, surgeons usually perform a more extensive dissection of regional lymph nodes. Code these cases as 2 if no further dissection of regional lymph nodes was undertaken, or 6 when regional lymph nodes were dissected during the same operative event.</td>
</tr>
<tr>
<td>6</td>
<td>Sentinel node biopsy and code 3, 4, or 5 at same time, or timing not stated</td>
<td>SLNBx and regional lymph node dissection (code 3, 4, or 5) during the same surgical event, or timing not known. Generally, SLNBx followed by a regional lymph node completion will yield a relatively large number of nodes. However, it is possible for these procedures to harvest only a few nodes. If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx only. Infrequently, a SLNBx is attempted, and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection.) When mapping fails, the surgeon usually performs a more extensive dissection of regional lymph nodes. Code these cases as 6.</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>Sentinel node biopsy and code 3, 4, or 5 at different times</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>--------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SLNBx and regional lymph node dissection (code 3, 4, or 5) in separate surgical events. Generally, SLNBx followed by regional lymph node completion will yield a relatively large number of nodes. However, it is possible for these procedures to harvest only a few nodes. If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx only.</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>Unknown or not applicable</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The status of regional lymph node evaluation should be known for surgically treated cases (i.e., cases coded A190-A900 or B190-B900 in the data item Surgery of Primary Site 2023. Review surgically treated cases coded 9 in Scope of Regional Lymph Node Surgery to confirm the code</td>
</tr>
</tbody>
</table>

**Coding Instructions for (SLNBx) Breast (C500-C509):**

- See [Coding Instructions All Sites (excluding Breast)](above), for coding instructions on all non-breast sites.

Effective January 1, 2012 and forward the following instructions apply:

- **Operative report takes precedence.** Use the entire operative report as the primary coding source to determine if a sentinel lymph node biopsy (SLNBx), an axillary node dissection (ALND), or a combination of both (SLNBx or ALND) was performed.
  - The body of the operative report will designate the surgeon’s planned procedure as well as a description of the procedure that was actually performed.
  - The pathology report may complement the information documented in the operative report, but the operative report takes precedence.

  **Note:** Do not use the number of lymph nodes removed and pathologically examined as the sole means of distinguishing between a SLNBx and an ALND.

- For code 1, an excisional biopsy or aspiration of regional lymph nodes for breast cancer is uncommon. Confirm this is not the more common, code 2.

- Code 2 if:
  - There are greater than 5 lymph nodes examined, must review operative report to confirm SLNBx only vs. additional ALND:
    - Assign code 2 when:
      - Only SLNBx performed.
- SLNBx attempted but “failed to map” and NO lymph removed.
- Assign code 6 when SLNBx and ALND performed during the same surgical procedure.
- Typically, ALND removes at least 7-9 lymph nodes but, can remove fewer. Check operative report to confirm ALND only vs additional SLNBx. Assign codes 3, 4, or 5 when only ALND is performed.
  - Code 6 if:
    - SLNBx and ALND performed during the same surgical event.
    - SLNBx attempted but “failed to map” and ALND performed during the same surgical event.
  - Code 7 if SLNBx and ALND performed during a separate surgical event.

Note: Applies to Breast (C50_) Only

Use the operative report as the primary source document to determine whether the operative procedure was a sentinel lymph node biopsy (SLNBx), an axillary node dissection (ALND), or a combination of both SLNBx and ALND. The operative report will designate the surgeon’s planned procedure as well as a description of the procedure that was actually performed. The pathology report may be used to complement the information appearing in the operative report, but the operative report takes precedence when attempting to distinguish between SLNBx and ALND, or a combination of these two procedures. Do not use the number of lymph nodes removed and pathologically examined as the sole means of distinguishing between a SLNBx and a ALND.

Codes (Breast Only):

For all other sites see, Codes (all sites excluding Breast)

<table>
<thead>
<tr>
<th>Code</th>
<th>Label</th>
<th>Breast (C50_)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No regional lymph node surgery</td>
<td>No regional lymph node surgery</td>
</tr>
<tr>
<td>1</td>
<td>Biopsy or aspiration of regional lymph node(s)</td>
<td>Excisional biopsy or aspiration of regional lymph nodes for breast cancer is uncommon. Review the operative report to confirm whether an excisional biopsy or aspiration of regional lymph nodes was actually performed; it is highly possible that the procedure is a SLNBx (code 2) instead. If additional procedures were performed on the lymph nodes, such as axillary lymph node dissection, use the appropriate code 2-7</td>
</tr>
<tr>
<td></td>
<td>Sentinel Lymph Node Biopsy</td>
<td>If a relatively large number of lymph nodes, more than 5, are pathologically examined, review the operative report to confirm the procedure was limited to a SLNBx and did not include an axillary lymph node dissection (ALND). Infrequently, a SLNBx is attempted, and the patient fails to map (i.e. no sentinel lymph nodes are identified by the dye and/or radio label injection) and no sentinel nodes are removed. Review the operative report to confirm that an axillary incision was made, and a node exploration was conducted. Patients undergoing SLNBx who fail to map will often undergo ALND. Code these cases as 2 if no ALND was performed, or 6 when ALND was performed during the same operative event. Enter the appropriate number of nodes examined and positive in the data items Regional Lymph Nodes Examined and Regional Lymph Nodes Positive.</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>2</td>
<td>Number of regional lymph nodes removed unknown or not stated; regional lymph nodes removed, NOS</td>
<td>Generally, ALND removes at least 7-9 nodes. However, it is possible for these procedures to remove or harvest fewer nodes. Review the operative report to confirm that there was not a SLNBx in addition to a more extensive regional lymph node dissection during the same procedure (code 6 or 7).</td>
</tr>
<tr>
<td>3</td>
<td>1-3 regional lymph nodes removed</td>
<td>Generally, ALND removes at least 7-9 nodes. However, it is possible for these procedures to remove or harvest fewer nodes. Review the operative report to confirm that there was not a SLNBx in addition to a more extensive regional lymph node dissection during the same procedure (code 6 or 7).</td>
</tr>
<tr>
<td>4</td>
<td>4 or more regional lymph nodes removed</td>
<td>Generally, ALND removes at least 7-9 nodes. However, it is possible for these procedures to remove or harvest fewer nodes. Review the operative report to confirm that there was not a SLNBx in addition to a more extensive regional lymph node dissection during the same procedure (code 6 or 7).</td>
</tr>
<tr>
<td>5</td>
<td>Sentinel node biopsy and code 3, 4, or 5 at different times</td>
<td>Generally, SLNBx followed by ALND will yield a minimum of 7-9 nodes. However, it is possible for these procedures to harvest fewer (or more) nodes if relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx, or whether a SLNBx plus an ALND was performed.</td>
</tr>
<tr>
<td>6</td>
<td>Sentinel node biopsy and code 3, 4, or 5 at same time, or timing not stated</td>
<td>Generally, SLNBx followed by ALND will yield a minimum of 7-9 nodes. However, it is possible for these procedures to harvest fewer (or more) nodes.</td>
</tr>
</tbody>
</table>
If relatively few nodes are pathologically examined, review the operative report to confirm whether the procedure was limited to a SLNBx only, or whether a SLNBx plus an ALND.

The status of regional lymph node evaluation should be known for surgically treated cases (i.e., cases coded 19-90 in the data item Surgery of Primary Site 2023 Review surgically treated cases coded 9 in Scope of Regional Lymph Node Surgery to confirm the code.

- Starting with cases diagnosed January 1, 2003 forward, RX Summ, Scope of Reg LN Surg is not to be coded according to site. It is coded using a single scheme for all sites. The three procedure data items must continue to be coded for 2003 forward cases.

### The codes for Scope of Regional LN's are as follows:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>NONE</td>
</tr>
<tr>
<td></td>
<td>No regional lymph node surgery; No lymph nodes found in the pathologic specimen</td>
</tr>
<tr>
<td>1</td>
<td>BIOPSY OR ASPIRATION OF REGIONAL LYMPH NODE, NOS</td>
</tr>
<tr>
<td></td>
<td>Biopsy or aspiration of regional lymph node(s) regardless of the extent of involvement of disease</td>
</tr>
<tr>
<td>2</td>
<td>SENTINEL LYMPH NODE BIOPSY</td>
</tr>
<tr>
<td></td>
<td>Biopsy of the first lymph node or nodes that drain a defined area of tissue within the body; Sentinel node(s) are identified by the injection of a dye or radio label at the site of the primary tumor</td>
</tr>
<tr>
<td>3</td>
<td>NUMBER OF REGIONAL NODES REMOVED UNKNOWN OR NOT STATED; REGIONAL LYMPH NODE REMOVED, NOS</td>
</tr>
<tr>
<td></td>
<td>Sampling or dissection of regional lymph node(s) and the number of nodes is unknown or not stated. The procedure is not specified as sentinel node biopsy</td>
</tr>
<tr>
<td>4</td>
<td>1-3 REGIONAL LYMPH NODES REMOVED</td>
</tr>
<tr>
<td></td>
<td>Sampling or dissection of regional lymph node(s) with fewer than four lymph nodes found in the specimen. The procedure is not specified as sentinel node biopsy</td>
</tr>
<tr>
<td>5</td>
<td>4 OR MORE REGIONAL LYMPH NODES REMOVED</td>
</tr>
<tr>
<td></td>
<td>Sampling or dissection of regional lymph nodes with at least four lymph nodes found in the specimen. The procedure is not specified as sentinel node biopsy</td>
</tr>
<tr>
<td>6</td>
<td>SENTINEL NODE BIOPSY AND CODE 3, 4, OR 5 AT SAME TIME, OR TIMING OUT NOT STATED</td>
</tr>
<tr>
<td></td>
<td>Code 2 was performed in a single surgical event with code 3, 4, or 5. Or, code 2 and 3, 4, or 5 was performed, but timing was not stated in patient record</td>
</tr>
</tbody>
</table>
| 7 | SENTINEL NODE BIOPSY AND CODE 3, 4, OR 5 AT DIFFERENT TIMES  
Code 2 was followed in a subsequent surgical event by procedures coded as 3, 4, or 5 |
| 9 | UNKNOWN OR NOT APPLICABLE  
It is unknown whether regional lymph node surgery was performed; death certificate-only; for lymphomas with a lymph node primary site; an unknown or ill-defined primary; primaries of the brain, meninges, spinal cord, cranial nerves and other part of the CNS (including the pituitary gland, craniopharyngeal duct, and pineal gland), or for leukemia/lymphoma histologies, hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease |
**VI.2.6.1 Date of Regional Lymph Node Dissection**

Records the date non-sentinel regional lymph node dissection (RLND) was performed. This data item can be used to more accurately assess the date of regional node dissection separate from the date of sentinel lymph node biopsy if performed. This data item is required by CoC-accredited facilities for all cases diagnosed January 1, 2018 and forward.

**Coding Instructions:**

- Enter the date of the non-sentinel, regional lymph node dissection performed, and documented in the *Regional Lymph Nodes Examined* data item.

- For Breast and Cutaneous Melanoma cases:
  - If both a sentinel lymph node biopsy (SLNBx) was done and then a subsequent, separate RLND, record the RLND in this data item, and record the date of the SLNBx procedure in the *Date of Sentinel Lymph Node Biopsy* data item.
    - If a SLNBx and a RLND are performed on the same date, the dates should be equal/the same.
    - If the RLND is done subsequently (on a later date), than the SLNBx, then dates for each procedure will differ.
  - For all other cases, record the date of the regional lymph node dissection in this data item.

- Record the date, procedure, and results in the associated text data item(s).

- Leave *Date Regional Lymph Node Dissection* blank when only a sentinel lymph node biopsy is performed.

See [Entering Dates](#) and [Date Format](#) for additional information regarding entering dates.
VI.2.6.2 Regional Lymph Nodes Positive
This data item records the exact number of regional lymph nodes examined by the pathologist and found to contain metastases.

Note: Effective with cases diagnosed January 1, 2016 and forward, the AJCC definition takes precedence if the definition of regional nodes differs between the current AJCC Cancer Staging Manual and the SEER Program Coding and Staging Manual.

Coding Instructions:

- **This data item is based on pathologic information only.**
- Record information **only** about regional lymph nodes in this data item.
  - Include lymph nodes that are regional in the current AJCC Staging or EOD 2018 Manuals.
- This data item is to be recorded regardless of whether the patient received preoperative treatment.
- This data item collects the **cumulative** count of lymph nodes found to be positive by pathologic examination.
  - From all procedures that remove lymph nodes through the completion of surgeries in the first course of treatment.
  - Record lymph nodes removed and found to be positive during an autopsy for autopsy-only cases.
- Tumors which are truly in-situ cannot have positive lymph nodes, so the only allowable codes are 00 (negative) or 98 (not examined). Codes 01-97 and 99 are not allowed.
- Do not count a positive aspiration or core biopsy of a lymph node in the same lymph node chain removed at surgery as an additional node in regional nodes positive when there are positive nodes in the resection.
- If the positive aspiration or core biopsy is from a regional node in a different node region then the regional lymph node chain surgically removed, include the node in the count of regional nodes positive.
- If the location of the lymph node that is core-biopsied or aspirated is not known, assume it is part of the lymph node chain surgically removed, and do not include it in the count of regional nodes positive.
- If there is a discrepancy regarding the number of positive lymph nodes, **use information in the following priority**:
  - final diagnosis
- synoptic report (also known as CAP protocol or pathology report checklist; the consolidated findings on the CAP protocol)
  - microscopic
  - gross
- If there are multiple primary cancers with different histologic types in the same organ, and the pathology report just states the number of nodes positive:
  - First, try to determine the histology of the metastases in the nodes and code the nodes as positive for the primary with that histology.
- If no further information is available, code the nodes as positive for all primaries.
- When Isolated Tumor Cells (ITCs) for all primary sites except cutaneous melanoma and Merkel cell carcinoma of skin are identified, count only lymph nodes that contain micrometastases or larger (metastases greater than 0.2 millimeters in size).
  - Do not include in the count of lymph nodes positive any nodes that are identified as containing isolated tumor cells (ITCs).
  - If the path report indicates that nodes are positive, but the size of metastasis is not stated, assume the metastases are larger than 0.2mm and count the lymph node(s) as positive.
  - For cutaneous melanoma and Merkel cell carcinoma of skin, count nodes with ITCs as positive lymph nodes.
- Code 95 when:
  - The only procedure for regional lymph nodes is a needle aspiration (cytology) or core biopsy (tissue).
  - A positive lymph node is aspirated and there are no surgically resected lymph nodes.
  - A positive lymph node is aspirated, and surgically resected lymph nodes are negative.
- Code 97 for:
  - Any combination of positive aspirated, biopsied, sampled or dissected lymph nodes if the number of involved nodes cannot be determined on the basis of cytology or histology.
  - Code 97 includes positive lymph nodes diagnosed by either cytology or histology.
  - Avoid using Regional Nodes Positive code 97 if possible, even if this means slightly undercounting the number of nodes positive.
• Code 98 may be used in several situations:
  o When the assessment of lymph nodes is clinical only.
  o When no lymph nodes are removed and examined.
  o When a “dissection” of a lymph node drainage area is found to contain no lymph nodes at the time of pathologic examination.
  o If Regional Nodes Positive is coded as 98, Regional Nodes Examined is usually coded 00.

• Code 99 when:
  o Primary site is C420, C421, C423, C424, C589, C700-C709, C710-C729, C751-C753, C761-C768, C770-C779, or C809.
  o 00790 Lymphoma (Excluding CLL/SLL)
  o 00795 Lymphoma (CLL/SLL)
  o 00822 Plasma Cell Disorders (excluding 9734/3)
  o Cases with no information about positive regional lymph nodes.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>All nodes examined negative</td>
</tr>
<tr>
<td>01-89</td>
<td>1 to 89 nodes positive (code exact number of nodes positive)</td>
</tr>
<tr>
<td>90</td>
<td>90 or more nodes positive</td>
</tr>
<tr>
<td>95</td>
<td>Positive aspiration or core biopsy of lymph node(s)</td>
</tr>
<tr>
<td>97</td>
<td>Positive nodes - number unspecified</td>
</tr>
<tr>
<td>98</td>
<td>No nodes examined</td>
</tr>
<tr>
<td>99</td>
<td>Unknown whether nodes are positive; not applicable; not documented in patient record</td>
</tr>
</tbody>
</table>
VI.2.6.3 Regional Lymph Nodes Examined

This data item records the total number of regional lymph nodes that were removed and examined by the pathologist.

**Note:** Effective with cases diagnosed January 1, 2016 and forward, the AJCC definition takes precedence if the definition of regional nodes differs between the AJCC Cancer Staging Manual and the SEER Program Coding and Staging Manual.

**Coding Instructions:**

- Record information **only** about regional lymph nodes in this data item.
  - Include lymph nodes that are regional in the current AJCC Staging or EOD 2018 Manuals.

- **This data item is based on pathologic information only.**

- This data item is to be recorded regardless of whether the patient received preoperative treatment.

- Record the total number of regional lymph nodes removed and examined by the pathologist.
  - The number of regional lymph nodes examined is cumulative from all procedures that removed lymph nodes through the completion of surgeries in the first course of treatment.
    - Record lymph nodes removed during an autopsy for autopsy-only cases.
  - Do not count a positive aspiration or core biopsy of a lymph node in the same lymph node chain removed at surgery as an additional node in Regional Nodes Examined data item.
  - If the positive aspiration or core biopsy is from a node in a different node region, include the node in the count of Regional Nodes Examined data item.
  - If the location of the lymph node that is aspirated or core-biopsied is not known, assume it is part of the lymph node chain surgically removed, and do not include it in the count of Regional Nodes Examined.
  - When neither the type of lymph node removal procedure nor the number of lymph nodes examined is known, use code 98.

- If there is a discrepancy regarding the number of lymph nodes examined, use information in the following priority:
  - final diagnosis
• Code 00 may be used in several situations:
  o The assessment of lymph nodes is clinical.
  o No lymph nodes are removed and examined.
  o A “dissection” of a lymph node drainage area is found to contain no lymph nodes at the time of pathologic examination.
  o **If Regional Nodes Examined is coded 00, Regional Nodes Positive is coded as 98.**

• Code 95 is used when the only procedure for regional lymph nodes is a needle aspiration (cytology) or core biopsy (tissue).

• Code 96 is used when:
  o The number of nodes removed by biopsy is not known.
  o A limited number of nodes are removed but the number is unknown. A lymph node “sampling” is removal of a limited number of lymph nodes. Other terms for removal of a limited number of nodes include lymph node biopsy, berry picking, sentinel lymph node procedure, sentinel node biopsy, selective dissection.

• Code 97 is used when:
  o More than a limited number of lymph nodes are removed, and the number is unknown. A lymph node “dissection” is the removal of most or all of the nodes in the lymph node chain(s) that drain the area around the primary tumor. Other terms include lymphadenectomy, radical node dissection, or lymph node stripping.
  o Both a lymph node sampling and a lymph node dissection are performed, and the total number of lymph nodes examined is unknown. The removal of lymph nodes during autopsy is a dissection.

• Code 98 when neither the type of lymph node removal procedure nor the number of lymph nodes examined is known.

• Code 99 when:
  o Primary site is C420, C421, C423, C424, C589, C700-C709, C710-C729, C751-C753, C761-C768, C770-C779, or C809.
  o 00790 Lymphoma (Excluding CLL/SLL)
  o 00795 Lymphoma (CLL/SLL)
- 00822 Plasma Cell Disorders (excluding 9734/3)
- Cases with no information about positive regional lymph nodes.

**Note:** Effective with cases diagnosed on or after January 1, 2003, the data items for *Rx Summ-Reg LN Examined* and *Rx Hosp-Reg LN Examined* are no longer required by the CCR and the CoC. Information regarding the number of lymph nodes has been incorporated into the scope data items.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>No nodes examined</td>
</tr>
<tr>
<td>01-89</td>
<td>1 to 89 nodes examined (code the exact number of regional nodes examined)</td>
</tr>
<tr>
<td>90</td>
<td>90 or more nodes examined</td>
</tr>
<tr>
<td>95</td>
<td>No regional nodes removed, but aspiration or core biopsy of regional nodes performed</td>
</tr>
<tr>
<td>96</td>
<td>Regional lymph node removal documented as a sampling, and the number of nodes unknown/not stated</td>
</tr>
<tr>
<td>97</td>
<td>Regional lymph node removal documented as dissection, and the number of nodes unknown/not stated</td>
</tr>
<tr>
<td>98</td>
<td>Regional lymph nodes surgically removed, but number of lymph nodes unknown/not stated and not documented as sampling or dissection; nodes examined, but the number unknown</td>
</tr>
<tr>
<td>99</td>
<td>Unknown whether nodes were examined; not applicable or negative; not documented in patient record</td>
</tr>
</tbody>
</table>
VI.2.7 Special Rules for Counting Lymph Nodes

Special rules for counting regional lymph nodes, gives guidance as to what to do when a core needle biopsy or aspiration is followed by a dissection.

Coding Instructions:

- Add 1 to the number of regional lymph nodes positive and examined when the core biopsy or aspiration is positive for metastases, and the lymph node dissection does not include the area where the core biopsy or aspiration was done, and that lymph node was a regional lymph node for the primary site.

  **Example:** Patient with breast cancer has a positive core biopsy of a supraclavicular node and an axillary dissection showing 3 of 8 nodes positive. **Code Regional Nodes Positive as 04 and Regional Nodes Examined as 09** because the supraclavicular lymph node is a regional lymph node for breast, but in a different lymph node chain.

Notes:

1. Do not add 1 to regional lymph nodes positive if the biopsy or aspiration was negative for metastases.
2. Do not add to the count of regional lymph nodes examined or positive when the area biopsied or aspirated is included in the dissection.

- If the location of the lymph node that is aspirated or biopsied is unknown, assume it was part of the lymph node chain surgically removed, and do not add it to the count of Regional Nodes Examined.

  **Example:** Records indicate a lymph node core biopsy was performed at another facility and 7 of 14 regional lymph nodes were positive at the time of resection. **Code Regional Nodes positive as 07 and Regional Nodes Examined as 14.**
VI.2.8 Surgery of Other Regional Sites, Distant Sites, or Distant Lymph Nodes

This data item refers to the surgical removal of sites other than the primary site. There are three one-character data items that capture the removal of tissue other than the primary tumor or organ of origin. This would not include an en bloc resection.

Coding Instructions:

- **RX Summ - Surg Oth Reg/Dis** and its corresponding procedure data items are not coded according to primary site. Rather, they are coded using a single scheme for all sites. This applies to cases diagnosed January 1, 2003 and forward.

- Code the removal of non-primary site tissue, which the surgeon may have suspected to be involved with malignancy even if the pathology was negative.

  **Example:** The patient has an excisional biopsy of a hard palate lesion removed from the roof of the mouth and a resection of a metastatic lung nodule during the same procedure. Code the resection of the lung nodule as 4 (distant site).

- Do not code the incidental removal of tissue for reasons other than malignancy.

  **Example:** During a colon resection, the surgeon noted that the patient had cholelithiasis and removed the gallbladder. Do not code removal of the gallbladder.

- Do not code tissue or organs such as appendix that were removed incidentally, and the organ was not involved with cancer.

  **Note:** Incidental removal of organs means that tissue was removed for reasons other than removing cancer or preventing the spread of cancer. The incidental removal of the appendix, gallbladder etc., during abdominal surgery, for example.

- Do not code removal of uninvolved contralateral breast in this data item. See Breast Surgery Codes in **Appendix K.2** - STORE Surgery Codes for Site-Specific Surgery Codes.

- Procedures are to be entered in chronological order.

- Leave this data item blank if no surgery was performed of other regional or distant sites or distant lymph nodes.

- Code 0 when:
Surgical procedures were performed that removed distant lymph nodes(s) or other tissue(s) or organ(s) beyond the primary site, or

First Course treatment was active surveillance/watchful waiting.

- **Codes are hierarchical, 1-5 have priority over codes 0 and 9.**
- **Code 1 when:**
  - The involved contralateral breast is removed for a single breast cancer.
  - Any surgery is performed to treat tumors for any case coded to primary site is C420, C421, C423, C424, C760-C768, C770-C779, or C809.

  **Exclusion:** Cases coded to Schema 00060 Cervical Lymph Nodes and Unknown Primary.

- **Code 2 for sites that are regional.** Include sites that are **regional** in the current AJCC Staging Manual or EOD 2018.
- **Code 4 for sites that are distant.** Include sites that are **distant** in the current AJCC Staging Manual or EOD 2018.
- **Code 9 for Death Certificate Only (DCO) cases.**
- **Record the date, surgical procedure, and results in the associated text data item.**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>NONE</td>
</tr>
<tr>
<td></td>
<td>No surgical procedure of nonprimary site</td>
</tr>
<tr>
<td>1</td>
<td>NONPRIMARY SURGICAL PROCEDURE PERFORMED</td>
</tr>
<tr>
<td></td>
<td>Nonprimary surgical resection to other site(s), unknown if whether the site(s) is regional or distant</td>
</tr>
<tr>
<td>2</td>
<td>NONPRIMARY SURGICAL PROCEDURE TO OTHER REGIONAL SITES</td>
</tr>
<tr>
<td></td>
<td>Resection of regional site</td>
</tr>
<tr>
<td>3</td>
<td>NONPRIMARY SURGICAL PROCEDURE TO DISTANT LYMPH NODE(S)</td>
</tr>
<tr>
<td></td>
<td>Resection of distant lymph node(s)</td>
</tr>
<tr>
<td>4</td>
<td>NONPRIMARY SURGICAL PROCEDURE TO DISTANT SITE</td>
</tr>
<tr>
<td></td>
<td>Resection of distant site</td>
</tr>
<tr>
<td>5</td>
<td>COMBINATION OF CODES</td>
</tr>
<tr>
<td></td>
<td>Any combination of surgical procedures 2, 3, or 4</td>
</tr>
<tr>
<td>9</td>
<td>UNKNOWN</td>
</tr>
<tr>
<td></td>
<td>It is unknown whether any surgical procedure of a nonprimary site was performed Death Certificate Only (DCO)</td>
</tr>
</tbody>
</table>
VI.2.9 Surgery of Synchronous Primaries

Synchronous Primaries are multiple histologically distinct tumors diagnosed simultaneously. Outlined below are surgical coding instructions for synchronous primaries.

Coding Instruction:

- If multiple primaries are excised at the same time, enter the appropriate code for each site.

Examples:

1. A total abdominal hysterectomy was performed for a patient with two primaries, one of the cervix and one of the endometrium. Code each site as having had a total abdominal hysterectomy.

2. A total colectomy was performed on a patient with multiple primaries in several segments of the colon. Code total colectomy for each of the primary segments.
VI.2.10 Systemic Therapy with Surgery Sequence

This data item documents the sequence in which systemic therapy and surgical procedures were performed as part of the first course of treatment.

**Note:** For the purpose of coding the data item Systemic Sequence with Surgery, “Surgery” is defined as a Surgical Procedure of Primary Site (codes 10-90) or Scope of Regional Lymph Node Surgery (codes 2-7) or Surgical Procedure of Other Site (codes 1-5).

**Coding Instructions:**

- This data item is required by the CCR to be coded for all primary sites. This applies to cases diagnosed January 1, 2006 and forward.
- Codes 2-9 for systemic therapy sequence with surgery if the first course of treatment includes codes for any of the following:
  - Surgery of the Primary Site
  - Scope of Regional Lymph Node Surgery
    - Do not count Scope of Regional Lymph Node Surgery code 1 as surgery for the purpose of coding this data item.
  - Surgery of other regional(s), distant site(s), or distant lymph node(s)
  - Systemic therapy
- Code 0 for all other cases.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No systemic therapy and/or surgical procedures; unknown if surgery and/or systemic therapy given</td>
</tr>
<tr>
<td>2</td>
<td>Systemic therapy before surgery</td>
</tr>
<tr>
<td>3</td>
<td>Systemic therapy after surgery</td>
</tr>
</tbody>
</table>
| 4    | Systemic therapy both before and after surgery  
**Note:** At least two courses of systemic therapy must be given to assign code 4 |
| 5    | Intraoperative systemic therapy |
| 6    | Intraoperative systemic therapy with other therapy administered before and/or after surgery |
| 7    | Surgery both before and after systemic therapy |
| 9    | Sequence unknown |
VI.2.11 Reason for No Surgery of the Primary Site

Record the reason the patient did not have surgery to the primary site. Reason for No Surgery only applies to the Surgery of the Primary Site 2023 data item, **not** Scope of Regional Lymph Node Surgery or Surgery Other Regional/Distant Sites.

**Coding Instructions:**

- Patient’s decision not to pursue surgery is not a refusal of surgery when:
  - The patient has discussed surgery with their physician, and then decides to pursue no treatment.
    - **Note:** Discussion does not equal a recommendation. However, when they are referred to a surgeon, it is considered a recommendation.
  - Code 0 to indicate Surgery of Primary Site 2023 was performed (coded 01-90).
- **Codes 1-8** when Surgery of Primary Site 2023 is coded A000.
- Code 1 when for the following scenarios:
  - Surgery of the Primary Site 2023 is coded A980 (not applicable).
  - Primary site is C420, C421, C423, C424, C760-C768, or C809
    - **Note:** Surgery is not standard treatment for these sites.
  - If the option of “no treatment” was accepted by the patient.
  - Surgery was one of multiple options and the patient chose the other option.
  - Surgery was part of the first course of treatment but was cancelled due to complete response to radiation and/or systemic therapy.
- Code 6 when all of the following are documented:
  - It is **known** that surgery was recommended, and
  - It is known that surgery was **not** performed, and
  - There is no documentation explaining why it was not done.
- Code 7 for either of the following scenarios:
  - The patient refuses recommended surgery.
  - The patient makes a blanket statement refusing all treatment when surgery is a customary option according to the NCCN guidelines and/or NCI PDQ for the primary site.
    - **Note:** Code 1 (above) when surgery is not normally performed for this site/histology.
- Code 8 when surgery is recommended, but unknown if actually done.
- Code 9 when:
  - There is no documentation that surgery was recommended or performed.
  - Death Certificate Only (DCO)
  - Autopsy Only cases

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Surgery of the primary site performed</td>
</tr>
<tr>
<td>1</td>
<td>Surgery of the primary site not performed because it was not part of the planned first course treatment</td>
</tr>
<tr>
<td>2</td>
<td>Surgery of the primary site not performed because of contraindications due to patient risk factors (comorbid conditions, advanced age, etc.)</td>
</tr>
<tr>
<td>5</td>
<td>Surgery of the primary site was not performed because the patient died prior to planned or recommended surgery (code added in 2003)</td>
</tr>
<tr>
<td>6</td>
<td>Surgery of the primary site was recommended but not performed. No reason was noted in the patient's record</td>
</tr>
<tr>
<td>7</td>
<td>Surgery of the primary site was recommended but refused by the patient, family member or guardian. The refusal is noted in the patient's record</td>
</tr>
<tr>
<td>8</td>
<td>Surgery of the primary site was recommended but unknown if performed. Further follow-up is recommended</td>
</tr>
<tr>
<td>9</td>
<td>Not known if surgery of the primary site was recommended or performed; Death Certificate Only; diagnosed at autopsy</td>
</tr>
</tbody>
</table>
VI.3 Radiation Therapy - First Course of Treatment

The new “phase” terminology replaces the traditional terms of “regional” and “boost.” The initial phase (Phase I) is frequently referred to as the initial plan and a subsequent (Phase II) may be referred to as the boost or cone down. A new phase begins when there is a change in the target volume of a body site, treatment fraction size, modality, or treatment technique. To accommodate this, three phases of radiation can now be documented.

Coding Instructions:

- Document the date, name or chemical symbol, as well as method of administration of any radiation therapy that is directed to tumor tissue in the appropriate text data item, even if given prophylactically.
  - This includes the administration of any radioactive material given orally, intracavitary, or by intravenous injection.

  Exceptions:
  1. Radiation for hormonal effect, such as irradiation of non-cancerous endocrine glands is not coded.
  2. Irradiation of the male breast to prevent gynecomastia is not coded.

- **Location of Radiation Treatment** is required by the CCR. It identifies the location of the facility in which radiation treatment was administered during first course of treatment. This applies to cases diagnosed 1/1/2008 forward.

- For additional information on coding radiation therapy, please see the CoC’s: [CTR Guide to Coding Radiation Therapy Treatment in the STORE](#).

- In the appropriate text field, enter the following information:
  - Record information for all radiation therapy phases in the first Text – Radiation Therapy field.
  - For each radiation phase, record in chronological order, the following information from the treatment summary:
    - Treatment start date
    - If therapy is neoadjuvant per the treatment plan.
    - If treatment is started, but not completed, as prescribed.
    - Primary Target Site/Treatment Volume, including radiation to draining lymph nodes.
      - E.g. RUL Lung
- Treatment modality
  - E.g. Ext Beam 6MV Photons or Intracavitary Brachytherapy, HDR
- External Beam Planning Technique
  - E.g. IMRT, Stereotactic radiotherapy
- Dose per fraction
  - E.g. 266 cGy
- Number of Fractions
  - E.g. 16fx

For additional information regarding recording text, please see Appendix T - Text Documentation Guidelines.
VI.3.1 Types of Radiation

The principal types of radiation therapy are the external administration of radioactive beams, implantation of radioactive material, and the internal administration of radioisotopes by other than implantation.

Radioactive materials include the following:

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Au$^{198}$</td>
<td>Gold</td>
</tr>
<tr>
<td>Co$^{60}$</td>
<td>Cobalt</td>
</tr>
<tr>
<td>Cr$^{32}$PO$_4$</td>
<td>Phosphocol</td>
</tr>
<tr>
<td>CrPO$_4$</td>
<td>Chromic phosphate</td>
</tr>
<tr>
<td>Cs</td>
<td>Cesium</td>
</tr>
<tr>
<td>I$^{125}$</td>
<td>Iodine</td>
</tr>
<tr>
<td>I$^{131}$</td>
<td>Iodine</td>
</tr>
<tr>
<td>Ir$^{192}$</td>
<td>Iridium</td>
</tr>
<tr>
<td>P$^{32}$</td>
<td>Phosphorus</td>
</tr>
<tr>
<td>Pb$^{210}$</td>
<td>Lead</td>
</tr>
<tr>
<td>Ra$^{226}$</td>
<td>Radium</td>
</tr>
<tr>
<td>Rn$^{222}$</td>
<td>Radon</td>
</tr>
<tr>
<td>Ru$^{106}$</td>
<td>Ruthenium</td>
</tr>
<tr>
<td>Sr$^{90}$</td>
<td>Strontium</td>
</tr>
<tr>
<td>Y$^{90}$</td>
<td>Yttrium</td>
</tr>
</tbody>
</table>
VI.3.1.1 External Beam Radiation
Radiation is classified as beam when the source of radioactivity is outside the patient, as in a cobalt machine or linear accelerator.

Examples of beam radiation are:

- Betatron
- Brachytron
- Cobalt
- Cyclotron
- Grenz ray
- Helium ion or other heavy particle beam
- Linear accelerator (LINAC)
- MeV
- Neutron beam
- Photon beam
- Proton beam
- Spray radiation
- Stereotactic radiosurgery, such as gamma knife and proton beam
- X-ray
VI.3.1.2 Radioactive Implants
Record the name or chemical symbol and method of administration of any radioactive material administered by implants, molds, seeds, needles, or intracavity applicators.

Coding Instructions:
- The following items are types of radioactive implants and should be coded in the Radiation Treatment Modality - Phases I-III data items:
  - Heyman capsules, Fletcher suit, and Fletcher after loader are methods of isotope application.
  - Record High Dose Rate (HDR) and Low Dose Rate (LDR).
  - I-125 treatment for prostate cancer to brachytherapy.
    - Treatment modality to low dose radiotherapy (LDR).
  - Tumor embolization using a radioactive agent or radioactive seeds.
VI.3.2 Date of Radiation Therapy
Enter the date in which radiation therapy for this diagnosis began at any facility as part of the first course treatment.

Coding Instructions:

- Enter the earliest/first date in which radiation was administered.
  - Include date and treatment performed in the corresponding text data item.
- Record only first course of treatment dates in this data item.
- Date radiation started will typically be found in the radiation oncologist’s summary letter for the first course of treatment.
  - Determination of the date radiation started may require assistance from the radiation oncologist.

See Entering Dates and Date Format for additional information regarding entering dates. Consult with your software vendor for specific data entry instructions.
VI.3.3 Radiation Phases I-III General Information

Radiation is commonly delivered in more than one phase. Typically, initial treatment is delivered to the primary tumor, draining lymph nodes or tumor bed in Phase I. The subsequent boost(s) may occur to tumor bed, lymph nodes, etc., with same or alternate radiation modalities. These are considered Phase II and Phase III.

For additional information on coding radiation therapy, please see the Commission on Cancer’s: CTR Guide to Coding Radiation Therapy Treatment in the STORE.
VI.3.3.1 Radiation Primary Treatment Volume - Phases I-III

These items identify the primary treatment volume or primary anatomic target delivered to the patient during each phase of radiation during the first course of therapy. This data item should be used to indicate the primary target volume, which might include the primary tumor or tumor bed. The CCR requirement for the Radiation Treatment Volume Phase I, II, and III data items are: Required by CoC-accredited facilities and as available by non-CoC accredited facilities for cases diagnosed January 1, 2018 and forward.

Coding Instructions:

- Enter the code for radiation given to the primary treatment Volume In the appropriate phase I, II, and III data items.
- Radiation treatment volume will typically be found in the radiation oncologist’s summary letter for the first course of treatment.
  - Determination of the exact treatment volume may require assistance from the radiation oncologist.
- Usually the phase breakdown is as follows:
  - Phase I – Initial plan
    - **Note**: Phase I, may include primary tumor bed and associated draining lymph node regions. In this situation:
      - Code the radiation to the primary tumor bed in this data item.
      - Code the radiation to the draining lymph nodes in the Radiation to Draining Lymph Nodes data item.
  - Phase II and/or III – Boost or cone down.
  - Codes 01 – 09 are only used when the lymph nodes are the primary target.
    - When the primary treatment Volume Is lymph nodes, draining lymph nodes are not targeted; therefore use code 88 to record Phase 1 Radiation to Draining Lymph Nodes.
  - Code Phase II and/or III as 00 when the patient receives just one and/or two phase(s) of treatment.
  - Code 98 for coding radioisotope treatment I-131 for thyroid cancer cells in the body, since there is no specific anatomical treatment volume involved.

**Note**: Code 93 has been reserved for whole body treatment with external beam radiation such as is done prior to bone marrow transplantation.

<table>
<thead>
<tr>
<th>Code</th>
<th>Label</th>
<th>Description</th>
</tr>
</thead>
</table>

368
<table>
<thead>
<tr>
<th>Code</th>
<th>Region Description</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>No radiation treatment</td>
<td>Radiation therapy was not administered to the patient; Diagnosed at autopsy</td>
</tr>
<tr>
<td>01</td>
<td>Neck lymph node regions</td>
<td>The primary treatment is directed at the lymph node regions of the neck. Example situations include treatment of lymphoma or lymph node recurrence (in the absence of primary site failure) following definitive surgery of the primary tumor. If radiation to the neck lymph nodes includes the supraclavicular region use code 03.</td>
</tr>
<tr>
<td>02</td>
<td>Thoracic lymph node regions</td>
<td>Radiation therapy is directed to some combination of hilar, mediastinal, and supraclavicular lymph nodes without concurrent treatment of a visceral organ site. Example situations include mantle or mini mantle for lymphomas, and treatment of lymphatic recurrence after complete surgical excision of a thoracic primary. Note that the supraclavicular region may be part of a head and neck lymph node region. Use code 03 for treatments directed at neck nodes and supraclavicular nodes with a head and neck primary. Use code 04 if supraclavicular lymph nodes are part of breast treatment.</td>
</tr>
<tr>
<td>03</td>
<td>Neck and thoracic lymph node regions</td>
<td>Treatment is directed to lymph nodes in the neck and thoracic region without concurrent treatment of a primary visceral tumor. This code might apply to some mantle or mini-mantle fields used in lymphoma treatments for lymphatic recurrences following definitive treatment for tumors of the head and neck or thoracic regions.</td>
</tr>
<tr>
<td>04</td>
<td>Breast/ Chestwall lymph node regions</td>
<td>Radiation is directed primary to some combination of axillary, supraclavicular, and/or internal mammary lymph node sites WITHOUT concurrent treatment of the breast or chest wall. If the breast AND lymph nodes are being treated, then code the Primary Treatment Volume to Breast (codes 40 or 41) and Breast/chest wall lymph nodes (code 04) in Radiation to Draining Lymph Nodes.</td>
</tr>
<tr>
<td>05</td>
<td>Abdominal lymph nodes</td>
<td>Treatment is directed to some combination of the lymph nodes of the abdomen, including retro-crusal, peri-gastric, peri-hepatic, portocaval and para-aortic nodes. Possible situations might include seminoma, lymphoma, or lymph node recurrence following surgical resection of the prostate, bladder or uterus.</td>
</tr>
<tr>
<td>06</td>
<td>Pelvic lymph nodes</td>
<td>Treatment is directed to some combination of the lymph nodes of the pelvis, including the common, internal and external iliac, obturator, inguinal and peri-rectal lymph nodes. This might be done for lymphoma or lymph node recurrence following definitive surgery for a pelvic organ.</td>
</tr>
<tr>
<td>07</td>
<td>Abdominal and pelvic lymph nodes</td>
<td>Treatment is directed to some combination of lymph nodes in both the abdomen and pelvis. This code includes extended fields (“hockey stick,” “dogleg,” “inverted Y,” etc.).</td>
</tr>
<tr>
<td>Code</td>
<td>Tissue/Region</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>09</td>
<td>Lymph node region, NOS</td>
<td>This category should be used to code treatments directed at lymph node regions that are not adequately described by codes 01-07</td>
</tr>
<tr>
<td>10</td>
<td>Eye/orbit/optic nerve</td>
<td>Treatment is directed at all of a portion of the eye, orbit and/or optic nerve</td>
</tr>
<tr>
<td>11</td>
<td>Pituitary</td>
<td>Treatment is directed at the pituitary gland</td>
</tr>
<tr>
<td>12</td>
<td>Brain</td>
<td>Treatment is directed at all the brain and its meninges (“whole brain”)</td>
</tr>
<tr>
<td>13</td>
<td>Brain (Limited)</td>
<td>Treatment is directed at one or more sub-sites of the brain but not the whole brain. Chart may describe “SRS,” “Stereotactic Radiosurgery,” “Gamma Knife”</td>
</tr>
<tr>
<td>14</td>
<td>Spinal cord</td>
<td>Treatment is directed at all of a portion of the spinal cord or its meninges</td>
</tr>
<tr>
<td>20</td>
<td>Nasopharynx</td>
<td>Treatment is directed at all or a portion of the nasopharynx</td>
</tr>
<tr>
<td>21</td>
<td>Oral Cavity</td>
<td>Treatment is directed at all or a portion of the oral cavity, including the lips, gingiva, alveolus, buccal mucosa, retromolar trigone, hard palate, floor of mouth and oral tongue</td>
</tr>
<tr>
<td>22</td>
<td>Oropharynx</td>
<td>Treatment is directed at all or a portion of the oropharynx, including the soft palate, tonsils, base of tongue and pharyngeal wall</td>
</tr>
<tr>
<td>23</td>
<td>Larynx (glottis) or hypopharynx</td>
<td>Treatment is directed at all or a portion of the larynx and/or hypopharynx</td>
</tr>
<tr>
<td>24</td>
<td>Sinuses/Nasal tract</td>
<td>Treatment is directed at all or a portion of the sinuses and nasal tract, including the frontal, ethmoid, sphenoid and maxillary sinuses</td>
</tr>
<tr>
<td>25</td>
<td>Parotid or other salivary glands</td>
<td>Treatment is directed at the parotid or other salivary glands, including the submandibular, sublingual and minor salivary glands</td>
</tr>
<tr>
<td>26</td>
<td>Thyroid</td>
<td>Treatment is directed at all or a portion of the thyroid. Code this volume when the thyroid is treated with I-131 radioisotope</td>
</tr>
<tr>
<td>29</td>
<td>Head and neck (NOS)</td>
<td>The treatment volume is directed at a primary tumor of the head and neck, but the primary sub-site is not a head and neck organ identified by codes 20-26 or it is an “unknown primary”</td>
</tr>
<tr>
<td>30</td>
<td>Lung or bronchus</td>
<td>Treatment is directed at all or a portion of the lung or bronchus</td>
</tr>
<tr>
<td>Code</td>
<td>Tissue/Region</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>--------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>31</td>
<td>Mesothelium</td>
<td>Treatment is directed to all or a portion of the mesothelium. This code should be used for mesothelioma primaries, even if a portion of the lung is included in the radiation field.</td>
</tr>
<tr>
<td>32</td>
<td>Thymus</td>
<td>Treatment is directed to all or a portion of the thymus.</td>
</tr>
<tr>
<td>39</td>
<td>Chest/lung (NOS)</td>
<td>The treatment is directed at a primary tumor of the chest, but the primary sub-site is unknown or not identified in codes 30-32. For example, this code should be used for sarcomas arising from the mediastinum.</td>
</tr>
<tr>
<td>40</td>
<td>Breast - whole</td>
<td>Treatment is directed to all the intact breast. Intact breast includes breast tissue that either was not surgically treated or received a lumpectomy or partial mastectomy.</td>
</tr>
<tr>
<td>41</td>
<td>Breast - partial</td>
<td>Treatment is directed at a portion of the intact breast but not the whole breast. The chart may have terms such as “Mammosite,” “interstitial (seed) implant),” or “(accelerated) partial breast irradiation.” Consider the possibility of partial breast irradiation when “IMRT” is documented in the record.</td>
</tr>
<tr>
<td>42</td>
<td>Chest wall</td>
<td>Treatment encompasses the chest wall (following mastectomy).</td>
</tr>
<tr>
<td>50</td>
<td>Esophagus</td>
<td>Treatment is directed at all or a portion of the esophagus. Include tumors of the gastro-esophageal junction.</td>
</tr>
<tr>
<td>51</td>
<td>Stomach</td>
<td>Treatment is directed at all or a portion of the stomach.</td>
</tr>
<tr>
<td>52</td>
<td>Small bowel</td>
<td>Treatment is directed at all or a portion of the small bowel.</td>
</tr>
<tr>
<td>53</td>
<td>Colon</td>
<td>Treatment is directed at all or a portion of the colon.</td>
</tr>
<tr>
<td>54</td>
<td>Rectum</td>
<td>Treatment is directed at all or a portion of the rectum.</td>
</tr>
<tr>
<td>55</td>
<td>Anus</td>
<td>Treatment is directed at all or a portion of the anus.</td>
</tr>
<tr>
<td>56</td>
<td>Liver</td>
<td>Treatment is directed at all or a portion of the liver.</td>
</tr>
<tr>
<td>57</td>
<td>Biliary tree or gallbladder</td>
<td>Treatment is directed at all or a portion of the biliary tree or gallbladder.</td>
</tr>
<tr>
<td>58</td>
<td>Pancreas or hepatopancreatic ampulla</td>
<td>Treatment is directed at all or a portion of the pancreas or the hepatopancreatic ampulla. Hepatopancreatic ampulla tumors are sometimes referred to as periampullary tumors.</td>
</tr>
<tr>
<td>59</td>
<td>Abdomen (NOS)</td>
<td>Treatment is directed at a primary tumor of the abdomen, but the primary sub-site is not an abdominal organ defined by codes 50-58 or it is considered to be an “unknown primary.” For example, this code should be used for sarcomas arising from the abdominal retroperitoneum.</td>
</tr>
<tr>
<td>60</td>
<td>Bladder - whole</td>
<td>Treatment is directed at all the bladder.</td>
</tr>
<tr>
<td>61</td>
<td>Bladder - partial</td>
<td>Treatment is directed at a portion of the bladder but not the whole bladder.</td>
</tr>
<tr>
<td>62</td>
<td>Kidney</td>
<td>Treatment is directed at all or a portion of the kidney.</td>
</tr>
<tr>
<td>Code</td>
<td>Location</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>63</td>
<td>Ureter</td>
<td>Treatment is directed at all of a portion of the ureter</td>
</tr>
<tr>
<td>64</td>
<td>Prostate - whole</td>
<td>Treatment is directed at all the prostate and/or seminal vesicles. Use this code even if seminal vesicles are not explicitly targeted</td>
</tr>
<tr>
<td>65</td>
<td>Prostate - partial</td>
<td>Treatment is directed at a portion of the prostate but not the whole prostate</td>
</tr>
<tr>
<td>66</td>
<td>Urethra</td>
<td>Treatment is directed at all or a portion of the urethra</td>
</tr>
<tr>
<td>67</td>
<td>Penis</td>
<td>Treatment is directed at all or a portion of the penis. Treatments of urethral primaries should be coded as 'urethra' (code 66)</td>
</tr>
<tr>
<td>68</td>
<td>Testicle or scrotum</td>
<td>Treatment is directed at all or a portion of the testicle and/or scrotum</td>
</tr>
<tr>
<td>70</td>
<td>Ovaries or fallopian tubes</td>
<td>Treatment is directed at all or a portion of the ovaries or fallopian tubes</td>
</tr>
<tr>
<td>71</td>
<td>Uterus or Cervix</td>
<td>Treatment is directed at all or a portion of the uterus, endometrium or cervix</td>
</tr>
<tr>
<td>72</td>
<td>Vagina</td>
<td>Treatment is directed at all or a portion of the vagina. Treatments of urethral primaries should be coded as 'urethra' (code 66)</td>
</tr>
<tr>
<td>73</td>
<td>Vulva</td>
<td>Treatment is directed at all or a portion of the vulva. Treatments of urethral primaries should be coded as 'urethra' (code 66)</td>
</tr>
<tr>
<td>80</td>
<td>Skull</td>
<td>Treatment is directed at all or a portion of the bones of skull. Any brain irradiation is a secondary consequence</td>
</tr>
<tr>
<td>81</td>
<td>Spine/vertebral bodies</td>
<td>Treatment is directed at all or a portion of the bones of the spine/vertebral bodies, including the sacrum. Spinal cord malignancies should be coded using 'spinal cord' (code 14)</td>
</tr>
<tr>
<td>82</td>
<td>Shoulder</td>
<td>Treatment is directed at all or a portion of the proximal humerus, scapula, clavicle, or other components of the shoulder complex</td>
</tr>
<tr>
<td>83</td>
<td>Ribs</td>
<td>Treatment is directed at all or a portion of the one or more ribs</td>
</tr>
<tr>
<td>84</td>
<td>Hip</td>
<td>Treatment is directed at all or a portion of the proximal femur or acetabulum</td>
</tr>
<tr>
<td>85</td>
<td>Pelvic bones</td>
<td>Treatment is directed at all or a portion of the bones of the pelvis other than the hip or sacrum</td>
</tr>
<tr>
<td>86</td>
<td>Pelvis (NOS, non visceral)-</td>
<td>Treatment is directed at a primary tumor of the pelvis, but the primary sub-site is not a pelvic organ or is not known or indicated. For example, this code should be used for sarcomas arising from the pelvis</td>
</tr>
<tr>
<td>88</td>
<td>Extremity bone, NOS</td>
<td>This treatment is directed at all or a portion of the bones of the arms or legs. This excludes proximal femur (hip, code</td>
</tr>
<tr>
<td>Label</td>
<td>Code</td>
<td>Definition</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Abdomen (NOS)</td>
<td>59</td>
<td>Treatment is directed at a primary tumor of the abdomen, but the primary sub-site is not an abdominal organ defined by codes 50-58 or it is considered to be an “unknown primary.” For example, this code should be used for sarcomas arising from the abdominal retroperitoneum.</td>
</tr>
<tr>
<td>Abdominal and pelvic lymph nodes</td>
<td>07</td>
<td>Treatment is directed to some combination of lymph nodes in both the abdomen and pelvis. This code includes extended fields (“hockey stick,” “dogleg,” “inverted Y,” etc.) utilized to treat seminomas and lymphomas or recurrence of a solid tumor</td>
</tr>
<tr>
<td>Location</td>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Abdominal lymph nodes</td>
<td>05</td>
<td>Treatment is directed to some combination of the lymph nodes of the abdomen, including retro-crural, peri-gastric, peri-hepatic, portocaval and para-aortic nodes. Possible situations might include seminoma, lymphoma, or lymph node recurrence following surgical resection of the prostate, bladder or uterus</td>
</tr>
<tr>
<td>Anus</td>
<td>55</td>
<td>Treatment is directed at all or a portion of the anus</td>
</tr>
<tr>
<td>Biliary tree or gallbladder</td>
<td>57</td>
<td>Treatment is directed at all or a portion of the biliary tree or gallbladder</td>
</tr>
<tr>
<td>Bladder - partial</td>
<td>61</td>
<td>Treatment is directed at a portion of the bladder but not the whole bladder</td>
</tr>
<tr>
<td>Bladder - whole</td>
<td>60</td>
<td>Treatment is directed at all the bladder</td>
</tr>
<tr>
<td>Brain</td>
<td>12</td>
<td>Treatment is directed at one or more sub-sites of the brain but not the whole brain. Chart may describe “SRS,” “Stereotactic Radiosurgery,” “Gamma Knife”</td>
</tr>
<tr>
<td>Brain (Limited)</td>
<td>13</td>
<td>Treatment is directed at one or more sub-sites of the brain but not the whole brain. Chart may describe “SRS,” “Stereotactic Radiosurgery,” “Gamma Knife”</td>
</tr>
<tr>
<td>Breast - partial</td>
<td>41</td>
<td>Treatment is directed at a portion of the intact breast but not the whole breast. The chart may have terms such as “Mammosite,” “interstitial (seed) implant,” or “(accelerated) partial breast irradiation.” Consider the possibility of partial breast irradiation when “IMRT” is documented in the record</td>
</tr>
<tr>
<td>Breast - whole</td>
<td>40</td>
<td>Treatment is directed at all the intact breast. Intact breast includes breast tissue that either was not surgically treated or received a lumpectomy or partial mastectomy</td>
</tr>
<tr>
<td>Breast/ Chestwall lymph node regions</td>
<td>04</td>
<td>Radiation is directed primarily to some combination of axillary, supraclavicular, and/or internal mammary lymph node sites WITHOUT concurrent treatment of the breast or chest wall. If the breast AND lymph nodes are being treated, then code the Primary Treatment Volume to Breast (codes 40 or 41) and Breast/chest wall lymph nodes (code 04) in Radiation to Draining Lymph Nodes.</td>
</tr>
<tr>
<td>Chest wall</td>
<td>42</td>
<td>Treatment encompasses the chest wall (following mastectomy)</td>
</tr>
<tr>
<td>Chest/lung (NOS)</td>
<td>39</td>
<td>The treatment is directed at a primary tumor of the chest, but the primary sub-site is unknown or not identified in codes 30-32. For example, this code should be used for sarcomas arising from the mediastinum</td>
</tr>
<tr>
<td>Colon</td>
<td>53</td>
<td>Treatment is directed at all or a portion of the colon</td>
</tr>
<tr>
<td>Esophagus</td>
<td>50</td>
<td>Treatment is directed at all or a portion of the esophagus. Include tumors of the gastro-esophageal junction</td>
</tr>
<tr>
<td>Extremity bone, NOS</td>
<td>88</td>
<td>This treatment is directed at all or a portion of the bones of the arms or legs. This <strong>excludes</strong> proximal femur (hip, code 84). This <strong>excludes</strong> the proximal humerus (Shoulder, code 82)</td>
</tr>
<tr>
<td>Region Description</td>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------------------------------------------------------</td>
<td>------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Eye/orbit/optic nerve</td>
<td>10</td>
<td>Treatment is directed at all of a portion of the eye, orbit and/or optic nerve</td>
</tr>
<tr>
<td>Head and neck (NOS)</td>
<td>29</td>
<td>The treatment volume is directed at a primary tumor of the head and neck, but the primary sub-site is not a head and neck organ identified by codes 20-26 or it is an “unknown primary”</td>
</tr>
<tr>
<td>Hemibody</td>
<td>92</td>
<td>A single treatment volume encompassing either all structures above the diaphragm, or all structures below the diaphragm. This is almost always administered for palliation of widespread bone metastasis in patients with prostate or breast cancer</td>
</tr>
<tr>
<td>Hip</td>
<td>84</td>
<td>Treatment is directed at all or a portion of the proximal femur or acetabulum</td>
</tr>
<tr>
<td>Invalid historical FORDS value</td>
<td>97</td>
<td>Conversion to new STORE data item could not take place due to an invalid FORDS volume code</td>
</tr>
<tr>
<td>Inverted Y (obsolete after 2017)</td>
<td>96</td>
<td>For conversion of historical data only</td>
</tr>
<tr>
<td>Kidney</td>
<td>62</td>
<td>Treatment is directed at all or a portion of the kidney</td>
</tr>
<tr>
<td>Larynx or (glottis) hypopharynx</td>
<td>23</td>
<td>Treatment is directed at all or a portion of the larynx and/or hypopharynx</td>
</tr>
<tr>
<td>Liver</td>
<td>56</td>
<td>Treatment is directed at all or a portion of the liver</td>
</tr>
<tr>
<td>Lower extended field (obsolete after 2017)</td>
<td>95</td>
<td>For conversion of historical data only</td>
</tr>
<tr>
<td>Lung or bronchus</td>
<td>30</td>
<td>Treatment is directed at all or a portion of the lung or bronchus</td>
</tr>
<tr>
<td>Lymph node region, NOS</td>
<td>09</td>
<td>This category should be used to code treatments directed at lymph node regions that are not adequately described by codes 01-07</td>
</tr>
<tr>
<td>Mantle, mini mantle (obsolete after 2017)</td>
<td>94</td>
<td>For conversion of historical data only</td>
</tr>
<tr>
<td>Mesothelium</td>
<td>31</td>
<td>Treatment is directed to all or a portion of the mesothelium. This code should be used for mesothelioma primaries, even if a portion of the lung is included in the radiation field</td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>20</td>
<td>Treatment is directed at all or a portion of the nasopharynx</td>
</tr>
<tr>
<td>Neck and thoracic lymph node regions</td>
<td>03</td>
<td>Treatment is directed to lymph nodes in the neck and thoracic region without concurrent treatment of a primary visceral tumor. This code might apply to some mantle or mini-mantle fields used in lymphoma treatments for lymphatic recurrences following definitive treatment for tumors of the head and neck or thoracic regions</td>
</tr>
<tr>
<td>Description</td>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td>Neck lymph node regions</td>
<td>01</td>
<td>The primary treatment is directed at the lymph node regions of the neck. Example situations include treatment of lymphoma or lymph node recurrence (in the absence of primary site failure) following definitive surgery of the primary tumor. If radiation to the neck lymph nodes includes the supraclavicular region use code 03.</td>
</tr>
<tr>
<td>No radiation treatment</td>
<td>00</td>
<td>Radiation therapy was not administered to the patient. Diagnosed at autopsy.</td>
</tr>
<tr>
<td>Oral Cavity</td>
<td>21</td>
<td>Treatment is directed at all or a portion of the oral cavity, including the lips, gingiva, alveolus, buccal mucosa, retromolar trigone, hard palate, floor of mouth and oral tongue.</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>22</td>
<td>Treatment is directed at all or a portion of the oropharynx, including the soft palate, tonsils, base of tongue and pharyngeal wall.</td>
</tr>
<tr>
<td>Other</td>
<td>98</td>
<td>Radiation therapy administered; treatment volume other than those previously categorized by codes 01-93.</td>
</tr>
<tr>
<td>Ovaries or fallopian tubes</td>
<td>70</td>
<td>Treatment is directed at all or a portion of the ovaries or fallopian tubes.</td>
</tr>
<tr>
<td>Pancreas or hepatopancreatic ampulla</td>
<td>58</td>
<td>Treatment is directed at all or a portion of the pancreas or the hepatopancreatic ampulla. Hepatopancreatic ampulla tumors are sometimes referred to as periampullary tumors.</td>
</tr>
<tr>
<td>Parotid or other salivary glands</td>
<td>25</td>
<td>Treatment is directed at the parotid or other salivary glands, including the submandibular, sublingual and minor salivary glands.</td>
</tr>
<tr>
<td>Pelvic bones</td>
<td>85</td>
<td>Treatment is directed at all or a portion of the bones of the pelvis other than the hip or sacrum.</td>
</tr>
<tr>
<td>Pelvic lymph nodes</td>
<td>06</td>
<td>Treatment is directed to some combination of the lymph nodes of the pelvis, including the common, internal and external iliac, obturator, inguinal and peri-rectal lymph nodes. This might be done for lymphoma or lymph node recurrence following definitive surgery for a pelvic organ.</td>
</tr>
<tr>
<td>Pelvis (NOS, non-visceral)</td>
<td>86</td>
<td>Treatment is directed at a primary tumor of the pelvis, but the primary sub-site is not a pelvic organ or is not known or indicated. For example, this code should be used for sarcomas arising from the pelvis.</td>
</tr>
<tr>
<td>Penis</td>
<td>67</td>
<td>Treatment is directed at all or a portion of the penis. Treatments of urethral primaries should be coded as ‘urethra’ (code 66).</td>
</tr>
<tr>
<td>Pituitary</td>
<td>11</td>
<td>Treatment is directed at the pituitary gland.</td>
</tr>
<tr>
<td>Prostate - partial</td>
<td>65</td>
<td>Treatment is directed at a portion of the prostate but not the whole prostate.</td>
</tr>
<tr>
<td>Prostate - whole</td>
<td>64</td>
<td>Treatment is directed at all the prostate and/or seminal vesicles. Use this code even if seminal vesicles are not explicitly targeted.</td>
</tr>
<tr>
<td>Rectum</td>
<td>54</td>
<td>Treatment is directed at all or a portion of the rectum.</td>
</tr>
<tr>
<td>Ribs</td>
<td>83</td>
<td>Treatment is directed at all or a portion of the one or more ribs.</td>
</tr>
<tr>
<td>Category</td>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Shoulder</td>
<td>82</td>
<td>Treatment is directed at all or a portion of the proximal humerus, scapula, clavicle, or other components of the shoulder complex</td>
</tr>
<tr>
<td>Sinuses/Nasal tract</td>
<td>24</td>
<td>Treatment is directed at all or a portion of the sinuses and nasal tract, including the frontal, ethmoid, sphenoid and maxillary sinuses</td>
</tr>
<tr>
<td>Skin</td>
<td>90</td>
<td>Treatment is directed at all or a portion of the skin. The primary malignancy originates in the skin and the skin is the primary target. So-called skin metastases are usually subcutaneous and should be coded as a soft tissue site</td>
</tr>
<tr>
<td>Skull</td>
<td>80</td>
<td>Treatment is directed at all or a portion of the bones of skull. Any brain irradiation is a secondary consequence</td>
</tr>
<tr>
<td>Small bowel</td>
<td>52</td>
<td>Treatment is directed at all or a portion of the small bowel</td>
</tr>
<tr>
<td>Soft tissue</td>
<td>91</td>
<td>This category should be used to code primary or metastatic soft tissue malignancies not fitting other categories</td>
</tr>
<tr>
<td>Spinal cord</td>
<td>14</td>
<td>Treatment is directed at all of a portion of the spinal cord or its meninges</td>
</tr>
<tr>
<td>Spine/vertebral bodies</td>
<td>81</td>
<td>Treatment is directed at all or a portion of the bones of the spine/vertebral bodies, including the sacrum. Spinal cord malignancies should be coded using ‘spinal cord’ (code 14)</td>
</tr>
<tr>
<td>Stomach</td>
<td>51</td>
<td>Treatment is directed at all or a portion of the stomach</td>
</tr>
<tr>
<td>Testicle or scrotum</td>
<td>68</td>
<td>Treatment is directed at all or a portion of the testicle and/or scrotum</td>
</tr>
<tr>
<td>Thoracic lymph node regions</td>
<td>02</td>
<td>Radiation therapy is directed to some combination of hilar, mediastinal, and supraclavicular lymph nodes without concurrent treatment of a visceral organ site. Example situations include mantle or mini mantle for lymphomas, and treatment of lymphatic recurrence after complete surgical excision of a thoracic primary. Note that the supraclavicular region may be part of a head and neck lymph node region. Use code 03 for treatments directed at neck nodes and supraclavicular nodes with a head and neck primary. Use code 04 if supraclavicular lymph nodes are part of breast treatment</td>
</tr>
<tr>
<td>Thymus</td>
<td>32</td>
<td>Treatment is directed to all or a portion of the thymus</td>
</tr>
<tr>
<td>Thyroid</td>
<td>26</td>
<td>Treatment is directed at all or a portion of the thyroid. Code this volume when the thyroid is treated with I-131 radioisotope</td>
</tr>
<tr>
<td>Unknown</td>
<td>99</td>
<td>This category should be used to code treatments for which there is no information available about the treatment volume, or it is unknown if radiation treatment was administered</td>
</tr>
<tr>
<td>Ureter</td>
<td>63</td>
<td>Treatment is directed at all of a portion of the ureter</td>
</tr>
<tr>
<td>Urethra</td>
<td>66</td>
<td>Treatment is directed at all or a portion of the urethra</td>
</tr>
<tr>
<td>Uterus or Cervix</td>
<td>71</td>
<td>Treatment is directed at all or a portion of the uterus, endometrium or cervix</td>
</tr>
<tr>
<td>Location</td>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-----------</td>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td>Vagina</td>
<td>72</td>
<td>Treatment is directed at all or a portion of the vagina. Treatments of urethral primaries should be coded as ‘urethra’ (code 66)</td>
</tr>
<tr>
<td>Vulva</td>
<td>73</td>
<td>Treatment is directed at all or a portion of the vulva. Treatments of urethral primaries should be coded as ‘urethra’ (code 66)</td>
</tr>
<tr>
<td>Whole body</td>
<td>93</td>
<td>Treatment is directed to the entire body included in a single treatment</td>
</tr>
</tbody>
</table>
VI.3.3.2 Radiation to Draining Lymph Nodes - Phases I-III

These data items identify any draining lymph nodes treated during radiation. The first phase commonly targets both the primary tumor and draining nodes as a secondary site. This data item indicates the draining LNs, if any, that were radiated during that phase of radiation. The CCR requirement for the Radiation to Draining Lymph Node data items are: Required by CoC-accredited facilities and as available by non-CoC accredited facilities for cases diagnosed January 1, 2018 and forward.

Coding Instructions:

- Enter the code for radiation given to the draining lymph nodes in the appropriate phase I, II, and III data items.
- Radiation treatment to draining lymph nodes will typically be found in the radiation oncologist’s summary letter for the first course of treatment.
  - Determination of the exact draining lymph nodes may require assistance from the radiation oncologist.
- Usually the phase breakdown is as follows:
  - Phase I – Initial plan
    - **Note**: Phase I, may include primary tumor bed and associated draining lymph node regions. In this situation:
      - Code the radiation to the draining lymph nodes in this data item.
      - Code the radiation to the primary tumor bed in the Radiation Primary Treatment Volume data item.
  - Phase II and/or III – Boost or cone down.
- Codes 01 – 09 are used when the lymph nodes are the primary target.
- When the primary treatment volume is lymph nodes, draining lymph nodes are not targeted, therefore, record code 88 in this data item.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>No radiation treatment to draining lymph nodes; Diagnosed at autopsy</td>
</tr>
<tr>
<td>01</td>
<td>Neck lymph node regions</td>
</tr>
<tr>
<td>02</td>
<td>Thoracic lymph node regions</td>
</tr>
<tr>
<td>03</td>
<td>Neck and thoracic lymph node regions</td>
</tr>
<tr>
<td>04</td>
<td>Breast/Chest wall lymph node regions</td>
</tr>
<tr>
<td>05</td>
<td>Abdominal lymph nodes</td>
</tr>
<tr>
<td>06</td>
<td>Pelvic lymph nodes</td>
</tr>
<tr>
<td>07</td>
<td>Abdominal and pelvic lymph nodes</td>
</tr>
<tr>
<td></td>
<td>Lymph node region, NOS</td>
</tr>
<tr>
<td>---</td>
<td>------------------------</td>
</tr>
<tr>
<td>08</td>
<td>Not applicable; Phase I <em>Radiation Primary Treatment Volume</em> is lymph nodes</td>
</tr>
<tr>
<td>88</td>
<td>Unknown if any radiation treatment to draining lymph nodes; Unknown if radiation treatment administered</td>
</tr>
</tbody>
</table>
VI.3.3.3 Radiation Treatment Modality - Phases I-III

These data items identify radiation modality administered during each phase of radiation treatment delivered during the first course of treatment. Radiation modality reflects whether treatment was external beam, brachytherapy, a radioisotope or their major subtypes, or a combination of modalities. The Radiation Treatment Modality data items are required by the CCR for cases diagnosed January 1, 2018 and forward.

Historically, the previously named Regional Treatment Modality data item included codes, which described a mixture of modalities, treatment planning techniques and delivery techniques commonly used by radiation oncologists. For 2018 implementation, radiation treatment information for Regional Treatment Modality and External Beam Planning Technique will be collected in separate mutually exclusive data items. A separate data item for delivery technique has not been implemented because this information is not consistently reported.

Coding Instructions:

- Enter the code for the radiation treatment modality administered in the appropriate phase I, II, and III data items.
- Radiation treatment modality will typically be found in the radiation oncologist’s treatment summary for the first course of treatment.
  - Segregation of treatment components into phases and determination of the respective treatment modality may require assistance from the radiation oncologist.
- This data item intentionally does not include reference to various MV energies because this is not a clinically important aspect of technique. A change in MV energy (e.g., 6MV to 12 MV) is not clinically relevant and does not represent a change in treatment technique. It is rare for change in MV energy to occur during any phase of radiation therapy.
- Usually the phase breakdown is as follows:
  - Phase I – Initial plan
  - Phase II and/or III – Boost or cone down
- For the purposes of this data item, photons, x-ray, and gamma-rays are equivalent.
- Code 13 for Radioisotopes, NOS for radioembolization procedures, e.g. intravascular Yttrium-90 for cases diagnosed January 1, 2018 and forward.
  - Code 07 for Brachytherapy, NOS for cases diagnosed prior to January 1, 2018.
• If this data item is coded to any of the external beam codes (01-06, or 12), the *External Beam Radiation Planning Technique* must be recorded in the appropriate phase I, II or III data items.

• If this data item is coded to any of the Brachytherapy or Radioisotope codes (07-16) the code of 88 must be recorded in data item *External Beam Radiation Planning Technique* for the appropriate phase I, II, or III data items.

**Note:** Do not code a radioiodine scan in this data item. Only treatment is recorded in this data item.

• Refer to the current *Standards for Oncology Registry Entry (STORE) Manual* and the *CTR Guide to coding Radiation Therapy in the STORE*.
  
  o Coding instructions for radiation modality based on the type of heavy equipment used for therapy, STORE-Appendix B – Coding Modality for the Heavy Equipment of Modern Radiation Therapy.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>No radiation treatment</td>
</tr>
<tr>
<td>01</td>
<td>External beam, NOS</td>
</tr>
<tr>
<td>02</td>
<td>External beam, photons</td>
</tr>
<tr>
<td>03</td>
<td>External beam, protons</td>
</tr>
<tr>
<td>04</td>
<td>External beam, electrons</td>
</tr>
<tr>
<td>05</td>
<td>External beam, neutrons</td>
</tr>
<tr>
<td>06</td>
<td>External beam, carbon ions</td>
</tr>
<tr>
<td>07</td>
<td>Brachytherapy, NOS</td>
</tr>
<tr>
<td>08</td>
<td>Brachytherapy, intracavitary, LDR</td>
</tr>
<tr>
<td>09</td>
<td>Brachytherapy, intracavitary, HDR</td>
</tr>
<tr>
<td>10</td>
<td>Brachytherapy, interstitial, LDH</td>
</tr>
<tr>
<td>11</td>
<td>Brachytherapy, Interstitial, HDR</td>
</tr>
<tr>
<td>12</td>
<td>Brachytherapy, electronic</td>
</tr>
<tr>
<td>13</td>
<td>Radioisotopes, NOS</td>
</tr>
<tr>
<td>14</td>
<td>Radioisotopes, radium-223</td>
</tr>
<tr>
<td>15</td>
<td>Radioisotopes, strontium-89</td>
</tr>
<tr>
<td>16</td>
<td>Radioisotopes, strontium-90</td>
</tr>
<tr>
<td>98</td>
<td>Radiation therapy administered; modality unknown</td>
</tr>
<tr>
<td>99</td>
<td>Unknown if radiation treatment administered</td>
</tr>
</tbody>
</table>
**VI.3.3.4 Radiation External Beam Planning Technique - Phases I-III**

These data items identify the external beam radiation planning technique used to define the target treatment area and/or administer each phase of radiation treatment during the first course of treatment. The *Radiation External Beam Planning Technique* data items are required by the CCR for cases diagnosed January 1, 2018 and forward.

**Coding Instructions:**

- Enter the code for the radiation external planning technique used in the appropriate phase I, II, and III data items.

- Radiation external beam treatment planning technique will typically be found in the radiation oncologist’s summary letter for the first course of treatment.
  - Determination of the external beam planning technique may require assistance from the radiation oncologist.

- Usually the phase breakdown is as follows:
  - Phase I – Initial plan
  - Phase II and/or III – Boost or cone down

- Code 00 when radiation is **not** performed or when diagnosed at autopsy.

- Code 04 for Conformal or 3-D Conformal therapy whenever either is explicitly mentioned.

- Code 05 for Intensity Modulated Therapy (IMRT) or Intensity Modulated Radiation Therapy (IMRT).

- Refer to the current [Standards for Oncology Registry Entry (STORE) Manual](#) and the [CTR Guide to coding Radiation Therapy in the STORE](#).

<table>
<thead>
<tr>
<th>Code</th>
<th>Label</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>No radiation treatment</td>
<td>Radiation therapy was not administered to the patient; Diagnosed at autopsy</td>
</tr>
<tr>
<td>01</td>
<td>External beam, NOS</td>
<td>The treatment is known to be external beam, but there is insufficient information to determine the specific planning technique</td>
</tr>
<tr>
<td>02</td>
<td>Low energy x-ray/photon therapy</td>
<td>External beam therapy administered using equipment with a maximum energy less than one (1) million volts (MV). Energies are typically expressed in units of kilovolts (kV). These types of treatments are sometimes referred to as electronic brachytherapy or orthovoltage or superficial therapy. Clinical notes may refer to the brand names of low energy x-ray delivery devices, e.g. Axxent®, INTRABEAM®, or Esteya®</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Description</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>-------------</td>
</tr>
<tr>
<td>03</td>
<td>2-D therapy</td>
<td>An external beam planning technique using 2-D imaging, such as plain film x-rays or fluoroscopic images, to define the location and size of the treatment beams. Should be clearly described as 2-D therapy; This planning modality is typically used only for palliative patients</td>
</tr>
<tr>
<td>04</td>
<td>Conformal or 3-D conformal therapy</td>
<td>An external beam planning technique using multiple, fixed beams shaped to conform to a defined target volume. Should be clearly described as conformal or 3-D therapy in patient record</td>
</tr>
<tr>
<td>05</td>
<td>Intensity modulated therapy</td>
<td>An external beam planning technique where the shape or energy of beam is optimized using software algorithms. Any external beam modality can be modulated but these generally refer to photon or proton beams. Intensity modulated therapy can be described as intensity modulated radiation therapy (IMRT), intensity modulated x-ray or proton therapy (IMXT/IMPT), volumetric arc therapy (VMAT) and other ways. If a treatment is described as IMRT with online re-optimization/re-planning, then it should be categorized as online re-optimization or re-planning</td>
</tr>
<tr>
<td>06</td>
<td>Stereotactic radiotherapy or radiosurgery, NOS</td>
<td>Treatment planning using stereotactic radiotherapy/radiosurgery techniques, but the treatment is not described as Cyberknife of Gamma Knife®. These approaches are sometimes described as SBRT (stereotactic body radiation), SABR (stereotactic ablative radiation), SRS (stereotactic radiosurgery), or SRT (stereotactic radiotherapy). If the treatment is described as robotic radiotherapy (e.g. Cyberknife®) or Gamma Knife®, use stereotactic radiotherapy subcodes below. If a treatment is described as stereotactic radiotherapy or radiosurgery with online re-optimization/re-planning, then it should be categorized as online re-optimization or re-planning</td>
</tr>
<tr>
<td>07</td>
<td>Stereotactic radiotherapy or radiosurgery, robotic</td>
<td>Treatment planning using stereotactic radiotherapy/radiosurgery techniques which is specifically described as robotic (e.g. Cyberknife®)</td>
</tr>
<tr>
<td>08</td>
<td>Stereotactic radiotherapy or radiosurgery Gamma Knife®</td>
<td>Treatment planning using stereotactic radiotherapy/radiosurgery techniques which uses a Cobalt-60 gamma ray source and is specifically described as Gamma Knife®. This is most commonly used for treatments in the brain</td>
</tr>
<tr>
<td>09</td>
<td>CT-guided online adaptive therapy</td>
<td>An external beam technique in which the treatment plan is adapted over the course of radiation to reflect changes in the patient’s tumor or normal anatomy radiation using a CT scan obtained at the treatment machine (online). These approaches are sometimes described as CT-guided online re-optimization or online re-planning. If a treatment</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
<td>Details</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
<td>---------</td>
</tr>
<tr>
<td>10</td>
<td>MR-guided online adaptive therapy</td>
<td>An external beam technique in which the treatment plan is adapted over the course of radiation to reflect changes in the patient’s tumor or normal anatomy radiation using and MRI scan obtained at the treatment machine (online). These approaches are sometimes described as MR-guided online re-optimization or online re-planning. If a treatment technique is described as both MR-guided online adaptive therapy as well as another external beam technique (IMRT, SBRT, etc.), then it should be categorized as MR-guided online adaptive therapy. If a treatment is described as “adaptive” but does not include the descriptor “online,” this code should not be used.</td>
</tr>
<tr>
<td>88</td>
<td>Not Applicable</td>
<td>Treatment not by external beam</td>
</tr>
<tr>
<td>98</td>
<td>Other, NOS</td>
<td>Other radiation, NOS; Radiation therapy administered, but the treatment modality is not specified or is unknown</td>
</tr>
<tr>
<td>99</td>
<td>Unknown</td>
<td>It is unknown whether radiation therapy was administered</td>
</tr>
</tbody>
</table>
VI.3.3.5 Dose per Fraction - Phases I-III

These data items identify the dose per fraction (treatment session) delivered to the patient in each phase of radiation during the first course of treatment. Radiation therapy is delivered in one or more phases with identified dose per fraction. The unit of measure is centiGray (cGy). The CCR requirement for the Dose per Fraction data items is: Required by CoC-accredited facilities and as available by non-CoC accredited facilities for cases diagnosed January 1, 2018 and forward.

Coding Instructions:

- Record the actual Phase dose delivered in cGy in the appropriate phase I, II, and III data items.
- Radiation treatment Phase(s) dosage(s) will typically be found in the radiation oncologist’s summary letter for the first course of treatment.
  - Determination of the Phase I, II, or III doses of radiation may require assistance from the radiation oncologist.
- Usually the phase breakdown is as follows:
  - Phase I – Initial plan
  - Phase II and/or III – Boost or cone down
- Record the dose delivered (not initially prescribed) as documented in the treatment summary.
- For proton therapy:
  - Dosage may occasionally be specified in cGe units (Cobalt Gray Equivalent) rather than cGy.
    - 1cGe = 100 cGy (for the Phase I, II, or III Total Dose multiply cGe by 100).
  - Note: Dose is still occasionally specified in “rads.” One rad is equivalent to one centi-Gray (cGy).
- Code the actual cGy if available when brachytherapy was administered to the patient (codes 07-12) for Phase I, II, III Treatment Modality.
  - If the dose is not available/provided in cGy for a brachytherapy procedure, code 99999.
- Code 99998 when radioisotopes were administered to the patient (codes 13-16) for Phase I, II, or III Radiation Treatment Modality.
- Code 99999 for Death Certificate Only (DCO) cases.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>00000</td>
<td>No radiation treatment</td>
</tr>
<tr>
<td>00001-99997</td>
<td>Record the actual Phase (I, II, and III) dose delivered in cGy</td>
</tr>
<tr>
<td>99998</td>
<td>Not applicable, radioisotopes administered to the patient</td>
</tr>
<tr>
<td>99999</td>
<td>Regional radiation therapy was administered but dose is unknown, it is unknown whether radiation therapy was administered; Death Certificate Only</td>
</tr>
</tbody>
</table>
VI.3.3.6 Number of Fractions - Phases I-III
These data items identify the number of fractions (treatment sessions) delivered in each phase of radiation during the first course of treatment. The CCR requirement for the Number of Fractions data items are: Required by CoC-accredited facilities and as available by non-CoC accredited facilities for cases diagnosed January 1, 2018 and forward.

Coding Instructions:
- Record the number of fractions used to deliver radiation in the appropriate phase I, II, and III data items.
- Number of fractions will typically be found in the radiation oncologist’s summary letter for the first course of treatment.
  - Determination of the number of fractions (number of treatments) may require assistance from the radiation oncologist.
- Usually the phase breakdown is as follows:
  - Phase I – Initial plan
  - Phase II and/or III – Boost or cone down
- Record the actual number of fractions delivered (not initially prescribed) as documented in the treatment summary.
- Count each separate administration of brachytherapy or implants as a single fraction or treatment.
- Code 999 for Death Certificate Only (DCO) cases.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>000</td>
<td>No radiation treatment</td>
</tr>
<tr>
<td>001-998</td>
<td>Number of fractions administered to the patient during each phase (I, II, or III) of radiation therapy</td>
</tr>
<tr>
<td>999</td>
<td>Phase I, II, or III radiation therapy was administered, but the number of fractions for each is unknown; It is unknown whether radiation therapy was administered</td>
</tr>
</tbody>
</table>
VI.3.3.7 Total Dose - Individual Phases I-III

These data items identify the total dose delivered in each phase of radiation during the first course of treatment. The CCR requirement for the Total Dose data items is: Required by CoC-accredited facilities and as available by non-CoC accredited facilities for cases diagnosed January 1, 2018 and forward.

Coding Instructions:

- Record the total dose delivered for each phase in the appropriate phase I, II, and III data items.

- Total dose for each phase (I, II, and/or III) will typically be found in the radiation oncologist’s summary letter for the first course of treatment.
  - Determination of the total dose for each phase (I, II, and/or III) may require assistance from the radiation oncologist.

- Usually the phase breakdown is as follows:
  - Phase I – Initial plan
  - Phase II and/or III – Boost or cone down

- Record the total dose delivered in each phase (not initially prescribed) as documented in the treatment summary.

- For proton therapy:
  - Dosage may occasionally be specified in cGe units (Cobalt Gray Equivalent) rather than cGy.
    - 1cGe = 100 cGy (for the Phase I, II, or III Total Dose multiply cGe by 100).

  **Note:** Dose is occasionally specified as “rads.” One rad is equivalent to one centi-Gray (cGy).

- Code the actual cGy if available when brachytherapy was administered to the patient (codes 07-12) for Phase I, II, III Radiation Treatment Modality.
  - Phase I Dose per Fraction and the Phase I Total Dose will be the same when only one fraction of brachytherapy was delivered.

- Code 999998 when radioisotopes were administered to the patient (codes 13-16) for Phase I, II, or III Radiation Treatment Modality.

- Code 999999 for Death Certificate Only (DCO) cases.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>000000</td>
<td>No radiation treatment; Diagnosed at autopsy</td>
</tr>
<tr>
<td>000001-999997</td>
<td>Record the actual total dose (phases I, II, and III) delivered in cGy</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>999998</td>
<td>Not applicable; radioisotopes administered to the patient</td>
</tr>
<tr>
<td>999999</td>
<td>Radiation therapy was administered, but the dose is unknown; it is unknown whether radiation therapy was administered; Death Certificate Only</td>
</tr>
</tbody>
</table>
VI.3.4 Number of Phases of Rad Treatment to this Volume

This data item identifies the total number of phases administered to the patient during the first course of treatment. A “phase” consists of one or more consecutive treatments delivered to the same anatomic volume with no change in the treatment technique. Although most courses of radiation therapy are completed in one or two phases (historically, the “regional” and “boost” treatments) there are occasions in which three or more phases are used, most typically with head and neck malignancies. The CCR requirement for the Number of Phases of Radiation Treatment to this Volume data item is: Required by CoC-accredited facilities and as available by non-CoC accredited facilities for cases diagnosed January 1, 2018 and forward.

Coding Instructions:

- Record the number of phases administered to the patient during the first course of treatment.

- The number of phases (I, II, and/or III combined) will typically be found in the radiation oncologist’s summary letter for the first course of treatment.

  - Determination of the combined number of phases may require assistance from the radiation oncologist.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>No radiation treatment</td>
</tr>
<tr>
<td>01</td>
<td>1 phase</td>
</tr>
<tr>
<td>02</td>
<td>2 phases</td>
</tr>
<tr>
<td>03</td>
<td>3 phases</td>
</tr>
<tr>
<td>04</td>
<td>4 or more phases</td>
</tr>
<tr>
<td>99</td>
<td>Unknown number of phases; Unknown if radiation therapy administered</td>
</tr>
</tbody>
</table>
VI.3.5 Radiation Total Dose - Phases Combined
This data item identifies the total radiation dose administered to the patient across all phases during the first course of treatment. The CCR requirement for the Total Dose (phases combined) data item is: Required by CoC-accredited facilities and as available by non-CoC accredited facilities for cases diagnosed January 1, 2018 and forward.

Coding Instructions:

- Record the total dose given in all phases (combined) to the patient during the first course of treatment.
- The total dose (all phases combined) will typically be found in the radiation oncologist’s summary letter for the first course of treatment.
  - If the total is not documented, add the dose from each phase (I, II, III, or IV or more) and document the total cumulative dose.
  - Doses should only be summed across phases to create a Total Dose when all of the phases were delivered sequentially to the same body site using the same modality and dose-fractionation.
    - Do not sum doses across phases if the phases used different treatment fraction sizes or modalities (i.e. external beam in Phase I and brachytherapy in Phase II), or phases were delivered simultaneously to multiple body sites (different volumes), e.g. simultaneous treatment to multiple metastatic sites, or dose-painting with any other different modality or different fractionation schemes. Use code 999998, Not applicable.
  - Determination of the combined number of phases may require assistance from the radiation oncologist.
- For proton therapy:
  - Dosage may occasionally be specified in cGe units (Cobalt Gray Equivalent) rather than cGy.
    - 1cGe = 100 cGy (for Total Dose multiply cGe by 100).
    - Note: Dose is occasionally specified as “rads.” One rad is equivalent to one centi-Gray (cGy).
- Code the actual cGy if available when brachytherapy was administered to the patient (codes 07-12) for Phase I, II, III Radiation Treatment Modality.
- Code 999998 when radioisotopes were administered to the patient (codes 13-16) for Phase I, II, or III Radiation Treatment Modality.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
</table>

392
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>000000</td>
<td>No therapy administered; Diagnosed at autopsy</td>
</tr>
<tr>
<td>000001-999997</td>
<td>Record the actual total dose (all phases combined) delivered in cGy</td>
</tr>
<tr>
<td>999998</td>
<td>Not applicable, radioisotopes administered to the patient, or the patient was treated with mixed modalities (e.g. external beam brachytherapy)</td>
</tr>
<tr>
<td>999999</td>
<td>Radiation therapy was administered, but the dose is unknown; it is unknown whether radiation therapy was administered</td>
</tr>
</tbody>
</table>
## VI.3.6 Radiation Sequence with Surgery

Code the sequence in which radiation and surgical procedures were performed as part of the first course of treatment.

**Note:** For the purpose of coding the data item *Radiation Sequence with Surgery*, “Surgery” is defined as a *Surgical Procedure of Primary Site* (codes 10-90) or *Scope of Regional Lymph Node Surgery* (codes 2-7) or *Surgical Procedure of Other Site* (codes 1-5).

### Coding Instructions:

- Use the appropriate radiation sequence code (2-9) if first course of treatment includes:
  1. Surgery of the Primary Site
  2. Scope of Regional Lymph Node(s)
     - Do not count *Scope of Regional Lymph Node Surgery* code 1 as surgery for the purpose of coding this data item.
  3. Surgery of Other Regional Site(s)
  4. Distant Site(s)
  5. Distant Lymph Node(s)
  6. Radiation

- For all other cases, use code 0.

<table>
<thead>
<tr>
<th>Code</th>
<th>Label</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No radiation therapy and/or surgical procedures</td>
<td>No radiation therapy given or unknown if radiation therapy given; and/or no surgery of the primary site; no scope of regional lymph node surgery; no surgery to other regional site(s), distant site(s), or distant lymph node(s), or it is unknown whether any surgery given</td>
</tr>
<tr>
<td>2</td>
<td>Radiation therapy before surgery</td>
<td>Radiation therapy given before surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s)</td>
</tr>
<tr>
<td>3</td>
<td>Radiation therapy after surgery</td>
<td>Radiation therapy given after surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s)</td>
</tr>
<tr>
<td>4</td>
<td>Radiation therapy both before and after surgery</td>
<td>At least two courses of radiation therapy are given before and at least two more after surgery to the primary site; scope of regional lymph node surgery, surgery to other regional site(s), or distant lymph node(s)</td>
</tr>
<tr>
<td>5</td>
<td>Intraoperative radiation therapy</td>
<td>Intraoperative therapy given during surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s)</td>
</tr>
<tr>
<td></td>
<td>Intraoperative radiation therapy with other therapy administered before or after surgery</td>
<td>Intraoperative radiation therapy given during surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s) with other radiation therapy administered before or after surgery to primary site; scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s)</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>6</td>
<td>Surgery both before and after radiation</td>
<td>Radiation was administered between two separate surgical procedures to the primary site; regional lymph nodes; surgery to other regional site(s), distant site(s), or distant lymph node(s)</td>
</tr>
<tr>
<td>7</td>
<td>Sequence unknown</td>
<td>Administration of radiation therapy and surgery to primary site, scope of regional lymph node surgery, surgery to other regional site(s), distant site(s), or distant lymph node(s) were performed and the sequence of treatment is not stated in the patient record</td>
</tr>
</tbody>
</table>
VI.3.7 Radiation Treatment Discontinued Early

This data item is used to identify patients/tumors whose radiation treatment course was discontinued earlier than initially planned. That is the patients/tumors received fewer treatment fractions (sessions) than originally intended by the treating physician. The CCR requirement for the Radiation Treatment Discontinued data item is: Required by CoC-accredited facilities and as available by non-CoC accredited facilities for cases diagnosed January 1, 2018 and forward.

Coding Instructions:

- Enter the code that describes the reason radiation treatment was discontinued early.
- Treatment discontinued early will typically be found in the radiation oncologist’s summary letter for the first course of treatment.
- Code 01 when there is no indication that radiation was discontinued or completed early.
- Codes 02-07 are used when there is an indication that radiation therapy was discontinued or was completed early.
- Code 99 is used when therapy is administered, but it is not clear if the treatment course was:
  - Discontinued early
  - Unknown if radiation was administered
  - Death Certificate Only (DCO)

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>No radiation treatment</td>
</tr>
<tr>
<td>01</td>
<td>Radiation treatment completed as prescribed</td>
</tr>
<tr>
<td>02</td>
<td>Radiation treatment discontinued early - toxicity</td>
</tr>
<tr>
<td>03</td>
<td>Radiation treatment discontinued early - contraindicated due to other patient risk factors (comorbid conditions, advanced age, progression of tumor prior to planned radiation etc.)</td>
</tr>
<tr>
<td>04</td>
<td>Radiation treatment discontinued early - patient decision</td>
</tr>
<tr>
<td>05</td>
<td>Radiation discontinued early - family decision</td>
</tr>
<tr>
<td>06</td>
<td>Radiation discontinued early - patient expired</td>
</tr>
<tr>
<td>07</td>
<td>Radiation discontinued early - reason not documented</td>
</tr>
<tr>
<td>99</td>
<td>Unknown if radiation treatment discontinued; Unknown whether radiation therapy administered; Death Certificate Only (DCO)</td>
</tr>
</tbody>
</table>
VI.3.8 Location of Radiation Treatment
Records the location of the facility in which radiation treatment was administered during first course of treatment. This applies to cases diagnosed January 1, 2008 and forward.

Coding Instructions:

- Enter the code for the location of the facility in which radiation treatment was administered during first course of treatment.
- Location of radiation treatment will typically be found in the radiation oncologist’s summary letter for the first course of treatment.
  - Determination of the location of radiation treatment may require assistance from the radiation oncologist.

<table>
<thead>
<tr>
<th>Code</th>
<th>Label</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No radiation treatment</td>
<td>No radiation therapy was administered to the patient; Diagnosed at autopsy</td>
</tr>
<tr>
<td>1</td>
<td>All radiation treatment at this facility</td>
<td>All radiation therapy was administered at the reporting facility</td>
</tr>
<tr>
<td>2</td>
<td>Regional treatment at this facility, boost elsewhere</td>
<td>Regional treatment was administered at the reporting facility; a boost dose was administered elsewhere</td>
</tr>
<tr>
<td>3</td>
<td>Boost radiation at this facility, regional elsewhere</td>
<td>Regional treatment was administered elsewhere; a boost dose was administered at the reporting facility</td>
</tr>
<tr>
<td>4</td>
<td>All radiation treatment elsewhere</td>
<td>All radiation therapy was administered elsewhere</td>
</tr>
<tr>
<td>8</td>
<td>Other, NOS</td>
<td>Radiation therapy was administered, but the pattern does not fit the above categories</td>
</tr>
<tr>
<td>9</td>
<td>Unknown</td>
<td>Radiation therapy was administered, but the location of the treatment facility is unknown or not stated in the patient record; or it is unknown whether radiation therapy was administered; Death Certificate Only (DCO)</td>
</tr>
</tbody>
</table>
VI.3.9 Reason for No Radiation
Record the reason the patient did not undergo radiation treatment.

Coding Instructions:
- Include radiation to the brain and central nervous system when coding this data item.
- Code 0 if the patient received regional radiation as part of first course therapy.
- Code 1 if the treatment plan offered multiple alternative treatment options and the patient selected a treatment that did not include radiation therapy.
- Code 7 when:
  - Patient refused recommended radiation therapy.
  - Patient refused all recommended treatment.
  - Patient refused all treatment before any treatment was recommended.
- Code 8 when:
  - It is known that the physician recommended radiation, but no further documentation is available to confirm it was performed.
  - Patient was referred to a radiation oncologist.
  **Note:** Follow up with the specialist or facility to determine if the patient actually had treatment (or not) and change this code as appropriate.
- Code 9 when:
  - The treatment plan offered multiple alternative options, but it is unknown which treatment, if any, was provided.
  - Death Certificate Only (DCO).
- Patient’s decision not to pursue radiation therapy is not a refusal of radiation therapy when:
  - The patient has discussed radiation therapy with their physician, and then decides to pursue no treatment.
  **Note:** Discussion does not equal a recommendation.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Radiation therapy administered</td>
</tr>
<tr>
<td>1</td>
<td>Radiation treatment not administered because it was not a part of the planned first course treatment; Diagnosed at autopsy</td>
</tr>
<tr>
<td></td>
<td>Description</td>
</tr>
<tr>
<td>---</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>2</td>
<td>Radiation therapy was not recommended/administered because it was contraindicated due to other patient risk factors (co-morbid conditions, advanced age, progression of tumor prior to planned radiation, etc.)</td>
</tr>
<tr>
<td>5</td>
<td>Radiation treatment not performed because the patient died prior to planned or recommended treatment</td>
</tr>
<tr>
<td>6</td>
<td>Radiation treatment was not administered. It was recommended by the patient’s physician, but not performed as part of the first course of treatment. No reason was noted in the patient record</td>
</tr>
<tr>
<td>7</td>
<td>Radiation treatment was not administered. It was recommended by the patient’s physician, but this treatment was refused by the patient, the patient’s family member, or the patient’s guardian; The refusal is noted in the patient’s record</td>
</tr>
<tr>
<td>8</td>
<td>Radiation therapy was recommended, but it is unknown whether it was administered</td>
</tr>
<tr>
<td>9</td>
<td>Unknown if radiation was recommended or performed; Death Certificate Only (DCO) cases only</td>
</tr>
</tbody>
</table>
VI.4 Chemotherapy - First Course of Treatment

Chemotherapy includes the use of any chemical to attack or treat cancer tissue, unless the chemical achieves its effect through change of the hormone balance or by affecting the patient’s immune system.

Coding Instructions:

• In coding, consider only the agent, not the method of administering it, although the method of administration may be recorded.
• Chemotherapy typically is administered orally, intravenously, or intracavitary, and sometimes topically or by isolated limb perfusion.
• The drugs are frequently given in combinations that are referred to by acronyms or protocols. Do not record the protocol numbers alone.
• Two or more single agents given at separate times during the first course of cancer directed therapy are considered a combination regimen.
• The physician may decide to change a drug during the first course of therapy because the patient cannot tolerate the original drug.
  o As long as the substitutions belong to the same group (alkylating, antimetabolites, natural products, targeted therapy, or other miscellaneous), the change in drug is a continuation of the first course of therapy.
  
  **Note:** Do not code the new agent as first course of therapy when the original agent is changed to one that is **not** in the same group.
  o Use SEER*Rx to compare the subcategory of each chemotherapy agent to determine whether they belong to the same group (subcategory).
• When chemotherapeutic agents are used as radiosensitizers or radioprotectants, they are given at a much lower dose and do not affect the cancer.
  o Radiosensitizers and radioprotectants are classified as ancillary drugs.
  
  **Note:** January 1, 2012 and forward, do not code chemotherapy when documented as being used for radio-sensitization.
  
  **Exception:** Cisplatin used for radio-sensitization.
• Use SEER*Rx to determine if the agent is chemotherapy, hormonal therapy, immunotherapy, or an ancillary agent (non-cancer directed).
  o If a drug regimen is given to the patient, review each agent in SEER*Rx separately.
o SEER*Rx indicates in the **Coding** section if the agent should be coded on the abstract. Only include information in text for agents that should be coded.

o Read the remarks in SEER*Rx carefully, as some agents should be coded only in specific circumstances (e.g. Prednisone is only coded if part of a drug regimen).

- Code as treatment for both primaries when the patient receives chemotherapy for invasive carcinoma in one breast and the patient also has in-situ carcinoma in the other breast.

- Record the following information in the appropriate text field (e.g. Chemotherapy agent recorded in Text-Chemotherapy).
  
  o Treatment start date
  
  o If therapy is neoadjuvant per the treatment plan
  
  o If treatment is started, but not completed, as prescribed
  
  o Agent(s)
  
  o Reason for no treatment if systemic therapy would be expected.
    
    ▪ E.g. Patient co-morbidities
    
    ▪ E.g. Patient refused recommended treatment

For additional information regarding recording text, please see **Appendix T - Text Documentation Guidelines**.
VI.4.1 Names of Chemotherapeutic Agents
Generic or trade names of the drugs used for chemotherapy must be recorded in the text data item.

Coding Instructions:

- Include agents that are in the investigative or clinical trial phase.
- Registrars must use SEER*Rx, for coding systemic treatment (i.e. chemotherapy, hormone therapy, and immunotherapy). This applies to cases diagnosed January 1, 2005 and forward.
  - SEER*Rx is the downloadable, interactive antineoplastic drug database that replaced the SEER Self-Instructional Manual Book 8, Antineoplastic Drugs.
  - The software can be downloaded from the SEER*Rx website.
VI.4.2 Date of Chemotherapy
Enter the date in which chemotherapy began at any facility as part of first course of treatment.

- See Entering Dates and Date Format for additional information regarding entering dates. Consult with your software vendor for specific data entry instructions.

Coding Instructions:
- Enter the earliest date in which chemotherapy was administered.
  - Include date and treatment performed in the corresponding text data items.
- Record only first course of treatment dates in this data item.
VI.4.3 Chemotherapy Codes
Chemotherapy is a drug treatment that utilizes powerful chemicals to kill fast-growing cancer cells.

Use the following codes for recording chemotherapy in the summary data item.

Coding Instructions:
- Codes 00-87 for recording chemotherapy in the at this facility data item.
- Code 00 in the following scenarios:
  - Record shows chemotherapy was not given as first course treatment.
  - No information in the record regarding chemotherapy and
    - It is known that chemotherapy is not typically performed for this type and/or stage of cancer or
    - There is no reason to suspect that the patient would have had chemotherapy.
  - The treatment plan offers multiple treatment options, and the patient selects a treatment that did not include chemotherapy.
  - Patient’s decision not to pursue chemotherapy is not a refusal of chemotherapy when:
    - The patient has discussed chemotherapy with their physician, and then decides to pursue no treatment.
    Note: Discussion does not equal a recommendation.
- Code chemoembolization as 01, 02, or 03 depending on the number of chemotherapeutic agents involved.
- Code 87 when:
  - Patient refuses chemotherapy.
  - Chemotherapy is a typical treatment option for the primary site/histology and
    - Patent made a blanket refusal of all recommended treatment or
    - Patient refused all treatment before any was recommended
- Code 88 when:
  - Patient referred to an oncologist.
    Note: Referral to a medical oncologist is considered a recommendation. This applies to cases diagnosed January 1, 2010 and forward.
  - Insertion of Port-a-Cath.
**Note:** Follow-up on cases coded to 88 is required to determine whether chemotherapy was administered or not, and code accordingly.

**Note:** Do not code 99 when recording therapy at this facility, if Class of Case is coded to 00, 30, or 31.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>None, chemotherapy was not part of the planned first course of therapy; Diagnosed at autopsy</td>
</tr>
<tr>
<td>01</td>
<td>Chemotherapy, NOS</td>
</tr>
<tr>
<td>02</td>
<td>Single-agent chemotherapy</td>
</tr>
<tr>
<td>03</td>
<td>Multi-agent chemotherapy administered as first course therapy</td>
</tr>
<tr>
<td>82</td>
<td>Chemotherapy was not recommended/administered because it was contraindicated due to patient risk factors (i.e., comorbid conditions, advanced age)</td>
</tr>
<tr>
<td>85</td>
<td>Chemotherapy not administered because the patient died prior to planned or recommended therapy</td>
</tr>
<tr>
<td>86</td>
<td>Chemotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record</td>
</tr>
<tr>
<td>87</td>
<td>Chemotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record</td>
</tr>
<tr>
<td>88</td>
<td>Chemotherapy was recommended, but it is unknown if it was administered</td>
</tr>
<tr>
<td>99</td>
<td>It is unknown whether a chemotherapeutic agent(s) was recommended or administered because it is not stated in patient record; Death Certificate Only (DCO)</td>
</tr>
</tbody>
</table>
VI.5 Hormone (Endocrine) Therapy - First Course of Treatment

Hormone Therapy is a form of systemic therapy that works to add, block or remove hormones from the body to slow or stop the growth of cancer cells. Report the administration of hormones, anti-hormones, or steroids to attack cancer tissue by changing the patient's hormone balance.

Coding Instructions:

- Record surgery performed for hormonal effect (such as castration) and radiation for hormonal effect for breast and prostate cancers only.
- When steroids are combined with chemotherapy, record their use, in addition to reporting the chemotherapy in the chemotherapy section.
- Use SEER*Rx to determine if the agent is chemotherapy, hormonal therapy, immunotherapy, or an ancillary agent (non-cancer directed).
  - If a drug regimen is given to the patient, review each agent in SEER*Rx separately.
  - SEER*Rx indicates in the Coding section if the agent should be coded on the abstract. Only include information in text for agents that should be coded.
  - Read the remarks in SEER*Rx carefully, as some agents should be coded only in specific circumstances (e.g. Prednisone is only coded if part of a drug regimen).
  - The software can be downloaded from the SEER*Rx website.
- Record the following information in the appropriate text field (e.g. Hormone Therapy recorded in Text-Hormone Therapy).
  - Treatment start date
  - If therapy is neoadjuvant per the treatment plan
  - If treatment is started, but not completed, as prescribed
  - Agent(s)
  - Reason for no treatment if systemic therapy would be expected.
    - E.g. Patient co-morbidities
    - E.g. Patient refused recommended treatment

For additional information regarding recording text, please see Appendix T - Text Documentation Guidelines.
**VI.5.1 Hormones**

Cancer-directed treatment with hormones and anti-hormones must be coded in the appropriate data item and must always have corresponding text documentation for all sites.

**Coding Instructions:**

- Report cancer directed use of adrenocorticotropic hormones for treatment of leukemia’s, lymphomas, multiple myelomas, and breast and prostate cancers. However, report as hormone therapy any hormonal agent that is given in combination with chemotherapy (e.g., MOPP or COPP) for cancer of any site whether it affects the cancer cells or not.

- For cases diagnosed 1/1/2005 forward, registrars must use SEER*Rx, for coding systemic treatment (i.e. chemotherapy, hormone therapy, and immunotherapy).
  - SEER*Rx is the downloadable, interactive antineoplastic drug database that replaced the SEER Self-Instructional Manual Book 8, Antineoplastic Drugs.
  - The software can be downloaded from the [SEER*Rx](#) website.
VI.5.2 Date of Hormone Therapy
Enter the date in which hormone therapy began at any facility as part of first course of treatment.

See Enter Dates and Date Format for additional information regarding entering dates. Consult with your software vendor for specific data entry instructions.

Coding Instructions:
- Enter the earliest date in which hormone therapy was administered.
  - Include date and treatment performed in the corresponding text data items.
- Record only first course of treatment dates in this data item.
VI.5.3 Hormone Therapy Codes

Use the following codes for recording hormone therapy in the summary data item.

Coding Instructions:

- Codes 00-87 are used for recording hormone therapy in the at this facility data item.
- The codes for reason no hormones have been incorporated into this data item.
- For recording therapy at this facility, do not use code 99 if Class of Case is coded to 00, 30, or 31.
- Referral to a medical oncologist is considered a recommendation. Follow-up on these cases is required to determine whether hormone therapy was administered or not, and code accordingly. This applies to cases diagnosed January 1, 2010 and forward.
- Patient’s decision not to pursue hormone therapy is not a refusal of hormone therapy when:
  - The patient has discussed hormone therapy with their physician, and then decides to pursue no treatment.

  **Note:** Discussion does not equal a recommendation.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>None, hormone therapy was not part of the planned first course therapy</td>
</tr>
<tr>
<td>01</td>
<td>Hormone therapy administered as first course therapy</td>
</tr>
<tr>
<td>82</td>
<td>Hormone therapy was not recommended/administered because it was contraindicated due to patient risk factors (i.e., comorbid conditions, advanced age)</td>
</tr>
<tr>
<td>85</td>
<td>Hormone therapy was not administered because the patient died prior to planned or recommended therapy</td>
</tr>
<tr>
<td>86</td>
<td>Hormone therapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course therapy. No reason was stated in patient record</td>
</tr>
<tr>
<td>87</td>
<td>Hormone therapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in the patient record</td>
</tr>
<tr>
<td>88</td>
<td>Hormone therapy was recommended, but it is unknown if it was administered</td>
</tr>
<tr>
<td>99</td>
<td>It is unknown whether a hormonal agent(s) was recommended or administered because it is not stated in patient record; Death certificate Only (DCO)</td>
</tr>
</tbody>
</table>
VI.6 Immunotherapy (Biological Response Modifier Therapy) - First Course of Treatment

Immunotherapy/biological response modifier therapy (BRM) is a generic term covering everything done to the immune system to alter it or change the host response to a cancer (defense mechanism).

Coding Instructions:

- Use SEER*Rx to determine if the agent is chemotherapy, hormonal therapy, immunotherapy, or an ancillary agent (non-cancer directed).
  - If a drug regimen is given to the patient, review each agent in SEER * Rx separately.
  - SEER*Rx indicates in the Coding section if the agent should be coded on the abstract. Only include information in text for agents that should be coded.
- Read the remarks in SEER*Rx carefully, as some agents should be coded only in specific circumstances (e.g. Prednisone is only coded if part of a drug regimen).
- The software can be downloaded from the SEER*Rx website.
- Record the following information in the appropriate text field (e.g. Immunotherapy agent recorded in Text-Immunotherapy).
  - Treatment start date
  - If therapy is neoadjuvant per the treatment plan
  - If treatment is started, but not completed, as prescribed
  - Agent(s)
  - Reason for no treatment if systemic therapy would be expected.
    - E.g. Patient co-morbidities
    - E.g. Patient refused recommended treatment
- Transplant/Endocrine Procedures should be recorded in Text-Immunotherapy since there is no corresponding text field for the Transplant/Endocrine data items. Record:
  - Date of transplant/procedure

For additional information regarding recording text, please see Appendix T - Text Documentation Guidelines.
VI.6.1 Immunotherapy Agents
Records the type of immunotherapy administered as first course treatment.

Coding Instructions:

- Cases diagnosed January 1, 2012 and forward, report the following as Immunotherapy:
  - Donor lymphocyte infusion - The lymphocyte donation from the original donor creates an immune reaction to the cancer cells.
- With cases diagnosed January 1, 2005 and forward, registrars must use SEER*Rx, for coding systemic treatment (i.e. chemotherapy, hormone therapy, and immunotherapy).
  - SEER*Rx is the downloadable, interactive antineoplastic drug database that replaced the SEER Self-Instructional Manual Book 8, Antineoplastic Drugs.
  - The software can be downloaded from the SEER*Rx website.
    - Report the following as immunotherapy:
      - ASILI (active specific intralymphatic immunotherapy)
      - Blocking factors
      - Interferon
      - Monoclonal antibodies *
      - Transfer factor (specific or non-specific)
      - Virus therapy

Note: Some monoclonal antibodies are used to deliver chemotherapy or radiation agents to the tumor, not to kill the tumor immunologically. Consult SEER*Rx to determine how to appropriately code monoclonal antibodies.
VI.6.2 Date of Immunotherapy
Enter the date in which immunotherapy began at any facility as part of first course of treatment.

See Entering Dates and Date Format for additional information regarding entering dates. Consult with your software vendor for specific data entry instructions.

Coding Instructions:
- Enter the earliest date in which immunotherapy was administered.
  - Include date and treatment performed in the corresponding text data items.
- Record only first course of treatment dates in this data item.
VI.6.3 Immunotherapy Codes
Enter the appropriate code below when coding immunotherapy in the summary data item.

Coding Instructions:
- Use codes 00-87 for recording immunotherapy in the at this facility data item.
- Immunotherapy agents must be recorded in the text data item.
- For recording therapy at this facility, do not use code 99 if Class of Case is coded to 00, 30, or 31.
- Referral to a medical oncologist is considered a recommendation. Follow-up on these cases is required to determine whether immunotherapy was administered or not, and code accordingly. This applies to cases diagnosed January 1, 2010 and forward.
- Patient’s decision not to pursue immunotherapy is not a refusal of immunotherapy when:
  - The patient has discussed immunotherapy with their physician, and then decides to pursue no treatment.
  - Note: Discussion does not equal a recommendation.
- Effective with cases diagnosed 1/1/2003, this data item was modified. Codes for transplants and endocrine procedures were removed and were coded in a separate data item called RX Summ - Transplnt/Endocr. The length of this data item was changed from 1 to 2 characters. The codes for reason for no immunotherapy (BRM) given were incorporated into this scheme.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>None, immunotherapy was not part of the planned first course of therapy</td>
</tr>
<tr>
<td>01</td>
<td>Immunotherapy administered as first course therapy</td>
</tr>
<tr>
<td>82</td>
<td>Immunotherapy was not recommended/administered because it was contraindicated due to patient risk factors (i.e. Comorbid conditions, advanced age)</td>
</tr>
<tr>
<td>85</td>
<td>Immunotherapy was not administered because the patient died prior to planned or recommended therapy</td>
</tr>
<tr>
<td>86</td>
<td>Immunotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of the first course of therapy. No reason was stated in patient record</td>
</tr>
<tr>
<td>87</td>
<td>Immunotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in the patient record</td>
</tr>
<tr>
<td>88</td>
<td>Immunotherapy was recommended, but it is unknown if it was administered</td>
</tr>
<tr>
<td>99</td>
<td>It is unknown whether an immunotherapeutic agent(s) was recommended or administered because it is not stated in patient record; Death certificate Only (DCO)</td>
</tr>
</tbody>
</table>
VI.7 Transplant/Endocrine - First Course of Treatment

Identifies systemic therapeutic procedures administered as part of the first course of treatment. For reporting purposes, endocrine surgery is defined as the total surgical removal of an endocrine gland (both glands or all of a remaining gland in the case of paired glands).

Coding Instructions:

- Procedures included for transplant/endocrine are:
  - Bone marrow transplants
  - Stem cell harvests
  - Surgical and/or radiation endocrine therapy

Note: Transplant/Endocrine treatment should be recorded in Immunotherapy.
VI.7.1 Date of Transplant/Endocrine Procedure
Enter the date in which the transplant/endocrine procedure took place at any facility as part of the first course treatment.

See Entering Dates and Date Format for additional information regarding entering dates. Consult with your software vendor for specific data entry instructions.

Coding Instructions:

• Enter the earliest date in which the transplant/endocrine procedure was performed.
  
  o Include date and treatment performed in the corresponding text data items.

  Note: There is no text data item for bone marrow transplant and endocrine procedures. Record text information regarding bone marrow transplants and endocrine procedures in the immunotherapy text data item.

• Record only first course of treatment dates in this data item.
VI.7.2 Transplant/Endocrine Procedures Codes

Record systemic therapeutic procedures administered as part of first course of treatment. For reporting purposes, endocrine surgery is defined as the total surgical removal of an endocrine gland (both glands or all of a remaining gland in the case of paired glands).

Coding Instructions:

- Codes 11 (bone marrow transplant autologous) and 12 (Bone marrow transplant allogenic) take priority over code 10 (BMT, NOS).
  - Code 10 when the patient has a bone marrow transplant, and it is unknown if it is autologous or allogenic.
- Code 20 for:
  - Allogeneic stem cell transplant
  - Peripheral blood stem cell transplant
  - Umbilical code stem cell transplant (single or double)
- Code 88 when:
  - Referral to a specialist for hematologic transplant or endocrine procedures is considered a recommendation.
  - The patient has a bone marrow or stem cell harvest, but it was not followed by a rescue or reinfusion as part of the first course treatment.

  **Note:** Follow-up on cases coded to 88 is required to determine whether a procedure was performed or not. Recode this accordingly. This applies to cases diagnosed January 1, 2010 and forward.
- Patient’s decision not to pursue transplant procedure or endocrine therapy is not a refusal of other therapy when:
  - The patient has discussed transplant procedure or endocrine therapy with their physician, and then decides to pursue no treatment.
  **Note:** Discussion does not equal a recommendation.
- Information on transplants and endocrine procedures was removed from the Rx Summ-BRM (Immunotherapy) data item and moved to this data item. Bone marrow and stem cell procedures are now coded in this data item along with endocrine surgery or radiation.
  - Record endocrine surgery for treatment of cancer of the breast or prostate only. The procedures are:
    - Adrenalectomy
    - Hypophysectomy
- Oophorectomy (breast)
- Orchiectomy (prostate)
  - If tumor tissue is present in a gland removed in the course of endocrine therapy, record the procedure as surgical treatment also.
- Report any type of radiation directed toward an endocrine gland to affect hormonal balance if:
  - The treatment is for cancers of the breast and prostate.
  - Both paired glands (ovaries, testes, adrenals), or all of a remaining gland have been irradiated.

**Notes:**

1. For recording therapy at this facility, do not use code 99 if Class of Case is coded to 00, 30, or 31.
2. Use the following codes for recording transplant/endocrine procedures in the summary data item.
3. Use codes 00-87 for recording transplant/endocrine procedures in the "at this facility data item."

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>No transplant procedure or endocrine therapy was administered as part of the first course therapy</td>
</tr>
<tr>
<td>10</td>
<td>A bone marrow transplant procedure was administered, but the type was not specified</td>
</tr>
<tr>
<td>11</td>
<td>Bone marrow transplant - autologous</td>
</tr>
<tr>
<td>12</td>
<td>Bone marrow transplant – allogeneic Syngeneic bone marrow transplant (identical twin)</td>
</tr>
<tr>
<td>20</td>
<td>Stem cell harvest and infusion (stem cell transplant)</td>
</tr>
<tr>
<td>30</td>
<td>Endocrine surgery and/or endocrine radiation therapy</td>
</tr>
<tr>
<td>40</td>
<td>Combination of endocrine surgery and/or radiation with a transplant procedure. (combination of codes 30 and 10, 11, 12, or 20)</td>
</tr>
<tr>
<td>82</td>
<td>Hematologic transplant and/or endocrine surgery/radiation were not recommended/administered because it was contraindicated due to patient risk factors (i.e., comorbid conditions, advanced age)</td>
</tr>
<tr>
<td>85</td>
<td>Hematologic transplant and/or endocrine surgery/radiation were not administered because the patient died prior to planned or recommended therapy</td>
</tr>
<tr>
<td>86</td>
<td>Hematologic transplant and/or endocrine surgery/radiation were not administered. It was recommended by the patient's physician, but was not</td>
</tr>
<tr>
<td>Page</td>
<td>Information</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td>87</td>
<td>Hematologic transplant and/or endocrine surgery/radiation were not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, a patient's family member, or the patient's guardian. The refusal was noted in patient record</td>
</tr>
<tr>
<td>88</td>
<td>Hematologic transplant and/or endocrine surgery/radiation was recommended, but it is unknown if it was administered</td>
</tr>
<tr>
<td>99</td>
<td>It is unknown whether hematologic transplant and/or endocrine surgery/radiation was recommended or administered because it is not stated in patient record; Death Certificate Only (DCO)</td>
</tr>
</tbody>
</table>
VI.8 Other Therapy - First Course of Treatment
Record the definitive cancer-directed treatment that cannot be assigned to any other category. Information on other therapy is used to describe and evaluate the quality of care and treatment practices.

Coding Instructions:

- Hyperbaric oxygen (as adjunct to definitive treatment).
- Hyperthermia (given alone or in combination with chemotherapy, as in isolated heated limb perfusion for melanoma).
- Photophoresis. Used only for thin melanoma or cutaneous T-cell lymphoma (mycosis fungoides).
- PUVA (Psoralen (P) and long-wave ultraviolet radiation (UVA)). Rarely used for thin melanoma or cutaneous T-cell lymphoma (mycosis fungoides).
- UVB Phototherapy for mycosis fungoides is coded to photodynamic therapy under Surgery of Primary Site 2023 for skin. See, Appendix K.2: Skin, for surgery codes.
- Cancer vaccines are still in the experimental phase. Currently, clinical trials use cancer vaccines for brain, breast, colon, kidney, lung, melanoma, and ovary.
- Optune treatment for Glioblastoma Multiforme (GBM), see Appendix A: Terms and Definitions for additional information.
- Any experimental drug that cannot be classified elsewhere.
- Double blind clinical trial information where the type of agent administered is unknown and/or there is any use of a placebo. However, after the code is broken, report the treatment under the appropriate category (a correction record should be submitted when the data are available).
- Unorthodox and unproven treatment, such as laetrile or krebiozen.

Note: Do not code pre-operative embolization of hypervascular tumors with agents such as particles, coils, or alcohol as treatment. These pre-surgical treatments are typically performed to prevent excess bleeding during the resection of the primary tumor.

- The principal treatment for certain reportable hematopoietic diseases could be supportive care that does not meet the usual definition of treatment that "modifies, controls, removes, or destroys" proliferating cancer tissue.
  - Supportive care may include phlebotomy, transfusion, or aspirin.

Note: To report the hematopoietic cases in which a patient received supportive care, SEER and the Commission on Cancer have agreed to
record treatments such as phlebotomy, transfusion, or aspirin as “Other Treatment” (Code 1) for certain hematopoietic diseases only.

- For hematopoietic and lymphoid cases, please refer to the SEER Hematopoietic and Lymphoid Neoplasm Database and Hematopoietic & Lymphoid Neoplasm Coding Manual for coding instructions regarding specific hematopoietic neoplasms in this item.

**Note: Do not** collect blood transfusions (whole blood, platelets, etc.) as treatment for any of these diseases. Blood transfusions are used widely to treat anemia and it is not possible to collect this procedure in a meaningful way. This applies to cases diagnosed January 1, 2012 and forward only.

- In the appropriate text field, enter the following information:
  - Date of therapy
  - Type of therapy. Provide enough information to justify the Other Therapy Code data item.

For additional information regarding recording text, please see Appendix T - Text Documentation Guidelines.
VI.8.1 Date of Other Therapy
Enter the date in which other therapy began at any facility as part of first course treatment.

See Entering Dates and Date Format for additional information regarding entering dates. Consult with your software vendor for specific data entry instructions.

Coding Instructions:
- Enter the earliest date in which other therapy was administered.
  - Include date and treatment performed in the corresponding text data items.
- Record only first course of treatment dates in this data item.
VI.8.2 Other Therapy Codes
This data item captures other therapy administered to the patient as first course treatment.

Coding Instructions:

- Enter the appropriate code below for other therapy administered to the patient.
- Codes 0-7 are used for recording other therapy in the at this facility data item.
- For recording therapy at this facility, do not use code 9 if Class of Case is coded to 00, 30, or 31.
- Referral to a specialist is considered a recommendation. Follow-up on these cases is required to determine whether treatment was administered or not, and code accordingly. This applies to cases diagnosed January 1, 2010 and forward.
- Patient’s decision not to pursue other therapy is not a refusal of other therapy when:
  - The patient has discussed other therapy with their physician, and then decides to pursue no treatment.

  Note: Discussion does not equal a recommendation.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No other cancer directed therapy except as coded elsewhere; Diagnosed at autopsy</td>
</tr>
</tbody>
</table>
| 1    | Other cancer directed therapy  
Examples:  
- Embolization using alcohol as an embolizing agent  
- PUVA (psoralen and long-wave ultraviolet radiation) treatments for melanoma  
- Photophoresis. This treatment is used only for thin melanoma or cutaneous T-cell lymphoma (mycosis fungoides)  
- Peptide Receptor Radionuclide Therapy (PRRT) |
| 2    | Other experimental cancer directed therapy (not included elsewhere) |
| 3    | Double blind clinical trial, code not yet broken |
| 6    | Unproven therapy  
Cancer therapy administered by nonmedical personnel |
| 7    | Patient or patient's guardian refused therapy which would have been coded 1–3 above |
| 8    | Other cancer directed therapy recommended, unknown if administered |
| 9 | Unknown if other therapy recommended or administered; Death Certificate Only (DCO) |
VI.9 RX Summary - Treatment Status

This data item is used to summarize the status for all treatment modalities. It is used in conjunction with Date of Initial RX and/or Date of 1st Course RX-CoC and each modality of treatment with their respective date data item to document whether treatment was given or not given, whether it is unknown if treatment was given, or whether treatment was given on an unknown date. Active surveillance (watchful waiting) is also documented. This data item is required by the CCR.

Coding Instructions:

- Code 0 when the patient does not receive any treatment.
  
  **Note:** Scope of Regional Lymph Node Surgery may be coded to 0, 1-7, or 9.

- Code 1 when the patient receives treatment collected in any of the following data items:
  
  o Surgery of Primary Site 2023
  
  o Surgical Procedure of Other Site
  
  o Radiation Treatment Modality, Phase I, II, III
  
  o Chemotherapy
  
  o Hormone Therapy
  
  o Immunotherapy
  
  o Hematologic Transplant and Endocrine Procedures
  
  o Other Therapy

- Do not count Scope of Regional Lymph Node Surgery code 1 as surgery for the purpose of coding this data item.

- Code 2 when active surveillance/watchful waiting/deferred therapy, or any other similar options are recorded in the medical record.

- Code 9 for Death Certificate Only (DCO) cases.

- Leave blank for cases diagnosed prior to January 1, 2010.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No treatment given, treatment refused, or physician decides not to treat for any reason such as the presence of comorbidities</td>
</tr>
<tr>
<td>1</td>
<td>Treatment given</td>
</tr>
<tr>
<td>2</td>
<td>Active surveillance (watchful waiting)</td>
</tr>
<tr>
<td>9</td>
<td>Unknown if treatment was given</td>
</tr>
</tbody>
</table>
VI.10 Protocol Participation
This data item collects the patient’s participation in a protocol study.

Coding Instructions:
- The CCR requires that this data item be collected and transmitted to the CCR for patient’s participation in a protocol study. This is effective with cases diagnosed January 1, 2001 and forward.
- Document in Text – Remarks the protocol study, clinical trial name or ID/number and study arm, as stated in the medical record.

Examples:
- Protocol: SWOG-S0777
- Protocol: NSAPB B-39, RTOG 04313
- Protocol: RTOG-00534
- Protocol: CodeBreak 300: Colorectal Cancer/NCT05198934
- For additional information regarding recording text, please see Appendix T -Text Documentation Guidelines.

- If a patient is on a treatment regimen that follows a protocol, but the patient is not actually enrolled in the study, then this data item does not apply. Assign code 00.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

National Protocols

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>01</td>
<td>NSABP</td>
</tr>
<tr>
<td>02</td>
<td>GOG</td>
</tr>
<tr>
<td>03</td>
<td>RTOG</td>
</tr>
<tr>
<td>04</td>
<td>SWOG</td>
</tr>
<tr>
<td>05</td>
<td>ECOG</td>
</tr>
<tr>
<td>06</td>
<td>POG</td>
</tr>
<tr>
<td>07</td>
<td>CCG</td>
</tr>
<tr>
<td>08</td>
<td>CALGB</td>
</tr>
<tr>
<td>09</td>
<td>NCI</td>
</tr>
<tr>
<td>10</td>
<td>ACS</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>11</td>
<td>National Protocol, NOS</td>
</tr>
<tr>
<td>12</td>
<td>ACOS-OG</td>
</tr>
<tr>
<td>13</td>
<td>VA [Veterans Administration]</td>
</tr>
<tr>
<td>14</td>
<td>COG (Children's Oncology Group)</td>
</tr>
<tr>
<td>15</td>
<td>CTSU [Clinical Trials Support Unit]</td>
</tr>
<tr>
<td>16-50</td>
<td>National Trials</td>
</tr>
</tbody>
</table>

**Locally Defined**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>51-79</td>
<td>Locally Defined</td>
</tr>
<tr>
<td>80</td>
<td>Pharmaceutical</td>
</tr>
<tr>
<td>81-84</td>
<td>Locally Defined</td>
</tr>
<tr>
<td>85</td>
<td>In-House Trial</td>
</tr>
<tr>
<td>86-88</td>
<td>Locally Defined</td>
</tr>
<tr>
<td>89</td>
<td>Other</td>
</tr>
<tr>
<td>90-98</td>
<td>Locally Defined</td>
</tr>
<tr>
<td>99</td>
<td>Unknown</td>
</tr>
</tbody>
</table>
Part VII. Follow-Up

Part IV of Volume I cover patient and tumor follow-up. It provides resources for where to obtain follow-up information while abstracting. There are great guidelines and instructions for collecting data items such as patient contact information, date of last contact, vital status, tumor status, and physician information.
VII.1 Follow-Up Information

A function of the California cancer reporting system is annual monitoring of patients to ascertain survival rates. Therefore, if follow-up information is available before an abstract is submitted, include the follow-up information in the abstract.

Guidelines:

- The CCR now requires facilities to use the Modified Record instead of the former Update/Correction and Follow-Up Records to transmit data modifications for abstracts already submitted as New Case Records. See Modified Record for more information regarding this change.

- Facilities with cancer programs approved by ACS must update follow-up data annually (consult ACS Guidelines for requirements).
  - Re-admission to the facility as an inpatient or outpatient.
  - A report by the patient's physician.
  - Direct response to a letter or phone call to the patient or other contact person.

- Additionally, regional registries may obtain further follow-up information using the following methods:
  - Registrar of voters
  - Welfare agencies
  - Labor unions
  - Religious groups
  - Death certificate

- Annual follow-up is not required for a reporting facility that does not have a tumor registry and is submitting an abstract only to meet state reporting requirements. The CCR does not impose follow-up requirements beyond what a hospital chooses to do for its own purposes.
  **Example:** A reporting facility elects not to follow non-analytic cases; the CCR will not expect to receive follow-up information for such cases.

- Current status is defined as contact with the patient within 15 months of the date of last reported follow-up. Although current follow-up information is preferred, any information, whether current or not, should still be reported.

Site-Specific Follow-up:

- Follow-up is required for the following tumors, although they are categorized in Class of Case 34 or 36. This applies to cases diagnosed January 1, 2010 and forward.
Benign and borderline CNS tumors diagnosed between January 1, 2001 and December 31, 2003 (before the national benign and borderline CNS tumor reporting requirement was implemented).

- VIN III
- VAIN III
- AIN III

**Shared Follow-Up:**

- In those cases, where a patient is being followed by more than one reporting facility, the Regional or the Central Registry may designate a facility responsible for follow-up in an effort to prevent physicians and patients from receiving requests for information from many sources.

- Shared follow-up which discloses the source or name of the facility requires a signed agreement from each participating registry.

- Follow-up may be shared without a signed agreement as long as the source is not disclosed.

- This does not preclude a facility's registry from submission of more current information about its patients. Shared follow-up is instituted only by agreement among participating facilities in a region.
VII.1.1 Required Data - Follow-Up

Some follow-up data items are optional for reporting to the CCR but might be required by the ACS, for shared follow-up involving other institutions, or by the reporting facility for in-house data.

Coding Instructions:

The CCR's required items for follow-up are:

- Date of Last Patient Contact
- Vital Status
- Date Last Tumor Status
- Tumor Status
- Last Follow-up Facility
- Death information
VII.1.2 Sources of Follow-Up Information

Follow-up information must be based on documentation of contact with the patient in one of the following forms:

- Direct response to a letter or phone call to the patient or other contact person
- A report by the patient's physician
- Re-admission to the facility as an inpatient or outpatient
- Death certificate

**Note:** It might be necessary to trace the patient through such agencies and organizations as the registrar of voters, welfare agencies, labor unions, religious groups, or the Office of the State Registrar for a death certificate.
VII.1.3 Current Status of Follow-Up Information
Current status is defined as contact with the patient within 15 months of the date the follow-up is reported. Although current follow up information is preferred, any information, whether current or not, should still be reported.
VII.1.4 Shared Follow-Up

In those cases, where a patient is being followed by more than one reporting facility, the Regional or the Central Registry may designate a facility responsible for follow-up to prevent physicians and patients from receiving requests for information from many sources.

Shared follow-up which discloses the source or name of the facility requires a signed agreement from each participating registry.

Follow-up may be shared without a signed agreement as long as the source is not disclosed.

This does not preclude a facility's registry from submission of more current information about its patients. Shared follow-up is instituted only by agreement among participating facilities in a region.
VII.2 Follow-Up Data Items
Follow-up data items provide information about the outcome of cancers and the results of treatment. A patient's survival time is calculated based on date of diagnosis and date of last contact.
VII.2.1 Date of Last Contact (AKA-Date Last Pt FU)
This data item captures the date the patient was last seen, heard from, or the date of death. It is important for researchers to calculate survival and outcome studies.

See Entering Dates and Date Format for additional information regarding entering dates. Consult with your software vendor for specific data entry instructions.

Coding Instructions:
- Enter the most current date the patient was seen, heard from, or their date of death.
- Enter the date of discharge from the reporting facility when no follow-up information has been received.
- Each abstract submitted on a patient who has multiple primaries, must contain the same date of last contact.
- Do not enter the date the follow-up information was forwarded or received.
- Change this date if new information received is obtained from the patient, a family member, or other non-physician.

Note: Follow-up information obtained from the physician or other official source documenting the patient’s tumor status is to be coded in Date of Last Cancer Status data items.
VII.2.2 Vital Status
This data item records the vital status of the patient on the date of last follow-up.

Coding Instructions:
- Enter the code representing whether the patient was still alive on the date of last contact.
- If a patient with more than one primary has died, be sure to record the fact in all the abstracts.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Dead</td>
</tr>
<tr>
<td>1</td>
<td>Alive</td>
</tr>
</tbody>
</table>
VII.2.3 Date of Last Cancer (Tumor) Status
This data item captures the date of the last information obtained on the primary cancer (tumor) being followed. It is important because it documents information on each tumor when the patient has multiple.

See Entering Dates and Date Format for additional information regarding entering dates. Consult with your software vendor for specific data entry instructions.

Coding Instructions:
- Enter the date on which the patient’s cancer status was known to be updated.
- Cancer status is based on information from the patient’s physician or other official source such as a death certificate.
  - Only change this date if new information received is from the physician or other official source.
    - **Note**: Follow-up information obtained from the patient, a family member, or other non-physician is to be coded in the Date of Last Contact data items.
- Cancer status changes if the patient has a recurrence or relapse.
- If there are multiple primaries, this date may be different for each depending on follow-up for each tumor.
VII.2.4 Cancer (Tumor) Status
This data item records the presence or absence of clinical evidence of the patient’s cancer (tumor) as of the Date of Last Cancer Status (AKA – Date of Tumor Status). It is important because it can be used to gauge disease-free survival.

Coding Instructions:
• The data item applies only to the cancer (tumor) for which the abstract is submitted, regardless of any other cancers (tumors) the patient might have.
• The value may be different for each primary.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Free - no evidence of this cancer</td>
</tr>
<tr>
<td>2</td>
<td>Not free - evidence still exists of this cancer</td>
</tr>
<tr>
<td>9</td>
<td>Unknown - status of this cancer is unknown</td>
</tr>
</tbody>
</table>
VII.2.5 Quality of Survival
Enter the code that best characterizes the patient's quality of survival. This item is not required by the CCR.

Coding Instructions:
- Reporting facilities may use another coding system or scale adopted by the facility's cancer committee.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Normal activity</td>
</tr>
<tr>
<td>1</td>
<td>Symptomatic and ambulatory</td>
</tr>
<tr>
<td>2</td>
<td>Ambulatory more than 50%, occasionally needs assistance</td>
</tr>
<tr>
<td>3</td>
<td>Ambulatory less than 50%, nursing care needed</td>
</tr>
<tr>
<td>4</td>
<td>Bedridden, may require hospitalization</td>
</tr>
<tr>
<td>8</td>
<td>Not applicable; dead</td>
</tr>
<tr>
<td>9</td>
<td>Unknown/Unspecified</td>
</tr>
</tbody>
</table>
VII.2.6 Last Type of Follow-Up
This data item captures the type of follow-up a patient has received.

Coding Instructions:

- There are two data items which are to be used to enter the source of the most recent follow-up information about the patient and the patient’s tumor:
  - See Last Type of Tumor Follow-Up
  - See Last Type of Patient Follow-Up
VII.2.6.1 Last Type of Tumor Follow-Up

This data item is to be used to enter information representing the source of the most up-to-date information on the tumor being followed.

Coding Instruction:
- Reporting facilities ordinarily use the codes 00-15.

Follow-up obtained by reporting facility from:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>Admission being reported</td>
</tr>
<tr>
<td>01</td>
<td>Readmission to reporting facility</td>
</tr>
<tr>
<td>02</td>
<td>Follow-up report from physician</td>
</tr>
<tr>
<td>03</td>
<td>Follow-up report from patient</td>
</tr>
<tr>
<td>04</td>
<td>Follow-up report from relative</td>
</tr>
<tr>
<td>05</td>
<td>Obituary</td>
</tr>
<tr>
<td>07</td>
<td>Follow-up report from hospice</td>
</tr>
<tr>
<td>08</td>
<td>Follow-up report from other facility</td>
</tr>
<tr>
<td>09</td>
<td>Other source</td>
</tr>
<tr>
<td>11</td>
<td>Telephone call to any source</td>
</tr>
<tr>
<td>12</td>
<td>Special studies</td>
</tr>
<tr>
<td>14</td>
<td>ARS (AIDS registry system)</td>
</tr>
<tr>
<td>15</td>
<td>Computer match with discharge data</td>
</tr>
<tr>
<td>16</td>
<td>Telephone call to any source</td>
</tr>
</tbody>
</table>

Follow-up obtained by regional registry from:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>Letter to a physician</td>
</tr>
<tr>
<td>22</td>
<td>Computer match with Medicare or Medicaid file</td>
</tr>
<tr>
<td>23</td>
<td>Computer match with HMO file</td>
</tr>
<tr>
<td>25</td>
<td>National death index</td>
</tr>
<tr>
<td>26</td>
<td>Computer match with state death tape</td>
</tr>
<tr>
<td>29</td>
<td>Computer match, other or NOS</td>
</tr>
<tr>
<td>30</td>
<td>Other source</td>
</tr>
<tr>
<td>31</td>
<td>Telephone call to any source</td>
</tr>
<tr>
<td>32</td>
<td>Special studies</td>
</tr>
<tr>
<td>33</td>
<td>Other source</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>34</td>
<td>ARS (AIDS registry system)</td>
</tr>
<tr>
<td>35</td>
<td>Computer match with discharge data</td>
</tr>
<tr>
<td>36</td>
<td>Obituary</td>
</tr>
</tbody>
</table>

**Follow-up obtained by Central (State) Registry from:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>Letter to a physician</td>
</tr>
<tr>
<td>41</td>
<td>Telephone call to any source</td>
</tr>
<tr>
<td>52</td>
<td>Computer match with Medicare or Medicaid file</td>
</tr>
<tr>
<td>53</td>
<td>Computer match with HMO file</td>
</tr>
<tr>
<td>55</td>
<td>National death index</td>
</tr>
<tr>
<td>56</td>
<td>Computer match with state death tape</td>
</tr>
<tr>
<td>59</td>
<td>Computer match, other or NOS</td>
</tr>
<tr>
<td>60</td>
<td>Other source</td>
</tr>
</tbody>
</table>

**Follow-up obtained by reporting facilities usually done by the Regional/Central Registry:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>73</td>
<td>Computer match with HMO file</td>
</tr>
<tr>
<td>76</td>
<td>Computer match with state death tape</td>
</tr>
</tbody>
</table>

**Additional Codes:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>99</td>
<td>Source unknown</td>
</tr>
</tbody>
</table>
VII.2.6.2 Last Type of Patient Follow-Up
This data item is to be used to enter the code representing the source of the most up-to-date information about the patient being followed.

Coding Instruction:
- Reporting facilities ordinarily use codes 00-16.

Follow-up obtained by reporting facilities from:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>Admission being reported</td>
</tr>
<tr>
<td>01</td>
<td>Readmission to reporting facility</td>
</tr>
<tr>
<td>02</td>
<td>Follow-up report from physician</td>
</tr>
<tr>
<td>03</td>
<td>Follow-up report from patient</td>
</tr>
<tr>
<td>04</td>
<td>Follow-up report from relative</td>
</tr>
<tr>
<td>05</td>
<td>Obituary</td>
</tr>
<tr>
<td>06</td>
<td>Follow-up report from Social Security Administration or Medicare</td>
</tr>
<tr>
<td>07</td>
<td>Follow-up report from hospice</td>
</tr>
<tr>
<td>08</td>
<td>Follow-up report from other facility</td>
</tr>
<tr>
<td>09</td>
<td>Other source</td>
</tr>
<tr>
<td>11</td>
<td>Telephone call to any source</td>
</tr>
<tr>
<td>12</td>
<td>Special studies</td>
</tr>
<tr>
<td>13</td>
<td>Equifax</td>
</tr>
<tr>
<td>14</td>
<td>ARS (AIDS registry system)</td>
</tr>
<tr>
<td>15</td>
<td>Computer match with discharge data</td>
</tr>
<tr>
<td>16</td>
<td>SSDI match</td>
</tr>
</tbody>
</table>

Follow-up obtained by regional registry from:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>Letter to a physician</td>
</tr>
<tr>
<td>21</td>
<td>Computer match with Department of Motor Vehicles file</td>
</tr>
<tr>
<td>22</td>
<td>Computer match with Medicare or Medicaid file</td>
</tr>
<tr>
<td>23</td>
<td>Computer match with HMO file</td>
</tr>
<tr>
<td>24</td>
<td>Computer match with voter registration file</td>
</tr>
<tr>
<td>25</td>
<td>National death index</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>26</td>
<td>Computer match with state death tape</td>
</tr>
<tr>
<td>27</td>
<td>Death master file (Social Security)</td>
</tr>
<tr>
<td>29</td>
<td>Computer match, other or NOS</td>
</tr>
<tr>
<td>30</td>
<td>Other source</td>
</tr>
<tr>
<td>31</td>
<td>Telephone call to any source</td>
</tr>
<tr>
<td>32</td>
<td>Special studies</td>
</tr>
<tr>
<td>33</td>
<td>Equifax</td>
</tr>
<tr>
<td>34</td>
<td>ARS (AIDS registry system)</td>
</tr>
<tr>
<td>35</td>
<td>Computer match with discharge data</td>
</tr>
<tr>
<td>36</td>
<td>Obituary</td>
</tr>
<tr>
<td>37</td>
<td>Computer match with change of address service</td>
</tr>
<tr>
<td>38</td>
<td>TRW</td>
</tr>
<tr>
<td>39</td>
<td>Regional registry follow-up list</td>
</tr>
</tbody>
</table>

**Follow-up obtained by Central (State) Registry from:**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>Letter to a physician</td>
</tr>
<tr>
<td>41</td>
<td>Telephone call to any source</td>
</tr>
<tr>
<td>50</td>
<td>CMS (Center for Medicare &amp; Medicaid Services)</td>
</tr>
<tr>
<td>51</td>
<td>Computer match with Department of Motor Vehicles file</td>
</tr>
<tr>
<td>52</td>
<td>Computer match with Medicare or Medicaid file</td>
</tr>
<tr>
<td>53</td>
<td>Computer match with HMO file</td>
</tr>
<tr>
<td>55</td>
<td>National death index</td>
</tr>
<tr>
<td>56</td>
<td>Computer match with state death tape</td>
</tr>
<tr>
<td>57</td>
<td>Computer match with Medi-Cal</td>
</tr>
<tr>
<td>58</td>
<td>Computer match with Social Security death tape</td>
</tr>
<tr>
<td>59</td>
<td>Computer match, other or NOS</td>
</tr>
<tr>
<td>60</td>
<td>Other source</td>
</tr>
<tr>
<td>61</td>
<td>Social Security – SSN</td>
</tr>
<tr>
<td>62</td>
<td>Special studies</td>
</tr>
<tr>
<td>65</td>
<td>Computer match with OSHPD hospital discharge database</td>
</tr>
<tr>
<td>66</td>
<td>Computer match with national change of address file</td>
</tr>
<tr>
<td>67</td>
<td>SSA - Epidemiological vital status</td>
</tr>
</tbody>
</table>
Property tax linkage
State death tape (incremental)

Follow-up obtained by reporting facilities usually done by the Regional/Central Registry:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>73</td>
<td>Computer match with HMO file</td>
</tr>
<tr>
<td>76</td>
<td>Computer match with state death tape</td>
</tr>
</tbody>
</table>

Regional Registry (Additional Codes):

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>80</td>
<td>Social Security Administration</td>
</tr>
<tr>
<td>81</td>
<td>Property tax linkage</td>
</tr>
<tr>
<td>82</td>
<td>PROBE360</td>
</tr>
<tr>
<td>83</td>
<td>SSDI – Internet</td>
</tr>
<tr>
<td>84</td>
<td>E-Path</td>
</tr>
<tr>
<td>85</td>
<td>Path labs</td>
</tr>
<tr>
<td>86</td>
<td>Patient</td>
</tr>
<tr>
<td>87</td>
<td>Relative</td>
</tr>
</tbody>
</table>

Additional Codes:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>99</td>
<td>Source unknown</td>
</tr>
</tbody>
</table>
**VII.2.7 Last Follow-Up Facility**
The CCR assigned reporting facility code for the reporting facility or agency that provided the most recent follow-up information.

**Coding Instructions:**
- Refer to the most current [California Reporting Facility Codes](https://www.ccrcal.org/) lists, located on the CCR website [https://www.ccrcal.org/](https://www.ccrcal.org/), Registrar Resources, Reporting Cancer in California, Volumes I-IV.
  - Lists are presented in both alphabetical and code order.
VII.2.8 Next Type Follow-Up
Record the method of obtaining follow-up information about the patient for the next report.

Coding Instructions:
- If the patient has died, leave the data item blank.
- Foreign residents may be followed at the reporting facility's discretion, in which case do not use code 8.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Submit a request for the patient's chart to the reporting facility's medical records department</td>
</tr>
<tr>
<td>1</td>
<td>Send a follow-up letter to the patient's physician</td>
</tr>
<tr>
<td>2</td>
<td>Send a follow-up letter to the person designated as the contact for the patient</td>
</tr>
<tr>
<td>3</td>
<td>Contact the patient or designated contact by telephone</td>
</tr>
<tr>
<td>4</td>
<td>Request follow-up information from another facility</td>
</tr>
<tr>
<td>5</td>
<td>Follow-up by a method not described above</td>
</tr>
<tr>
<td>6</td>
<td>Send a follow-up letter to the patient</td>
</tr>
<tr>
<td>7</td>
<td>Patient presumed lost, stop printing follow-up letters</td>
</tr>
<tr>
<td>8</td>
<td>Foreign resident, follow-up discontinued or not initiated</td>
</tr>
<tr>
<td>9</td>
<td>Do not follow-up (except code 8)</td>
</tr>
</tbody>
</table>
VII.2.9 Follow-Up Physician
Enter the name or code number of the attending physician—not a resident or intern—responsible for the patient. (See Physician License Numbers for instructions about entering codes).

Coding Instructions:

- Enter code 99999999 if there is no Follow-Up Physician.
- Enter code 99999999 if the Follow-Up Physician is "unknown" or "license number not assigned."
- Enter the physician NPI code in the respective data item if it is available. See Appendix P - National Provider Identifier (NOP) Codes for further details.
VII.2.10 Date of First Recurrence
This data item records the date of the first recurrence. Recurrence occurs when a patient's primary tumor persisted after a period of complete remission. *Date of First Recurrence* is required if available by the CCR (if the information is obtainable for abstracting, it is required) by CoC-accredited facilities for cases transmitted 1, 2021 and forward.

**Coding Instructions:**
- Code **only the first recurrence** and do not update the data items except to correct data entry errors.
- Enter the physician diagnoses the first progression, metastasis, or recurrence of disease after a disease-free period.
  - See [Entering Dates](#) and [Date Format](#) for additional information regarding entering dates.
- If the exact date is not known, enter an estimate based on the best available information.
- If the patient was never free of the primary tumor or did not experience a recurrence, leave the data item as zeros.
VII.2.10.1 Type of First Recurrence
This data item identifies the type of first recurrence after a period of documented disease-free intermission or remission. Type of First Recurrence is required if available by the CCR (if the information is obtainable for abstracting, it is required) by CoC-accredited facilities for cases transmitted 1, 2021 and forward.

Note: First recurrence may occur well after completion of the first treatment or after subsequent treatment.

Coding Instructions:
- Review SEER Program Manual or the Solid Tumors Rules to determine which subsequent tumors should be coded as recurrences.
- If the patient has never been disease-free (code 70)
  - Continue to track for disease-free status.
- If the patient is disease-free (code 00)
  - Continue to track until a recurrence occurs.
- Once a recurrence has been recorded (code 04-62 or 88), subsequent recurrences are not to be recorded.
- Codes 00 through 70 are hierarchical.
  - Record the highest-numbered applicable response, with the following limits.
    - The first time a patient converts from disease status (70) to disease-free, change the code to 00.
    - Then the first time a patient converts from 00 to a recurrence, then record the proper code for the recurrence.
    - No further changes (other than corrections) should be made.
- If the tumor was originally diagnosed as in-situ, code recurrence to 06, 16, 17, 26, 27, 36, or 46 only.
  Exceptions: Do not use those codes for any other tumors. Codes 00, 88, or 99 may apply to any tumor.
- Codes 51–59 (organ or organ system of distant recurrence) apply only if all first occurrences were in a single category. There may be multiple metastases (or “seeding”) within the distant location.
- Code lymphomas or leukemias that are in remission 00.
  - If the patient relapses, then code recurrence as 59.
  - If one of these is controlled by drugs (for example, Gleevec for CML), the patient is in remission.
- If there is more than one primary tumor and the physician is unable to decide which has recurred, code the recurrent disease for each tumor.
  - If the recurrent primary is identified later, revise the codes appropriately.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>Patient became disease-free after treatment and has not had a recurrence.</td>
</tr>
<tr>
<td>04</td>
<td>In-situ recurrence of an invasive tumor</td>
</tr>
<tr>
<td>06</td>
<td>In-situ recurrence of an in-situ tumor</td>
</tr>
<tr>
<td>10</td>
<td>Local recurrence, and there is insufficient information available to code to 13–17. Local recurrence includes recurrence confined to the remnant of the organ of origin, to the organ of origin, to the anastomosis, or to scar tissue where the organ previously existed</td>
</tr>
<tr>
<td>13</td>
<td>Local recurrence of an invasive tumor</td>
</tr>
<tr>
<td>14</td>
<td>Trocar recurrence of an invasive tumor. Includes recurrence in the trocar path or entrance site following prior surgery</td>
</tr>
<tr>
<td>15</td>
<td>Both local and trocar recurrence of an invasive tumor (both 13 and 14)</td>
</tr>
<tr>
<td>16</td>
<td>Local recurrence of an in-situ tumor, NOS</td>
</tr>
<tr>
<td>17</td>
<td>Both local and trocar recurrence of an in-situ tumor.</td>
</tr>
<tr>
<td>20</td>
<td>Regional recurrence, and there is insufficient information available to code to 21–27</td>
</tr>
<tr>
<td>21</td>
<td>Recurrence of an invasive tumor in adjacent tissue or organ(s) only</td>
</tr>
<tr>
<td>22</td>
<td>Recurrence of an invasive tumor in regional lymph nodes only</td>
</tr>
<tr>
<td>25</td>
<td>Recurrence of an invasive tumor in adjacent tissue or organ(s) and in regional lymph nodes (both 21 and 22) at the same time</td>
</tr>
<tr>
<td>26</td>
<td>Regional recurrence of an in-situ tumor, NOS</td>
</tr>
<tr>
<td>27</td>
<td>Recurrence of an in-situ tumor in adjacent tissue or organ(s) and in regional lymph nodes at the same time</td>
</tr>
<tr>
<td>30</td>
<td>Both regional recurrence of an invasive tumor in adjacent tissue or organs(s) and/or regional lymph nodes (20–25) and local and/or trocar recurrence (10, 13, 14, or 15)</td>
</tr>
<tr>
<td>36</td>
<td>Both regional recurrence of an in-situ tumor in adjacent tissue or organ(s) and/or regional lymph nodes (26 or 27) and local and/or trocar recurrence (16 or 17)</td>
</tr>
<tr>
<td>40</td>
<td>Distant recurrence, to a site not listed in 46-62 or there is insufficient information available to code to 46–62</td>
</tr>
<tr>
<td>46</td>
<td>Distant recurrence of an in-situ tumor</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td>51</td>
<td>Distant recurrence of an invasive tumor in the peritoneum only. Peritoneum includes peritoneal surfaces of all structures within the abdominal cavity and/or positive ascitic fluid</td>
</tr>
<tr>
<td>52</td>
<td>Distant recurrence of an invasive tumor in the lung only. Lung includes the visceral pleura</td>
</tr>
<tr>
<td>53</td>
<td>Distant recurrence of an invasive tumor in the pleura only. Pleura includes the pleural surface of all structures within the thoracic cavity and/or positive pleural fluid</td>
</tr>
<tr>
<td>54</td>
<td>Distant recurrence of an invasive tumor in the liver only</td>
</tr>
<tr>
<td>55</td>
<td>Distant recurrence of an invasive tumor in bone only. This includes bones other than the primary site</td>
</tr>
<tr>
<td>56</td>
<td>Distant recurrence of an invasive tumor in the CNS only. This includes the brain and spinal cord, but not the external eye</td>
</tr>
<tr>
<td>57</td>
<td>Distant recurrence of an invasive tumor in the skin only. This includes skin other than the primary site</td>
</tr>
<tr>
<td>58</td>
<td>Distant recurrence of an invasive tumor in lymph node only. Refer to the staging scheme for a description of lymph nodes that are distant for a particular site</td>
</tr>
<tr>
<td>59</td>
<td>Distant systemic recurrence of an invasive tumor only. This includes lymphoma, leukemia, bone marrow metastasis, carcinomatosis, generalized disease</td>
</tr>
<tr>
<td>60</td>
<td>Distant recurrence of an invasive tumor in a single distant site (51–58) and local, trocar and/or regional recurrence (10–15, 20–25, or 30)</td>
</tr>
<tr>
<td>62</td>
<td>Distant recurrence of an invasive tumor in multiple sites (recurrences that can be coded to more than one category 51–59)</td>
</tr>
<tr>
<td>70</td>
<td>Since diagnosis, patient has never been disease-free. This includes cases with distant metastasis at diagnosis, systemic disease, unknown primary, or minimal disease that is not treated</td>
</tr>
<tr>
<td>88</td>
<td>Disease has recurred, but the type of recurrence is unknown</td>
</tr>
<tr>
<td>99</td>
<td>It is unknown whether the disease has recurred or if the patient was ever disease-free</td>
</tr>
</tbody>
</table>
VII.2.11 Place of Death - Country

*Place of Death - Country* is intended to collect information on the patient’s country of death. Consult with your software vendor for possible auto-generation of this data item.

**Coding Instructions:**

- Enter the code for the Country in which the death occurred.
  - [Appendix C](#) - Codes for Countries.
  - See also [Vital Status](#).
    - If the patient is alive, this data item must be blank.
**VII.2.11.1 Place of Death - State**

*Place of Death - State* is intended to collect information on the state of death.

**Coding Instructions:**

- Enter the abbreviation for the state in which the death occurred. *Appendix B* - Postal Abbreviations for States and Territories of the United States.
- See also *Vital Status*.
  - If the patient is alive, this data item must be blank.
VII.3 Follow-Up Contact Name/Address File
The Contact Name/Address File is for generating follow-up letters to the patient or designated contact(s).

Coding Instructions:
- Space is provided for the name and address of the patient, including state and country, and up to five contacts for information about the patient.
- Enter names and addresses exactly as they are to appear in the heading of the letter, using capital and lower-case letters, punctuation, and special characters like # for number.
- In the Phone data item, enter the area code and number without spaces, dashes, or other marks.
- For Country of residence, see Appendix C - Codes for Countries.
- A supplemental data item has been added which provides the ability to record additional address information such as the name of a place or facility (i.e., a nursing home or name of an apartment complex). This supplemental data item is limited to 60 characters.
VII.3.1 Follow-Up Contact 1
This data item captures the person who will be the contact for follow up. This data item is usually designated for the patient, however in some circumstances it may be a parent or guardian. It is where patient follow up letters are sent.

Coding Instructions:

- Enter the patient's name and preceding Mr., Mrs., Ms., or followed by Jr. or Sr. (up to 60 characters and spaces).
- Enter the current address information:
  - Street address or post office box (up to 60 characters and spaces).
  - Current city (up to 50 characters and spaces).
- Two-character Postal Service abbreviation for the state (Appendix B - Postal Abbreviations for States and Territories of the United States).
  - Zip code (up to ten characters and spaces).
  - Country code (three characters) if the address is outside the United States. If the patient lives within the United States, this data item may be left blank. (See Appendix C - Codes for Countries).
- If the patient is under 18, enter a parent's name and address.
- Addresses in foreign countries may be entered, including foreign postal codes.
- Entry of a telephone number is required for all patients alive at the time the case is abstracted. Include the area code.
- If the telephone number changes at the time of follow-up, it needs to be changed in this data item. If there is no phone, enter all 0's.
- In the Patient Address Current--Supplemental data item, record the place or facility (i.e., nursing home or name of an apartment complex) of the patient's current usual residence.
  - If the patient has multiple tumors, the address should be the same.
  - Update this data item if a patient's address changes.
  - This supplemental data item is limited to 60 characters.
VII.3.2 Follow-Up Contacts 2 - 6
If available in the abstracting software, these follow up contact data items collect the other contacts the patient has listed in their chart (usually on the face sheet). These contacts are not the patient. They are relatives, friends, neighbors, etc.

**Coding Instructions:**

- Enter the names, addresses, including country, and phone numbers of up to six people designated as contacts for the case.
- The contacts name preceded by Mr., Mrs., Ms., or followed by Jr. or Sr. (up to 60 characters and spaces).
- The current street address or post office box (up to 60 characters and spaces).
- Current city (up to 50 characters and spaces).
- Two-character Postal Service abbreviation for the state (see Appendix B - Postal Abbreviations for States and Territories of the United States).
- Zip code (up to ten characters and spaces).
- The three-character country code.
  - [Appendix C - Codes for Countries](#).
- A supplemental follow-up contact data item has been added. This data item provides the ability to store additional address information such as the name of a place or facility, a nursing home, or the name of an apartment complex.

**Notes:**

- A supplemental follow-up contact data item has been added. This data item provides the ability to store additional address information such as the name of a place or facility, a nursing home, or the name of an apartment complex.
  - It can be used to generate a follow-up inquiry, and must correspond to the other data items in the follow-up contact address.
  - If the patient has multiple tumors, *Follow-Up Contact--Supplemental* should be the same.
  - This supplemental data item is limited to 60 characters.
Part VIII. Remarks, Final Diagnosis and Extra Reporting Facility Information

Part VIII of Volume I include directives for the data items “Text-Remarks” and “Text Final Diagnosis” data items. This section also includes items that are Regional specific and facility specific, also called “user data.”
VIII.1 Text - Remarks
Textual information that does not fit into its designated data item can be recorded in the Text-Remarks area.

Coding Instructions:
- Use standard medical abbreviations when possible. See Appendix I - Common Acceptable Symbols and Abbreviations.
- Use phrases not complete sentences. Separate phrases using either periods (.) or semi-colons (;).
- Avoid using only uppercase/capitals in text documentation.
- The following required data must be recorded in the Text - Remarks section:
  - Other tumors (see Other Tumors/Primaries).
  - Full Name of Parent or guardian of a child whose case is being reported. (Information about the parent is also entered in the Follow-Up Contact #1 area. See Follow-Up Contacts 2 - 6.
  - If the patient is participating in a protocol study, document the protocol study, clinical trial name or ID/number and study arm, as stated in the medical record. See Protocol Participation.

Examples:
- Protocol: SWOG-SO777
- Protocol: NSAPB B-39, RTOG 04313
- Protocol: RTOG-00534
- Protocol: CodeBreak 300: Colorectal Cancer/NCT05198934
- The following demographics may be entered in either the Text-Physical Exam or Text-Remarks data items, but it is preferred to record it in Text-Remarks:
  - Age
    - Include text verification in the remarks text data item when the patient is 100 years or older.
  - Race
    - Include text verification for the race of patient in the Text-Remarks data item, when coded as "Other" or if there is conflicting race information. See Race and Ethnicity.
  - Hispanic Origin
  - Sex
  - Height, Weight
- Smoking information to support tobacco codes
- Place of Birth – if it differs from race

- Supplemental information, which cannot be coded numerically but may be useful to clarify unusual circumstances or situations.
  - Patient moved to live with family and will receive additional treatment in another state.

- Record other pertinent information for which there is no designated data item.

- If text from another data item is being continued in Text-Remarks:
  - In the data item where the text is continued from, enter * text-remarks to indicate more information is in Text-Remarks.
  - In Text-Remarks, include the data item being extended and enter the overflow information. (e.g. * x-rays/scans: 4/2/20 CT AP: no mets).

For additional information regarding recording text, please see Appendix T -Text Documentation Guidelines.
VIII.2 Text - Final Diagnosis
This text data item is designated for recording the final diagnosis (FDX) as determined by a recognized medical practitioner.

Coding Instructions:

- This information is ideally found in the discharge summary or progress notes.
- Record the date of the notation and the final diagnosis, including stage if given.
- If there is no final diagnosis in the medical record, please state FDX: NR; do not leave this data item blank.
- If the only information available is a pathology report, which has already been recorded, then document “No MD FDX reported” in the FDX data item.

For additional information regarding recording text, please see Appendix T -Text Documentation Guidelines.
VIII.3 Regional Data

Use of the *Regional Data* fields is determined by the Regional registry, which designates the codes to be entered.
VIII.4 Extra Facility Information
The Extra Facility Information data items (also called user data) are provided for the convenience of the reporting facility, which determines how they are to be used. All the data items may be left blank. The information is not sent to the CCR.
Part IX. Transmittal of Case Information and Quality Control

Part IX of Volume I include information on transmitting new and modified cases to the CCR. The second portion explains quality control areas such as completeness, accuracy, timeliness.
IX.1 Transmittal of Case Information
The process for transmitting cases to the regional registry is specific to each region. Contact your regional registry for regional specific guidelines. General case transmission guidelines are outlined below.

Coding Instructions:

- All cases must be transmitted electronically.
- Cases are to be transmitted via a secure portal.
- Generally, abstracts are submitted when all required information has been entered, usually no later than six months after admission.
- The types of files transmitted include:
  - New case abstracts
  - Modified Record: Includes any changes to the original abstract submitted
  - Deleted cases

Note: Software vendors may have options for direct transmission of the abstract to the Central Registry. If this capability exists, please refer to the vendor for their protocol.
IX.1.1 Timeliness - Transmission
Submit all abstracts per agreement to the Regional or Central Registry.

Guideline:
- Generally, abstracts are submitted when all required information has been entered, usually no later than six months after admission.
IX.1.2 Modified Record

The CCR now requires facilities to use the Modified Record to transmit data modifications for abstracts already submitted as New Case Records.

Guidelines:

- The Modified Record, record type M, contains the same data items as the New Case Record, record type A.
- The data item Follow-up Flag is no longer required as per the 2023 data changes. Unlike the former Update/Correction record, the Modified Record is designed to allow facilities to submit only one latest modified record per updated case in a modified record transmit file, regardless of the number of types of changes made since the case was last included in a new or modified transmit file.
- The following CCR specific data items will be required as of 2023.
  - **Date/Time New Case First Exported** – the date and time a case was originally included in a new case transmit file.
  - **Date/Time Case Last Changed** – the latest date and time one or more case data item values with a “yes” in the Update Triggers Modified Record column of the CCR’s Volume II, Appendix A: New Case and Modified Record Items was last changed at the facility (e.g., 2023-11-01 17:41:52.000).
  - **Date/Time Modified Record Last Exported** - the date and time a case was last included in a modified record transmit file (e.g., 2023-12-01 07:25:05.000).

  - A case must ONLY be included in the next modified record transmit file when ALL of the following conditions are true:
    - The current Date/Time Case Last Changed is later than the Date/Time New Case First Exported (later date or same date but later time).
    - Date/Time Modified Record Last Exported is blank OR Date/Time Case Last Changed is later than Date/Time Modified Record Last Exported (later date or same date but later time).
    - At least one item changed since the latest export (modified record or initial new case if that’s all there is) is an item with an Update Triggers Modified Record specification of yes in the CCR’s Volume II, Appendix A: New Case and Modified Record Items.

See Volume II, II.3.3 Modified Record for additional detailed information.
IX.1.2.1 Modified Record - Changing Items in an Abstract

Changes or modifications to an abstract already submitted as New Case Records will be submitted as a Modified Record. Some possible reasons for updating an abstract are described in this section.

Coding Instructions:

- The reasons for changes are not limited to first course of treatment.
  
  **Example:** *Diagnostic Confirmation* is a data item that can be changed **ANY TIME** during the patient’s course of disease to a lower code.

- To correct coding or abstracting errors found at the facility.

- When clarifications or rule changes retroactively affect the data item coded.

- When better information is available at a later date.
  
  **Example:** Follow-up on treatment coded as 88 (recommended, unknown if given) and the patient did have treatment. Update the code in the appropriate treatment data item, along with supporting text in the associated text data item.

- The date of diagnosis is confirmed in retrospect to be earlier than the original date abstracted.

- Updates to an abstract may also be made due to feedback from the Regional Registry (examples below). If these are the ONLY updates to a case, then a Modified record should not be submitted as these changes have already been made in the central registry database. See Volume II for further details.
  
  - Visual Editing Discrepancies
  
  - Recoding Audits
  
  - Re-Abstracting Audits
  
  - Follow-up information collected by the Regional Registry and shared with the facility
IX.1.3 Deletions
Deletions are cases that are to be, or have been deleted from the database.

Coding Instructions:

- Delete any duplicate records if a case is found to have been abstracted and sent to the Regional or Central Registry more than once.
  - Deletions cannot be submitted for a case to be re-abstracted under a new reporting facility if the case was previously abstracted under another reporting source.

- Delete a previously reported case if subsequent evidence disproves the presence of cancer, or if what was thought to be a new primary cancer is later found to be a manifestation of an earlier primary cancer.

- All deletions must be reported to the Regional or Central Registry.
  - Mass deletions must be approved by the Regional or Central Registry in advance.
IX.2 Quality Control

The California Cancer Registry (CCR) and Regional Registries have procedures for assuring the quality of the data produced by the reporting system. Staff from the Regional Registry visit cancer reporting facilities to perform quality control audits and submit copies of their final reports to the CCR.

The CCR has established uniform standards of quality for facility data in three areas:

- Completeness
- Accuracy
- Timeliness
IX.2.1 Completeness - Quality Control
Completeness is the extent to which all required cases have been reported. The minimum acceptable level of completeness for a reporting facility is 97 percent of expected case counts per year.
IX.2.2 Accuracy - Quality Control

Accuracy is the extent to which the data submitted has been correctly coded and matches the information in the medical record and have been correctly coded. It encompasses accurate abstracting, correct application of coding rules, text documentation to support codes, and correct entry into and retrieval from the computer.

Both Analytic and Non-analytic cases are included in the accuracy rate and are evaluated using various methods:

1. Visual Editing:
   - The CCR's Regional Registries perform visual editing on a percentage of the abstracts submitted by reporting facilities. Feedback is provided to reporting facilities on the results of visual editing.
   - A visual editing accuracy rate was established at 97% in January 2000. This rate applies to cancer reporting facilities and not to individual cancer registry abstractors. The reporting facility is responsible for cancer reporting requirements, not specific individuals; therefore, an accuracy rate reflects the facility's compliance with regulations. Please refer to the CCR web site at: https://www.crrcal.org/submit-data/cancer-registrars-hospitals-and-facilities/reporting-by-cancer-registrars/#visually-edited-data, for the current list of visually edited data items.
   - Discrepancy Reports are provided to each facility outlining the coding errors identified by visual editors. Facility abstractors are expected to update their database with the corrected codes identified by visual editors, thereby ensuring that future Modified Records will reflect the accurate code(s).

2. Computer Edits:
   - Computer edits are also used to assess the quality of data submitted. The CCR provides a standard set of edits for abstracting software. These edits are performed on data at the time of abstracting. The measure used to evaluate accuracy is the percent of a facility's cases that fail an edit. CCR's cases must pass the inter-data item edits specified in Cancer Reporting in California: Data Standards for Regional Registries and California Cancer Registry (California Cancer Reporting System Standards, Volume III).
   - The CCR's edit set contains a number of edits that require review. After review and confirmation that the abstracted information is correct, a flag must be set so that repeated review is not necessary, and a case can be set to complete. Please follow the instructions
provided by your facility’s abstracting software vendor for using these flags.

- The Central Registry is committed to ensuring high quality data in the database. Business rules have been implemented in the database to evaluate coded data items based on pre-determined criteria and then auto-correct miscoded data item(s) based on programmed criteria. These rules have been developed by CTRs at the Central Registry and have been rigorously tested prior to implementation.

3. Re-Abstracting Audits:

- Another method of assessing accuracy is to re-abstract cases in the facilities. A sample of cases from each facility is re-abstracted by specially trained personnel. The measure used is the number of discrepancies found in related categories of items.
IX.2.3 Timeliness - Quality Control
Timeliness involves how quickly the reporting facility submits a case to a Regional Registry or Central Registry after admission of the patient. Regional registries and the central registry monitor the timeliness of data submitted by facilities.

Guidelines:

• The standard established by the CCR is that 97 percent of cases must be received by the Regional Registry or Central Registry within six months of admission and 100 percent must be received within 12 months of admission.

• Although every effort should be made to complete cases before they are transmitted to the Regional Registry or Central Registry, it is recognized that some cancer cases undergo treatment later than six-months from the date of admission.

• Submit treatment information in a Modified Record as available.
Appendices

The Appendices section of Volume I includes resources and supplemental information for the abstractor to access for specific coding. Examples of what is included in the appendices section are items such as postal abbreviations, surgery codes, multiple primary information, and race codes.

To access California Cancer Reporting System Standards, Volume I: Abstracting and Coding Procedures –, please see: